<SEC-DOCUMENT>0001213900-20-014802.txt : 20200817
<SEC-HEADER>0001213900-20-014802.hdr.sgml : 20200817
<ACCEPTANCE-DATETIME>20200612150014
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-20-014802
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20200612
<PUBLIC-REL-DATE>20200817
DATE AS OF CHANGE:		20200612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Universe Pharmaceuticals INC
		CENTRAL INDEX KEY:			0001809616
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			F4
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03139
		FILM NUMBER:		20959958

	BUSINESS ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGJIJISHU KAIFA DISTRICT, JINGGANGSHAN
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
		BUSINESS PHONE:		86-0796-8404999

	MAIL ADDRESS:	
		STREET 1:		265 JINGJIU AVENUE
		STREET 2:		JINGJIJISHU KAIFA DISTRICT, JINGGANGSHAN
		CITY:			JI'AN, JIANGXI
		STATE:			F4
		ZIP:			343100
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Confidential Draft No. 2 as confidentially
submitted to the Securities and Exchange Commission on June 12, 2020. This draft registration statement has not been publicly
filed with the Securities and Exchange Commission and all information herein remains strictly confidential.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-[&#9679;]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM F-1<BR>
REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Universe Pharmaceuticals INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman
    Islands</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of<BR>
    incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary Standard
    Industrial<BR>
    Classification Code Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
    Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">265 Jingjiu Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jingji Jishu Kaifa District, Jinggangshan,
Ji&rsquo;an</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Jiangxi, China<BR>
+86-0796-8404999</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hunter Taubman Fischer &amp; Li LLC<BR>
1450 Broadway, 26th Floor<BR>
New York, NY 10018<BR>
(212) 530-2206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, address, including zip code, and
telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>With a Copy to:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Ying Li,
                           Esq.</B> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Guillaume de Sampigny, Esq.
        </B> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Hunter Taubman Fischer &amp;
        Li LLC<BR>
        1450 Broadway, 26<SUP>th</SUP>&nbsp;Floor<BR>
        New York, NY 10018<BR>
        212-530-2206</B> </P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Elizabeth
                                         Fei Chen, Esq.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>Pryor Cashman LLP</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>7 Times Square</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <B>New York, NY 10036</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> 212-326-0199 </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate date of commencement of
proposed sale to the public:</B> Promptly after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any
    of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
    the Securities Act of 1933 check the following box.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Form is
    filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
    following box and list the Securities Act registration statement number of the earlier effective registration statement for
    the same offering.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Form is
    a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
    Act registration statement number of the earlier effective registration statement for the same offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Form is
    a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
    Act registration statement number of the earlier effective registration statement for the same offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check
    mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company
    </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth
    company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has
    elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
    pursuant to Section 7(a)(2)(B) of the Securities Act</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Title of Each Class of Securities to
    Be Registered</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount to<BR> Be<BR> Registered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Proposed<BR> Maximum<BR> Offering<BR>
    Price per<BR> Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed<BR>
    Maximum<BR> Aggregate<BR> Offering<BR> Price<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of<BR> Registration<BR> Fee<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares, par value US$1.00 per share<SUP>(3)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriter&rsquo;s
    warrants<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Ordinary shares, par value US$1.00
    per share, underlying the underwriter&rsquo;s warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated solely
    for the purpose of determining the amount of registration fee in accordance with Rule 457(a) under the Securities Act. Includes
    the offering price attributable to additional shares that the underwriter has the option to purchase to cover over-allotments,
    if any.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated pursuant
    to Rule 457(a) under the Securities Act, based on an estimate of the proposed maximum aggregate offering price</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with
    Rule 416(a), we are also registering an indeterminate number of additional ordinary shares that shall be issuable pursuant
    to Rule 416 to prevent dilution resulting from share splits, share dividends or similar transactions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT> </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                    Registrant will issue to the underwriter warrants to purchase a number of ordinary shares
                                    equal to an aggregate of 6% of the ordinary shares sold in the offering, excluding the ordinary
                                    shares sold as a result of the underwriter&rsquo;s election to exercise its over-allotment
                                    option. The exercise price of the underwriter&rsquo;s warrants is equal to 110% of the offering
                                    price of the ordinary shares offered hereby. The underwriter&rsquo;s warrants are exercisable
                                    at any time, and from time to time, in whole or in part, within 5 years commencing from the
                                    effective date of the offering.</FONT> </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The Registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: black 1.5pt solid; padding: 3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">The
    information in this prospectus is not complete and may be changed. We may not sell the securities until the registration statement
    filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and
    it is not soliciting any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>SUBJECT TO
COMPLETION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>PRELIMINARY
PROSPECTUS DATED [&#9679;], 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[</I></B><I>&#9679;<B>] Ordinary
Shares</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I><B>&nbsp;</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo_001.jpg" ALT="" STYLE="width: 650px; height: 213px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Universe Pharmaceuticals INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is an initial public offering of
our ordinary shares. We are offering on a firm commitment basis our ordinary shares, par value $1.00 per share (&ldquo;Ordinary
Shares&rdquo;). Prior to this offering, there has been no public market for our Ordinary Shares. We expect the initial public
offering price to be in the range of $[&#9679;] to $[&#9679;] per Ordinary Share. We have reserved the symbol &ldquo;[&#9679;]&rdquo;
for purposes of listing our Ordinary Shares on [New York Stock Exchange/NASDAQ Capital Market] and plan to apply to list our Ordinary
Shares on [New York Stock Exchange/NASDAQ Capital Market].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our Ordinary Shares involves
a high degree of risk, including the risk of losing your entire investment. See &ldquo;Risk Factors&rdquo; beginning on page
9 to read about factors you should consider before buying our Ordinary Shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and will be subject to reduced public company reporting requirements. Please read
the disclosures beginning on page  28 of this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Following the completion of this offering,
our largest shareholder will beneficially own approximately [&#9679;]% of the aggregate voting power of our outstanding Ordinary
Shares. As such, we may be deemed a &ldquo;controlled company&rdquo; within the meaning of [the NYSE listing rules/the NASDAQ
listing standards]. However, even if we are deemed as a &ldquo;controlled company,&rdquo; we do not intend to avail ourselves
of the corporate governance exemptions afforded to a &ldquo;controlled company&rdquo; under [the NYSE listing rules/the NASDAQ
listing standards]. <I>See &ldquo;Risk Factors&rdquo; and &ldquo;Management&mdash;Controlled Company.&rdquo;</I> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: justify">Initial public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter&rsquo;s discounts<SUP>(1)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proceeds to our company before expenses<SUP>(2)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0"> We have also agreed to issue, on the closing date of this offering,
                                    underwriter&rsquo;s warrants to the underwriter in an amount equal to 6% of the aggregate
                                    number of Ordinary Shares sold by us in this offering, excluding the Ordinary Shares sold
                                    as a result of the underwriter&rsquo;s election to exercise its over-allotment option. See
                                    <I>&ldquo;Underwriting&rdquo; </I>in this prospectus for more information regarding our arrangements
                                    with the underwriter. </P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif">We&nbsp;expect
                                    our total cash expenses for this&nbsp;offering&nbsp;(including cash expenses payable to our
                                    underwriter for its out-of-pocket expenses) not to exceed&nbsp;$230,000,&nbsp;exclusive of
                                    the above discounts. In addition, we will pay additional items of value in connection with
                                    this&nbsp;offering&nbsp;that are viewed by the Financial Industry Regulatory&nbsp;Authority,&nbsp;or
                                    FINRA, as underwriting compensation, such as 1% of the total offering amount as the underwriter&rsquo;s
                                    non-accountable expenses. These payments will further reduce proceeds available to us before
                                    expenses. For a detailed description of the compensation to be received by the underwriter,
                                    see &ldquo;Underwriting.</FONT> </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> This offering is being conducted on a firm
commitment basis. The underwriter is obligated to take and pay for all of the Ordinary Shares if any such Ordinary Shares are
taken. We have granted the underwriter an option for a period of 45 days after the effective date of this registration statement
to purchase up to 15% of the total number of the Ordinary Shares to be offered by us pursuant to this offering (excluding Ordinary
Shares subject to this option), solely for the purpose of covering over-allotments, at the public offering price less the underwriting
discounts. If the underwriter exercises the option in full, the total underwing discounts payable will be $[&#9679;] based on
an assumed offering price of $[&#9679;] per Ordinary Share, and the total gross proceeds to us, before underwriting discounts
and expenses, will be $[&#9679;]<B>.</B> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter expects to deliver the
Ordinary Shares against payment as set forth under &ldquo;Underwriting,&rdquo; on or about [&#9679;], 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prospectus dated [&#9679;], 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS SUMMARY</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE OFFERING</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">6</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY CONSOLIDATED FINANCIAL AND OPERATING DATA</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">7</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c4"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK FACTORS</B></FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">9</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c5"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">28</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c6"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENFORCEABILITY OF CIVIL LIABILITIES</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">29</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c7"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USE OF PROCEEDS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">30</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c8"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIVIDEND POLICY</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">31</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c9"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAPITALIZATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">32</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c10"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DILUTION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">33</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c11"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORPORATE HISTORY AND STRUCTURE</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">34</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><A HREF="#c12"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">36</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c13"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDUSTRY</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">58</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c14"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUSINESS</B></FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">63</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c15"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGULATIONS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">75</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c16"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">85</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c27"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE COMPENSATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">89</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c28"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL SHAREHOLDERS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">90</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c17"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED PARTY TRANSACTIONS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">92</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c18"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION OF SHARE CAPITAL</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">93</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c19"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">111</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">113</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c21"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDERWRITING</B></FONT></A></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">121</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c22"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPENSES RELATING TO THIS OFFERING</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">125</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c23"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL MATTERS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">126</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c24"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">126</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c25"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHERE YOU CAN FIND MORE INFORMATION</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">126</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><A HREF="#c26"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX TO FINANCIAL STATEMENTS</B></FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely on the information contained
in this prospectus or in any related free writing prospectus. We have not authorized anyone to provide you with information different
from that contained in this prospectus or in any related free writing prospectus. We are offering to sell, and seeking offers
to buy the Ordinary Shares, only in jurisdictions where offers and sales are permitted. The information contained in this prospectus
is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter have taken
any action to permit a public offering of the Ordinary Shares outside the United States or to permit the possession or distribution
of this prospectus or any filed free-writing prospectus outside the United States. Persons outside the United States who come
into possession of this prospectus or any filed free writing prospectus must inform themselves about and observe any restrictions
relating to the offering of the Ordinary Shares and the distribution of this prospectus or any filed free-writing prospectus outside
the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Until , 2020 (the 25<SUP>th</SUP> day
after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating in
this offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions.</B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 6pt 3pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c1"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary is qualified
in its entirety by, and should be read in conjunction with, the more detailed information and financial statements included elsewhere
in this prospectus. In addition to this summary, we urge you to read the entire prospectus carefully, especially the risks of
investing in our Ordinary Shares, discussed under &ldquo;Risk Factors,&rdquo; before deciding whether to buy our Ordinary Shares.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Traditional Chinese Medicine (&ldquo;TCM&rdquo;)
is a comprehensive form of healthcare that has been widely adopted in China for more than 23 centuries. TCM rests upon the assumption
that the human body is an ecosystem, embodying the fusion of Shen (psyche), Essence (soma), Qi, Moisture (body fluids), and Blood
(tissue). Health in the context of TCM is more than just the absence of diseases, but to identify imbalance in human body and
restore harmony. TCM is not only intended to cure diseases but to enhance the capacity for fulfillment, happiness and general
well-being of people.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We are a pharmaceutical company based
in Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives
(&ldquo;TCMD&rdquo;) products targeting the elderly with the goal of addressing their physical conditions in the aging process
and to promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD products from the National
Medical Products Administration (the &ldquo;NMPA&rdquo;), and we currently produce 13 varieties of TCMD products, which are sold
in approximately 280 cities of 31 provinces in China as of the date of this prospectus. In addition, through our wholly owned
subsidiary Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&ldquo;Universe Trade&rdquo;), we sell biomedical drugs,
medical instruments, Traditional Chinese Medicine Pieces (&ldquo;TCMP&rdquo;) products, and dietary supplements manufactured by
third-party pharmaceutical companies. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Products manufactured by us. </I>The
13 TCMD products currently manufactured by us fall into two categories: (1) treatment and relief for common chronic health conditions
in the elderly designed to achieve physical wellness and longevity (&ldquo;Chronic Condition Treatments&rdquo;), and (2) cold
and flu medications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chronic
    Condition Treatments</B>: Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral
    Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan
    Dabu Medicinal Liquor.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cold
    and flu medicines</B>: Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As people age, they have an increasing
risk of developing chronic health conditions. According to a report published by the Chinese Center for Disease Control and Prevention
in March 2019, 75.8% of seniors have at least one chronic health condition, and 35.1% of them have two or more. Some of the most
common chronic diseases in the elderly include arthritis, chronic kidney disease, fatigue, and low back pain. Our products under
the category of Chronic Condition Treatments are designed to address some of the aforementioned diseases. Our cold and flu medicines,
on the other hand, include products designed to treat and relieve symptoms of respiratory illnesses caused by bacteria and viruses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <I>Our third-party products. </I>Through
Universe Trade, we also distribute and sell products manufactured by third-party producers, including biomedical drugs, medical
instruments, TCMP products and dietary supplements. As of March 31, 2020, we had distributed over 4,000 third-party products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our <I>Customers. </I>Our major customers
are pharmaceutical companies, hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province,
Guangdong Province, and 27 other provinces in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we have implemented a
successful business model, and our business has grown substantially since our inception. Our customer base continue to grow
meaningfully, from a total of 1,304 customers in 2017 to 2,603 customers at the end of fiscal year 2019. Our revenues from
selling our own products increased from $17,620,823 for the fiscal year ended September 30, 2018 to $20,895,542 for the
fiscal year ended September 30, 2019. Our revenues from distributing and selling products manufactured by third-party
companies increased from $10,893,357 for the fiscal year ended September 30, 2018 to $12,333,774 for the fiscal year ended
September 30, 2019. Our net income was $7,602,933 for the fiscal year ended September 30, 2018 and $7,551,465 for the fiscal
year ended September 30, 2019.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the following competitive
strengths have contributed to our success and differentiated us from our competitors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a recognized
    manufacturer of TCMD products in China&rsquo;s rapidly growing health and wellness market; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rigorous quality
    control standards and manufacturing protocols; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">visionary management
    team with substantial industry experience; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">strong record of
    growth and profitability. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Growth Strategies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to implement the following strategies
to achieve growth in the future:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">build
    a strong brand image to achieve national recognition; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enhance our distribution
    network to increase market penetration; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate our internal
    manufacturing capacity to ensure production, supply and selection of products; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">further grow our
    research and development capacities. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Challenges </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to execute our strategies
and realize our vision is subject to risks and uncertainties, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to compete effectively in the Chinese patent medicine industry; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract
    new customers and retain existing customers and expand our customer relationships; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to improve
    our products to keep up with the rapidly changing demands, preferences, or trends in the Chinese patent medicine industry;
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to generate
    and maintain sufficient cash inflows from operating activities; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply
    with applicable laws and regulations in China; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to protect
    our intellectual property rights and proprietary rights. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our History and Corporate Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We initially conducted our business through
Jiangxi Universe Pharmaceuticals Co., Ltd. (&ldquo;Jiangxi Universe&rdquo;), a PRC company incorporated in 1998 and Jiangxi Universe
Pharmaceuticals Trade Co., Ltd. (&ldquo;Universe Trade&rdquo;), a PRC company incorporated in 2010, a wholly owned subsidiary
of Jiangxi Universe. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> With the growth of our business and in
order to facilitate international capital investment in our Company, we underwent an offshore reorganization in 2019 and 2020.
On December 11, 2019, our holding company, Universe Pharmaceuticals INC (&ldquo;Universe INC&rdquo;), was incorporated under the
laws of the Cayman Islands as an exempted company with limited liability. Our wholly owned subsidiary Universe Pharmaceuticals
Group (International) Limited (&ldquo;Universe HK&rdquo;) was incorporated in Hong Kong on May 21, 2018 as an intermediate holding
company. Universe HK in turn holds all the capital stock of Jiangxi Universe Pharmaceuticals Technology Co., Ltd. (&ldquo;Universe
Technology&rdquo;), a wholly foreign owned enterprise incorporated in China on Aril 8, 2019. Universe Technology holds all the
capital stock and controls Jiangxi Universe. Jiangxi Universe holds 100% equity interest in Universe Trade. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Universe INC is a holding company with
no business operation other than holding the shares in Universe HK; Universe HK is a pass-through entity with no business operation.
Universe Technology is exclusively engaged in the business of managing the operation of Jiangxi Universe. Jiangxi Universe specializes
in manufacturing our own TCMD products. Universe Trade specializes in the distribution and sales of our own TCMD products and
third-party pharmaceutical products. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Foshan Shangyu Investment Holding Co.,
Ltd. (&ldquo;Foshan Shangyu&rdquo;) is our affiliated entity, 90% owned by and controlled by Mr. Gang Lai, our controlling shareholder.
Foshan Shangyu was formed in 2004 in China as a holding company for Mr. Gang Lai. Foshan Shangyu has no business operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following diagram illustrates our
corporate structure as of the date of this prospectus and upon completion of this offering based on proposed number of [&#9679;]
Ordinary Shares being offered. For more detail on our corporate history, please refer to &ldquo;Corporate History and Structure&rdquo;.</P>

</DIV>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt; border: Black 1.5pt solid">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 265 Jingjiu Avenue, Jingji Jishu District, Jinggangshan, Ji&rsquo;an, Jiangxi Province, People&rsquo;s Republic of China. Our
phone number is +86-0796-8404999. Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box
31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &ndash; 1205 Cayman Islands, and the phone number of
our registered office is +1-(345)769-9372.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors should submit any inquiries
to the address and telephone number of our principal executive offices. We maintain a corporate website at http://www.dzrzy.com.
The information contained in, or accessible from, our website or any other website does not constitute a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Our Being an &ldquo;Emerging
Growth Company&rdquo; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than $1.07 billion
in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. An &ldquo;emerging growth company&rdquo; may take advantage of reduced reporting
requirements that are otherwise applicable to larger public companies. In particular, as an emerging growth company, we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may present only
    two years of audited financial statements and only two years of related Management&rsquo;s Discussion and Analysis of Financial
    Condition and Results of Operations, or &ldquo;MD&amp;A;&rdquo;</FONT></TD></TR>
</TABLE>

</DIV>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt; border: Black 1.5pt solid">
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required
    to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how
    those elements fit with our principles and objectives, which is commonly referred to as &ldquo;compensation discussion and
    analysis&rdquo;;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required
    to obtain an attestation and report from our auditors on our management&rsquo;s assessment of our internal control over financial
    reporting pursuant to the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are not required
    to obtain a non-binding advisory vote from our shareholders on executive compensation or golden parachute arrangements (commonly
    referred to as the &ldquo;say-on-pay,&rdquo; &ldquo;say-on frequency&rdquo; and &ldquo;say-on-golden-parachute&rdquo; votes);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are exempt from
    certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are eligible to
    claim longer phase-in periods for the adoption of new or revised financial accounting standards under &sect;107 of the JOBS
    Act; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will not be required
    to conduct an evaluation of our internal control over financial reporting until our second annual report on Form 20-F following
    the effectiveness of our initial public offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to take advantage of all of
these reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised
financial accounting standards under &sect;107 of the JOBS Act. Our election to use the phase-in periods may make it difficult
to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted
out of the phase-in periods under &sect;107 of the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the JOBS Act, we may take advantage
of the above-described reduced reporting requirements and exemptions until we no longer meet the definition of an emerging growth
company. The JOBS Act provides that we would cease to be an &ldquo;emerging growth company&rdquo; at the end of the fiscal year
in which the fifth anniversary of our initial sale of common equity pursuant to a registration statement declared effective under
the Securities Act of 1933, as amended, herein referred to as the Securities Act, occurred, if we have more than $1.07 billion
in annual revenues, have more than $700 million in market value of our Ordinary Share held by non-affiliates, or issue more than
$1 billion in principal amount of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Foreign Private Issuer Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a foreign private issuer within
the meaning of the rules under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). As such, we are
exempt from certain provisions applicable to United States domestic public companies. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are
    not required to provide as many Exchange Act reports, or as frequently, as a domestic public company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for interim reporting,
    we are permitted to comply solely with our home country requirements, which are less rigorous than the rules that apply to
    domestic public companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required
    to provide the same level of disclosure on certain issues, such as executive compensation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exempt from
    provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required
    to comply with the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect
    of a security registered under the Exchange Act; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not required
    to comply with Section 16 of the Exchange Act requiring insiders to file public reports of their share ownership and trading
    activities and establishing insider liability for profits realized from any &ldquo;short-swing&rdquo; trading transaction.</FONT></TD></TR>
</TABLE>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conventions That Apply to This Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise indicated or the context
requires otherwise, references in this prospectus to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&ldquo;Affiliated
    Entities&rdquo; are to our subsidiaries; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;BVI&rdquo;
    are to the British Virgin Islands; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;China&rdquo;
    or the &ldquo;PRC&rdquo; are to the People&rsquo;s Republic of China, excluding Taiwan and the special administrative regions
    of Hong Kong and Macau for the purposes of this prospectus only;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Jiangxi Universe&rdquo;
    are to Jiangxi Universe Pharmaceuticals Co., Ltd., a limited liability company organized under the laws of the PRC, which
    is wholly owned by Universe Technology;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;shares,&rdquo;
    &ldquo;Shares,&rdquo; or &ldquo;Ordinary Shares&rdquo; are to the ordinary shares of the Company, par value US$1.00 per share;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Universe
    HK&rdquo; are to Universe INC&rsquo;s wholly owned subsidiary, Universe Pharmaceuticals Group (International) Limited, a Hong
    Kong corporation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Universe
    INC&rdquo; are to Universe Pharmaceuticals INC, an exempted company with limited liability incorporated under the laws of
    Cayman Islands;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Universe
    Trade&rdquo; are to Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd., a limited liability company organized under
    the laws of the PRC, which is a wholly owned by Jiangxi Universe;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;we,&rdquo;
    &ldquo;us,&rdquo; or the &ldquo;Company&rdquo; are to one or more of Universe INC, and its subsidiaries, as the case may be;
    and </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;WFOE&rdquo;
    or &ldquo;Universe Technology&rdquo; are to Jiangxi Universe Pharmaceuticals Technology Co., Ltd., a limited liability company
    organized under the laws of the PRC, which is wholly owned by Universe HK. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the context indicates otherwise,
all information in this prospectus assumes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the filing and effectiveness
    of our amended and restated memorandum and articles of associations, which will occur immediately prior to the completion
    of this offering; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">no exercise by the underwriter of its over-allotment option.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is conducted by Jiangxi Universe
and Universe Trade, our wholly owned subsidiaries in the PRC using Chinese Yuan (&ldquo;RMB&rdquo;), the currency of China. Our
consolidated financial statements are presented in U.S. dollars. In this prospectus, we refer to assets, obligations, commitments,
and liabilities in our consolidated financial statements in United States dollars. These dollar references are based on the exchange
rate of RMB to U.S. dollars, determined as of a specific date or for a specific period. Changes in the exchange rate will affect
the amount of our obligations and the value of our assets in terms of U.S. dollars which may result in an increase or decrease
in the amount of our obligations (expressed in dollars) and the value of our assets, including accounts receivable (expressed
in dollars).</P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c2"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares offered by us</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 66%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]
    million Ordinary Shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price per Ordinary
    Share</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently estimate
    that the initial public offering price will be in the range of $[&#9679;] to $[&#9679;] per Ordinary Share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares
    outstanding prior to completion of this offering</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000 Ordinary
    Shares</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares
    outstanding immediately after this offering</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[&#9679;] Ordinary Shares assuming
        no exercise of the underwriter&rsquo;s over-allotment option and excluding [&#9679;] Ordinary Shares underlying the underwriter
        warrants.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[&#9679;] Ordinary Shares assuming
        full exercise of the underwriter&rsquo;s over-allotment option and excluding [&#9679;] Ordinary Shares underlying the
        underwriter warrants.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Listing</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will apply to
    have our Ordinary Shares listed on [New York Stock Exchange/NASDAQ Capital Market].</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading symbol</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;[&#9679;]&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Agent</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to use
    the proceeds from this offering for working capital and general corporate purposes, including the expansion of our business.
    See &ldquo;Use of Proceeds&rdquo; on page  30 for more information.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Ordinary Shares
    offered hereby involve a high degree of risk. You should read &ldquo;Risk Factors,&rdquo; beginning on page  9 for
    a discussion of factors to consider before deciding to invest in our Ordinary Shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We, our directors
    and executive officers, our existing shareholders have agreed with the underwriter not to sell, transfer or dispose of any
    Ordinary Shares or similar securities for a period of [180] days after the date of this prospectus, subject to certain exceptions.
    See &ldquo;Shares Eligible for Future Sale&rdquo; and &ldquo;Underwriting.&rdquo;</FONT></TD></TR>
</TABLE>

</DIV>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c3"></A>SUMMARY CONSOLIDATED FINANCIAL AND OPERATING
DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables set forth selected
historical statements of operations for the fiscal years ended September 30, 2019 and 2018, and balance sheet data as of September
30, 2019 and 2018, which have been derived from our audited consolidated financial statements for those periods. Our historical
results are not necessarily indicative of the results that may be expected in the future. You should read this data together with
our consolidated financial statements and related notes appearing elsewhere in this prospectus as well as &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; appearing elsewhere in the prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Selected Statements of Operations Information:
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the years ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 30, </B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: justify">REVENUE</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">33,229,316</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">28,514,180</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">COST OF REVENUE</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,821,831</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,105,265</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,407,485</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,408,915</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,578,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680,258</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282,946</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">618,437</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">789,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,654,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,752,586</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">INCOME FROM OPERATIONS</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,752,829</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,656,329</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OTHER INCOME(EXPENSES)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(129,268</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(164,922</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Other income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,760</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Equity investment income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,741</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,630</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Total other expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(99,767</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(138,278</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">INCOME BEFORE INCOME TAX PROVISION</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,653,062</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,518,051</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">INCOME TAX PROVISION</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,101,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,915,118</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">NET INCOME</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,551,465</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,602,933</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OTHER COMPREHENSIVE INCOME (LOSS)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(645,978</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(587,693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">COMPREHENSIVE INCOME</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,905,487</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,015,240</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">EARNINGS PER SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">151.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">152.1</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



</DIV>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 6pt 3pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Selected Balance Sheet Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    of September&nbsp;30,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ASSETS</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT ASSETS</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 76%; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,177,321</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,190,176</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    receivable, net</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,420,986</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,637,177</FONT></TD>
    <TD STYLE="text-align: right"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories,
    net</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,615,155</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,120,436</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,300</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,484</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL
    CURRENT ASSETS</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,229,762</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,956,273</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify; text-indent: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
    plant and equipment, net</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,566,932</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,075,695</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
    assets, net</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,610</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">183,583</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify; text-indent: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment
    in equity securities </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">700,500</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">728,000</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; text-indent: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax assets</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">168,075</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">135,021</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL
    NONCURRENT ASSETS</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,607,117</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,122,299</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL
    ASSETS</B></FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,836,879</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,078,572</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LIABILITIES
    AND SHAREHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT LIABILITIES</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    bank loans</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,521,800</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,620,800</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,937,095</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,938,221</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes
    payable</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">551,049</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">893,512</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to related party </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,705</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55,709</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    payable </FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,648,000</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses and other current liabilities</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">388,171</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,758</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL
    CURRENT LIABILITIES</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,452,820</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,397,000</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITMENTS AND
    CONTINGENCIES</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHAREHOLDERS&rsquo;
    EQUITY</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    shares, $1.00 par value, 50,000 shares authorized, issued and outstanding</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,679,000</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,679,000</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statutory
    reserve</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,439,535</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,439,535</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
    earnings</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,180,757</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,832,292</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    other comprehensive income </FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,767</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">680,745</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL
    SHAREHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,384,059</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,681,572</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL
    LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,836,879</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,078,572</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: justify">&nbsp;</TD></TR>
</TABLE>

</DIV>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c4"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Investment in our securities involves
a high degree of risk. You should carefully consider the risks described below together with all of the other information included
in this prospectus before making an investment decision. The risks and uncertainties described below represent our known material
risks to our business. If any of the following risks actually occurs, our business, financial condition or results of operations
could suffer. In that case, you may lose all or part of your investment. You should not invest in this offering unless you can
afford to lose your entire investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business and Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Price increases in raw materials
and sourced products could harm the Company&rsquo;s financial results. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal raw materials include angelica,
codonopsis, poria mushroom isatis root, and other herbs and plant extracts. These raw materials are subject to price volatility
and inflationary pressures. Our success is dependent, in part, on our ability to reduce our exposure to increase in those costs
through a variety of ways, while maintaining and improving margins and market share. These manufactures are also subject to price
volatility and labor cost and other inflationary pressures, which may in turn result in an increase in the amount we pay for sourced
products. Raw materials and sourced product price increases may offset our productivity gains and price increases and may adversely
impact our financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>High quality materials for our products
may be difficult to obtain or substantially increase our production costs. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raw materials account for a portion of
our manufacturing costs and we rely on third-party suppliers to provide almost all raw materials. Suppliers may be unable or unwilling
to provide the raw materials we need in the quantities requested, at a price we are willing to pay, or that meet our quality standards.
We are also subject to potential delays in the delivery of raw materials caused by events beyond our control, including transportation
interruptions, delivery delays, labor disputes and changes in government regulations. Our business could be adversely affected
if we are unable to obtain a reliable source of the raw materials used in the manufacturing of our products that meets our quality
standards. Any significant delay in or disruption of the supply of raw materials could, among other things, substantially increase
the cost of such materials, require reformulation or repackaging of products, require the qualification of new suppliers, or result
in our inability to meet customer demands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We operate in a highly competitive
industry. Our failure to compete effectively could adversely affect our market share, revenues and growth prospects</I></B><I>.
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chinese patent medicine industry in
China are subject to significant competition and pricing pressures. We will experience significant competitive pricing pressures
as well as competitive products. Several significant competitors may offer products at the same or lower prices than our products.
The market is highly sensitive to the introduction of new products, which may rapidly capture a significant share of the market.
It is possible that one or more of our competitors could develop a significant research advantage over us that allows them to
provide superior products that are more attractive to consumers, which could put us in a competitive disadvantage. Continued pricing
pressure or improvements in research and shifts in customer preference could adversely impact our customer base or pricing structure
and have a material and adverse effect on our business, financial conditions, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to maintain or enhance our
brands or image could have a material adverse effect on our business and results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe several of our brands, such
as &ldquo;Bai Nian Dan (&#30334;&#24180;&#20025;)&rdquo;, &ldquo;Hu Zhuo Ren (&#32993;&#21331;&#20154;)&rdquo; and &ldquo;Long
Zhong (&#40857;&#31181;)&rdquo;, are well-recognized among our clients and other Chinese patent medicine industry players. Our
brand is integral to our sales and marketing efforts. Our continued success in maintaining and enhancing our brand and image depends
to a large extent on our ability to satisfy customer needs by further developing effective and better-quality products, as well
as our ability to respond to competitive pressures. If we are unable to satisfy customer needs or if our public image or reputation
were otherwise diminished, our business transactions with our customers may decline, which could in turn adversely affect our
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to appropriately respond
to changing consumer preferences and demand for new products could significantly harm our customer relationships and product sales.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is particularly subject to
changing consumer trends and preferences. Our continued success depends in part on our ability to anticipate and respond to these
changes, and we may not be able to respond in a timely or commercially appropriate manner to these changes. If we are unable to
do so, our customer relationships and product sales could be harmed significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Chinese patent medicine
industry is characterized by rapid and frequent changes in demand and new product introductions. Our failure to accurately depict
these trends could negatively impact consumer opinion of our stores as a source for latest products. This could harm our customer
relationships and cause losses to our market share. The success of our new product offerings depends upon a number of factors,
including our ability to: accurately anticipate customer needs; innovate and develop new products; successfully commercialize
new products in a timely manner; price our products competitively; manufacture and deliver our products in sufficient volumes
and in a timely manner; and differentiate our product offerings from those our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not introduce new products or
make enhancements to meet the changing needs of our customers in a timely manner, some of our products could become obsolete,
which could have a material adverse effect on our revenues and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our products do not have the
effects intended or cause undesirable side effects, our business may suffer</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although many of the ingredients in our
current products for which there is a long history of human consumption and we believe that all of these products and the combinations
of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken
as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not have the effect
intended if they are not taken in accordance with instructions, which may include dietary restrictions. Furthermore, there can
be no assurance that any of these products, even when used as directed, will have the effects intended or will not have harmful
side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in
the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition,
results of operations, and prospects could be harmed significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to evolving regulatory
requirements, non-compliance with which, or changes in which, may adversely affect our business and prospects. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a manufacturer of products designed
for human consumption, we are subject to legal and regulatory requirements applicable to the Chinese patent medicine industry
in the PRC. We have been subject to penalties by PRC regulatory authorities in the past due to our failure to comply with their
requirements, including noncompliance with the Good Manufacturing Practice for Drugs and the National Drug Standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The regulations to which we are subject
in this area is evolving. As a result, the interpretation of these laws and their enforcement is often uncertain. Predicting the
application of these laws can be difficult, and unexpected outcomes in the interpretation and enforcement of the applicable regulations
may have an adverse impact on our business and operations. Additionally, any future changes in regulation may render our business
non-compliant or require changes to our business practices or licensing arrangements to ensure compliance. These changes may involve
significant costs, which in turn may adversely affect our business and prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Various regulatory authorities of the
PRC government regulate the manufacturing and trading of Chinese patent medicine. Violations of regulations may lead to the imposition
of significant penalties which may affect our business, operations, reputation and financial prospects. See &ldquo;Regulations&rdquo;
for details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we introduce new products to our customers,
we may be required to comply with additional laws and regulations that are yet to be determined. To comply with such additional
laws and regulations, we may be required to obtain necessary certificates, licenses or permits, as well as expend additional resources
to monitor regulatory and policy developments. Our failure to adequately comply with such additional laws and regulations may
delay, or possibly prevent, some of our products from being offered to customers, which may have a material adverse effect on
our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business is subject to inherent
risks relating to product liability and personal injury claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a manufacturer of products designed
for human consumption, we are subject to product liability claims if the use of our products is alleged to have resulted in injury.
For instance, adverse reactions resulting from human consumption of the ingredients contained in our products could occur. We
may also be obligated to recall affected products. If we are found liable for product liability claims, we could be required to
pay substantial monetary damages. Furthermore, even if we successfully defend ourselves against this type of claim, we could be
required to spend significant management, financial and other resources, which could disrupt our business, and our reputation
as well as our brand name may also suffer. We, like many other similar companies in China, do not carry product liability insurance.
As a result, any imposition of product liability could materially harm our business, financial condition and results of operations.
In addition, we do not have any business interruption insurance due to the limited coverage of any available business interruption
insurance in China, and as a result, any business disruption or natural disaster could severely disrupt our business and operations
and significantly decrease our revenue and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be successful in expanding
a distribution network. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we intend to expand our distribution
network including additional cities and rural areas in the PRC in an effort to increase our geographic appearance. Our distribution,
logistics and products may encounter various competition from similar or substitutive businesses. Therefore, the success of expansion
will depend upon many factors, including our ability to form relationships with, and manage an increasing number of, customers
base and optimize our distribution network. If we fail to expand our distribution network as planned, our business, financial
condition and results of operations may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on certain key
personnel and loss of these key personnel could have a material effect on our business, financial condition and results of operations.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our success is, to a certain extent, attributable
to the management, sales and marketing, and research and development expertise of key personnel. We are dependent upon the services
of Mr. Gang Lai, our chairman of the Board and our chief executive officer, for the continued growth and operation of the Company,
due to his industry experiences and management experiences. Although we have no reason to believe that Mr. Gang Lai will discontinue
his services with us, the interruption or loss of his services would adversely affect our ability to effectively run our business
and pursue our business strategy as well as our results of operation. There can be no assurance that we will be able to retain
them after the terms of their employment expire. The loss of these officers could have a material adverse effect upon our business,
financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not effectively manage our
growth, which could materially harm our business</I></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that our business will continue
to grow, which may place a significant strain on our management, personnel, systems and resources. We must continue to improve
our operational and financial systems and managerial controls and procedures, and we will need to continue to expand, train and
manage our technology and workforce. We must also maintain close coordination among our compliance, accounting finance, marketing
and sales organizations. We cannot assure you that we will manage our growth effectively. If we fail to do so, our business could
be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our continued growth will require an increased
investment by us in technology, facilities, personnel and financial and management systems and controls. It also will require
expansion of our procedures for monitoring and assuring our compliance with applicable regulations, and we will need to integrate,
train and manage a growing employee base. The expansion of our existing businesses, any expansion into new businesses and the
resulting growth of our employee base will increase our need for internal audit and monitoring processes that are more extensive
and broader in scope than those we have historically acquired. We may not be successful in identifying or implementing all of
the processes that are necessary. Further, unless our growth results in an increase in our revenues that is proportionate to the
increase in our costs associated with this growth, our operating margins and profitability will be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to hire and retain
qualified personnel to support our growth and if we are unable to retain and hire these personnel in the future, our ability to
improve our products and implement our business objects could be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must attract, recruit and retain a
sizeable workforce of technically competent employees. Competition for senior management and personnel in the PRC is intense and
the pool of qualified candidates in the PRC is very limited. We may not be able to retain the services of our senior executives
or personnel, or attract and retain high-quality senior executives or personnel in the future. This failure could materially and
adversely affect our future growth and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our success depends on our ability
to protect our intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently own 11 patents and 22 trademarks
in China. We believe that our success depends on our ability to obtain and maintain patent protection for products developed utilizing
our technologies, in the PRC and in other countries, and to enforce these patents. There is no assurance that any of our existing
and future patents will be held valid and enforceable against third-party infringement or that our products will not infringe
any third-party patent or intellectual property. Although we have filed additional patent applications with Patent Administration
Department of PRC, there is no assurance that they will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any patents relating to our technologies
may not be sufficiently broad to protect our products. In addition, our patents may be challenged, potentially invalidated or
potentially circumvented. Our patents may not afford us protection against competitors with similar technology or permit the commercialization
of our products without infringing third-party patents or other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on or intend to rely on our
trademarks, trade names and brand names to distinguish our products from the products of our competitors, and have registered
or will apply to register a number of these trademarks. However, third parties may oppose our trademark applications or otherwise
challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand
our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing
these new brands. Further, our competitors may infringe our trademarks, or we may not have adequate resources to enforce our trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we also have trade secrets,
non-patented proprietary expertise and continuing technological innovation that we shall seek to protect, in part, by entering
into confidentiality agreements with licensees, suppliers, employees and consultants. These agreements may be breached and there
may not be adequate remedies in the event of a breach. Disputes may arise concerning the ownership of intellectual property or
the applicability of confidentiality agreements. Moreover, our trade secrets and proprietary technology may otherwise become known
or be independently developed by our competitors. If patents are not issued with respect to products arising from research, we
may not be able to maintain the confidentiality of information relating to these products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we rely on our manufacturing
operations to produce a significant amount of the products we sell, disruptions in our manufacturing system or losses of manufacturing
certifications could adversely affect our sales and customer relationships. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our manufacturing operations produced
approximately 62.9% of the total value of the products we sold for the year ended September 30, 2019. Our products are produced
in our manufacturing facility located in Jinggangshan, Jiangxi Province, China. For the year ended September 30, 2019, one vendor
supplied more than 10% of our raw materials. In the event any of our third-party suppliers or vendors becomes unable or unwilling
to continue to provide raw materials in the required volumes or quality levels or in a timely manner, we would be required to
identify and obtain acceptable replacement supply sources. If we are unable to identity and obtain alternative supply sources,
our business could be adversely affected. Any significant disruption in our operations at our manufacturing facility for any reason,
including government-imposed regulatory requirements, the loss of certifications, power interruptions, fires, war, or other force
of nature, could disrupt our supply of products, adversely affecting our sales and customer relationships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face risks related to our sales
of products obtained from third-party suppliers. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell a significant number of products
that are manufactured by third-party suppliers over which we have no direct control. While we have implemented processes and procedures
to try to ensure that the suppliers we use are complying with all applicable regulations, there can be no assurances that such
suppliers in all instances will comply with such processes and procedures or otherwise with applicable regulations. Noncompliance
could result in our marketing and distribution of contaminated or dangerous products which would subject us to liabilities and
could result in the imposition by government authorities of penalties that could restrict or eliminate our ability to purchase
products. Any or all of these effects could adversely affect our business, financial condition and results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The growth of our business depends
on our ability to finance new product innovations and these increased costs may reduce our cash flows and, if the products in
which we have invested fail, it would reduce our profitability. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate in the Chinese patent medicine
industry, which is characterized by significant competition and rapid change. New products appear with increasing frequency to
supplant existing products. If we fail to adapt to those conditions in a timely and efficient manner, our revenues and profits
would likely decline. To remain competitive, we must continue to incur significant costs in product research and development,
marketing, equipment and facilities and to make capital investment. These costs may increase, resulting in greater fixed costs
and operating expenses. Our future operating results will depend to a significant extent on our ability to continue to provide
new products that compare favorably based on time to market, cost and performance with the design and manufacturing capabilities
and competing third-party suppliers and technologies. Our failure to increase our net sales sufficient to offset these increased
costs would reduce our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future acquisitions may have an
adverse effect on our ability to manage our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may acquire businesses, technologies,
services or products which are complementary to our core business of manufacturing and selling TCMD products. Future acquisitions
may expose us to potential risks, including risks associated with: the integration of new products, services and personnel; unforeseen
or hidden liabilities; the diversion of resources from our existing business; our potential inability to generate sufficient revenue
to offset new costs; the expenses of acquisitions; or the potential loss of or harm to relationships with both employees and advertising
clients resulting from our integration of new businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any of the potential risks listed above
could have a material and adverse effect on our ability to manage our business, our revenues and net income. We may need to raise
additional debt funding or sell additional equity securities to make such acquisitions. The raising of additional debt funding
by us, if required, would result in increased debt service obligations and could result in additional operating and financing
covenants, or liens on our assets, that would restrict our operations. The sale of additional equity securities could result in
additional dilution to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Increase in labor costs in the PRC
may adversely affect our business and our profitability. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">China&rsquo;s economy has experienced
increases in labor costs in recent years. China&rsquo;s overall economy and the average wage in China are expected to continue
to grow. The average wage level for our employees has also increased in recent years. We expect that our labor costs, including
wages and employee benefits, will continue to increase. Unless we are able to pass on these increased labor costs to our customers
by increasing prices for our products or services, our profitability and results of operations may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have been subject to stricter
regulatory requirements in terms of entering into labor contracts with our employees and paying various statutory employee benefits,
including pensions, housing fund, medical insurance, work-related injury insurance, unemployment insurance and childbearing insurance
to designated government agencies for the benefit of our employees. Pursuant to the PRC Labor Contract Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;)
(the &ldquo;Labor Contract Law&rdquo;) that became effective in January 2008 and its implementing rules that became effective
in September 2008 and its amendments that became effective in July 2013, employers are subject to stricter requirements in terms
of signing labor contracts, minimum wages, paying remuneration, determining the term of employees&rsquo; probation and unilaterally
terminating labor contracts. In the event that we decide to terminate some of our employees or otherwise change our employment
or labor practices, the Labor Contract Law and its implementation rules may limit our ability to effect those changes in a desirable
or cost-effective manner, which could adversely affect our business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the interpretation and implementation
of labor-related laws and regulations are still evolving, we cannot assure you that our employment practice does not and will
not violate labor-related laws and regulations in China, which may subject us to labor disputes or government investigations.
If we are deemed to have violated relevant labor laws and regulations, we could be required to provide additional compensation
to our employees and our business, financial condition and results of operations could be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The tariffs by the U.S. government
and the trade war between the U.S. and China, and on a larger scale, internationally, may dampen global growth. If the U.S. government,
in the future, subjects the services that we provide to tariffs, our business operations and revenues may be negatively impacted.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. government has recently, among
other actions, imposed new or higher tariffs on specified products imported from China to penalize China for what it characterizes
as unfair trade practices and China has responded by imposing new or higher tariffs on specified products imported from the United
States. Based on our analysis of the list of products affected by the tariffs, we expect that the tariffs will not have a material
direct impact on our business operations, as currently, we are based in the PRC, and sell products to customers exclusively located
within the PRC market. The imposed tariffs, however, may cause the depreciation of the RMB currency and a contraction of certain
PRC industries that will likely be affected by the tariffs. As such, there may be potential decrease in the spending powers of
advertising customers, which in turn, may lead to a contraction of the PRC advertising market. As such, we may have access to
fewer business opportunities and our operation may be negatively impacted. In addition, future actions or escalations by either
the United States or China that affect trade relations may cause global economic turmoil and potential have a negative impact
on our business and we cannot provide any assurance as to whether such actions will occur or the form that they may take.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Natural disasters (whether or not
caused by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts and global political events
could cause permanent or temporary distribution center or store closures, impair our ability to purchase, receive or replenish
inventory, or cause customer traffic to decline, all of which could result in lost sales and otherwise adversely affect our financial
performance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of one or more natural
disasters, such as hurricanes, fires, floods and earthquakes (whether or not caused by climate change), unusually adverse weather
conditions, pandemic outbreaks, terrorist acts or disruptive global political events, such as civil unrest in countries in which
our suppliers are located, or similar disruptions could adversely affect our operations and financial performance. To the extent
these events result in the closure of one or more of our distribution centers, a significant number of stores, a manufacturing
facility or our corporate headquarters, or impact one or more of our key suppliers, our operations and financial performance could
be materially adversely affected through an inability to make deliveries to our stores and through lost sales. In addition, these
events could result in increases in fuel (or other energy) prices or a fuel shortage, delays in opening new stores, the temporary
lack of an adequate work force in a market, the temporary or long-term disruption in the supply of products from some local and
overseas suppliers, the temporary disruption in the transport of goods from overseas, delay in the delivery of goods to our distribution
centers or stores, the temporary reduction in the availability of products in our stores and disruption to our information systems.
These events also could have indirect consequences, such as increases in the cost of insurance, if they were to result in significant
loss of property or other insurable damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The outbreak of the coronavirus
in China may have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business could be materially and adversely
affected by health epidemics such as the outbreak of the coronavirus disease 2019 (&ldquo;COVID-19&rdquo;) in China. The World
Health Organization has declared the COVID-19 outbreak a public health emergency of international concern. As this virus is transmitted
between humans, the Chinese government has imposed travel restrictions in certain parts of the country. The development of the
COVID-19 outbreak could materially disrupt our business and operations, slow down the overall economy, curtail consumer spending,
interrupt our sources of supply, and make it difficult to adequately staff our operations. As a result, our operating results,
financial conditions and cash flows could be materially adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the COVID-19 outbreak,
our factory was closed during the first two weeks of February 2020 at the mandate of the Chinese government and reopened in on
February 13, 2020. This impacted the manufacturing productivity of our factory, and therefore our inventory and sales to customers.
Our factory has been fully running as normal since March 2, 2020. We expect the negative impacts of the COVID-19 outbreak on our
manufacturing and sales to be temporary and our revenues to grow in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Doing Business in
China </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PRC regulation of loans to, and
direct investments in, PRC entities by offshore holding companies may delay or prevent us from using proceeds from this offering
and/or future financing activities to make loans or additional capital contributions to our PRC operating subsidiaries.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As an offshore holding company with PRC
subsidiaries, we may transfer funds to our PRC subsidiaries or finance our operating entity by means of loans or capital contributions.
Any capital contributions or loans that we, as an offshore entity, make to our Company&rsquo;s PRC subsidiaries, including from
the proceeds of this offering, are subject to PRC regulations. Any loans to our PRC subsidiaries, which are foreign-invested enterprises,
cannot exceed statutory limits based on the difference between the amount of our investments and registered capital in such subsidiaries,
and shall be registered with China&rsquo;s State Administration of Foreign Exchange (&ldquo;SAFE&rdquo;), or its local counterparts.
Furthermore, any capital increase contributions we make to our PRC subsidiaries, which are foreign-invested enterprises, are subject
to the requirement of making necessary filings in the Foreign Investment Comprehensive Management Information System, or FICMIS,
and registration with other government authorities in China. We may not be able to obtain these government registrations or approvals
on a timely basis, if at all. If we fail to obtain such approvals or make such registration, our ability to make equity contributions
or provide loans to our Company&rsquo;s PRC subsidiaries or to fund their operations may be negatively affected, which may adversely
affect their liquidity and ability to fund their working capital and expansion projects and meet their obligations and commitments.
As a result, our liquidity and our ability to fund and expand our business may be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We must remit the offering proceeds
to China before they may be used to benefit our business in China, and this process may take several months to complete. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proceeds of this offering must be
sent back to China, and the process for sending such proceeds back to China may take as long as six months after the closing of
this offering. In utilizing the proceeds of this offering in the manner described in &ldquo;Use of Proceeds,&rdquo; as an offshore
holding company of our PRC operating subsidiaries, we may make loans to our PRC subsidiaries, or we may make additional capital
contributions to our PRC subsidiaries. Any loans to our PRC subsidiaries are subject to PRC regulations. For example, loans by
us to our subsidiaries in China, which are foreign-invested enterprises, to finance their activities cannot exceed statutory limits
and must be registered with SAFE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To remit the proceeds of the offering,
we must take the following steps:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
    we will open a special foreign exchange account for capital account transactions. To open this account, we must submit to
    SAFE certain application forms, identity documents, transaction documents, form of foreign exchange registration of overseas
    investments of the domestic residents, and foreign exchange registration certificate of the invested company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
    we will remit the offering proceeds into this special foreign exchange account.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
    we will apply for settlement of the foreign exchange. In order to do so, we must submit to SAFE certain application forms,
    identity documents, payment order to a designated person, and a tax certificate.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timing of the process is difficult
to estimate because the efficiencies of different SAFE branches can vary significantly. Ordinarily the process takes several months
but is required by law to be accomplished within 180 days of application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also decide to finance our subsidiaries
by means of capital contributions. These capital contributions must be subject to the requirement of making necessary filings
in the FICMIS, and registration with other government authorities in China. We cannot assure you that we will be able to obtain
these government approvals on a timely basis, if at all, with respect to future capital contributions by us to our subsidiaries.
If we fail to receive such approvals, our ability to use the proceeds of this offering and to capitalize our Chinese operations
may be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business. If we
fail to receive such approvals, our ability to use the proceeds of this offering and to capitalize our Chinese operations may
be negatively affected, which could adversely affect our liquidity and our ability to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may rely on dividends paid by
our subsidiaries for our cash needs, and any limitation on the ability of our subsidiaries to make payments to us could have a
material adverse effect on our ability to conduct business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a holding company, we conduct substantially
all of our business through our consolidated subsidiaries incorporated in China. We may rely on dividends paid by these PRC subsidiaries
for our cash needs, including the funds necessary to pay any dividends and other cash distributions to our shareholders, to service
any debt we may incur and to pay our operating expenses. The payment of dividends by entities established in China is subject
to limitations. Regulations in China currently permit payment of dividends only out of accumulated profits as determined in accordance
with accounting standards and regulations in China. In accordance with the Article 166, 168 of the Company Law of the PRC (Amended
in 2018) (the &ldquo;PRC Company Law&rdquo;), each of our PRC subsidiaries is required to set aside at least 10% of its after-tax
profit based on PRC accounting standards each year to its general reserves or statutory capital reserve fund until the aggregate
amount of such reserves reaches 50% of its respective registered capital. A company may discontinue the contribution when the
aggregate sum of the statutory surplus reserve is more than 50% of its registered capital. The statutory common reserve fund of
a company shall be used to cover the losses of the company, expand the business and production of the company or be converted
into additional capital. As a result, our PRC subsidiaries are restricted in their ability to transfer a portion of their net
assets to us in the form of dividends. In addition, if any of our PRC subsidiaries incurs debt on its own behalf in the future,
the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Any limitations
on the ability of our PRC subsidiaries to transfer funds to us could materially and adversely limit our ability to grow, make
investments or acquisitions that could be beneficial to our business, pay dividends and otherwise fund and conduct our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Adverse changes in political, economic
and social conditions, as well as government policies in China could have a material adverse effect on our business results of
operations, financial conditions and prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all of our business operations
are conducted in China. Accordingly, our financial condition, results of operations and prospects are, to a material extent, subject
to economic, political and legal developments in China. The economy in China differs from the economies of developed countries
in many respects, including, among other things, the degree of government involvement, control of investment, level of economic
development, growth rate, foreign exchange controls and resource allocation. Although the economy in China has been transitioning
from a planned economy to a more market-oriented economy for about four decades, a substantial portion of productive assets in
China is still owned by the PRC government. The PRC government also exercises significant control over the economic growth of
China through allocating resources, controlling payments of foreign currency denominated obligations, setting monetary policy
and providing preferential treatment to particular industries or companies. In recent years, the PRC government has implemented
measures emphasizing the utilization of market forces in economic reform, the reduction of state ownership of productive assets
and the establishment of sound corporate governance practices in business enterprises. Some of these measures benefit the overall
economy in China, but may adversely affect us. For example, our financial condition and results of operations may be adversely
affected by government policies on the Chinese patent medicine industry in China or changes in tax regulations applicable to us.
If the business environment in China deteriorates, our business in China may also be materially and adversely affected.</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Uncertainties with respect to the
PRC legal system could adversely affect us. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conduct all of our business through
our subsidiaries in China. Our operations in China are governed by PRC laws and regulations. Our PRC subsidiaries are generally
subject to laws and regulations applicable to foreign investments in China and, in particular, laws and regulations applicable
to wholly foreign-owned enterprises. The PRC legal system is based on statutes. Prior court decisions may be cited for reference
but have limited precedential value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since 1979, PRC legislation and regulations
have significantly enhanced the protections afforded to various forms of foreign investments in China. However, China has not
developed a fully integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects of
economic activities in China. In particular, because these laws and regulations are relatively new, and because of the limited
volume of published decisions and their nonbinding nature, the interpretation and enforcement of these laws and regulations involve
uncertainties. In addition, the PRC legal system is based in part on government policies and internal rules (some of which are
not published on a timely basis or at all) that may have a retroactive effect. As a result, we may not be aware of our violation
of these policies and rules until sometime after the violation. In addition, any litigation in China may be protracted and result
in substantial costs and diversion of resources and management attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PRC regulation of loans and direct investment
by offshore holding companies to PRC entities may delay or prevent us from using the proceeds of this offering to make loans or
additional capital contributions to our PRC subsidiaries, which could materially and adversely affect our liquidity and our ability
to fund and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Labor Contract Law and other labor-related
laws in the PRC may adversely affect our business and our results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 28, 2012, the PRC government
released the revision of the Labor Contract Law, which became effective on July 1, 2013. Pursuant to the Labor Contract Law, employers
are subject to stricter requirements in terms of signing labor contracts, minimum wages, paying remuneration, determining the
term of employees&rsquo; probation and unilaterally terminating labor contracts. In the event that we decide to terminate some
of our employees or otherwise change our employment or labor practices, the Labor Contract Law and its implementation rules may
limit our ability to effect those changes in a desirable or cost-effective manner, which could adversely affect our business and
results of operations. According to the PRC Social Insurance Law (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#31038;&#20250;&#20445;&#38505;&#27861;&#12299;),
employees must participate in pension insurance, work-related injury insurance, medical insurance, unemployment insurance and
maternity insurance and the employers must, together with their employees or separately, pay the social insurance premiums for
such employees. As the interpretation and implementation of labor-related laws and regulations are still evolving, we cannot assure
you that our employment practices do not and will not violate labor-related laws and regulations in China, which may subject us
to labor disputes or government investigations. We cannot assure you that we have complied or will be able to comply with all
labor-related law and regulations regarding including those relating to obligations to make social insurance payments and contribute
to the housing provident fund. If we are deemed to have violated relevant labor laws and regulations, we could be required to
provide additional compensation to our employees and our business, financial condition and results of operations will be adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There are significant uncertainties
under the Enterprise Income Tax Law, or the EIT Law, relating to the withholding tax liabilities of our PRC subsidiaries, and
dividends payable by our PRC subsidiaries to our offshore subsidiaries may not qualify to enjoy certain treaty benefits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">China passed the EIT Law, and it is implementing
rules, both of which became effective on January 1, 2008. Under the PRC EIT Law and its implementation rules, the profits of an
FIE generated through operations, which are distributed to its immediate holding company outside the PRC, will be subject to a
withholding tax rate of 10%. Pursuant to a special arrangement between Hong Kong and the PRC, such rate may be reduced to 5% if
a Hong Kong resident enterprise owns more than 25% of the equity interest in the PRC company. Our PRC subsidiaries, Universe Technology,
Jiangxi Universe and Universe Trade, are wholly-owned by our Hong Kong subsidiary. Moreover, under the Notice of the State Administration
of Taxation on Issues regarding the Administration of the Dividend Provision in Tax Treaties promulgated on February 20, 2009,
the tax payer needs to satisfy certain conditions to enjoy the benefits under a tax treaty. The beneficial owner of the relevant
dividends and the corporate shareholder to receive dividends from the PRC subsidiary must have continuously met the direct ownership
thresholds during the 12 consecutive months preceding the receipt of the dividends. Further, the State Administration of Taxation
promulgated the Notice on How to Comprehend and Determine the &ldquo;Beneficial Owner&rdquo; in Tax Treaties (&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&rdquo;&#21463;&#30410;&#25152;&#26377;&#20154;&rdquo;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
on February 3, 2018, which limits the &ldquo;beneficial owner&rdquo; to individuals, projects or other organizations normally
engaged in substantive operations, and sets forth certain detailed factors in determining the &ldquo;beneficial owner&rdquo; status.
In current practice, a Hong Kong enterprise must obtain a tax resident certificate from the relevant Hong Kong tax authority to
apply for the 5% lower PRC withholding tax rate. As the Hong Kong tax authority will issue such a tax resident certificate on
a case-by-case basis, we cannot assure you that we will be able to obtain the tax resident certificate from the relevant Hong
Kong tax authority. As of the date of this prospectus, we have not commenced the application process for a Hong Kong tax resident
certificate from the relevant Hong Kong tax authority, and there is no assurance that we will be granted such a Hong Kong tax
resident certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after we obtain the Hong Kong tax
resident certificate, we are required by applicable tax laws and regulations to file required forms and materials with relevant
PRC tax authorities to prove that we can enjoy 5% lower PRC withholding tax rate. Universe HK intends to obtain the required materials
and file with the relevant tax authorities when it plans to declare and pay dividends, but there is no assurance that the PRC
tax authorities will approve the 5% withholding tax rate on dividends received from Universe HK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify"><B><I>Failure to qualify for or obtain
any preferential tax treatments that are available in China could adversely affect our results of operations and financial condition.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">The EIT Law and its implementation
rules generally impose a uniform income tax rate of 25% on all enterprises, but grant preferential treatment to &ldquo;high and
new technology enterprises strongly supported by the state,&rdquo; or HNTEs, with a preferential enterprise tax rate of 15%. Our
subsidiary Jiangxi Universe is currently accredited as an HNTE. According to the relevant administrative measures, to qualify
as an &ldquo;HNTE,&rdquo; Jiangxi Universe must meet certain financial and non-financial criteria and complete verification procedures
with the administrative authorities. Continued qualification as an HNTE is subject to review by the relevant government authorities
in China every three years, and in practice, certain local tax authorities may require annual evaluation of the qualification.
In the event that Jiangxi Universe fails to renew its status as&nbsp;HNTE&nbsp;with the local tax authority, it will be subject
to the standard PRC enterprise income tax rate of 25%.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify"><B><I>Under the EIT Law, we may be
classified as a &ldquo;Resident Enterprise&rdquo; of China. Such classification will likely result in unfavorable tax consequences
to us and our non-PRC shareholders. </I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">The EIT Law and its implementing rules
became effective on December 9, 2019. Under the EIT Law, an enterprise established outside of China with &ldquo;de facto management
bodies&rdquo; within China is considered a &ldquo;resident enterprise&rdquo; meaning that it can be treated in a manner similar
to a Chinese enterprise for enterprise income tax purposes. The implementing rules of the EIT Law define de facto management as
&ldquo;substantial and overall management and control over the production and operations, personnel, accounting, and properties&rdquo;
of the enterprise.&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">If the PRC tax authorities determine
that we are a &ldquo;resident enterprise&rdquo; for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences
could follow. First, we may be subject to the enterprise income tax at a rate of 25% on our worldwide taxable income as well as
PRC enterprise income tax reporting obligations. In our case, this would mean that income such as non-China source income would
be subject to PRC enterprise income tax at a rate of 25%. Currently, we do not have any non-China source income, as we conduct
our sales in China. Second, under the EIT Law and its implementing rules, dividends paid to us from our PRC subsidiaries would
be deemed as &ldquo;qualified investment income between resident enterprises&rdquo; and therefore qualify as &ldquo;tax-exempt
income&rdquo; pursuant to the clause 26 of the EIT Law. Finally, it is possible that future guidance issued with respect to the
new &ldquo;resident enterprise&rdquo; classification could result in a situation in which the dividends we pay with respect to
our Ordinary Shares, or the gain our non-PRC shareholders may realize from the transfer of our Ordinary Shares, may be treated
as PRC-sourced income and may therefore be subject to a 10% PRC withholding tax. The EIT Law and its implementing regulations
are, however, relatively new and ambiguities exist with respect to the interpretation and identification of PRC-sourced income,
and the application and assessment of withholding taxes. If we are required under the EIT Law and its implementing regulations
to withhold PRC income tax on dividends payable to our non-PRC shareholders, or if non-PRC shareholders are required to pay PRC
income tax on gains on the transfer of their Ordinary Shares, our business could be negatively impacted and the value of your
investment may be materially reduced. Further, if we were treated as a &ldquo;resident enterprise&rdquo; by PRC tax authorities,
we would be subject to taxation in both China and such countries in which we have taxable income, and our PRC tax may not be creditable
against such other taxes.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify"><B><I>We may be exposed to liabilities
under the Foreign Corrupt Practices Act and Chinese anti-corruption law. </I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">In connection with this offering,
we will become subject to the U.S. Foreign Corrupt Practices Act (the &ldquo;FCPA&rdquo;), and other laws that prohibit improper
payments or offers of payments to foreign governments and their officials and political parties by U.S. persons and issuers as
defined by the statute for the purpose of obtaining or retaining business. We are also subject to Chinese anti-corruption laws,
which strictly prohibit the payment of bribes to government officials. We have operations, agreements with third parties, and
make sales in China, which may experience corruption. Our activities in China create the risk of unauthorized payments or offers
of payments by one of the employees of our Company, because these parties are not always subject to our control.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">Although we believe to date we have
complied in all material respects with the provisions of the FCPA and Chinese anti-corruption law, our existing safeguards and
any future improvements may prove to be less than effective, and the employees of our Company may engage in conduct for which
we might be held responsible. Violations of the FCPA or Chinese anti-corruption law may result in severe criminal or civil sanctions,
and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.
In addition, the government may seek to hold our Company liable for successor liability FCPA violations committed by companies
in which we invest or that we acquire.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify"><B><I>The enforcement of stricter
advertisement laws and regulations in the PRC may adversely affect our business and our profitability.</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">In October 2018, the Standing Committee
of the National People&rsquo;s Congress (the &ldquo;SCNPC&rdquo;) promulgated the PRC Advertising Law, effective on October 26,
2018. According to the Advertising Law, advertisements shall not have any false or misleading content, or defraud or mislead consumers.
Furthermore, an advertisement will be deemed as a &ldquo;false advertisement&rdquo; if any of the following situations exist:
(i) the advertised product or service does not exist; (ii) there is any inconsistency that has a material impact on the decision
to purchase in what is included in the advertisement with the actual circumstances with respect to the product&rsquo;s performance,
functions, place of production, uses, quality, specification, ingredient, price, producer, term of validity, sales condition,
and honors received, among others, or the service&rsquo;s contents, provider, form, quality, price, sales condition, and honors
received, among others, or any commitments, among others, made on the product or service; (iii) fabricated, forged or unverifiable
scientific research results, statistical data, investigation results, excerpts, quotations, or other information have been used
as supporting material; (iv) effect or results of using the good or receiving the service are fabricated; or (v) other circumstances
where consumers are defrauded or misled by any false or misleading content.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 8pt; text-align: justify">Our current marketing relies on advertisements
on media platforms. The laws and regulations of advertising are relatively new and evolving and there is substantial uncertainty
as to the interpretation of &ldquo;false advertisement&rdquo; by the State Administration for Industry and Commerce (the &ldquo;SAIC&rdquo;).
If any of the advertisements published by our customers is deemed to be a &ldquo;false advertisement&rdquo; by the SAIC or its
local branch, we could be subject to various penalties, such as discontinuation of publishing the target advertisement, imposition
of fines and obligations to eliminate any adverse effects incurred by such&nbsp;false advertisement. Any such penalties may disrupt
our business and our competition with competitors, which could affect our results of operations and financial conditions.&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We were not in compliance with the PRC&rsquo;s
regulations relating to employee&rsquo;s social insurance and housing funds prior to April 2020, and as a result, we may be subject
to penalties for such non-compliance.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Pursuant to the Social Insurance Law of
the PRC (the &ldquo;Social Insurance Law&rdquo;), which was promulgated by the SCNPC on October 28, 2010 and amended on December
29, 2018, and the Administrative Regulations on the Housing Provident Funds, which was promulgated by the State Council on April
3, 1999 and last amended on March 24, 2019, employers are required to make contributions, on behalf of their employees, to a number
of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational
injury insurance, maternity insurance and to housing provident funds. Prior to April 2020, we only contributed to the social insurance
and housing provident funds for some, but not all, of our employees. Since April 2020, we have started contributing to the social
insurance and housing funds for our eligible full-time employees in accordance with the aforementioned PRC laws and regulations.
Even though we are currently making contributions in accordance with applicable PRC laws, there is a risk that the labor security
administration authority may take enforcement action to collect from us all the outstanding contributions of the social insurance
and housing provident funds required to be made for the employees in the past, and we may be subject to a late charge at the rate
of 0.05% per day on the total outstanding contribution. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>U.S. regulatory bodies may be limited
in their ability to conduct investigations or inspections of our operations in China.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Securities and Exchange Commission
(the &ldquo;SEC&rdquo;), the U.S. Department of Justice and other U.S. authorities may also have difficulties in bringing and
enforcing actions against us or our directors or executive officers in the PRC. The SEC has stated that there are significant
legal and other obstacles to obtaining information needed for investigations or litigation in China. China has recently adopted
a revised securities law that became effective on March 1, 2020, Article 177 of which provides, among other things, that no overseas
securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the
PRC. Accordingly, without governmental approval in China, no entity or individual in China may provide documents and information
relating to securities business activities to overseas regulators when it is under direct investigation or evidence discovery
conducted by overseas regulators, which could present significant legal and other obstacles to obtaining information needed for
investigations and litigation conducted outside of China. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>You may experience difficulty in
effecting service of process, enforcing foreign judgments or bringing actions against our directors and officers. </I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are a Cayman Islands exempted company
with limited liability and most of our assets are located outside of the United States. In addition, all of our directors and
executive officers are residents of the PRC, and substantially all of their assets and our assets are located in the PRC. As a
result, it may be difficult or impossible for you to effect service of process within the United States upon our directors and
executive officers. It may also be difficult for you to enforce in the United States courts judgments obtained in the United States
courts based on the civil liability provisions of the United States federal securities laws against us and our officers and directors
who reside and whose assets are located outside the United States.&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In addition, there is uncertainty as to
whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of the United States courts against us
or such persons predicated upon the civil liability provisions of the securities laws of the United States or any state. The recognition
and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce
foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and
the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties
or other forms of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign judgments.
In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors
and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty, security or public
interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the
United States. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp;<B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Further, pursuant to the PRC Civil Procedures
Law, any matter, including matters arising under U.S. federal securities laws, in relation to assets or personal relationships
may be brought as an original action in China, only if the institution of such action satisfies the conditions specified in the
PRC Civil Procedures Law. As a result of the conditions set forth in the PRC Civil Procedures Law and the discretion of the PRC
courts to determine whether the conditions are satisfied and whether to accept the action for adjudication, there remains uncertainty
as to whether an investor will be able to bring an original action in a PRC court based on U.S. federal securities laws. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because our business is conducted
in the RMB and the price of our Ordinary Shares is quoted in United States dollars, changes in currency conversion rates may affect
the value of your investments.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is conducted in the PRC,
our books and records are maintained in the RMB, the legal currency of the PRC, and the financial statements that we file with
the SEC and provide to our shareholders are presented in United States dollars. Changes in the exchange rate between the RMB and
dollar affect the value of our assets and the results of our operations in United States dollars. The value of the RMB against
the United States dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC&rsquo;s
political and economic conditions and perceived changes in the economy of the PRC and the United States. Any significant revaluation
of the RMB may materially and adversely affect our cash flows, revenue and financial condition. Further, our Ordinary Shares offered
by this prospectus are offered in United States dollars, we will need to convert the net proceeds we receive into RMB in order
to use the funds for our business. Changes in the conversion rate between the United States dollar and the RMB will affect that
amount of proceeds we will have available for our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Government control in currency conversion
may adversely affect our financial condition and ability to remit dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, the RMB cannot be freely converted
into any foreign currency, and conversion and remittance of foreign currencies are subject to PRC foreign exchange regulations.
It cannot be guaranteed that under a certain exchange rate, we will have sufficient foreign exchange to meet our foreign exchange
requirements. Under the current PRC foreign exchange control system, foreign exchange transactions under the current account conducted
by us, including the payment of dividends, do not require advance approval from SAFE, but we are required to present documentary
evidence of such transactions and conduct such transactions at designated foreign exchange banks within China that have the licenses
to carry out foreign exchange business. Foreign exchange transactions under the capital account conducted by us, however, must
be approved in advance by SAFE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under existing foreign exchange regulations,
following the completion of this offering, we will be able to pay dividends in foreign currencies without prior approval from
SAFE by complying with certain procedural requirements. However, we cannot assure you that these foreign exchange policies regarding
payment of dividends in foreign currencies will continue in the future. In addition, any insufficiency of foreign exchange may
restrict our ability to obtain sufficient foreign exchange for dividend payments to shareholders or to satisfy any other foreign
exchange requirements. If we fail to obtain approval from SAFE to convert the RMB into any foreign exchange for any of the above
purposes, our capital expenditure plans, and even our business, operating results and financial condition, may be materially and
adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business may be materially and
adversely affected if any of our PRC subsidiaries declare bankruptcy or become subject a dissolution or liquidation proceeding.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Enterprise Bankruptcy Law of the PRC,
or the Bankruptcy Law, came into effect on June 1, 2007. The Bankruptcy Law provides that an enterprise will be liquidated if
the enterprise fails to settle its debts as and when they fall due and if the enterprise&rsquo;s assets are, or are demonstrably,
insufficient to clear such debts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our PRC subsidiaries hold certain assets
that are important to our business operations. If any of our PRC subsidiaries undergoes a voluntary or involuntary liquidation
proceeding, unrelated third-party creditors may claim rights to some or all of these assets, thereby hindering our ability to
operate our business, which could materially and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to SAFE&rsquo;s Notice of the
State Administration of Foreign Exchange on Further Improving and Adjusting Foreign Exchange Administration Policies for Direct
Investment, effective on December 17, 2012, and the Provisions for Administration of Foreign Exchange Relating to Inbound Direct
Investment by Foreign Investors, effective May 13, 2013, if any of our PRC subsidiaries undergoes a voluntary or involuntary liquidation
proceeding, prior approval from SAFE for remittance of foreign exchange to our shareholders abroad is no longer required, but
we still need to conduct a registration process with the SAFE local branch. It is not clear whether &ldquo;registration&rdquo;
is a mere formality or involves the kind of substantive review process undertaken by SAFE and its relevant branches in the past.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Our current corporate structure and
business operations may be affected by the newly enacted PRC Foreign Investment Law.</I></B> <B><I> </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On March 15, 2019, the National People&rsquo;s
Congress approved the Foreign Investment Law, which became effective on January 1, 2020. The PRC Foreign Investment Law defines
the &ldquo;foreign investment&rdquo; as the investment activities in China conducted directly or indirectly by foreign investors
in the following manners: (i) the foreign investor, by itself or together with other investors establishes a foreign invested
enterprises in China; (ii) the foreign investor acquires shares, equities, asset tranches, or similar rights and interests of
enterprises in China; (iii) the foreign investor, by itself or together with other investors, invests and establishes new projects
in China; (iv) the foreign investor invests through other approaches as stipulated by laws, administrative regulations or otherwise
regulated by the State Council. If our PRC subsidiaries are recognized as &ldquo;foreign investment enterprises,&rdquo; PRC governmental
authorities will regulate foreign investment by applying the principle of re-entry national treatment together with a &ldquo;negative
list,&rdquo; which will be promulgated by or promulgated with approval by the State Council. Foreign investors are prohibited
from making any investments in the industries which are listed as &ldquo;prohibited&rdquo; in such negative list; and, after satisfying
certain additional requirements and conditions as set forth in the &ldquo;negative list,&rdquo; are allowed to make investments
in industries which are listed as &ldquo;restricted&rdquo; in such negative list. For any foreign investor that fails to comply
with the negative list, the competent authorities are entitled to ban its investment activities, require such investor to take
measures to correct its non-compliance and impose other penalties. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Pharmaceutical production and distribution
activities that we conduct through our PRC subsidiaries are not subject to foreign investment restrictions or prohibitions set
forth in the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2019) (the &ldquo;2019
Negative List&rdquo;). We do not intend to conduct any types of business activities restricted or prohibited under the 2019 Negative
List in the future. However, it is unclear whether any updated &ldquo;negative list&rdquo; to be published by the State Council
in the future will be different from the 2019 Negative List. If future laws, administrative regulations or provisions of the State
Council set forth restrictions or prohibitions on foreign investment in our current business activities, and that our PRC subsidiaries
are recognized as &ldquo;foreign investment enterprises,&rdquo; we may be required to take appropriate and timely measures to
comply with such regulatory requirements. If we fail to do so, our business operations could be materially and adversely affected. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;<B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with PRC regulations
relating to the establishment of offshore special purpose companies by PRC residents may subject our PRC resident shareholders
to personal liability, may limit our ability to acquire PRC companies or to inject capital into our PRC subsidiaries, may limit
the ability of our PRC subsidiaries to distribute profits to us or may otherwise materially and adversely affect us</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Circular on relevant issues
concerning Foreign Exchange Administration of Overseas Investment and Financing and Return Investments Conducted by Domestic Residents
through Overseas Special Purpose Vehicle (&#12298;&#20851;&#20110;&#22659;&#20869;&#23621;&#27665;&#36890;&#36807;&#29305;&#27530;&#30446;&#30340;&#20844;&#21496;&#22659;&#22806;&#25237;&#34701;&#36164;&#21450;&#36820;&#31243;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;)
(the &ldquo;Circular 37&rdquo;), which was promulgated by SAFE, and became effective on July 4, 2014, (1) a PRC resident must
register with the local SAFE branch before he or she contributes assets or equity interests in an overseas special purpose vehicle,
or an Overseas SPV, that is directly established or indirectly controlled by the PRC resident for the purpose of conducting investment
or financing; and (2) following the initial registration, the PRC resident is also required to register with the local SAFE branch
for any major change, in respect of the Overseas SPV, including, among other things, a change in the Overseas SPV&rsquo;s PRC
resident shareholder, name of the Overseas SPV, term of operation, or any increase or reduction of the contributions by the PRC
resident, share transfer or swap, and merger or division. Additionally, pursuant to the Circular of SAFE on Further Simplifying
and Improving the Direct Investment-related Foreign Exchange Administration Policies (&#12298;&#20851;&#20110;&#36827;&#19968;&#27493;&#31616;&#21270;&#21644;&#25913;&#36827;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;)
(the &ldquo;Circular 13&rdquo;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the aforesaid
registration shall be directly reviewed and handled by qualified banks in accordance with the Circular 13, and SAFE and its branches
shall perform indirect regulation over the foreign exchange registration via qualified banks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> As confirmed by our PRC counsel, Mr.
Gang Lai completed the initial foreign exchange registration on June 3, 2019. As it remains unclear how Circular 37 and Circular
13 will be interpreted and implemented, and how or whether SAFE will apply them to us. Therefore, we cannot predict how they will
affect our business operations or future strategies. For example, the ability of our present and prospective PRC subsidiaries
to conduct foreign exchange activities, such as the remittance of dividends and foreign currency-denominated borrowings, may be
subject to compliance with Circular 37 and Circular 13 by our PRC resident beneficial holders. In addition, as we have little
control over either our present or prospective, direct or indirect Shareholders or the outcome of such registration procedures,
we cannot assure you that these Shareholders who are PRC residents will amend or update their registration as required under Circular
37 and Circular 13 in a timely manner or at all. Failure of our present or future shareholders who are PRC residents to comply
with Circular 37 and Circular 13 could subject these shareholders to fines or legal sanctions, restrict our overseas or cross-border
investment activities, limit the ability of our PRC subsidiaries to make distributions or pay dividends or affect our ownership
structure, which could adversely affect our business and prospects. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to complete a business
combination transaction efficiently or on favorable terms due to complicated merger and acquisition regulations and certain other
PRC regulations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2006, six PRC regulatory
authorities, including the MOFCOM, the State Assets Supervision and Administration Commission, the State Administration of Taxation
(the &ldquo;SAT&rdquo;), the SAIC, the China Securities Regulatory Commission (the &ldquo;CSRC&rdquo;) and the SAFE, jointly issued
the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors (&#12298;&#20851;&#20110;&#22806;&#22269;&#25237;&#36164;&#32773;&#24182;&#36141;&#22659;&#20869;&#20225;&#19994;&#30340;&#35268;&#23450;&#12299;)
(the &ldquo;M&amp;A Rules&rdquo;), which became effective on September 8, 2006 and was amended in June 2009. The M&amp;A Rules,
governing the approval process by which a PRC company may participate in an acquisition of assets or equity interests by foreign
investors, requires the PRC parties to make a series of applications and supplemental applications to the government agencies,
depending on the structure of the transaction. In some instances, the application process may require presentation of economic
data concerning a transaction, including appraisals of the target business and evaluations of the acquirer, which are designed
to allow the government to assess the transaction. Accordingly, due to the M&amp;A Rules, our ability to engage in business combination
transactions has become significantly more complicated, time-consuming and expensive, and we may not be able to negotiate a transaction
that is acceptable to our Shareholders or sufficiently protect their interests in a transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The M&amp;A Rules allow PRC government
agencies to assess the economic terms of a business combination transaction. Parties to a business combination transaction may
have to submit to the MOFCOM and other relevant government agencies an appraisal report, an evaluation report and the acquisition
agreement, all of which form part of the application for approval, depending on the structure of the transaction. The M&amp;A
Rules also prohibit a transaction at an acquisition price obviously lower than the appraised value of the business or assets in
China and in certain transaction structures, require that consideration must be paid within defined periods, generally not in
excess of a year. In addition, the M&amp;A Rules also limit our ability to negotiate various terms of the acquisition, including
aspects of the initial consideration, contingent consideration, holdback provisions, indemnification provisions and provisions
relating to the assumption and allocation of assets and liabilities. Transaction structures involving trusts, nominees and similar
entities are prohibited. Therefore, such regulation may impede our ability to negotiate and complete a business combination transaction
on legal and/or financial terms that satisfy our investors and protect our shareholders&rsquo; economic interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We face uncertainties with respect
to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SAT released a circular on December
15, 2009 that addresses the transfer of shares by nonresident companies, generally referred to as Circular 698. Circular 698,
which became effective retroactively to January 1, 2008, may have a significant impact on many companies that use offshore holding
companies to invest in China. Circular 698 has the effect of taxing foreign companies on gains derived from the indirect sale
of a PRC company. Where a foreign investor indirectly transfers equity interests in a PRC resident enterprise by selling the shares
in an offshore holding company, and the latter is located in a country or jurisdiction that has an effective tax rate less than
12.5% or does not tax foreign income of its residents, the foreign investor must report this indirect transfer to the tax authority
in charge of that PRC resident enterprise. Using a &ldquo;substance over form&rdquo; principle, the PRC tax authority may disregard
the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose
of avoiding PRC tax. As a result, gains derived from such indirect transfer may be subject to PRC withholding tax at a rate of
up to 10.0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAT subsequently released public notices
to clarify issues relating to Circular 698, including the Announcement on Several Issues concerning the EIT on the Indirect Transfers
of Properties by Nonresident Enterprises (&#12298;&#20851;&#20110;&#38750;&#23621;&#27665;&#20225;&#19994;&#38388;&#25509;&#36716;&#35753;&#36130;&#20135;&#20225;&#19994;&#25152;&#24471;&#31246;&#33509;&#24178;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
(the &ldquo;SAT Notice 7&rdquo;), which became effective on February 3, 2015. SAT Notice 7 abolished the compulsive reporting
obligations originally set out in Circular 698. Under SAT Notice 7, if a non-resident enterprise transfers its shares in an overseas
holding company, which directly or indirectly owns PRC taxable properties, including shares in a PRC company, via an arrangement
without reasonable commercial purpose, such transfer shall be deemed as indirect transfer of the underlying PRC taxable properties.
Accordingly, the transferee shall be deemed as a withholding agent with the obligation to withhold and remit the EIT to the competent
PRC tax authorities. Factors that may be taken into consideration when determining whether there is a &ldquo;reasonable commercial
purpose&rdquo; include, among other factors, the economic essence of the transferred shares, the economic essence of the assets
held by the overseas holding company, the taxability of the transaction in offshore jurisdictions, and economic essence and duration
of the offshore structure. SAT Notice 7 also sets out safe harbors for the &ldquo;reasonable commercial purpose&rdquo; test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 17, 2017, the SAT released
the Notice on Several Issues concerning the Withholding and Collection of Income Tax of Non-resident Enterprises from the Source
(&#12298;&#20851;&#20110;&#38750;&#23621;&#27665;&#20225;&#19994;&#25152;&#24471;&#31246;&#28304;&#27849;&#25187;&#32564;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;)
(the &ldquo;SAT Notice 37&rdquo;). SAT Notice 37 clarifies: (1) matters concerning the withholding and collection of corporate
income tax, and property transfer of non-resident enterprises based on the EIT Law; (2) the currencies required to be used by
the withholding agents (when the payments is made in a currency rather than RMB), as well as the time, venue and business for
the performance of the withholding and collection obligations; and (3) the abolishment of Circular 698.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is little guidance and practical
experience regarding the application of SAT Notice 7 and SAT Notice 37 and the related SAT notices. Moreover, the relevant authority
has not yet promulgated any formal provisions or formally declared or stated how to calculate the effective tax rates in foreign
tax jurisdictions. As a result, due to our complex offshore restructuring, we may become at risk of being taxed under SAT Notice
7 and SAT Notice 37 and we may be required to expend valuable resources to comply with SAT Notice 7 and SAT Notice 37 or to establish
that we should not be taxed under SAT Notice 7 and SAT Notice 37, which could have a material adverse effect on our financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Offering and our
Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The initial public offering price
of our Ordinary Shares may not be indicative of the market price of our Ordinary Shares after this offering. In addition, an active,
liquid and orderly trading market for our Ordinary Shares may not develop or be maintained, and our share price may be volatile.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, our Ordinary Shares
were not traded on any market. Any active, liquid and orderly trading market for our Ordinary Shares may not develop or be maintained
after this offering. Active, liquid and orderly trading markets usually result in less price volatility and more efficiency in
carrying out investors&rsquo; purchase and sale orders. The market price of our Ordinary Shares could vary significantly as a
result of a number of factors, some of which are beyond our control. In the event of a drop in the market price of our Ordinary
Shares, you could lose a substantial part or all of your investment in our Ordinary Shares. The initial public offering price
will be determined by us, based on numerous factors and may not be indicative of the market price of our Ordinary Shares after
this offering. Consequently, you may not be able to sell our Ordinary Shares at a price equal to or greater than the price paid
by you in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following factors could affect our
share price:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating and financial performance; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quarterly
    variations in the rate of growth of our financial indicators, such as net income per share, net income and revenues;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    public reaction to our press releases, our other public announcements and our filings with the SEC;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">strategic
    actions by our competitors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in revenue or earnings estimates, or changes in recommendations or withdrawal of research coverage, by equity research analysts;
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    failure of research analysts to cover our Ordinary Shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our Ordinary Shares by us or other shareholders, or the perception that such sales may occur;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles, policies, guidance, interpretations or standards;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key management personnel;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    by our shareholders;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">domestic
    and international economic, legal and regulatory factors unrelated to our performance; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    realization of any risks described under this &ldquo;Risk Factors&rdquo; section.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The stock markets in general have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations
may adversely affect the trading price of our Ordinary Shares. Securities class action litigation has often been instituted against
companies following periods of volatility in the overall market and in the market price of a company&rsquo;s securities. Such
litigation, if instituted against us, could result in very substantial costs, diver our management&rsquo;s attention and resources
and harm our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may not be an active, liquid
trading market for our Ordinary Shares</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been
no public market for our Ordinary Shares. An active trading market for our Ordinary Shares may not develop or be sustained following
this offering. You may not be able to sell your shares at the market price, if at all, if trading in our shares is not active.
The initial public offering price was determined by negotiations between us and our advisors based upon a number of factors. The
initial public offering price may not be indicative of prices that will prevail in the trading market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You will experience immediate and
substantial dilution</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
initial public offering price of our shares is substantially higher than the pro forma net tangible book value per share of our
Ordinary Shares. Assuming the completion of the offering, if you purchase shares in this offering, you will incur immediate dilution
of approximately $[</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">] per share or approximately [</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">]%
from the offering price of $[</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">] per share, and after deducting
the underwriting discounts, non-accountable expense allowance and estimated offering expenses payable by us. Accordingly, if you
purchase shares in this offering, you will incur immediate and substantial dilution of your investment. See &ldquo;Dilution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Shares eligible for future sale
may adversely affect the market price of our Ordinary Shares if the shares are successfully listed on [New York Stock Exchange/Nasdaq
Capital Market] or other stock markets, as the future sale of a substantial amount of outstanding Ordinary Shares in the public
marketplace could reduce the price of our Ordinary Shares. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
market price of our shares could decline as a result of sales of substantial amounts of our shares in the public market, or the
perception that these sales could occur. In addition, these factors could make it more difficult for us to raise funds through
future offerings of our Ordinary Shares. An aggregate of [</FONT>&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">]
shares will be outstanding before the consummation of this offering all of which, except those held by management, are or will
be freely tradable immediately upon effectiveness of this registration statement. All of the shares sold in the offering will
be freely transferable without restriction or further registration under the Securities Act. The remaining shares will be &ldquo;restricted
securities&rdquo; as defined in Rule 144. These shares may be sold without registration under the Securities Act to the extent
permitted by Rule 144 or other exemptions under the Securities Act. See &ldquo;Shares Eligible for Future Sale.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are a &ldquo;controlled company&rdquo;
within the meaning of the [NYSE listing rules/Nasdaq Stock Market Rules] and, as a result, may rely on exemptions from certain
corporate governance requirements that provide protection to shareholders of other companies.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a &ldquo;controlled company&rdquo;
as defined under [Rule 5615(c)(1) of the Nasdaq Marketplace Rules/ NYSE Listed Company Manual 303A.00] because Mr. Gang Lai holds
more than 50% of our voting power, and we expect we will continue to be a controlled company upon completion of this offering.
For so long as we remain a controlled company under that definition, we are permitted to elect to rely, and may rely, on certain
exemptions from the obligation to comply with certain corporate governance requirements, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that our director nominees must be selected or recommended solely by independent directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that we have a corporate governance and nominating committee that is composed entirely of independent directors
    with a written charter addressing the committee&rsquo;s purpose and responsibilities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, you will not have the same
protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of the [NYSE
listing rules/NASDAQ Stock Market Rules], if we utilize such exemptions. We currently do not intend to utilize the controlled
company exemptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A sale or perceived sale of a substantial
number of our Ordinary Shares may cause the price of our Ordinary Shares to decline. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our shareholders sell substantial amounts
of our Ordinary Shares in the public market, the market price of our Ordinary Shares could fall. Moreover, the perceived risk
of this potential dilution could cause shareholders to attempt to sell their shares and investors to short our ordinary shares.
These sales also make it more difficult for us to sell equity-related securities in the future at a time and price that we deem
reasonable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay dividends
for the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to retain any further
earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable
future. As a result, you may only receive a return on your investment in our Ordinary Shares if we are successfully listed and
the market price of our Ordinary Shares increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur substantial increased
costs as a result of being a public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of this offering, we
will incur significant legal, accounting and other expenses as a public company that we did not incur as a private company. The
Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and[the New York Stock Exchange/Nasdaq], impose
various requirements on the corporate governance practices of public companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with these rules and regulations
increases our legal and financial compliance costs and makes some corporate activities more time-consuming and costlier. We have
incurred additional costs in obtaining director and officer liability insurance. In addition, we incur additional costs associated
with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our
board of directors or as executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
as defined in the JOBS Act and will remain an emerging growth company until the earlier of (1) the last day of the fiscal year
(a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at
least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Ordinary
Shares that is held by non-affiliates exceeds $700 million as of the prior March 31, and (2) the date on which we have issued
more than $1.0 billion in non-convertible debt during the prior three-year period. An emerging growth company may take advantage
of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions
include exemption from the auditor attestation requirement under Section 404 in the assessment of the emerging growth company&rsquo;s
internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time
as those standards apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After we are no longer an &ldquo;emerging
growth company,&rdquo; or until five years following the completion of our initial public offering, whichever is earlier, we expect
to incur significant additional expenses and devote substantial management effort toward ensuring compliance with the requirements
of Section 404 and the other rules and regulations of the SEC. For example, as a public company, we have been required to increase
the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently evaluating and monitoring
developments with respect to these rules and regulations, and we cannot predict or estimate with any degree of certainty the amount
of additional costs we may incur or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There can be no assurance that we
will not be a passive foreign investment company (&ldquo;PFIC&rdquo;) for United States federal income tax purposes for any taxable
year, which could subject United States holders of our Ordinary Shares could be subject to adverse United States federal income
tax consequences. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-United States corporation will be
a passive foreign investment company, or PFIC, for United States federal income tax purposes for any taxable year if either (i)
at least 75% of its gross income for such taxable year is passive income or (ii) at least 50% of the value of its assets (based
on average of the quarterly values of the assets) during such year is attributable to assets that that produce or are held for
the production of passive income. Based on the current and anticipated value of our assets and the composition of our income assets,
we do not expect to be a PFIC for United States federal income tax purposes for our current taxable year ended September 30, 2020
or in the foreseeable future. However, the determination of whether or not we are a PFIC according to the PFIC rules is made on
an annual basis and depend on the composition of our income and assets and the value of our assets from time to time. Therefore,
changes in the composition of our income or assets or value of our assets may cause us to become a PFIC. The determination of
the value of our assets (including goodwill not reflected on our balance sheet) may be based, in part, on the quarterly market
value of Ordinary Shares, which is subject to change and may be volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The classification of certain of our income
as active or passive, and certain of our assets as producing active or passive income, and hence whether we are or will become
a PFIC, depends on the interpretation of certain United States Treasury Regulations as well as certain IRS guidance relating to
the classification of assets as producing active or passive income. Such regulations guidance are potentially subject to different
interpretations. If due to different interpretations of such regulations and guidance the percentage of our passive income or
the percentage of our assets treated as producing passive income increases, we may be a PFIC in one of more taxable years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are a PFIC for any taxable year
during which a United States person holds Ordinary Shares, certain adverse United States federal income tax consequences could
apply to such United States person. See &ldquo;Taxation &ndash; Certain United States Federal Income Tax Considerations &ndash;
Passive Foreign Investment Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>For as long as we are an emerging
growth company, we will not be required to comply with certain reporting requirements, including those relating to accounting
standards and disclosure about our executive compensation, that apply to other public companies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are classified as an &ldquo;emerging
growth company&rdquo; under the JOBS Act. For as long as we are an emerging growth company, which may be up to five full fiscal
years, unlike other public companies, we will not be required to, among other things, (i) provide an auditor&rsquo;s attestation
report on management&rsquo;s assessment of the effectiveness of our system of internal control over financial reporting pursuant
to Section 404(b) of the Sarbanes-Oxley Act, (ii) comply with any new requirements adopted by the PCAOB requiring mandatory audit
firm rotation or a supplement to the auditor&rsquo;s report in which the auditor would be required to provide additional information
about the audit and the financial statements of the issuer, (iii) provide certain disclosure regarding executive compensation
required of larger public companies, or (iv) hold nonbinding advisory votes on executive compensation. We will remain an emerging
growth company for up to five years, although we will lose that status sooner if we have more than $1.07 billion of revenues in
a fiscal year, have more than $700 million in market value of our Ordinary Shares held by non-affiliates, or issue more than $1.0
billion of non-convertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that we rely on any of the
exemptions available to emerging growth companies, you will receive less information about our executive compensation and internal
control over financial reporting than issuers that are not emerging growth companies. If some investors find our Ordinary Shares
to be less attractive as a result, there may be a less active trading market for our Ordinary Shares and our share price may be
more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to establish and maintain
proper internal financial reporting controls, our ability to produce accurate financial statements or comply with applicable regulations
could be impaired. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, we were a private
company with limited accounting personnel and other resources with which to address our internal controls and procedures. Our management
has not completed an assessment of the effectiveness of our internal controls over financial reporting, and our independent registered
public accounting firm has not conducted an audit of our internal control over financial reporting. In the course of auditing our
consolidated financial statements for the years ended September 30, 2019 and 2018, we identified several material weaknesses in
our internal control over financial reporting and other control deficiencies as of September 30, 2019. A &ldquo;material weakness&rdquo;
is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable
possibility that a material misstatement of the company&rsquo;s annual or interim financial statements will not be prevented or
detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The material weaknesses identified to date
relate to (i) a lack of accounting staff and resources with appropriate knowledge of generally accepted accounting principles in
the United States (&ldquo;U.S. GAAP&rdquo;) and SEC reporting and compliance requirements; (ii) a lack of sufficient documented
financial closing policies and procedures; (iii) a lack of independent directors and an audit committee; (iv) lack of risk assessment
in accordance with the requirement of COSO 2013 framework and (v) a lack of an effective review process by the accounting manager
which led to material audit adjustments to the financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the identification of the material
weaknesses and control deficiencies, we plan to continue to take remedial measures including (i) hiring more qualified accounting
personnel with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function
and to set up a financial and system control framework; (ii) implementing regular and continuous U.S. GAAP accounting and financial
reporting training programs for our accounting and financial reporting personnel; (iii) setting up an internal audit function
as well as engaging an external consulting firm to assist us with assessment of Sarbanes-Oxley compliance requirements and improvement
of overall internal control; and (iv) appointing independent directors, establishing an audit committee, and strengthening corporate
governance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to take measures to remedy these material weaknesses.
The implementation of these measures may not fully address the material weaknesses in our internal control over financial reporting,
and we cannot conclude that they have been fully remedied. Our failure to correct theses material weaknesses or our failure to
discover and address any other material weaknesses could result in inaccuracies in our financial statements and could also impair
our ability to comply with applicable financial reporting requirements and related regulatory filings on a timely basis. As a result,
our business, financial condition, results of operations and prospects, as well as the trading price of our Ordinary Shares, may
be materially and adversely affected. Moreover, ineffective internal control over financial reporting significantly hinders our
ability to prevent fraud. Upon the completion of this offering, we will become a public company in the United States subject to
the Sarbanes-Oxley Act of 2002. Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, will require that we include a report
from management on our internal control over financial reporting in our annual report on Form 20-F beginning with our annual report
for the fiscal year ending September 30, 2021. In addition, once we cease to be an &ldquo;emerging growth company&rdquo; as such
term is defined in the JOBS Act, our independent registered public accounting firm must attest to and report on the effectiveness
of our internal control over financial reporting. Our management may conclude that our internal control over financial reporting
is not effective. Moreover, even if our management concludes that our internal control over financial reporting is effective, our
independent registered public accounting firm, after conducting its own independent testing, may issue a report that is qualified
if it is not satisfied with our internal controls or the level at which our controls are documented, designed, operated or reviewed,
or if it interprets the relevant requirements differently from us. In addition, after we become a public company, our reporting
obligations may place a significant strain on our management, operational and financial resources and systems for the foreseeable
future. We may be unable to timely complete our evaluation testing and any required remediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the course of documenting and testing
our internal control procedures, in order to satisfy the requirements of Section 404, we may identify weaknesses and deficiencies
in our internal control over financial reporting. In addition, if we fail to maintain the adequacy of our internal control over
financial reporting, as these standards are modified, supplemented or amended from time to time, we may not be able to conclude
on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404. Generally
speaking, if we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements
in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence
in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations
and lead to a decline in the trading price of our Ordinary Shares, if and when they trade. Additionally, ineffective internal
control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential
delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a foreign private issuer, we
are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit the
information publicly available to our shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a foreign private issuer we are not
required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and therefore there
may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we are not subject to
the proxy rules in the United States and disclosure with respect to our annual general meetings will be governed by Cayman Islands
requirements. In addition, our officers, directors and principal shareholders are exempt from the reporting and &ldquo;short-swing&rdquo;
profit recovery provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know
on a timely basis when our officers, directors and principal shareholders purchase or sell our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As a foreign private issuer, we
are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from
the [New York Stock Exchange listing rules/Nasdaq listing standards]. These practices may afford less protection to shareholders
than they would enjoy if we complied fully with corporate governance listing standards.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a foreign private issuer, we are permitted
to take advantage of certain provisions in the [New York Stock Exchange listing rules/Nasdaq listing standards] that allow us
to follow Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may
differ significantly from corporate governance listing standards as, except for general fiduciary duties and duties of care, Cayman
Islands law has no corporate governance regime which prescribes specific corporate governance standards. Currently, we do not
intend to rely on home country practice with respect to our corporate governance after we complete with this offering. However,
if we choose to follow home country practice in the future, our shareholders may be afforded less protection than they otherwise
would have under corporate governance listing standards applicable to U.S. domestic issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may lose our foreign private
issuer status in the future, which could result in significant additional costs and expenses. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed above, we are a foreign private
issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of
the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an issuer&rsquo;s
most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50%
of our Ordinary Shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements necessary
to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required
to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive
than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements,
and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions
of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance
requirements under the [New York Stock Exchange listing rules/Nasdaq listing standards]. As a U.S. listed public company that
is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur
as a foreign private issuer, and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the
use of the net proceeds from our initial public offering and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent (i) we raise more money
than required for the purposes explained in the section titled &ldquo;Use of Proceeds&rdquo; or (ii) we determine that the proposed
uses set forth in that section are no longer in the best interests of our Company, we cannot specify with any certainty the particular
uses of such net proceeds that we will receive from our initial public offering. Our management will have broad discretion in
the application of such net proceeds, including working capital, possible acquisitions, and other general corporate purposes,
and we may spend or invest these proceeds in a way with which our shareholders disagree. The failure by our management to apply
these funds effectively could harm our business and financial condition. Pending their use, we may invest the net proceeds from
our initial public offering in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of the Ordinary Shares
and other terms of this offering have been determined by us along with our underwriter. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you purchase our Ordinary Shares in
this offering, you will pay a price that was not established in a competitive market. Rather, you will pay a price that was determined
by us along with our underwriter. The offering price for our Ordinary Shares may bear no relationship to our assets, book value,
historical results of operations or any other established criterion of value. The trading price, if any, of the Ordinary Shares
that may prevail in any market that may develop in the future, for which there can be no assurance, may be higher or lower than
the price you paid for our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The laws of the Cayman Islands may
not provide our shareholders with benefits comparable to those provided to shareholders of corporations incorporated in the United
States.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate affairs are governed by
our amended and restated memorandum and articles of association, by the Companies Law (2020 Revision) of the Cayman Islands and
by the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions by minority
shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed
by the common law of the Cayman Islands. The common law in the Cayman Islands is derived in part from comparatively limited judicial
precedent in the Cayman Islands and from English common law. Decisions of the Privy Council (which is the final Court of Appeal
for British overseas territories such as the Cayman Islands) are binding on a court in the Cayman Islands. Decisions of the English
courts, and particularly the Supreme Court and the Court of Appeal are generally of persuasive authority but are not binding in
the courts of the Cayman Islands. Decisions of courts in other Commonwealth jurisdictions are similarly of persuasive but not
binding authority. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law
are not as clearly established as they would be under statutes or judicial precedents in the United States. In particular, the
Cayman Islands has a less developed body of securities laws relative to the United States. Therefore, our public shareholders
may have more difficulty protecting their interests in the face of actions by our management, directors or controlling shareholders
than would shareholders of a corporation incorporated in a jurisdiction in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may be unable to present proposals
before annual general meetings or extraordinary general meetings not called by shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands law provides shareholders
with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal
before a general meeting. These rights, however, may be provided in a company&rsquo;s amended and restated articles of association.
Our amended and restated articles of association allow our shareholders holding shares representing in aggregate not less than
10% of our voting share capital in issue, to requisition a general meeting of our shareholders, in which case our directors are
obliged to call such meeting. Advance notice of at least 21 clear days is required for the convening of our annual general shareholders&rsquo;
meeting and at least 14 days&rsquo; notice any other general meeting of our shareholders. A quorum required for a meeting of shareholders
consists of at least one shareholder present or by proxy, representing not less than one-third of the total issued shares carrying
the right to vote at a general meeting of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The obligation to disclose information
publicly may put us at a disadvantage to competitors that are private companies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of this offering, we will
be a public company in the United States. As a public company, we will be required to file periodic reports with the Securities
and Exchange Commission upon the occurrence of matters that are material to our Company and shareholders. Although we may be able
to attain confidential treatment of some of our developments, in some cases, we will need to disclose material agreements or results
of financial operations that we would not be required to disclose if we were a private company. Our competitors may have access
to this information, which would otherwise be confidential. This may give them advantages in competing with our Company. Similarly,
as a U.S. public company, we will be governed by U.S. laws that our competitors, which are mostly private Chinese companies, are
not required to follow. To the extent compliance with U.S. laws increases our expenses or decreases our competitiveness against
such companies, our public company status could affect our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c5"></A>DISCLOSURE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains forward-looking
statements that reflect our current expectations and views of future events, all of which are subject to risks and uncertainties.
Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these statements by the
use of words such as &ldquo;approximates,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
&ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;may&rdquo; or other similar expressions in this prospectus. These statements
are likely to address our growth strategy, financial results and product and development programs. You must carefully consider
any such statements and should understand that many factors could cause actual results to differ from our forward-looking statements.
These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are
known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. Factors
that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assumptions
    about our future financial and operating results, including revenues, income, expenditures, cash balances and other financial
    items;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to execute
    our growth, and expansion, including our ability to meet our goals;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">current and future
    economic and political conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to compete
    in the highly-competitive Chinese patent medicine industry;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our capital requirements
    and our ability to raise any additional financing which we may require;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to attract
    clients and further enhance our brand recognition; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to hire
    and retain qualified management personnel and key employees in order to enable us to develop our business;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">trends and competition
    in the Chinese patent medicine industry; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other assumptions
    described in this prospectus underlying or relating to any forward-looking statements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We describe certain material risks, uncertainties
and assumptions that could affect our business, including our financial condition and results of operations, under &ldquo;Risk
Factors.&rdquo; We base our forward-looking statements on our management&rsquo;s beliefs and assumptions based on information
available to our management at the time the statements are made. We caution you that actual outcomes and results may, and are
likely to, differ materially from what is expressed, implied or forecast by our forward-looking statements. Accordingly, you should
be careful about relying on any forward-looking statements. Except as required under the federal securities laws, we do not have
any intention or obligation to update publicly any forward-looking statements after the distribution of this prospectus, whether
as a result of new information, future events, changes in assumptions, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry Data and Forecasts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains data related
to the Chinese patent medicine industry in China. This industry data includes projections that are based on a number of assumptions
which have been derived from industry and government sources which we believe to be reasonable. The Chinese patent medicine industry
may not grow at the rate projected by industry data, or at all. The failure of these industries to grow as anticipated is likely
to have a material adverse effect on our business and the market price of our Ordinary Shares. In addition, the rapidly changing
nature of the Chinese patent medicine industry subjects any projections or estimates relating to the growth prospects or future
condition of our industries to significant uncertainties. Furthermore, if any one or more of the assumptions underlying the industry
data turns out to be incorrect, actual results may, and are likely to, differ from the projections based on these assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c6"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are incorporated under the laws of
the Cayman Islands as an exempted company with limited liability. We incorporated under the laws of the Cayman Islands because
of certain benefits associated with being a Cayman Islands company, such as political and economic stability, an effective judicial
system, a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability of professional
and support services. The Cayman Islands, however, has a less developed body of securities laws as compared to the United States
and provides significantly less protection for investors than the United States. Additionally, Cayman Islands companies may not
have standing to sue in the Federal courts of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all of our assets are located
in the PRC. In addition, all of our directors and officers are nationals or residents of jurisdictions other than the United States
and all or a substantial portion of their assets are located outside the United States. As a result, it may be difficult for investors
to effect service of process within the United States upon us or these persons, or to enforce against us or them judgments obtained
in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United
States or any state in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have appointed Hunter Taubman Fischer
&amp; Li LLC as our agent to receive service of process with respect to any action brought against us in the United States District
Court for the Southern District of New York under the federal securities laws of the United States or of any state in the United
States or any action brought against us in the Supreme Court of the State of New York in the County of New York under the securities
laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ogier, our counsel with respect to the
laws of the Cayman Islands, and AllBright Law Offices, our counsel with respect to PRC law, have advised us that there is uncertainty
as to whether the courts of the Cayman Islands or the PRC would (i) recognize or enforce judgments of United States courts obtained
against us or our directors or officers predicated upon the civil liability provisions of the securities laws of the United States
or any state in the United States or (ii) entertain original actions brought in the Cayman Islands or the PRC against us or our
directors or officers predicated upon the securities laws of the United States or any state in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ogier has further advised us that there
is currently no statutory enforcement or treaty between the United States and the Cayman Islands providing for enforcement of
judgments. A judgment obtained in the United States, however, may be recognized and enforced in the courts of the Cayman Islands
at common law, without any re-examination on the merits of the underlying dispute, by an action commenced on the foreign judgment
debt in the Grand Court of the Cayman Islands, provided such judgment: (i) is given by a foreign court of competent jurisdiction;
(ii) is final; (iii) is not in respect of taxes, a fine or a penalty; and (iv) was not obtained in a manner and is not of a kind
the enforcement of which is contrary to natural justice or public policy of the Cayman Islands. Furthermore, it is uncertain that
Cayman Islands courts would enforce: (1) judgments of U.S. courts obtained in actions against us or other persons that are predicated
upon the civil liability provisions of the U.S. federal securities laws; or (2) original actions brought against us or other persons
predicated upon the Securities Act. Ogier has informed us that there is uncertainty with regard to Cayman Islands law relating
to whether a judgment obtained from the U.S. courts under civil liability provisions of the securities laws will be determined
by the courts of the Cayman Islands as penal or punitive in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AllBright Law Offices has further advised
us that the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedure Law. PRC courts may
recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedure Law based either on treaties
between China and the country where the judgment is made or on reciprocity between jurisdictions. There are no treaties or other
forms of reciprocity between China and the United States for the mutual recognition and enforcement of court judgments. AllBright
Law Offices has further advised us that under PRC law, PRC courts will not enforce a foreign judgment against us or our officers
and directors if the court decides that such judgment violates the basic principles of PRC law or national sovereignty, security
or public interest, thus making the recognition and enforcement of a U.S. court judgment in China difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c7"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon an assumed initial public offering
price of $[&#9679;] per Ordinary Share and assuming the underwriter exercises its over-allotment option in full, we estimate that
we will receive net proceeds from this offering, after deducting the estimated underwriting discounts, non-accountable expense
allowance, and the estimated offering expenses payable by us, of approximately $[&#9679;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to use the net proceeds we receive
from this offering for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately [</FONT><FONT STYLE="font-size: 10pt">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">]%
    for [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;];</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately [</FONT><FONT STYLE="font-size: 10pt">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">]%
    for [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;];</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately [</FONT><FONT STYLE="font-size: 10pt">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">]%
    for [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]; and</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The balance to fund
    working capital and for other general corporate purposes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing represents our current intentions
based upon our present plans and business conditions to use and allocate the net proceeds of this offering. Our management, however,
will have significant flexibility and discretion to apply the net proceeds of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an unforeseen event occurs or business
conditions change, we may use the proceeds of this offering differently than as described in this prospectus. See &ldquo;Risk
Factors &mdash; Risks Relating to the Offering and Our Ordinary Shares &mdash; We have broad discretion in the use of the net
proceeds from our initial public offering and may not use them effectively.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the net proceeds we
receive from this offering are not immediately used for the above purposes, we intend to invest our net proceeds in short-term,
interest-bearing bank deposits or debt instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c8"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has discretion
on whether to distribute dividends. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend
may exceed the amount recommended by our board of directors. In either case, all dividends are subject to certain restrictions
under Cayman Islands law, namely that the company may only pay dividends out of profits or share premium, and provided always
that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall
due in the ordinary course of business. Even if we decide to pay dividends, the form, frequency and amount will depend upon our
future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other
factors that the board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any present plan to pay
any cash dividends on our ordinary shares in the foreseeable future after this offering. We currently intend to retain most, if
not all, of our available funds and any future earnings to operate and expand our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company with limited
liability incorporated in the Cayman Islands. We may rely on dividends from our subsidiaries in China for our cash requirements,
including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiaries to pay
dividends to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we pay any dividends on our ordinary
shares, we will pay those dividends which are payable in respect of our Ordinary Shares to the depositary, as the registered holder
of such Ordinary Shares, and the depositary then will pay such amounts to the holders of our Ordinary Share, subject to the terms
of the deposit agreement, including the fees and expenses payable thereunder. See &ldquo;Description of Share Capital.&rdquo;
Cash dividends on our ordinary shares, if any, will be paid in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c9"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our capitalization
as of September 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an as adjusted
    basis to reflect the issuance and sale of the Ordinary Shares by us in this offering at the assumed initial public offering
    price of $[&#9679;] per Ordinary Share, which is the midpoint of the estimated initial public offering price range set forth
    on the cover page of this prospectus, after deducting the underwriting discounts, non-accountable expense allowance and estimated
    offering expenses payable by us and assuming no exercise of the underwriter&rsquo;s over-allotment option.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this capitalization table
in conjunction with &ldquo;Use of Proceeds,&rdquo; &ldquo;Selected Consolidated Financial and Operating Data,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the consolidated financial statements and
the related notes appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, <BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma As Adjusted</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US$</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: justify">Long-term loans</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Share capital $1.00 par value, 50,000 Ordinary Shares authorized, 50,000 Ordinary Shares issued and outstanding as of September 30, 2019; [&#9679;] Ordinary Shares issued and outstanding, as adjusted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional paid-in capital<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Statutory reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,439,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Retained earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,180,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Accumulated other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,767</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,384,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Adjusted total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,384,059</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reflects the sale
    of Ordinary Shares in this&nbsp;offering&nbsp;at an assumed initial public&nbsp;offering&nbsp;price of $[&#9679;] per share,
    and after deducting the estimated underwriting discounts, non-accountable expense allowance and estimated&nbsp;offering&nbsp;expenses
    payable by us. The pro forma as adjusted information is illustrative&nbsp;only,&nbsp;and we will adjust this information based
    on the actual initial public&nbsp;offering&nbsp;price and other terms of this&nbsp;offering&nbsp;determined at pricing. Additional
    paid-in capital reflects the net proceeds we expect to receive, after deducting the underwriting discounts, non-accountable
    expense allowance and estimated offering expenses payable by us.&nbsp;We estimate that such net proceeds&nbsp;will be approximately
    $[&#9679;].</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A $1.00 increase (decrease) in the assumed
initial public offering price of $[&#9679;] per Ordinary Share would increase (decrease) each of additional paid-in capital, total
shareholders&rsquo; equity and total capitalization by $[&#9679;] million, assuming the number of Ordinary Shares offered by us,
as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts,
non-accountable expense allowance and estimated expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c10"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our Ordinary Shares,
your interest will be diluted for each Ordinary Share you purchase to the extent of the difference between the initial public
offering price per Ordinary Share and our net tangible book value per Ordinary Share after this offering. Dilution results from
the fact that the initial public offering price per Ordinary Share is substantially in excess of the net tangible book value per
Ordinary Share attributable to the existing shareholders for our presently outstanding Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net tangible book value as of September
30, 2019, was $12,384,059, or $247.7 per Ordinary Share. Net tangible book value represents the amount of our total consolidated
tangible assets, less the amount of our total consolidated liabilities. Dilution is determined by subtracting the net tangible
book value per Ordinary Share (as adjusted for the offering) from the initial public offering price per Ordinary Share and after
deducting the underwriting discounts, non-accountable expense allowance, and the estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving effect to our sale of [&#9679;]
Ordinary Shares offered in this offering based on the initial public offering price of $[&#9679;] per Ordinary Share after deduction
of the underwriting discounts, non-accountable expense allowance and estimated offering expenses payable by us, our as adjusted
net tangible book value as of September 30, 2019, would have been $[&#9679;], or $[&#9679;] per outstanding Ordinary Share. This
represents an immediate increase in net tangible book value of $[&#9679;] per Ordinary Share to the existing shareholders, and
an immediate dilution in net tangible book value of $[&#9679;] per Ordinary Share to investors purchasing Ordinary Shares in this
offering. The as adjusted information discussed above is illustrative only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates such dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Post-Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Full Exercise of Over-Allotment Option</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Assumed Initial public offering price per Ordinary Share</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Net tangible book value per Ordinary Share as of September 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">As adjusted net tangible book value per Ordinary Share attributable to payments by new investors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Pro forma net tangible book value per Ordinary Share immediately after this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Amount of dilution in net tangible book value per Ordinary Share to new investors in the offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Assumes that the underwriter&rsquo;s over-allotment
    option has not been exercised.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the underwriter exercises its over-allotment
option in full, the pro forma as adjusted net tangible book value per Ordinary Share after the offering would be $[&#9679;], the
increase in net tangible book value per Ordinary Share to existing shareholders would be $[&#9679;], and the immediate dilution
in net tangible book value per Ordinary Share to new investors in this offering would be $[&#9679;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes, on a pro
forma as adjusted basis as of September 30, 2019, the differences between existing shareholders and the new investors with respect
to the number of Ordinary Shares purchased from us, the total consideration paid and the average price per Ordinary Share before
deducting the underwriting discounts, non-accountable expense allowance, and the estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares<BR> purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Average<BR> price per<BR> Ordinary</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center">($ in thousands)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify">Existing shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">New investors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">$</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pro forma as adjusted information
as discussed above is illustrative only. Our net income book value following the completion of this offering is subject to adjustment
based on the actual initial public offering price of our Ordinary Shares and other terms of this offering determined at the pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c11"></A>CORPORATE HISTORY AND STRUCTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Corporate History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We initially conducted our business through
Jiangxi Universe Pharmaceuticals Co., Ltd. (&ldquo;Jiangxi Universe&rdquo;), a PRC company incorporated in 1998 and Jiangxi Universe
Pharmaceuticals Trade Co., Ltd. (&ldquo;Universe Trade&rdquo;), a PRC company incorporated in 2010, a wholly owned subsidiary
of Jiangxi Universe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> With the growth of our business and
in order to facilitate international capital investment in our Company, we underwent an offshore reorganization in 2019 and 2020.
On December 11, 2019, our holding company, Universe Pharmaceuticals INC (&ldquo;Universe INC&rdquo;), was incorporated under the
laws of the Cayman Islands as an exempted company with limited liability. Our wholly owned subsidiary Universe Pharmaceuticals
Group (International) Limited (&ldquo;Universe HK&rdquo;) was incorporated in Hong Kong on May 21, 2018 as an intermediate holding
company. Universe HK in turn holds all the capital stocks of Jiangxi Universe Pharmaceuticals Technology Co., Ltd. (&ldquo;Universe
Technology&rdquo;), a wholly foreign owned enterprise incorporated in China on Aril 8, 2019. Universe Technology holds all the
capital stocks and controls Jiangxi Universe. Jiangxi Universe holds 100% of the equity interests in Universe Trade. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Universe INC is a holding company with
no business operation other than holding the shares in Universe HK; Universe HK is a pass-through entity with no business operation.
Universe Technology is exclusively engaged in the business of managing the operation of Jiangxi Universe. Jiangxi Universe specializes
in manufacturing our own TCMD products. Universe Trade specializes in the distribution and sales of our own TCMD products and
third-party pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Foshan Shangyu Investment Holding Co.,
Ltd. (&ldquo;Foshan Shangyu&rdquo;) is our affiliated entity, 90% owned by and controlled by Mr. Gang Lai, our controlling shareholder.
Foshan Shangyu was formed in 2004 in China as a holding company of Mr. Gang Lai. Foshan Shangyu has no business operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 265 Jingjiu Avenue, Jingji Jishu District, Jinggangshan, Ji&rsquo;an, Jiangxi Province, People&rsquo;s Republic of China. Our
phone number is +86-0796-8404999. Our registered office in the Cayman Islands is located at Vistra (Cayman) Limited, P.O. Box
31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KYI &ndash; 1205 Cayman Islands, and the phone number of
our registered office is +1-(345)769-9372.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Our Corporate Structure </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following diagram illustrates our
corporate structure, including our subsidiaries, as of the date of this prospectus and upon completion of this offering based
on a proposed number of [&#9679;] Ordinary Shares being offered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For details of each shareholder&rsquo;s ownership,
please refer to the beneficial ownership table in the section captioned &ldquo;Principal Shareholders.&rdquo;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="c12"></A>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF<BR>
FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify"><I>The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with our financial statements and the related
notes included elsewhere in this prospectus. This discussion contains forward-looking statements reflecting our current expectations
that involve risks and uncertainties. See &ldquo;Disclosure Regarding Forward-Looking Statements&rdquo; for a discussion of the
uncertainties, risks, and assumptions associated with these statements. Actual results and the timing of events could differ materially
from those discussed in our forward-looking statements as a result of many factors, including those set forth under &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus.</I><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&nbsp;<I>&nbsp;</I><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a pharmaceutical company
specializing in the development, manufacturing, marketing and sale of traditional Chinese medicine derivatives
(&ldquo;TCMD&rdquo;) products targeted to the elderly to address their physical conditions in the aging process and to
promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD products from the
National Medical Products Administration (the &ldquo;NMPA&rdquo;), and we currently produce 13 varieties of TCMD products and
sell them in 280 cities in 31 provinces in China as of the date of this prospectus. In addition, we also sell biomedical drugs, medical
instruments, traditional Chinese medicine pieces (&ldquo;TCMP&rdquo;) products and dietary supplements manufactured by
third-party pharmaceutical companies (collectively referred to as &ldquo;third-party products&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our major customers are pharmaceutical companies,
hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province,
Fujian Province, Guangxi Province and Shandong Province, and 24 other provinces in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have been profitable since 2015 and we believe
we are well-positioned to benefit from the rapid growth of the TCMD market in China and to leverage the leading market position
of our flagship products in order to further grow our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Organization </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universe INC was incorporated under the laws
of the Cayman Islands on December 11, 2019 as an exempted company with limited liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universe INC owns 100% equity interest of Universe
HK, an entity incorporated on May 21, 2018 in accordance with the laws and regulations in Hong Kong.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universe Technology was formed on April 8,
2019, as a WOFE in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Universe INC, Universe HK and Universe Technology
are currently not engaging in any active business operations and merely acting as holding companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Jiangxi Universe was incorporated on March
2, 1998 in accordance with PRC laws and is engaged in the research and development and manufacturing of modernized traditional
Chinese medicines. Jiangxi Universe&rsquo;s subsidiary, Universe Trade, which was incorporated on March 10, 2010, handles the
sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe and third-party pharmaceutical manufacturers. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Reorganization</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reorganization of our legal structure (&ldquo;Reorganization&rdquo;)
was completed on December 11, 2019. The reorganization involved the incorporation of Universe INC and Universe Technology, and
the transfer of the 100% equity interest of Jiangxi Universe to Universe Technology. Consequently, Universe INC, through its subsidiary
Universe HK, directly controls Universe Technology and Jiangxi Universe, and became the ultimate holding company of all other entities
mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Reorganization has been accounted for as
a recapitalization among entities under common control since the same controlling shareholders controlled all these entities before
and after the Reorganization. The consolidation of Universe INC and its subsidiaries has been accounted for at historical cost
and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented
in the accompanying consolidated financial statements. Results of operations for the periods presented comprise those of the previously
separate entities combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our revenues increased by $4,715,136, or 16.5%,
from $28,514,180 for the fiscal year ended September 30, 2018, to $33,229,316 for the fiscal year ended September 30, 2019. Revenues
from sales of TCMD products manufactured by us accounted for 62.9% and 61.8% of our total revenues for the fiscal years ended September
30, 2019 and 2018, respectively, revenues from sales of TC products manufactured by third-party pharmaceutical companies accounted
for 37.1% and 38.2% of our total revenues for the fiscal years ended September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates the amount
and percentage of our revenue derived from our different products sold:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Amount</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>% of revenue</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Amount</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>% of revenue</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify; text-indent: -10pt; padding-left: 10pt">Revenue from sales of self-manufactured TCMD products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,895,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">62.9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,620,823</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">61.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Revenue from sales of third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,893,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total revenue</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,229,316</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,514,180</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Key Factors that Affect Our Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">We believe the following key factors may affect
our financial condition and results of operations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Ability to Attract Additional Customers
and Increase the Spending Per Customer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our major customers are pharmaceutical companies,
hospitals, clinics and drugstore chains. We currently sell our products to these customers in 243 cities in 30 provinces in China,
with significant customers located in Jiangxi Province, Jiangsu Province, Guangdong Province, Hubei Province, Fujian Province,
Guangxi Province and Shandong Province in China. For the years ended September 30, 2019 and 2018, we had total 2,603 and 1,518
customers, and no single customer accounted for more than 10% of our total revenue, respectively. However, our top 10 customers
in the aggregate accounted for 34.5% and 31.6% of our total revenues, respectively. Our dependence on a small number of larger
customers could expose us to the risk of substantial losses if a single large customer stops purchasing our products, purchases
fewer of our products or goes out of business and we cannot find substitute customers on equivalent terms. If any of our significant
customers reduces the quantity of the products they purchase from us or stops purchasing from us, our net revenues would be materially
and adversely affected. Therefore, the success of our business in the future depends on our effective marketing efforts to expand
our distribution network including additional cities and rural areas in the PRC in an effort to increase our geographic appearance.
The success of expansion will depend upon many factors, including our ability to form relationships with, and manage an increasing
number of, customers base and optimize our distribution network. If our marketing efforts fail to convince customers to accept
our products, we may find it difficult to maintain the existing level of sales or to increase such sales. Should this happen, our
net revenues would decline and our growth prospectus would be severely impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Ability to Increase Awareness of
Our Brand and Develop Customer Loyalty</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
brand, such as &ldquo;Bai Nian Dan (</FONT>&#30334;&#24180;&#20025;<FONT STYLE="font-family: Times New Roman, Times, Serif">)&rdquo;
and &ldquo;Hu Zhuo Ren (</FONT>&#32993;&#21331;&#20154;<FONT STYLE="font-family: Times New Roman, Times, Serif">)&rdquo;, are well-recognized
among our clients and other Chinese medicine industry players. Our brand is integral to our sales and marketing efforts. We believe
that maintaining and enhancing our brand name recognition in a cost-effective manner is critical to achieving widespread acceptance
of our current and future products and is an important element in our effort to increase our customer base. Successful promotion
of our brand name will depend largely on our marketing efforts and ability to provide reliable and quality products at competitive
prices. Brand promotion activities may not necessarily yield increased revenue, and even if they do, any increased revenue may
not offset the expenses we will incur in marketing activities. If we fail to successfully promote and maintain our brand, or if
we incur substantial expenses in an unsuccessful attempt to promote and maintain our brand, we may fail to attract new customers
or retain our existing customers, in which case our business, operating results and financial condition, would be materially adversely
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Our Ability to Control Costs and Expenses
and Improve Our Operating Efficiency</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business growth is dependent on our ability
to attract and retain qualified and productive employees, identify business opportunities, secure new contracts with customers
and our ability to control costs and expenses to improve our operating efficiency. Our inventory costs (including raw materials,
labor, packaging cost, depreciation and amortization, freight costs, overhead and third-party products purchase costs) have a direct
impact on our profitability. The raw materials used in manufacturing of our TCMD products are subject to price volatility and inflationary
pressures. Our success is dependent, in part, on our ability to reduce our exposure to increase in those costs through a variety
of ways, while maintaining and improving margins and market share. We also rely on third-party manufacturers as a source for a
portion of components for a portion of components for our products. These manufactures are also subject to price volatility and
labor cost and other inflationary pressures, which may, in turn, result in an increase in the amount we pay for sourced products.
Raw materials and sourced product price increases may offset our productivity gains and price increases and may adversely impact
our financial results. In addition, our staffing costs (including payroll and employee benefit expense) and administrative expenses
also have a direct impact on our profitability. Our ability to drive the productivity of our staff and enhance our operating efficiency
affects our profitability. To the extent that the costs we are required to pay to our suppliers and our staffs exceeds our estimates,
our profit may be impaired. If we fail to implement initiatives to control costs and improve our operating efficiency over time,
our profitability will be negatively impacted.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><B><I>Our Ability to
Compete Successfully</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chinese patent medicine industry we are
in is highly competitive and evolving in China. The development and commercialization of new pharmaceutical products is highly
competitive, and the industry currently is characterized by rapidly changing technologies, significant competition and a strong
emphasis on intellectual property. We will face competition with respect to our current and future pharmaceutical product candidates
from major pharmaceutical companies in China. Potential competitors also include academic institutions, government agencies and
other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements
for research, development, manufacturing and commercialization of pharmaceutical products. Some of our current or potential competitors
may have significantly greater financial resources and expertise in research and development, manufacturing, product testing, obtaining
regulatory approvals and marketing approved products than we do., which could result in our competitors establishing a strong market
position before our new products are able to enter the market. Additionally, technologies developed by our competitors may render
our product candidates uneconomical or obsolete. If we do not compete effectively, our operating results could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A Severe or Prolonged Slowdown in The
Global or Chinese Economy Could Materially and Adversely Affect Our Business and Our Financial Condition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The rapid growth of the Chinese economy has
slowed down since 2012 and this slowdown may continue in the future. There is considerable uncertainty over trade conflicts between
the United States and China and the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks
and financial authorities of some of the world&rsquo;s leading economies, including the United States and China. The withdrawal
of these expansionary monetary and fiscal policies could lead to a contraction. There continue to be concerns over unrest and terrorist
threats in the Middle East, Europe, and Africa, which have resulted in volatility in oil and other markets. There are also concerns
about the relationships between China and other Asian countries, which may result in or intensify potential conflicts in relation
to territorial disputes. The eruption of armed conflict could adversely affect global or Chinese discretionary spending, either
of which could have a material and adverse effect on our business, results of operation in financial condition. Economic conditions
in China are sensitive to global economic conditions, as well as changes in domestic economic and political policies and the expected
or perceived overall economic growth rate in China. Any severe or prolonged slowdown in the global or Chinese economy would likely
materially and adversely affect our business, results of operations and financial condition. In addition, continued turbulence
in the international markets may adversely affect our ability to access capital markets to meet liquidity needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>COVID-19 Impact</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, a novel strain of coronavirus
was reported in Wuhan, China. On March 11, 2020, the World Health Organization categorized it as a pandemic. To contain the spread
of the COVID-19, the government took stringent measures, including restricting access to provinces and cities, reducing gathering
events, and postponing non-essential business activities. As of the date of this prospectus, the COVID-19 coronavirus outbreak
in China appears to have slowed down and certain provinces and cities have resumed some business activities under the guidance
and support of the government. Our business has been negatively impacted by the COVID-19 coronavirus outbreak to a certain extent.
In the beginning of February, we had to temporary suspend our manufacturing and sales activities due to government restrictions
on business activities. During the temporary business closure period, our employees had very limited access to our manufacturing
facilities, and as a result, we experienced difficulty delivering our products to our customers on a timely basis. In addition,
due to the COVID-19 outbreak, some of our customers or suppliers may experience financial distress, delay or default on their
payments, reduce the scale of their business, or suffer disruptions in their business due to the outbreak. Any increased difficulty
in collecting accounts receivable, delayed raw materials supply, bankruptcy of small and medium businesses, or early termination
of agreements due to deterioration in economic conditions could negatively impact our results of operations. We resumed our work
on March 2, 2020. In light of the current circumstances and available information, we estimate that for the period from February
to April 2020, our revenues could be approximately 11% lower as compared to the same period of last year, to an estimated amount
of $6.8 million. At the same time, our employee salaries and benefits as well as some fixed overhead costs did not decrease during
the period when we were temporarily closed. As a result, we expect that our net income could be approximately 32% lower as compared
to the same period of last year, to an estimated amount of $1.4 million <FONT STYLE="font-family: Times New Roman, Times, Serif">for
the period of </FONT>February to April 2020. However, since our factory has been fully running as normal since March 2, 2020,
we expect the negative impact of the COVID-19 coronavirus outbreak on our business to be temporary and our revenues to grow.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the effects of the outbreak of COVID-19
discussed above, to the extent that we experience a more adverse operating environment, incur unanticipated capital expenditures,
or if we decide to accelerate our growth, then additional financing may be required. We cannot guarantee, however, that additional
financing, if required, would be available at all or on favorable terms. Such financing may include carrying additional debts or
selling additional equity securities. Any financing which involves the sale of equity securities or instruments that are convertible
into equity securities could result in immediate and possibly significant dilution to our existing shareholders.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Key Financial Performance Indicators </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing our financial performance, we
consider a variety of financial performance measures, including principal growth in net revenue and gross profit, our ability to
control costs and operating expenses to improve our operating efficiency and net income. Our review of these indicators facilitates
timely evaluation of the performance of our business and effective communication of results and key decisions, allowing our business
to respond promptly to competitive market conditions and different demands and preferences from our customers. The key measures
that we use to evaluate the performance of our business are set forth below and are discussed in greater details under &ldquo;Results
of Operations&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Net Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our net revenue is equal to gross revenue minus
sales returns; sales incentives that we offer to our customers, such as discounts that are offset to gross sales. Our net revenue
is driven by changes in the number of customers, sales volume, selling price, and mix of products sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Years Ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>September 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Revenue from sales of self-manufactured TCMD products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">62.9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">61.8</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18.6</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Revenue from sales of third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">13.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: justify; padding-bottom: 4pt">Total revenue</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Number of customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,603</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Sales volume by unit -TCMD products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,766,549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,045,824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Sales volume by unit &ndash;third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,734,333</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,669,369</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: justify; padding-bottom: 4pt">Total sales volume</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">25,500,882</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,715,193</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">7.5</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Average selling price per unit - TCMD products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.18</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">7.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Average selling price per unit &ndash; Third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">12.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenues from sales of TCMD products manufactured
by us accounted for 62.9% and 61.8% of our total revenues for the fiscal years ended September 30, 2019 and 2018, respectively.
The 13 TCMD products manufactured by us fall into two categories: Chronic Condition Treatments and cold and flu medications. Our
Chronic Condition Treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup,
Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor,
and Shiquan Dabu Medicinal Liquor, and our cold and flu medications primarily include Paracetamol Granule for Children, Isatis
Root Granule and Qiangli Pipa Syrup. Sales volume of our TCMD products increased by 10.7%, from 16,045,824 units sold in fiscal
year 2018 to 17,766,549 units sold in fiscal year 2019, while average selling price of our TCMD products increased by 7.1% from
$1.10 per unit in fiscal year 2018 to $1.18 per unit in fiscal year 2019. In addition, the number of our customers increased by
71.5% from 1,518 in fiscal year 2018 to 2,603 in fiscal year 2019. These factors led to an 18.6% increase in our revenue from sales
of our TCMD products from fiscal year 2018 to fiscal year 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to diversify our product offerings
and product mix, in addition to sales of TCMD products manufactured by us, we also sell products manufactured by third-party pharmaceutical
companies, including (i) biomedical drugs, such as liquid glucose, prednisolone, and citicoline, (ii) medical instruments, such
as drug-eluting stents, surgical tubes and syringes, (iii) TCMP products, such as red sage tables, Longdan Xiegan pills, and Chinese
skullcap capsules, and (iv) dietary supplements, such as vitamins, probiotic powder, and calcium tablets. Revenues from sales of
third-party products accounted for 37.1% and 38.2% of our total revenues for the fiscal years ended September 30, 2019 and 2018,
respectively. Sales volume of third-party products increased by 0.8% from 7,669,369 units sold in fiscal year 2018 to 7,734,333
units sold in fiscal year 2019, while the average selling price of third-party products increased by 12.3% from $1.42 per unit
in fiscal year 2018 to $1.59 per unit in fiscal year 2019 due to the increase in purchase costs of third-party products. In addition,
the number of our customers increased by 71.5% from 1,518 in fiscal year 2018 to 2,603 in fiscal year 2019. These factors led to
a 13.2% increase in our revenue from sales of our third-party products from fiscal year 2018 to in fiscal year 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Gross Profit</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross profit is equal to net revenue minus
cost of goods sold. Cost of goods sold primarily includes inventory costs (raw materials, labor, packaging cost, depreciation and
amortization, third-party products purchase price, freight costs and overhead). Cost of goods sold generally changes as our production
costs change, as these are affected by factors including the market price of raw materials, labor productivity, or the purchase
price of third-party products, and as the customer and product mix changes. Our cost of revenues accounted for 59.7% and 53.0%
of our total revenue for the fiscal year 2019 and 2018, respectively. We expect our cost of revenues to increase as we further
expand our operations in the foreseeable future. Our gross margin was 40.3% for fiscal year 2019, a decrease by 6.7% from gross
margin of 47.0% in fiscal year 2018, primarily attributable to the increase in cost of revenue from sales of TCMD products when
the purchase price of several Chinese herb materials used in the manufacturing of our TCMD products increased in fiscal year 2019,
which led to the increase in our related production cost. In addition, our gross profit and gross margin is also affected by sales
of different product mix during each reporting period. Our gross margin increases when more products with lower costs and higher
margin are sold, while our gross margin decreases when more products with higher costs and lower margin are sold. In fiscal year
2019, more products with higher costs and lower margin were sold. Furthermore, in August and September 2019 we conducted maintenance
for our manufacturing facility to improve its environment, including cleaning and upgrading the machineries and equipment, in order
to both meet the strict requirements for renewing our Good Manufacturing Practice Certificate (&ldquo;GMP Certificate&rdquo;) and
ensure the quality and safety of our products. In doing so, we temporarily suspended our manufacturing activities. We resumed our
manufacturing activities in late September 2019 after we successfully renewed our GMP Certificate. Costs associated with the factory
maintenance (such as depreciation, maintenance and repair, base salary for workers) of approximately $0.26 million were included
in the total cost of revenue for this period. These factors led to the increase in our costs of revenue and decrease in our gross
profit and gross margin. See detailed discussion under &ldquo;&ndash;Results of Operation&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Operating Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating expenses consist of selling expenses,
general and administrative expenses and research and development expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our selling expenses primarily include salary
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase the awareness of our brand, shipping
ad delivery expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related
expenses. Our selling expenses accounted for 4.8% and 5.9% of our total revenue for the years ended September 30, 2019 and 2018,
respectively. We expect that our overall selling expenses, including but not limited to, advertising expenses, brand promotion
expenses and salaries, will continue to increase in the foreseeable future if our business further grows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance
expenses, office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service
expenses. General and administrative expenses were 4.4% and 4.5% of our revenue for the years ended September 30, 2019 and 2018,
respectively. We expect our general and administrative expenses, including, but not limited to, salaries and business consulting
expenses, to continue to increase in the foreseeable future, as we plan to hire additional personnel and incur additional expenses
in connection with the expansion of our business operations. We expect our professional fees for legal, audit, and advisory services
to increase as we become a public company upon the completion of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chinese patent medicine industry is characterized
by rapid and frequent changes in customer demand and launches of new products. If we do not launch new products or improve our
existing products to meet the changing demands of our customers in a timely manner, some of our products could become uncompetitive
in the market, thereby adversely affecting on our revenues and operating results. Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities,
materials and supplies used in the development and testing of new TCMD products, depreciation, and other miscellaneous expenses.
Research and development expenses were 1.9% and 2.8% of our revenue for the years ended September 30, 2019 and 2018, respectively.
As we continue to develop new products and diversify our product offerings to satisfy customer demand, we expect our research and
development expenses to continue to increase in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><U>Results of Operations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Comparison of Results of Operations for
the Years Ended September 30, 2019 and 2018</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the results
of our operations during the fiscal years ended September 30, 2019 and 2018, respectively, and provides information regarding the
dollar and percentage increase or (decrease) during such years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of revenue</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of revenue</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 28%; font-weight: bold; text-align: left">REVENUE</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">33,229,316</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">28,514,180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,715,136</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">COST OF REVENUE</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,821,831</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,105,265</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">53.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,716,566</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,407,485</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,408,915</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">47.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,430</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,578,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(101,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282,946</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174,447</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">618,437</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">789,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(170,945</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,654,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,752,586</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(97,930</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2.6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">INCOME FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,752,829</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,656,329</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">33.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">96,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">OTHER INCOME (EXPENSE)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(129,268</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.4</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(164,922</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.6</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(21.6</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,644</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,857</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(99,767</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(138,278</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38,511</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">INCOME BEFORE INCOME TAX PROVISION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,653,062</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,518,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">PROVISION FOR INCOME TAXES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,101,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,915,118</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">186,478</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">NET INCOME</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,551,465</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22.7</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,602,933</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">26.7</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(51,467</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.7</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenues. </I></B>We currently produce
and sell 13 varieties of TCMD products and also sell products manufactured by third-party pharmaceutical companies, to our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">&nbsp;Revenue - TCMD products sales</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,895,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,620,823</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,274,719</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">18.6</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;Revenue &ndash; third-party products sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,893,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,440,418</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">&nbsp;Total revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28,514,180</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,715,136</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16.5</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our total revenues increased by $4,715,136,
or 16.5%, to $33,229,316 for the year ended September 30, 2019 from $28,514,080 for the year ended September 30, 2018. The increase
in our revenues was attributable to the increase in sales volume by 7.5% from 23,715,193 units of TCMD and third-party products
sold in fiscal year 2018 to 25,500,882 units of TCMD and third-party products sold in fiscal year 2019. In addition, the weighted
average per unit selling price of our TCMD products increased by 7.0%, from $1.1 per unit in fiscal year 2018 to $1.2 per unit
in fiscal year 2019, and the weighted average per unit selling price of third-party products increased by 15.9%, from $1.4 per
unit in fiscal year 2018 to $1.6 per unit in fiscal year 2019. Also, through our effective marketing efforts, we have expanded
our distribution network and attracted more customers including pharmaceutical companies, hospitals, clinics and drugstore chains,
with the total number of customers increasing by 71.5% from 1,518 in fiscal year 2018 to 2,603 in fiscal year 2019. These factors
all contributed to the increase in our revenues by 16.5% from fiscal year 2018 to fiscal year 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="54" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>For
    the years ended September 30,</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>2019</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>2018</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>Change</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Average</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Average</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>% of</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>%
    of revenue</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>%
    of revenue</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>%</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>QTY sold 2019</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>QTY sold 2018</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>QTY change</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>% of change</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>price 2019</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>price 2018</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>Price change</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"><B>change in price</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; font-weight: bold; text-align: left; text-indent: -5pt"><FONT STYLE="font-size: 8pt">Sales of TCMD products:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt; width: 18.8%"><FONT STYLE="font-size: 8pt">Shiquan Dabu
    Medicinal Liquor</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">636,362</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">1.9</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">961,856</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">3.4</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">(325,494</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">(33.8</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">331,063</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">508,138</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">(177,075</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">(34.8</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">1.92</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">1.89</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">0.03</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5.5%; text-align: right"><FONT STYLE="font-size: 8pt">1.5</FONT></TD><TD STYLE="width: 0.1%; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Shenrong Medicinal Liquor</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">538,235</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">564,426</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(26,191</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(4.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">202,335</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">254,249</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(51,914</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(20.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.66</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.22</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.44</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">19.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">&nbsp;Fengtong Medicinal
    Liquor</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">978,217</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,124,208</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(145,991</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(13.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">794,959</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">969,942</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(174,983</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(18.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.23</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.16</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">&nbsp;Fengshitong Medicinal
    Liquor</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">65,305</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">67,048</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,743</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(2.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">58,546</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">54,445</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.23</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(8.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Qishe Medicinal Liquor,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">137,896</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">139,746</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1,849</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">55,618</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">52,296</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,322</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.48</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.67</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.19</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(7.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Guben Yanling Pill</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,767,341</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">32.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,374,646</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">25.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,392,695</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">46.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,229,035</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,469,573</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">759,462</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">30.8</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.99</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.34</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">11.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Quanlu Pill</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">141,396</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">303,337</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(161,941</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(53.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">134,496</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">309,157</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(174,661</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(56.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.05</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.98</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Shenrong Weisheng Pill</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,753,747</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,470,953</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">282,795</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">19.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,834,898</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,031,029</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">803,869</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">39.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.62</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.72</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.10</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(13.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Yangxue Danggui Syrup</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,167,048</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,283,824</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4.5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(116,777</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(9.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,243,625</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,284,537</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(40,912</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.94</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(6.1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Wuzi Yanzong Oral Liquid</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">226,696</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">96,882</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">129,814</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">134.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">122,105</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">46,785</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">75,320</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">161.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.07</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.21</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(10.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Qiangli Pipa Syrup</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,308,512</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,341,830</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(33,318</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(1.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,090,867</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,249,568</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(158,701</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(3.7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.56</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.55</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">&nbsp;Isatis Root Granule</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,653,536</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,507,037</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">146,499</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9.7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,333,506</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,987,233</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">346,273</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">17.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.71</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.76</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.05</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(6.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">&nbsp;Paracetamol
    Granule for Children</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">521,251</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8pt">1.6</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">385,031</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1.4</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">136,220</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">35.4</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">2,335,496</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,828,872</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">506,624</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">27.7</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.22</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.21</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.01</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">6.0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Subtotal:
    sales of TCMD products</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">20,895,542</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8pt">62.9</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">17,620,823</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">61.8</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">3,274,718</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">18.6</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">17,766,549</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">16,045,824</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,720,725</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">10.7</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1.18</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1.10</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.08</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">7.1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Sales
    of third party products:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Biochemical drugs</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,508,816</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">28.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,226,228</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">25.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,282,588</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">31.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">7,153,518</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,704,511</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">449,008</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6.7</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.33</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.08</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.25</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">23.3</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Traditional Chinese Medicine
    Pieces</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">142,409</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">175,503</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(33,095</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(18.9</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">56,915</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">56,807</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">108</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2.50</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3.09</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(0.59</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(19.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Medical instruments</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,668,422</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8.0</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,483,052</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">12.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(814,630</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(23.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">521,753</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">903,280</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(381,527</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">(42.2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5.11</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3.86</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1.25</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">32.4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Dietary
    supplements</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">14,127</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8pt">0.0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">8,574</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">5,554</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">64.8</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">2,147</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">4,771</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(2,624</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(55.0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">6.58</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1.80</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">4.78</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">266.2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Subtotal:&nbsp;&nbsp;sales
    of third party products</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">12,333,774</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-size: 8pt">37.1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">10,893,357</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">38.2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,440,418</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">13.2</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">7,734,333</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">7,669,369</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">64,964</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.8</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1.59</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1.42</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">0.17</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">12.3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 8pt">Total
    revenue</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">33,229,316</FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: right"><FONT STYLE="font-size: 8pt">100.0</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">28,514,180</FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">100.0</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">4,715,136</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">16.5</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">25,500,882</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">23,715,193</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">1,785,689</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">7.5</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">1.30</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">1.20</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.10</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 8pt">8.4</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 8pt">%</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Revenue from sales of our TCMD products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our TCMD products primarily include Chronic
Condition Treatments such as Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral
Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan
Dabu Medicinal Liquor, as well as our cold and flu medications such as Paracetamol Granule for Children, Isatis Root Granule and
Qiangli Pipa Syrup. Revenue from sales of our TCMD products accounted for 62.9% and 61.8% of our total revenue for the years ended
September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our TCMD products sales increased by $3,274,718
or 18.6%, from $17,620,823 in fiscal year 2018 to $20,895,542 in fiscal year 2019, because the sales volume of our TCMD products
increased by 10.7% from 16,045,824 units sold in fiscal year 2018 to 17,766,549 units sold in fiscal year 2019, and that the average
selling price of our TCMD products increased by 7.1% from $1.10 per unit in fiscal year 2018 to $1.18 per unit in fiscal year 2019.
Among the 13 varieties of TCMD products we manufacture, the sales of Guben Yanling Pill, one of our representative products, accounted
for 32.4% and 25.9% of our total revenue for the years ended September 30, 2019 and 2018, respectively. The sales of Guben Yanling
Pill increased by $3,392,695 or 759,462 units or 30.8% from fiscal year 2018 to fiscal year 2019. In addition, the sales of our
Shenrong Weisheng Pill, Wuzi Yanzong Oral Liquid, Isatis Root Granule and Paracetamol Granule for Children also increased by $282,795,
$129,814, $146,499 and $136,220, representing a 19.2%, 134.0%, 9.7% and 35.4% increase, respectively, and their sales volume increased
by 39.6%, 161.0%, 17.4% and 27.7% from fiscal year 2018 to fiscal year 2019, respectively. The increase in revenue and sales volume
of the above-mentioned products was attributable to the increase in the number of our customers by 71.5% as a result of our strengthened
marketing and sales efforts which led to increased brand awareness. In addition, since the market prices of certain key raw materials
used in our production fluctuate, we adjusted our selling price to tailor such market price fluctuation while considering the best
pricing strategy to stimulate customer orders. For example, the purchase price of several Chinese herbs used in the manufacturing
of Guben Yanling Pill increased in fiscal year 2019, which increased its production costs. In light of the increase in demand and
sales orders of Guben Yanling Pill, we increased its selling price. As a result, the average per unit selling price of Guben Yanling
Pill increased by $0.34, or 11.3%, from $2.99 in fiscal year 2018 to $3.33 in fiscal year 2019. In addition, our research and development
efforts in improving the formulation of our products may help lower our production costs , allowing us to sell products at lower
prices, and making our products more attractive to our customers. For example, we improved the formulation of Shenrong Weisheng
Pill, Wuzi Yanzong Oral Liquid and Isatis Root Granule in 2019, which decreased the unit cost of these products by 8.3%, 4.7% and
8.5%, respectively, and allowed us to lower the selling price for these products by 13.2%, 10.3% and 6.6%, respectively. As a result,
purchase orders of these products from our customers increased in fiscal year 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-size: 10pt"><B><I>Revenue from
sales of third-party products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to diversify our product portfolio
and offerings and to increase our sales, we also sell pharmaceutical products manufactured by third-party companies, including
(i) biochemical drugs, such as such as liquid glucose, prednisolone, and citicoline, (ii) medical instruments, such as drug-eluting
stents, surgical tubes and syringes, (iii) TCMP products, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules
and (iv) dietary supplements, including vitamins, probiotic powder, and calcium tablets. Revenue generated from sales of third-party
products accounted for 37.1% and 38.2% of our total revenue for the years ended September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of third-party products increased by
$1,440,418, or 13.2%, from $10,893,357 in fiscal year 2018 to $12,333,774 in fiscal year 2019, because of an increase in the sales
volume of third-party products by 0.8%, from 7,669,369 units sold in fiscal year 2018 to 7,734,333 units sold in fiscal year 2019,
and an increase in their average selling price by 12.3%, from $1.42 per unit in fiscal year 2018 to $1.59 per unit in fiscal year
2019. Among the total sales of third-party products, sales of biochemical drugs increased by 31.6% or $2,282,588, from $7,226,228
in fiscal year 2018 to $9,508,816 in fiscal year 2019 because of 6.7% increase in sales volume and 23.3% increase in average selling
price, while sales of medical instruments decreased by $814,630 or 23.4% due to decreased sales volume by 381,527 units or 42.2%
and offset by an increase in average selling price by $1.25 per unit. Sales of TCMP products decreased by $33,095, or 18.9%, from
$175,503 in fiscal year 2018 to $142,409 in fiscal year 2019, primarily because we lowered the average selling price by 19.0% to
promote our sales of other products. Sales of dietary supplements products slightly increased by $5,554, or 64.8%, from $8,574
in fiscal year 2018 to $14,127 in fiscal year 2019, due to an increase in average selling price. However, sales of dietary supplements
products are immaterial in our total sales. In fiscal year 2019, due to an overall increase in the market prices of raw materials
used in the manufacturing of third-party products, we paid higher purchase prices when we purchased those products from third-party
pharmaceutical companies. The average per unit cost of dietary supplements, biochemical drugs and TCMP products increased by 145.5%,
6.9% and 1.0%, respectively, and as a result, our average selling price on dietary supplements, biochemical drugs and TCMP products
was adjusted to tailor this change, and increased by $4.78, $0.25 and $1.25 per unit, respectively. On the other hand, the average
unit cost of medical instruments only increased by $0.02 per unit or 1%. In order to reduce the slow-moving inventory stock of
some medical instruments we had purchased and to promote the sales of our products to customers, we lowered the average selling
price of medical instruments by 19%, or $0.59 per unit, which led to a 23.4% decrease in the sales revenue of medical instrument
as discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cost of Revenues. </I></B>Our cost of
revenues primarily consists of inventory costs (raw materials, labor, packaging cost, depreciation and amortization, third-party
products purchase price, freight costs and overhead) and business tax. Cost of revenues generally changes as our production costs
change, which are affected by factors including the market price of raw materials, labor productivity, or the purchase price of
third-party products, and as the customer and product mix changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify">&nbsp;Cost of revenues - TCMD products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,894,117</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,628,763</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,265,354</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">55.9</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;Cost of revenues &ndash;third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,927,714</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,476,502</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">451,212</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">&nbsp;Total cost of revenues</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,821,831</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,105,265</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,716,566</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">31.2</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our cost of revenues increased by $4,716,566,
or 31.2%, from $15,105,265 for the year ended September 30, 2018 to $19,821,831 for the year ended September 30, 2019. The increase
in our cost of revenues was due to the following reasons: (1) an increase in sales volume by 7.5% from 23,715,193 units of products
sold in fiscal year 2018 to 25,500,882 units of products sold in fiscal year 2019. As sales volume increased, our cost of revenues
also increased; (2) in addition, the weighted cost per unit for our TCMD products increased by 40.8%, from $0.48 per unit in fiscal
year 2018 to $0.67 per unit in fiscal year 2019, which was attributable to an increase in the costs of raw materials used in our
production, the weighted average cost per unit for third-party products increased by 6.2%, from $0.97 per unit in fiscal year 2018
to $1.03 per unit in fiscal year 2019 due to higher purchase costs of third-party products. As a result, weighted per unit cost
for all of our products sold during fiscal year 2019 increased by $0.14, or 22.0%, from $0.64 in fiscal year 2018 to $0.78 in fiscal
year 2019; (3) in June 2019, as a local government policy change, Jiangxi Food and Drug Administration (&ldquo;Jiangxi FDA&rdquo;)
strengthened the administration and monitoring of all pharmaceutical companies within Jiangxi Province where our factory is located.
New policies require that the GMP Certificate, the certification that a pharmaceutical company complies with the Good Manufacturing
Practice standards, shall no longer be issued by local FDA authorities, and that all pharmaceutical companies within Jiangxi Province
shall renew or reapply for their GMP Certificates with the Jiangxi FDA at the provincial level. Pursuant to the new policies, in
August and September 2019 we conducted maintenance for our manufacturing facility to improve its environment, including cleaning
and upgrading the machineries and equipment, in order to both meet the strict requirements for the renewal of our GMP Certificate
and ensure the quality and safety of our products. In doing so, we temporarily suspended our manufacturing activities. Costs associated
with the maintenance of manufacturing facilities, including depreciation, maintenance and repair, and base salary paid to workers
totaled $262,049 (RMB 1.8 million) has been included in the cost of revenue during this period. We resumed our manufacturing activities
in late September 2019 after we successfully renewed our GMP Certificate. As a result of the above-mentioned reasons, our cost
of revenues increased by $4,716,566, or 31.2%, in fiscal year 2019 compared to fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="38" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended September 30,</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Unit cost</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Unit cost</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Unit cost</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold">% of</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> 2018</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> change</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> change</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; font-weight: bold; text-indent: -5pt">Costs of TCMD products:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; width: 27%; text-indent: -5pt">Shiquan Dabu Medicinal Liquor</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">298,893</TD><TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1.5</TD><TD STYLE="width: 0.1%; text-align: left">%</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">404,236</TD><TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">2.7</TD><TD STYLE="width: 0.1%; text-align: left">%</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">(105,342</TD><TD STYLE="width: 0.1%; text-align: left">)</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">(26.1</TD><TD STYLE="width: 0.1%; text-align: left">)%</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.90</TD><TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.80</TD><TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">0.10</TD><TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0.1%">&nbsp;</TD>
    <TD STYLE="width: 0.1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">12.2</TD><TD STYLE="width: 0.1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Shenrong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">242,021</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">259,029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,008</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.6</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">&nbsp;Fengtong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">642,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">667,275</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,076</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.8</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17.4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Fengshitong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,363</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(419</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.9</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.06</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.7</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Qishe Medicinal Liquor,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Guben Yanling Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,808,839</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,848,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,960,589</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Quanlu Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">232,698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(132,126</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(56.8</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.7</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Shenrong Weisheng Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,242,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">806,539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">435,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Yangxue Danggui Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">845,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">736,542</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">109,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.3</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Wuzi Yanzong Oral Liquid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,742</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.04</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.03</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.3</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Qiangli Pipa Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,678,414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,365,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.09</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27.7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">&nbsp;Isatis Root Granule</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,358,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">867,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">491,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.58</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33.4</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; padding-bottom: 1.5pt; text-indent: -5pt">Paracetamol Granule for Children</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">441,631</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">295,592</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">146,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">49.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.16</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.03</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; padding-bottom: 1.5pt; text-indent: -5pt">Subtotal: costs of TCMD products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,894,117</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,628,763</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,265,354</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.67</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.48</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; font-weight: bold; text-align: left; text-indent: -5pt">Costs of third party products:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Biochemical drugs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,317,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,477,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">840,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.9</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Traditional Chinese Medicine Pieces</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">935</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; text-indent: -5pt">Medical instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,479,063</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,869,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(390,360</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20.9</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.76</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-align: left; padding-bottom: 1.5pt; text-indent: -5pt">Dietary supplements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,479</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,888</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">592</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.02</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.23</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.79</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">145.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-align: left; padding-bottom: 1.5pt; text-indent: -5pt">Subtotal:&nbsp;&nbsp;costs of third party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,927,714</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,476,502</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">49.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">451,212</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.03</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.97</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.06</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -5pt">Total costs of revenue</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">19,821,831</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,105,265</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,716,566</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">31.2</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.78</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.64</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0.14</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Cost of revenues of TCMD products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues of TCMD products accounted
for 60.0% and 50.5% of our total costs of revenues for the fiscal year 2019 and 2018, respectively. Cost of revenues of TCMD products
increased by $4,265,354, or 55.9%, from $7,628,763 in fiscal year 2018 to $11,894,117 in fiscal year 2019. The increase in cost
of revenues of our TCMD products was due to the following reasons: (1) sales volume of TCMD products increased by 10.7%, from 16,045,824
units sold in fiscal year 2018 to 17,766,549 units sold in fiscal year 2019, while the average per unit cost of our TCMD products
increased by $0.19, or 40.8%, from $0.48 in fiscal year 2018 to $0.67 in fiscal year 2019. Among the 13 varieties of TCMD products,
cost of revenues of Guben Yanling Pill, one of our representative product, accounted for 24.3% and 12.2% of our total cost of revenues
for the years ended September 30, 2019 and 2018, respectively. Sales of Guben Yanling Pill increased by $3,392,695, because sales
volume increased by 759,462 units, or 30.8%. However, the purchase price of several Chinese herbs used in the manufacturing of
Guben Yanling Pill increased in fiscal year 2019, which increased its production costs. As a result, costs of Guben Yanling Pill
increased from $0.75 per unit to $1.49 per unit, thereby increasing the total cost of revenues of Guben Yanling Pill by $2,960,589,
which represented the most significant increase in our cost of revenues associated with our TCMD products sales. In addition, due
to the increase in the purchase price of raw materials, unit production cost of Shengrong Medicinal Liquor and Fengtong Medicinal
liquor, Qishe Medicinal liquor, Yangxue Danggui Syrup, Qiangli Pipa Syrup, Isatis Root Granule and Paracetamol Granule for Children
increased by 17.4%, 17.4%, 23.5%, 20.3%, 27.7%, 33.4% and 17.0%, respectively. These factors increased the overall of cost of revenues
associated with our TCMD products sales; (2) as discussed above, our manufacturing activities were temporarily suspended from August
to late September 2019. Costs associated with the maintenance of manufacturing facilities, including depreciation, maintenance
and repair, and base salary paid to workers totaled $262,049 (RMB 1.8 million) has been included in the cost of revenue during
this period. The increase in our cost of revenues of our TCMD products in fiscal year 2019 as compared to fiscal year 2018 reflected
the above mentioned factors combined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>Cost of revenues of third-party products
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of revenues of third-party products accounted
for 40.5% and 49.5% of our total costs of revenues for the fiscal year 2019 and 2018, respectively. Cost of revenues of third-party
products increased by $451,212, or 6.0%, from $7,476,502 in fiscal year 2018 to $7,927,714 in fiscal year 2019, because of an increase
in sales volume by 0.8%, from 7,669,369 units sold in fiscal year 2018 to 7,734,333 units sold in fiscal year 2019, and an increase
in the average unit cost of third-party products by $0.06 per unit, or 6.2%, from $0.97 per unit in fiscal year 2018 to $1.03 per
unit in fiscal year 2019. In fiscal year 2019, due to an overall increase in the market prices of raw materials used in the manufacturing
of third-party products, we sourced third-party products at higher prices from third-party pharmaceutical companies, the average
unit cost of biochemical drugs, TCMP products, medical instruments and dietary supplements increased by 6.9%, 1%, 36.5% and 145.5%,
respectively, as a result, our unit cost on biochemical drugs, TCMP products, medical instruments and dietary supplements has been
adjusted to tailor this change, and increased by $0.06, $0.02, $0.76 and $1.79 per unit, respectively. In addition, as discussed
above, our manufacturing activities were temporarily suspended from August to late September 2019. During this period of time,
we fulfilled our sales orders primarily through purchasing third-party products instead of manufacturing our own TCMD products.
As a result, our sales volume of third-party products increased and accordingly, our cost of revenue associated with the third-party
products also increased. These factors led to the increase in cost of revenues associated with third-party product sales in fiscal
year 2019 as compared to fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Gross profit </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our gross profit decreased by $1,430, from
$13,408,915 in fiscal year 2018 to $13,407,485 in fiscal year 2019. Our gross margin decreased by 6.7% from 47.0% in fiscal year
2018 to 40.3% in fiscal year 2019. The decrease in our gross profit was primarily due to the increase in cost of revenues of our
TCMD products as the raw material purchase price for several Chinese herb materials used in the manufacturing of our TCMD products
increased. In addition, during our temporary suspension of our manufacturing activities from August to late September 2019, a one-time
maintenance cost of $262,049 further reduced our gross profit. Our gross margin was affected by the sales of different product
mix during each reporting period. The decrease in our gross margin was primarily due to the sales of more products with lower margin
during fiscal year 2019 as compared to fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Gross profit &ndash; sales of TCMD products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,001,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,992,060</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(990,635</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(9.9</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Gross profit &ndash; sales of third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,406,060</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,416,855</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">989,205</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total gross profit</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,407,485</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,408,915</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,430</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(0.0</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gross margin &ndash; sales of TCMD products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13.6</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Gross margin &ndash; sales of third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total gross margin</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">47.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Average selling price per unit - TCMD products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.18</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.10</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.08</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Average cost per unit &ndash; third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.67</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.48</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Average selling price per unit &ndash; third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.17</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Average cost per unit &ndash; third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.03</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.97</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.06</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross profit from TCMD products sales decreased
by $990,635 or 9.9%, from $9,992,060 in fiscal year 2018 to $9,001,425 in fiscal year 2019, while gross margin of TCMD products
sales decreased by 13.6% from 56.7% in fiscal year 2018 to 43.1% in fiscal year 2019. The decrease in our gross profit from TCMD
product sales was due to the following reasons: (1) during our temporary suspension of our manufacturing activities from August
to late September 2019, we reported a one-time maintenance costs of $262,049 as our costs of revenue, which reduced our gross profit
for fiscal year 2019; (2) as discussed above, the weighted average cost per unit for our TCMD products increased by $0.19, or 40.8%,
from $0.48 in fiscal year 2018 to $0.67 in fiscal year 2019, because of an increase in the costs of raw materials used in our production,
and an increase in the weighted average selling price of our TCMD products by $0.08 per unit, or 7%, which was outpaced by the
larger increase in the weighted average unit cost by $0.19 per unit. As a result, our gross margin associated with sales of our
TCMD products decreased by 13.6%, from 56.7% in fiscal year 2018 to 43.1% in fiscal year 2019; (3) in addition, our gross profit
and gross margin are also affected by sales of different product mix during each reporting period. Our gross margin increase as
we sell more products with lower costs and higher margin, while our gross margin decrease as we sell more high costs and lower
margin products are sold. For example, in fiscal year 2019, sales of Guben Yanling Pill increased by $3,392,695 since its sales
volume increased, but related cost of revenues increased by $2,960,589 due to the increase in unit costs, which resulted from an
increase in raw material costs, and as a result, our gross profit on Guben Yanling Pill decreased by $432,106. This contributed
to the largest portion of our decrease in gross profit associated with our TCMD products sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross profit from third-party product sales
increased by $989,205, or 29.0%, from $3,416,855 in fiscal year 2018 to $4,406,060 in fiscal year 2019, while the gross margin
of third-party product sales increased by 4.4%, from 31.4% in fiscal year 2018 to 35.7% in fiscal year 2019. As discussed above,
during August to late September 2019, our manufacturing activities were temporarily suspended from August to late September 2019,
during which time we fulfilled our sales orders primarily through purchasing third-party products. Due to an increase in the overall
market price of raw materials used in the manufacturing of third-party products, the purchase price of third-party products was
higher, with the average per unit cost of third-party products increased by $0.06, or 6.2%, from $0.97 in fiscal year 2018 to $1.03
in fiscal year 2019. However, the weighted average selling price of third-party products increased by $0.23 per unit, or 12.3%,
from $1.42 per unit in fiscal year 2018 to $1.59 per unit in fiscal year 2019, which absorbed the increase in the weighted average
unit cost by $0.06. As a result, our gross margin associated with sales of third-party products increased by 4.3%, from 31.4% in
fiscal year 2018 to 35.7% in fiscal year 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Operating expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the breakdown
of our operating expenses for the fiscal years ended September 30, 2019 and 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of revenue</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% of revenue</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold; text-align: left">Total revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">33,229,316</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">28,514,180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,715,136</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,578,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(101,432</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,497,351</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282,946</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">214,405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left; padding-bottom: 1.5pt">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">618,437</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">789,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(170,945</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total operating expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,694,614</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11.1</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,752,586</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13.2</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(57,972</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.5</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Selling expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our selling expenses primarily include salaries
and welfare benefit expenses paid to our sales personnel, advertising expenses to increase our brand awareness, shipping ad delivery
expenses, expenses incurred for our business travel, meals and other sales promotion and marketing activities related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">657,370</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">41.6</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">567,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">33.8</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">89,703</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">15.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advertising expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">367,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">488,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,910</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24.8</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shipping and delivery expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">457,407</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(43,252</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8.6</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Business travel and meals expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,039</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,574</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20.8</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other sales promotion related expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,071</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23.5</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total selling expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,578,826</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,680,258</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(101,432</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(6.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our selling expenses decreased by $101,432,
or 6.0%, from $1,680,258 in fiscal year 2018 to $1,578,826 in fiscal year 2019, primarily attributable to (i) a decrease in advertising
expenses by $120,910, or 24.8%, from $488,423 in fiscal year 2018 to $367,513 in fiscal year 2019; We use outdoor billboard, magazine
and social media such as WeChat and Weibo to advertise our brand and products in order to increase customer awareness. In fiscal
year 2018, in connection with our sales promotion of several new products to targeted customers, we spent more on advertising than
we did in fiscal year 2019, which led to higher advertising expenses in fiscal 2018; (ii) a decrease in shipping and delivery expenses
by $43,252, or 8.6%, from $500,659 in fiscal year 2018 to $457,407 in fiscal year 2019, because we formed our own logistic team
to deliver some of the products to customers located in nearby cities in 2019. In 2018, we outsourced most of the shipping and
delivery services to third-party logistic companies, which resulted in higher shipping and delivery expenses in fiscal 2018 as
compared to fiscal 2019; (iii) a decrease in business travel and meals expenses by $15,574, or 20.8%, from $75,039 in fiscal year
2018 to $59,465 in fiscal year 2019; from August to late September 2019, we temporarily suspended our manufacturing activities
for the renewal of our GMP Certificate. During that period, we fulfilled our sales orders primarily through purchasing third-party
products instead of manufacturing our own TCMD products. Since our sales and marketing activities were temporarily reduced during
this period, our travel and meals expenses associated with our sales activities decreased; (iv) an increase in our salary and benefit
expenses paid to our sales employees by $89,703, or 15.8%, from $567,667 in fiscal year 2018 to $657,370 in fiscal year 2019. The
number of our sales employees increased from 45 in fiscal year 2018 to 47 in fiscal year 2019. In addition, in early fiscal 2019,
we increased our employee salary base to reflect inflation. These above-mentioned factors combined led to the increase in our selling
expenses in fiscal year 2019 as compared to fiscal year 2018. As a percentage of revenues, our selling expenses accounted for 4.8%
and 5.9% of our total revenue for the years ended September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our general and administrative expenses primarily
consist of employee salaries, welfare and insurance expenses, depreciation, bad debt reserve expenses, inspection and maintenance
expenses, office supply and utility expenses, business travel and meals expenses, land and property taxes and professional service
expenses. As a percentage of revenues, general and administrative expenses were 4.4% and 4.5% of our revenue for the years ended
September 30, 2019 and 2018, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expense</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">529,745</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">36.3</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">502,306</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">39.2</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">27,439</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">209,194</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">233,811</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,617</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10.5</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Bad debt reserve expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,972</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">194,526</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Land and property tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,100</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4.9</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Office supply and utility expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22.3</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transportation, business travel and meals expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,928</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49.9</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Consulting fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Inspection and maintenance fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,384</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Stamp tax and other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">71,718</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">78,245</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,527</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total general and administrative expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,457,393</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,282,946</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">174,447</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13.6</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our general and administrative expenses increased
by $174,447 or 13.6% from $1,282,946 for the year ended September 30, 2018 to $1,457,393 for the year ended September 30, 2019,
primarily attributable to (i) an increase in our salaries, welfare expenses and insurance expenses paid to administration employees
by $27,439, or 5.5%. The number of our administrative employees increased from 25 in fiscal year 2018 to 30 in fiscal year 2019.
In addition, in early fiscal 2019, we adjusted the employee salary base to reflect inflation. These factors led to an increase
in our salary and employee benefit expenses in fiscal year 2019; (ii) our bad debt reserve expenses increased by $194,526, or 188.0%,
from $103,446 in fiscal year 2018 to $297,972 in fiscal year 2019. We generally extend our customers a credit term of 90 days.
Based on our management&rsquo;s assessment of the collectability of our outstanding accounts receivable, we accrued increased bad
debt reserve than we did in fiscal year 2018. This led to the increase in our bad debt reserve expenses in fiscal year 2019 as
compared to fiscal year 2018; (iii) our business travel, transportation and meals expenses decreased by $51,375, or 49.9%, from
$102,928 in fiscal year 2018 to $51,553 in fiscal year 2019, primarily as a result of the temporary suspension of our manufacturing
facility in August and September 2019 as discussed above, which also led to a decrease in our office supply and utility expenses
by $22,189 in fiscal year 2019 as compared to fiscal year 2018; (v) our professional consulting expenses increased by $54,906 in
fiscal year 2019 as compared to fiscal year 2018. In order to prepare for listing in overseas market, we consulted with professional
service providers for legal structure setup and business strategy in fiscal year 2019. The overall increase in our general and
administrative expenses in fiscal year 2019 as compared to fiscal year 2018 reflected the above-mentioned factors combined. As
a percentage of revenues, general and administrative expenses were 4.5% and 4.5% of our revenue for the years ended September 30,
2019 and 2018, respectively.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and development expenses </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses primarily
consist of salaries, welfare and insurance expenses paid to our employees involved in the research and development activities,
materials and supplies used in the development and testing new TCMD products, depreciation and other miscellaneous expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">Salary and employee benefit expenses to R&amp;D staff</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">76,973</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12.4</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">90,427</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11.5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(13,454</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(14.9</TD><TD STYLE="width: 1%; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Materials used in R&amp;D activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">524,094</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">674,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(149,939</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22.2</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Depreciation and others</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,370</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,922</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,552</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(30.3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">618,437</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">789,382</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(170,945</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(21.7</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses decreased
by $170,945, or 21.7%, from $789,382 for the fiscal year 2018 to $618,437 for the fiscal year 2019, primarily attributable to a
decrease in the materials used in the R&amp;D activities by $149,939. In fiscal year 2018, in order to develop new products and
improve the formulation of several existing products, we conducted more testing on product stability and safety, and as a result,
more materials were used in our R&amp;D activities. As a percentage of revenues, research and development expenses were 1.9% and
2.8% of our revenue for the years ended September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other income (expenses)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our other income (expenses) primarily include
interest expenses incurred on our short-term bank loans, gain or loss from disposal of fixed assets and investment income from
our long-term investment in exchange for a 5% ownership interest in a local bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest expenses decreased by $35,654, or
21.6%, from $164,922 in fiscal year 2018 to $129,268 in fiscal year 2019. The decrease in our interest expenses was because we
carried lower amount of bank loans during fiscal year 2019 as compared to fiscal year 2018. Our subsidiaries Jiangxi Universe and
Universe Trade obtained loans from Luling Rural Commercial Bank (&ldquo;LRC Bank&rdquo;) for working capital purposes. At the beginning
of fiscal year 2018, we had an aggregate of RMB 30.2 million ($4.5 million) loans payable to LRC bank. During the fiscal year 2018,
we repaid a total of RMB36 million ($5.5 million) loans upon maturity, and also obtained additional RMB23.8 million ($3.6 million)
loans from LRC bank. As of September 30, 2018, the balance of our outstanding loans payable was RMB18 million ($2.62 million),
and the weighted average loan balance we carried on a daily basis for the year ended September 30, 2018 was RMB 22,122,527 ($3,384,747).
For the year ended September 30, 2019, we paid back a RMB21 million ($3.1 million) bank loan upon maturity, and then we obtained
a loan in the amount of RMB 21million ($3.1 million) from LRC Bank in the second half of fiscal year 2019. As a result, the weighted
average loan balance we carried on a daily basis during the fiscal year ended September 30, 2019 amounted to RMB15,824,176 ($2,302,418).
As of September 30, 2019, we carried a total of RMB18 million ($2.5 million) outstanding bank loans. Therefore, our interest expense
for the year ended September 30, 2019 was lower because of the lower weighted average loan balance we carried during the fiscal
year 2019, as compared to fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our other income was $29,501 and $26,644 for
the years ended September 30, 2019 and 2018, respectively, primarily consisting of investment income of $26,741 and $21,630 and
other income of $2,760 and $5,014 for the years ended September 31, 2019 and 2018, respectively. From March 2009 to September 2017,
we invested approximately RMB5 million ($0.7 million) in Jiangxi Jian Rural Commercial Bank (&ldquo;JX RCB Bank&rdquo;) in exchange
for a 5% ownership interest in the bank. The purpose of these equity investment agreements with JX RCB Bank was to earn investment
income as the bank continues to grow. We account for this investment using the measurement alternative in accordance with ASC 321.
As of September 30, 2019 and 2018, the value of this investment amounted to $700,500 and $728,000, respectively, and was reported
as long-term investment in equity investee on our consolidated balance sheets. During fiscal year 2019, JX RCB Bank reported higher
amount of profit, and accordingly our investment income increased from $21,630 in fiscal year 2018 to $26,741 in fiscal year 2019.
Our other income of $2,760 and $5,014 for fiscal year 2019 and 2018, respectively, primarily included rental payments we received
for renting the roof of one of our factory building to a local energy company for purposes of installing solar panel, as well as
gain from disposal of fixed assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Provision for Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our provision for income taxes was $2,101,597
in fiscal year ended September 30, 2019, an increase of, $186.478, or 9.7% from $1,915,118 in fiscal year ended September 30, 2018
due to our increased taxable income. Under the EIT Law, domestic enterprises and Foreign Investment Enterprises (&ldquo;FIEs&rdquo;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption
may be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&ldquo;HNTEs&rdquo;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply
for their HNTE status every three years. Jiangxi Universe, one of our main operating subsidiaries in the PRC, was approved as a
HNTE and was entitled to a reduced income tax rate of 15% beginning November&nbsp;2016 with a term of three years. Jiangxi Universe&rsquo;s
HNTE status was successfully renewed in December 2019 for a term of three additional years. EIT is typically enforced by the local
tax authorities in the PRC. Each local tax authority has the discretion to grant tax holidays to local enterprises as a way to
encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years ended September 30, 2019 and 2018
were reported at a blended reduced rate since Jiangxi Universe enjoys a 15% reduced income tax rate due to its HNTE status and
Universe Trade is subject to a standard 25% income tax rate. The impact of the tax holidays noted above decreased the corporate
income taxes for our PRC subsidiaries by $312,357 and $471,275 for the years ended September 30, 2019 and 2018, respectively. The
benefits of tax holidays on net income per share (basic and diluted) were $6.25 and $9.43 for the years ended September 30, 2019
and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Net Income </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of the foregoing, we reported a
net income of $7,551,465 for the fiscal year ended September 30, 2019, representing a $51,468 decrease from a net income of $7,602,933
for the fiscal year ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>B. Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, we had $3,177,321
in cash on hand as compared to $6,190,176 as of September 30, 2018. We also had $6,420,986 in accounts receivable. Our accounts
receivable primarily include balance due from customers for our pharmaceutical products sold and delivered to customers. As of
the date of this prospectus, approximately 98%, or $6.3 million of our net accounts receivable balance as of September 30, 2019
have been subsequently collected. We expect to collect the remaining balance by June 2020. Collected accounts receivable will be
used as working capital in our operations, if necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, our inventory balance
amounted to $2,615,155, primarily consisting of raw materials and work-in-progress and finished TCMD products, which we believe
are able to be sold quickly based on the analysis of the current trends in demand for our products. We also had short-term bank
loans of $2,521,800 that we obtained from LRC Bank for working capital purposes. We expect that we will be able to renew all of
the existing bank loans upon their maturity based on past experiences and our outstanding credit history. The balance of our due
to related parties was$54,705 as of September 30, 2019, representing cash advances from our controlling shareholders to be used
as our working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, our working capital
balance was $6,776,942. In assessing our liquidity, management monitors and analyzes our cash on-hand, our ability to generate
sufficient revenue in the future, and our operating and capital expenditure commitments. We believe that our current cash and cash
flows provided by operating activities, borrowings from banks and from our principal shareholders will be sufficient to meet our
working capital needs in the next 12 months from the date the audited financial statements were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the coming years, we will be looking to
other sources, such as raising additional capital by issuing shares of stock, to meet our needs for cash. Even though we face uncertainties
in regards to the size and timing of capital-raising, we are confident that we can continue to meet operational needs solely by
utilizing cash flows generated from our operating activities and shareholder working capital funding, as necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth summary of our
cash flows for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash provided by operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,203,755</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,455,599</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86,033</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145,095</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash used in financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,003,857</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,914,580</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of exchange rate change on cash and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(126,720</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(189,162</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,012,855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(793,238</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash, beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,190,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,983,414</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,177,321</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,190,176</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Operating Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by operating activities was
$13,203,755 for the year ended September 30, 2019, primarily consisting of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
income of $7,551,466 for the fiscal year;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accounts receivable of $665,485 because we collected the same amount of accounts receivable. Our accounts receivable primarily includes balance due from customers for our pharmaceutical products sold and delivered to customers. As of date of this prospectus, approximately 98%, or $6.3 million of our net accounts receivable balance as of September 30, 2019 have been subsequently collected. Collected accounts receivable will be used as working capital in our operations, if necessary.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in inventory balance of $5,586,177. As discussed above, our manufacturing activities were temporarily suspended from August and September 2019 we conducted maintenance for our manufacturing facility to improve its environment, including cleaning and upgrading the machineries and equipment, in order to both meet the strict requirements for the renewal of our GMP Certificate renewal and ensure the quality and safety of our products. During the period when our business was temporarily closed, we reduced the purchase of our raw material inventories, which led a decrease in our ending inventory balance as of September 30, 2019. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accounts payable of $924,444 for the fiscal year. The decrease in our accounts payable balance as of September 30, 2019 was largely attributable to our temporary suspension of our manufacturing activities in August and September 2019 as discussed above. During this period, we conducted maintenance for our manufacturing facility to improve its environment, including cleaning and upgrading the machineries and equipment, in order to both meet the strict requirements for the renewal of our GMP Certificate renewal and ensure the quality and safety of our products. As a result, we reduced the purchase of raw materials on credit from our suppliers, which led to a decrease in our accounts payable balance as of September 30, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in taxes payable of $320,611 for the fiscal year primarily due to our reduced VAT tax payable from decrease in the amount of &nbsp;raw materials purchased in August and September 2019 when our manufacturing facility was temporarily closed.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by operating activities was
$4,455,599 in fiscal year ended September 30, 2018, primarily consisted of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income of $7,602,933 for the fiscal year; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in accounts receivable of $2,815,443 due to an increase in credit sales to our customers. Our accounts receivable primarily include balance due from customers for our pharmaceutical products sold and delivered to customers. As of September 30, 2018, we had outstanding accounts receivable of $7,637,177. Approximately $7.3million, or 95%, of the accounts receivable balance as of September 30, 2018 was collected back during fiscal year 2019. Collected accounts receivable will be used as working capital in our operations, if necessary;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in inventory balance of $327,259 because based on our increased sales&nbsp;&nbsp;in 2018, we increased the purchase of raw materials in preparation for production to fulfill future sales orders;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A decrease in accrued expenses and other current liabilities of $1,129,019, which was primarily attributable to a decrease in other payable balance. In May 2016, we outsourced our sewage construction project to a third-party, Jiangxi Minda Industrial Co., Ltd., to construct the sewage pipeline and related facilities in our manufacturing facility, with the total contract price of approximately RMB8.1 million ($1.2 million). The project was completed in May 2017 and passed inspection in late 2017. We paid $1.2 million to this third-party during fiscal year 2018, resulting in a decrease in our other payable balance as of September 30, 2018.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in taxes payable of $444,790 primarily due to an increase in VAT tax payables when we increased our raw materials purchase during fiscal 2018, which was in line with our increased inventory balance as of September 30, 2018. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities amounted
to $86,033 for the year ended September 30, 2019, and primarily included the purchase of fixed assets of $86,324 and proceeds of
$291 from disposal of fixed assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities amounted
to $145,095 for the year ended September 30, 2018, and primarily included the purchase of fixed assets in the same amount.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Financing Activities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in financing activities amounted
to $16,003,857 for the year ended September 30, 2019, primarily include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term bank loans of $3,055,500. During fiscal year 2019, our subsidiaries Jiangxi Universe and Universe Trade obtained additional loans in an aggregate amount of RMB 21 million ($3.1 million) from LRC Bank for working capital purposes. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of short-term bank loans of $3,055,500 upon loan maturities. In fiscal year 2018, our subsidiaries Jiangxi Universe and Universe Trade obtained additional loans in an aggregate amount of RMB21 million from LRC Bank for working capital purposes. We repaid these loans upon maturity and entered into new loan contracts with LRC bank during fiscal year 2019.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend payment of $16,005,000. On September 21, 2016, September 13, 2017, February 2, 2018, September 20, 2018 and February 21, 2019, the board of directors of our subsidiary Jiangxi Universe approved resolutions to pay cash dividends of RMB 40 million, RMB 30 million, RMB 20 million, RMB 10 million and RMB 30 million, respectively, to its shareholders at the time of record out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when Jiangxi Universe has sufficient available earnings funds. A total of $19.1 million (RMB130 million) cash dividend was declared from September 2016 to February 2019, among which $3.1 million (RMB20 million) &nbsp;was paid in cash to its shareholders in fiscal year 2018 and the remaining $16 million (RMB 110 million) was paid to its shareholders in fiscal year 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party borrowings of $1,143. The balance due to related party mainly consisted of advances from our principal shareholder for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in financing activities amounted
to $4,914,580 for the year ended September 30, 2018, primarily include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from short-term bank loans of $3,641,400. During fiscal year 2018, our subsidiaries Jiangxi Universe and Universe Trade obtained additional loans in an aggregate amount of RMB 23.8 million from LRC Bank for working capital purposes. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of short-term bank loans of $5,508,000 upon loan maturities. In fiscal year 2017, our subsidiaries Jiangxi Universe and Universe Trade obtained loans in an aggregate amount of RMB 36 million from LRC Bank for working capital purposes. We repaid these loans upon maturity and entered into new loan contracts with LRC bank during fiscal year 2018.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend payment of $3,060,000. On September 21, 2016, September 13, 2017, February 2, 2018, September 20, 2018 and February 21, 2019, the Board of Directors of our subsidiary Jiangxi Universe approved resolutions to pay cash dividend of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30 million, respectively, to its shareholders at the time of record out of the retained earnings balance of Jiangxi Universe, to be paid to these shareholders when Jiangxi Universe has sufficient available earnings and funds. A total of RMB130 million ($19.1 million) cash dividend was declared from September 2016 to February 2019, among which RMB20 million ($3.1 million) was paid in cash to the shareholders in fiscal year 2018 and the remaining RMB110 million ($16 million) was paid to its shareholders in fiscal year 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679; </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds from related party borrowings of $12,020. The balance due to related party mainly consisted of advances from our principal shareholder for working capital purposes during our normal course of business. These advances were non-interest bearing and due on demand. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Commitments and contingencies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we are a party to various
legal actions arising in the ordinary course of business. We accrue costs associated with these matters when they become probable
and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
For the years ended September 30, 2019 and 2018, we did not have any material legal claims or litigation that, individually or
in aggregate, could have a material adverse impact on our consolidated financial position, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have material commitments as of September
30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Trend Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other than as disclosed elsewhere in this prospectus,
we are not aware of any trends, uncertainties, demands, commitments, or events that are reasonably likely to have a material effect
on our net revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported
financial information not necessarily to be indicative of future operating results or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not have any off-balance sheet arrangements
as of September 30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Inflation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflation does not materially affect our business
or the results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Seasonality </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Seasonality does not materially affect our
business or the results of our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our discussion and analysis of our financial
condition and results of operations are based upon our consolidated financial statements. These financial statements are prepared
in accordance with U.S. GAAP, which requires us to make estimates and assumptions that affect the reported amounts of our assets
and liabilities and revenues and expenses, to disclose contingent assets and liabilities on the date of the consolidated financial
statements, and to disclose the reported amounts of revenues and expenses incurred during the financial reporting period. The most
significant estimates and assumptions include the valuation of accounts receivable and inventories, useful lives of property, plant
and equipment and intangible assets, the recoverability of long-lived assets, provision necessary for contingent liabilities, and
revenue recognition. We continue to evaluate these estimates and assumptions that we believe to be reasonable under the circumstances.
We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual
results could differ from those estimates. Some of our accounting policies require higher degrees of judgment than others in their
application. We believe critical accounting policies as disclosed in this prospectus reflect the more significant judgments and
estimates used in preparation of our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks and Uncertainties </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our main operation is located in the PRC.
Accordingly, our business, financial condition, and results of operations may be influenced by political, economic, and legal environments
in the PRC, as well as by the general state of the PRC economy. Our results may be adversely affected by changes in the political,
regulatory and social conditions in the PRC. Although we have not experienced losses from these situations and believes that we
are in compliance with existing laws and regulations including our organization and structure, this may not be indicative of future
results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business, financial condition and
results of operations may also be negatively impacted by risks related to natural disasters, extreme weather conditions, health
epidemics and other catastrophic incidents, such as the recent outbreak and spread of the COVID-19, which could significantly
disrupt our operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The development and commercialization of
new pharmaceutical products is highly competitive, and the industry currently is characterized by rapidly changing technologies,
significant competition and a strong emphasis on intellectual property. We may face competition with respect to our current and
future pharmaceutical product candidates from major pharmaceutical companies in China.&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following critical accounting policies
rely upon assumptions and estimates and were used in the preparation of our consolidated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Uses of estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America (&ldquo;US GAAP&rdquo;), management
makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. These estimates are based on information as of the date of the consolidated financial statements. Significant estimates
required to be made by management include, but are not limited to, the allowance for estimated uncollectible receivables, inventory
valuation, useful lives of property, plant and equipment, intangible assets, the recoverability of long-lived assets, provision
necessary for contingent liabilities, revenue recognition and realization of deferred tax assets. Actual results could differ
from those estimates.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Accounts receivable, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable are presented net of allowance
for doubtful accounts. We determine the adequacy of reserves for doubtful accounts based on individual account analysis and historical
collection trend. We establish a provision for doubtful receivables when there is objective evidence that we may not be able to
collect amounts due. The allowance is based on management&rsquo;s best estimate of specific losses on individual exposures, as
well as a provision on historical trends of collections. Actual amounts received may differ from management&rsquo;s estimate of
credit worthiness and the economic environment. Delinquent account balances are written-off against the allowance for doubtful
accounts after management has determined that the likelihood of collection is not probable. Allowance for uncollectable balances
amounted to $517,754 and $239,904 as of September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;Inventories, net</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at net realizable value
using weighted average method. Costs include the cost of raw materials, freight, direct labor and related production overhead.
Any excess of the cost over the net realizable value of each item of inventories is recognized as a provision for diminution in
the value of inventories. Net realizable value is the estimated selling price in the normal course of business less any costs to
complete and sell products. We evaluate inventories on a quarterly basis for its net realizable value adjustments, and reduces
the carrying value of those inventories that are obsolete or in excess of the forecasted usage to their estimated net realizable
value based on various factors including aging, expiration dates, as applicable, taking into consideration historical and expected
future product sales. We recorded inventory reserve of $179,412 and $373,855 as of September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenue recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted Accounting Standards Codification
(&ldquo;ASC&rdquo;) 606 using the modified retrospective approach. The adoption of this standard did not have a material impact
on our consolidated financial statements. Therefore, no adjustments to opening retained earnings were necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 606, Revenue from Contracts with customers,
establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising
from the entity&rsquo;s contracts to provide goods or services to customers. The core principle requires an entity to recognize
revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects to
be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 606 requires the use of a five-step model
to recognize revenue from customer contracts. The five-step model requires that we (i) identify the contract with the customer,
(ii) identify the performance obligations in the contract, (iii) determine the transaction price, including variable consideration
to the extent that it is probable that a significant future reversal will not occur, (iv) allocate the transaction price to the
respective performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation.
The application of the five-step model to the revenue streams compared to the prior guidance did not result in significant changes
in the way we record our revenue. We have assessed the impact of the guidance by reviewing our existing customer contracts and
current accounting policies and practices to identify differences that will result from applying the new requirements, including
the evaluation of its performance obligations, transaction price, customer payments, transfer of control and principal versus agent
considerations. Based on the assessment, we concluded that there was no change to the timing and pattern of revenue recognition
for our current revenue streams.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance to ASC 606, we recognize revenue
when we transfer our goods and services to customers in an amount that reflects the consideration to which we expect to be entitled
in such exchange. We account for the revenue generated from sales of TCMD and third-party products on a gross basis as we are acting
as a principal in these transactions, are subject to inventory risk, have latitude in establishing prices, and are responsible
for fulfilling the promise to provide customers the specified goods, which we have control of the goods and has the ability to
direct the use of goods to obtain substantially all the benefits. All of our contracts have one single performance obligation as
the promise is to transfer the individual goods to customers, and there is no separately identifiable other promises in the contracts.
Our revenue streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods, which
generally occurs at delivery. Our products are sold with no right of return and we do not provide other credits or sales incentive
to customers. Revenue is reported net of all value added taxes (&ldquo;VAT&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>Contract Assets and Liabilities </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Payment terms are established on our pre-established
credit requirements based upon an evaluation of customers&rsquo; credit quality. Contract assets are recognized for in related
accounts receivable. Contract liabilities are recognized for contracts where payment has been received in advance of delivery.
The contract liability balance can vary significantly depending on the timing when an order is placed and when shipment or delivery
occurs. As of September 30, 2019 and 2018, other than accounts receivable and advances from customers, we had no other material
contract assets, contract liabilities or deferred contract costs recorded on its consolidated balance sheet. Costs of fulfilling
customers&rsquo; purchase orders, such as shipping, handling and delivery, which occur prior to the transfer of control, are recognized
in selling, general and administrative expense when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Disaggregation of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We disaggregate our revenue from contracts
by product types, as we believe it best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are
affected by economic factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The summary of our total revenues by product
categories for the years ended September 30, 2019 and 2018 was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Revenue by product source </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&nbsp;the&nbsp;year ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Sales of TCMD products manufactured by us</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,895,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,620,823</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Sales of third-party products </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,893,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total revenue</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,229,316</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,514,180</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Revenue by product categories </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended<BR>
 September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Sales of TCMD products:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Medicinal liquor products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,356,015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,857,283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other chronic condition treatment products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,056,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,529,642</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Cold and flu medicines</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,483,299</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,233,898</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Sub-total of TCMD products sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,895,542</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,620,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Sales of third-party products:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Biochemical drugs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,508,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,226,228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Traditional Chinese medicine pieces</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Medical instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,668,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,483,052</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Dietary supplements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,127</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,574</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Subtotal of third-party products sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,893,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28,514,180</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Income Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We account for current income taxes in accordance
with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the
tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period including the enactment date. Valuation allowances are established, when necessary, to reduce deferred
tax assets to the amount expected to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An uncertain tax position is recognized only
if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination. The amount recognized
is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting
the &ldquo;more likely than not&rdquo; test, no tax benefit is recorded. Penalties and interest incurred related to underpayment
of income tax are classified as income tax expense in the period incurred. No significant penalties or interest relating to income
taxes have been incurred during the years ended September 30, 2019 and 2018. We do not believe there was any uncertain tax provision
at September 30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating subsidiary in China is subject
to the income tax laws of the PRC. No significant income was generated outside the PRC for the fiscal years ended September 30,
2019 and 2018. As of September 30, 2019, all of our tax returns of our PRC Subsidiaries remain open for statutory examination by
PRC tax authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recently Issued Accounting Pronouncements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued Accounting
Standards Update (ASU) No. 2016-02,&nbsp;Leases (Topic 842), which requires lessees to recognize a right-of-use asset and lease
liability on the balance sheet for all leases, including operating leases, with a term in excess of 12 months. The guidance also
expands the quantitative and qualitative disclosure requirements. The new guidance requires the lessee to record operating leases
on the balance sheet with a right-of-use asset and corresponding liability for future payment obligations. In July 2018, FASB issued
ASU 2018-11 Leases (Topic 842) &ndash; Targeted Improvements&nbsp;that reduces costs and eases implementation of the leases standard
for financial statement preparers. The ASU simplifies transition requirements and, for lessors, provides a practical expedient
for the separation of non-lease components from lease components. In November 2019, FASB released ASU No. 2019-10, Financial Instruments&mdash;Credit
Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which modified the implementation
date of the standard. For public entities, the guidance will be effective for fiscal year beginning after December 15, 2018 and
interim periods therein. For all other entities, the guidance is effective for fiscal years beginning after December 15, 2020 and
interim periods within fiscal years beginning after December 15, 2021. As an emerging growth company, we will adopt this guidance
effective October 1, 2021. We do not expect the cumulative effect resulting from the adoption of this guidance will have a material
impact on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB ASU No. 2018-13, &ldquo;Fair
Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement&rdquo; (&ldquo;ASU
2018-13&rdquo;). ASU 2018-13 modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for all
entities for fiscal years and interim periods within those fiscal years beginning after December 15, 2019, with early adoption
permitted for any removed or modified disclosures. The removed and modified disclosures will be adopted on a retrospective basis
and the new disclosures will be adopted on a prospective basis. We do not expect this guidance will have a material impact on its
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13,
Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets
held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces
the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized
cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19, <I>Codification Improvements to Topic 326, Financial
Instruments&mdash;Credit Losses</I>, Accounting Standards Update 2019-04 <I>Codification Improvements to Topic 326, Financial Instruments&mdash;Credit
Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</I>, and Accounting Standards Update 2019-05,
<I>Targeted Transition Relief.</I> For public entities, ASU 2016-13 and its amendments is effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2019. For all other entities, this guidance and its amendments
will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early
application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2018. As an emerging growth company, we plan to adopt this guidance effective October 1, 2022. We are currently evaluating
the impact of our pending adoption of ASU No. 2016-13 on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, the FASB issued ASU No. 2019-12,
Income Taxes (Topic 740)&mdash;Simplifying the Accounting for Income Taxes. ASU 2019-12 is intended to simplify accounting for
income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent
application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and interim periods within those fiscal
years, which is fiscal 2021 for us, with early adoption permitted. We do not expect adoption of the new guidance to have a significant
impact on our financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="c13"></A>INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>All the information and data presented in
this section have been derived from Frost &amp; Sullivan (Beijing) Inc., Shanghai Branch Co.&rsquo;s industry report commissioned
by us in December 2019 entitled &ldquo;The PRC Chinese Patent Medicine Industry Independent Market Research&rdquo;, unless otherwise
noted. Frost &amp; Sullivan has advised us that the statistical and graphical information contained herein is drawn from its database
and other sources. The following discussion projections for future growth, which may not occur at the rates that are projected
or at all. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>OVERVIEW OF THE MACROECNOMIC ENVIRONMENT
IN THE PRC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Population of High-Aged Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Source: National Bureau of Statistics of
China, Frost &amp; Sullivan Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to the National Bureau of Statistics
of China, by the end of 2018, the Chinese population aged 65 or above reached 166.6 million, accounting for 11.9% of the total
population in China. With the rising life expectancy and the &ldquo;One Child Policy&rdquo; from the 1980s to the 2010s in the
PRC, population is aging fast with the population aged 65 or above growing at a CAGR of approximately 4.9% from 2014 to 2018.
Demand for healthcare products and services is also increasing rapidly due to the aging population and the rise of chronic diseases
such as arthritis, asthma, diabetes and etc. It is forecasted that the Chinese population aged 65 or above will reach 208.0 million
by the end of 2023, accounting for 14.7% of the total population in China.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Per Capita Annual Disposable Income</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Source: National Bureau of Statistics of
China, Frost &amp; Sullivan Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to the National Bureau of Statistics
of China, during the past five years, in line with the steady economic growth, per capita annual disposable income of the PRC rose
from RMB20.2 thousand in 2014 to RMB28.2 thousand in 2018, representing a CAGR of approximately 9.0% from 2014 to 2018. The rise
in disposable income contributes to improvements in living standards and increase in health awareness, supporting the development
of the Chinese patent medicine market in the PRC. It is expected that the per capita annual disposable income in the PRC will grow
from RMB30.6 thousand in 2019 to RMB43.2 thousand in 2023, with a CAGR of approximately 8.9%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>OVERVIEW OF THE CHINESE PATENT MEDICINE
MARKET IN THE PRC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Definition and Categorization of Traditional
Chinese Medicine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Traditional Chinese medicine (TCM) has been
widely accepted and used in the PRC for thousands of years to treat wounds and diseases, with the use of traditional Chinese medicine
such as herbs, herbal materials, herbal preparations and finished products. The traditional Chinese medicine market consists of
four segments based on the complexity of processing and product types, namely Chinese herbal medicine, decoction pieces, Chinese
patent medicine and traditional Chinese dietary supplements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Chinese herbal medicine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chinese herbal medicine represents the raw
or unfinished products of Chinese herbs. It usually refers to the medicinal parts of plants, animals and mineral materials that
can be used to produce decoction pieces and Chinese patent medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Decoction pieces</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Decoction pieces are produced by further processing
raw Chinese herbs based on TCM theories and procedures including dehairing, slicing, chopping, boiling, steaming, frying and etc.
Recent years have witnessed the development of modernized decoction technologies such as modernized extraction, concentration,
ultra-fine pulverization and etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Chinese patent medicine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chinese patent medicine or propriety Chinese
medicine refers to any proprietary product composed solely of Chinese herbal medicines and/or materials of herbal, animal or mineral
origin, formulated in a finished dose form and used for the diagnosis, treatment, prevention or alleviation of disease or symptom
of a disease in human beings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Traditional Chinese dietary supplements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Traditional Chinese dietary supplements
are Chinese herbal supplements used for the prevention of disease. Compared to herbal medicine, traditional Chinese dietary supplements
usually choose herbs that are considered mild and moderate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Value Chain Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_005.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <I>Note: The Company is a vertically integrated
Chinese patent medicine enterprise engaging in the supply, manufacture and distribution of Chinese patent medicine in the PRC.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Source: Frost &amp; Sullivan Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The upstream of Chinese patent medicine market
in the PRC mainly refers to raw material suppliers such as crop and livestock producers who provide mineral, animal and plant tissues
that can be used for the manufacture of TCM. Midstream Chinese patent medicine manufacturers procure TCM herbs through direct sales
or distributors and produce Chinese patent medicine. Finished products will be sold to downstream medical service providers such
as hospitals, clinics and etc. directly or through distributors. Downstream healthcare consumers can purchase Chinese patent medicine
from medical service providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Size of Chinese Patent Medicine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_006.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Source: Frost &amp; Sullivan Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As stated in the Frost &amp; Sullivan Report,
from 2014 to 2018, stimulated by favorable government policies including the expansion of the National Drug Catalog for Basic Medical
Insurance, Work-Related Injury Insurance, and Maternity Insurance and rising market demand for Chinese patent medicine, the total
market size of Chinese patent medicine by principal business revenue in the PRC grew from RMB580.7 billion in 2014 to RMB630.9
billion in 2018, representing a CAGR of approximately 2.1%. The market experienced a fall in 2017, primarily due to more stringent
regulations and the winding up of a number of manufacturing enterprises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to the Frost &amp; Sullivan Report,
in spite of the continuously aging population and rising awareness of healthcare, the market size of Chinese patent medicine in
the PRC is anticipated to increase at a CAGR of approximately 6.0% in the next five years, from RMB668.8 billion in 2019 to RMB844.3
billion by the end of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Size of Traditional Chinese Dietary
Supplements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_007.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>Source: Frost &amp; Sullivan Report</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alongside rising healthcare awareness and improving
living standards of the PRC population, the traditional Chinese dietary supplements market experienced a rapid growth from RMB60.9
billion in 2014 to RMB86.6 billion in 2018, representing a CAGR of approximately 9.2%. Looking forward, with the expanding expenditure
on healthcare product and service, market size of traditional Chinese dietary supplements by revenue is anticipated to rise with
a CAGR of approximately 9.6%, from RMB93.7 billion in 2019 to RMB135.1 billion by the end of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Drivers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Increasing disposable income and healthcare
awareness.</I> Under supportive economic policies promulgated by the PRC government, the PRC has maintained a stable economic growth
amidst the uncertainties in the global economic environment over the past five years. Consumers in the PRC are paying more attention
on improvements in living standards and healthcare products and service, accompanying the economic development and rise in disposable
income. According to International Monetary Fund (IMF), per capita annual disposable income of the PRC increased with a CAGR of
approximately 9.0%, reaching RMB28,200 by the end of 2018. In addition, with the healthcare reform and the implementation of the
13th Five-Year Plan, per capita annual expenditure on healthcare attained RMB1,766.9 in 2018 with a CAGR of approximately 12.0%
from 2014, which supports the steady development of Chinese patent medicine market in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Growing aging population and prevalence
of chronic diseases. </I>As stated by the National Bureau Statistics of China, the PRC population is aging rapidly with the population
aged 65 or above increasing at a CAGR of approximately 4.9% during the period from 2014 to 2018. The aging population usually have
weaker immune systems and higher possibility of illness. In particular, chronic diseases are prevalent among the elderly, driving
the healthcare demand among people aged 65 or above. In addition, as TCM products are usually considered helpful in protecting
and improving the health and well-being of people, consumers in the PRC usually prefer TCM products and service to maintain health,
and prevent and treat diseases, which brings sustained market demand for Chinese patent medicine. In the next five years, the aging
population is forecasted to account for 14.7% of the total population of the PRC, continuously driving the market of Chinese patent
medicine in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Favorable governmental policies and regulations.</I>
In February 2017, the Ministry of Human Resources and Social Security issued a new version of the National Drug Catalogue for Basic
Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance to include additional types of pharmaceutical products
in the coverage of insurance and reimbursement. The total number of products in the Catalogue reached 2,535, with 1,238 being Chinese
patent medicine. Compared to the old version, the total number of Chinese patent medicine increased by 25.4%, accounting for 48.8%
of the total number of products in the Catalogue. Insurance and reimbursement coverage by the PRC government is forecasted to encourage
market demand and consumption of Chinese patent medicine in the PRC. In addition, the Outline for the Strategic Development of
Chinese Medicine (2016-2030) (&#12298;&#20013;&#21307;&#33647;&#21457;&#23637;&#25112;&#30053;&#35268;&#21010;&#32434;&#35201;(2016-2030)&#12299;)
aims to allow every citizen to enjoy quality TCM services by the end of 2020. The Outline of the 13th Five-Year Plan for the National
Economic and Social Development of the People&rsquo;s Republic of China (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22269;&#27665;&#32463;&#27982;&#21644;&#31038;&#20250;&#21457;&#23637;&#31532;&#21313;&#19977;&#20010;&#20116;&#24180;&#35268;&#21010;&#32434;&#35201;&#12299;)
also highlights the importance of TCM and sets TCM as a strategic priority in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Outbreak of COVID-19.</I> A new corona virus,
COVID-19, emerged in December 2019 and then spread rapidly worldwide in 2020. The outbreak of COVID-19 caused 81,669 infections
and 3,329 deaths in the PRC as of April 4, 2020, based on official numbers. Common symptoms of COVID-19 include fever, cough, and
shortness of breath. Currently, there is no specific antiviral treatment of COVID-19 or cure for an infection. Treatments focusing
on managing symptoms are generally accepted in the clinical applications. For example, according to Shanghai Municipal Health Commission,
paracetamol is recognized as the only recommended antipyretic-analgesic drug for the clinical application of COVID-19 treatment.
Apart from conventional treatment, the use of TCM as a supplement to conventional therapy has been recommended by Wuhan Municipal
Health Commission and National Health Commission of the PRC. Furthermore, as consumers in the PRC usually prefer TCM products to
maintain health and prevent disease, the Chinese patent medicine market in the PRC is expected to demonstrate a strong growth in
2020 and afterwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Trend</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Integration of e-commerce.</I> Starting
from 2016, with the issue of the &ldquo;Internet + Human Resources and Social Security&rdquo; 2020 Program (&#12298;&ldquo;&#20114;&#32852;&#32593;+&#20154;&#31038;&rdquo;2020&#34892;&#21160;&#35745;&#21010;&#12299;)
by the Ministry of Human Resources and Social Security, e-commerce platform became the new main retail sales channel for Chinese
patent medicine in the PRC. In 2017, the National Administration of Traditional Chinese Medicine, a state agency under the jurisdiction
of National Health Commission that oversees China&rsquo;s traditional Chinese medicine industry published the Guiding Opinions on Promoting
the Integration of Traditional Chinese Healthcare Service and Internet, which supports online development of TCM product and service.
It is expected that with the supportive government policies and rising adoption of e-commerce in the PRC, online expansion and
integration of e-commerce will become a new market trend in the Chinese patent medicine market in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21pt"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Development of overseas market. </I>The
National Development and Reform Commission and the National Administration of Traditional Chinese Medicine of the PRC
together issued the Development Plan for the &ldquo;Belt and Road Initiative&rdquo; of Traditional Chinese Medicine
(2016-2020)
(&#12298;&#20013;&#21307;&#33647;&ldquo;&#19968;&#24102;&#19968;&#36335;&rdquo;&#21457;&#23637;&#35268;&#21010;(2016-2020&#24180;)
&#12299;) (the &ldquo;Development Plan&rdquo;). Based on the Development Plan, China plans to establish 30 TCM centers and 50
TCM demonstration bases for promoting traditional Chinese medicine in foreign countries. Expansion and development of an
overseas TCM market is expected to be another trend of the Chinese patent medicine market in the next five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>COMPETITIVE LANDSCAPE OF CHINESE PATENT
MEDICINE MARKET IN THE PRC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competition Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chinese patent medicine market in the PRC
is fragmented with over 1,500 sizable Chinese patent medicine enterprises by the end of 2018. As stated in the 13th Five Year Plan,
the PRC government will encourage mergers and acquisitions in the industry, which is expected to increase the concentration of
the overall Chinese patent medicine market in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Major Competitors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Company Name</TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Year of Establishment</TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Headquarter</TD><TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Description</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: middle; text-align: center">Guangzhou Pharmaceutical Holdings Ltd.</TD><TD STYLE="vertical-align: middle; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center">1951</TD><TD STYLE="vertical-align: middle; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center">Guangzhou, the PRC</TD><TD STYLE="vertical-align: middle; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center">Guangzhou Pharmaceutical is dedicated to the research and development of Chinese patent medicine, Chinese herbal medicine, chemical pharmaceutical products, biological medicine and healthcare products. It engages in the supply, manufacture, logistics and distribution of healthcare products and services.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: middle; width: 18%; text-align: center">Beijing Ton Ren Tang Group Co., Ltd.</TD><TD STYLE="vertical-align: middle; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; width: 10%; text-align: center">1669</TD><TD STYLE="vertical-align: middle; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; width: 18%; text-align: center">Beijing, the PRC</TD><TD STYLE="vertical-align: middle; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; width: 51%; text-align: center">With a history of over 300 years, Tong Ren Tang is a Chinese pharmaceutical company specializing in the manufacturing and retail sales of TCM. It has 5 manufacturing bases with over 40 production lines to produce over 1,000 types of products.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: middle; text-align: center"> Yunnan Baiyao Group Co., Ltd. <BR>(SZSE: 000538) </TD><TD STYLE="vertical-align: middle; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: middle; text-align: center"> 1971 </TD><TD STYLE="vertical-align: middle; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: middle; text-align: center"> Kunming, the PRC </TD><TD STYLE="vertical-align: middle; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: middle; text-align: center"><P STYLE="margin: 0; font: 10pt/107% Times New Roman, Times, Serif"> With
                                         over 100 years of history, Yunnan Baiyao is a pharmaceutical enterprise which develops,
                                         manufactures, distributes and sells TCM products. Its products are sold in the PRC, Southeast
                                         Asia and other regions and countries. Yunnan Baiyao Group Co., Ltd. was listed on the
                                         Shenzhen Stock Exchange in 1993. </P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Entry Barrier Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>License and qualification. </I>Market participants
in the Chinese patent medicine market in the PRC are required to obtain a Pharmaceutical Production License from the National
Medical Products Administration. The license will be issued only after it is determined, through an inspection, that the a company&rsquo;s
relevant production facilities are at or above the applicable standards for sanitary conditions, quality assurance systems, management
structure and equipment standards. Meanwhile, manufacturers must produce in accordance with the Standards for Quality Control
of Pharmaceutical Production formulated by the Department of Pharmaceutical Supervisory and Administrative under the State Council
and obtain GMP Certificate.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Qualified and experienced personnel. </I>Chinese
patent medicine enterprises rely heavily on qualified and experienced talents, as their expertise and knowledge will directly affect
the research and development, manufacturing, and distribution activities of market participants. Established market participants
with proven track record and good industry reputation are more likely to attract professional talents. New market entrants may
not be able to recruit enough qualified workers to establish their business in the Chinese patent medicine market in the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Significant capital investment.</I> It is
crucial for Chinese patent medicine market participants to have sufficient capital for the research and development for new products,
maintenance and upgrade of manufacturing and production facilities and etc. Market participants with years of establishment generally
possess sufficient capital for the R&amp;D and manufacturing activities. In addition, established market participants have a proven
track record and industry reputation to raise external funds. New market entrants, on the other hand, may find it hard to raise
sufficient initial capital investment to enter the Chinese patent medicine market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="c14"></A>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Mission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our mission is to provide solutions to the
physical conditions of the elderly during their aging process and to promote their general well-being.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Traditional Chinese Medicine (&ldquo;TCM&rdquo;)
is a comprehensive form of healthcare that has been widely adopted in China for more than 23 centuries. TCM rests upon the assumption
that the human body is an ecosystem, embodying the fusion of Shen (psyche), Essence (soma), Qi, Moisture (body fluids), and Blood
(tissue). Health in the context of TCM is more than just the absence of diseases, but to identify imbalance in human body and restore
harmony. TCM is not only intended to cure diseases but to enhance the capacity for fulfillment, happiness and general well-being
of people.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a pharmaceutical company based in
Jiangxi, China, specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine
derivatives (&ldquo;TCMD&rdquo;) products targeting the elderly with the goal of addressing their physical conditions in the
aging process and to promote their general well-being. We have registered and obtained approval for 26 varieties of TCMD
products from the National Medical Products Administration (the &ldquo;NMPA&rdquo;), and we currently produce 13 varieties of
TCMD products, which are sold in approximately 280 cities of 31 provinces in China as of the date of this prospectus. In
addition, through our subsidiary Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&ldquo;Universe Trade&rdquo;),
we sell biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (&ldquo;TCMP&rdquo;) products, and dietary
supplements manufactured by third-party pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Products manufactured by us. </I>The 13
TCMD products currently manufactured by us fall into two categories: (1) treatment and relief for common chronic health conditions
in the elderly designed to achieve physical wellness and longevity (&ldquo;Chronic Condition Treatments&rdquo;), and (2) cold and
flu medications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chronic
Condition Treatments</B>: Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid,
Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal
Liquor.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cold
and flu medicines</B>: Paracetamol Granule for Children, Isatis Root Granule and Qiangli Pipa Syrup.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As people age, they have an increasing risk
of developing chronic health conditions. According to a report published by the Chinese Center for Disease Control and Prevention
in March 2019, 75.8% of seniors have at least one chronic health condition, and 35.1% of them have two or more. Some of the most
common chronic diseases in the elderly include arthritis, chronic kidney disease, fatigue, and low back pain. Our products under
the category of Chronic Condition Treatments are designed to address some of the aforementioned diseases. Our cold and flu medicines,
on the other hand, include products designed to treat and relieve symptoms of respiratory illnesses caused by bacteria and viruses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Our third-party products. </I>Through our
subsidiary, Universe Trade, we also distribute and sell products manufactured by third-party producers, including biomedical drugs,
medical instruments, TCMP products and dietary supplements. As of March 31, 2020, we had distributed over 4,000 third-party products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our <I>Customers. </I>Our major customers are
pharmaceutical companies, hospitals, clinics and drugstore chains, primarily located in Jiangxi Province, Jiangsu Province, Guangdong
Province, and 27 other provinces in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe we have implemented a
successful business model, and our business has grown substantially since our inception. Our customer base continue to grow
meaningfully, from a total of 1,304 customers in 2017 to 2,603 customers at the end of fiscal year 2019. Our revenues from
selling our own products increased from $17,620,823 for the fiscal year ended September 30, 2018 to $20,895,542 for the
fiscal year ended September 30, 2019. Our revenues from distributing and selling products manufactured by third-party
companies increased from $10,893,357 for the fiscal year ended September 30, 2018 to $12,333,774 for the fiscal year ended
September 30, 2019. Our net income was $7,602,933 for the fiscal year ended September 30, 2018 and $7,551,465 for the fiscal
year ended September 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe we have the following competitive
strengths:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A recognized manufacturer of TCMD products
in China&rsquo;s rapidly growing health and wellness market</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a recognized manufacturer of TCMD products
in China&rsquo;s rapidly growing health and wellness market. We own a number of famous brands in the industry, which are also our
registered trademarks in China. For instance, our brand &ldquo;Hu Zhuo Ren (&#32993;&#21331;&#20154;)&rdquo;, with over 17 years
of history, is especially well-recognized in Jiangxi Province. Further, our brand &ldquo;Bai Nian Dan (&#30334;&#24180;&#20025;)&rdquo;
is famous for specializing in products targeted at the physical wellness of older population. Our other recognized brands include
&ldquo;Long Zhong (&#40857;&#31181;)&rdquo;, &ldquo;Yi Ke Ting (&#30410;&#20811;&#20572;)&rdquo;, &ldquo;Xue Li (&#34880;&#21147;)&rdquo;,
&ldquo;Duo Lai Mei (&#26421;&#26469;&#32654;)&rdquo;, &ldquo;Shu Er Kang (&#33298;&#20799;&#24247;)&rdquo;, &ldquo;Hu Zhuo Ren
(&#32993;&#21331;&#20161;)&rdquo;, &ldquo;Ai Bi Xin (&#29233;&#24517;&#27427;)&rdquo;, and &ldquo;Yong He Shuang Feng (&#27704;&#21644;&#21452;&#20964;)&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chinese patent medicine industry is growing
rapidly and steadily in China. According to Frost &amp; Sullivan, from 2014 to 2018, the total market size of Chinese patent medicine
grew from RMB580.7 billion ($89.3 billion) in 2014 to RMB630.9 billion ($97.1 billion) in 2018, representing a Compound Annual
Growth Rate (&ldquo;CAGR&rdquo;) of 2.1%, and is expected to further increase to RMB844.3 billion ($122.4 billion) in 2023, representing
a CAGR of 6.0% between 2019 and 2023. The primary growth drivers of China&rsquo;s Chinese patent medicine industry include the
increasing disposable income and healthcare awareness in China, growing aging population and the prevalence of chronic diseases,
and favorable governmental policies and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We attribute our success to our recognized
brand names, strong relationships with our suppliers, loyal and stable customer base, and proven capability to develop and manufacture
TCMD products aligned with the preferences of end consumers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Rigorous quality control standards and
manufacturing protocols</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that the quality of our products
is crucial to our success as a pharmaceutical company, and we have implemented an overall quality control system, as well as strict
manufacturing protocols specifically designed for each product. Our quality control system starts from procurement. The raw materials
we source from our suppliers must first be examined and certified for quality. We review the performance of our suppliers based
on the quality of their products and adjust future orders from them accordingly. Further, an average of three inspections are made
by our personnel throughout the manufacturing process to ensure that the manufacturing protocols are strictly followed, and that
the quality of semi-products are at or above standard. After completion of manufacturing, our personnel will perform an overall
quality examination. Through the implementation of a quality control system, we are able to identify the weakness in our production
process and improve our operations overtime. We believe our quality control standards and manufacturing protocols have contributed
to the high quality and consistency of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Visionary management team with substantial
industry experience</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our visionary management team is the bedrock
of our success. Many members of our leadership possess extensive experience in the pharmaceutical, biomedical, chemical and related
industries. For instance, our chief executive officer, Mr. Gang Lai, has over 20 years of corporate management experiences. Mr.
Xiaojun Deng, the deputy manufacturing manager of Jiangxi Universe, holds a degree in Traditional Chinese Medicine Manufacturing
from Jiangxi Medical School with over 25 years of working experience in the Chinese patent medicine industry. Ms. Lin Yang, our
chief financial officer, has over 14 years of finance and management experience working in pharmaceutical companies. Mr. Yajun
Hu, the general manager of Jiangxi Universe, has over five years of experiences in managing a pharmaceutical company. Moreover,
many members of the team have worked together for an extended period of time and helped build the Company from the ground up. The
rapport that the team has built extends beyond the talent and skills of individual team members and contributes to a collective
sense of mission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Strong record of growth and profitability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have been profitable since 2008 and we believe
we are well-positioned to benefit from the rapid growth of the TCMD market in China and to leverage the leading market position
of our flagship products in order to further grow our business. Our revenue was $33,229,316 for the fiscal year ended September
30, 2019, which represents an increase of $4,715,316, or 16.5%, compared with the revenue of $28,514,180 for the fiscal year ended
September 30, 2018. Our net income was $7,551,465 for the fiscal year ended September 30, 2019, which represents a slight decrease
of $51,468, or 0.7%, compared with the net income of $7,602,933 for the fiscal year ended September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Growth Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Build a Strong Brand Image to Achieve
National Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that broader recognition and favorable
perception of our brand by consumers in our target markets are crucial to our future success. Our brand has gained a solid reputation
in Southern China, especially Jiangxi Province, and we plan to increase the awareness of our brand among consumers in other parts
of China. Specifically, we plan to build a strong brand image that we are a TCMD producer specializing in the development and manufacture
of products designed to address the physical conditions of the elderly during the aging process and to promote their general well-being.
To achieve our goal, we plan to spend most of our efforts on the development and marketing of our brand &ldquo;Bai Nian Dan (&#30334;&#24180;&#20025;)&rdquo;
as the brand to be associated with our ideal brand image because &ldquo;Bai Nian&rdquo; (&#30334;&#24180;) signifies longevity
in the Chinese language, and &ldquo;Dan&rdquo; (&#20025;) alludes to our signature product, Guben Yanlin Pill. We also intend to
advertise targeting at older customers, including transmitting our advertisements through traditional media platforms such as television,
live radio stations, newspapers, as well as in-person marketing at drug stores and clinics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Enhance Our Distribution Network to Increase
Market Penetration and Customer Stickiness</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this prospectus, our products
are sold in 31 provinces in China. We plan to enter the markets in other parts of China. To achieve this goal, we have made efforts
to further strengthen and expand our distribution network through connecting with more local distributors, chain drugstores, malls
and supermarkets in other parts of China. Currently, our strategic focus is to attract more marketing talents and build a stronger
sales and marketing team to keep us on top of the latest information of local markets, customer preferences and industry trends.
We also plan to create an online store to reach a wider consumer demographic. In the future, we plan to start our own retail chain
stores and further diversify our distribution channels to increase our market penetration and customer base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Integrate Our Internal Manufacturing
Capability to Ensure Productivity, Supply, and Selection of Products </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to further optimize our production
facilities to increase the productivity, supply and selection of our products, so that we may gain competitive edges over our competitors.
Specifically, we intend to increase productivity and supply by expanding the existing production lines and converting them into
automated production lines. To increase the selection of our products, we plan to build additional production facilities for our
licensed TCMD products to be launched in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Further Grow Our Research and Development
Capacities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">According to the Frost &amp; Sullivan Report,
the size of the Chinese patent medicine market have been growing steadily. To respond to increasing market demand, we will continue
to provide financial and operational resources to focus on the research and development of TCMD products and dietary supplements
designed to address the physical conditions of the elderly during the aging process and promote their general well-being.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Manufactured Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, we have been manufacturing,
marketing and selling 13 different TCMD products to about 2,603 customers in 30 different provinces in China. Our TCMD products
fall under two categories: Chronic Condition Treatments and cold and flu medications. The following list outlines our current products:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Product </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage oxf Gross Sales</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Category</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Product Name</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; text-align: center"><B>Posology</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2018</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Intended Uses</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 12%; font-weight: bold; text-align: center">Chronic Condition Treatments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 18%; text-align: center">Guben Yanling Pill</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: center">Pills</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">32.4</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">25.9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center">To relieve fatigue, palpitation, low back pain, and generalized weakness and soreness.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Shenrong Weisheng Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Pills</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To relieve fatigue, dizziness, excessive sweating, and pain in the waist and the knees.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Quanlu Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Pills</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To improve kidney functions and spleen functions, and relieve fatigue, low back pain, and knee pain.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Wuzi Yanzong Oral Liquid</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Oral liquid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To improve kidney functions.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Yangxue Danggui Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To improve blood circulation and treating dizziness, headaches and menstrual pains.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Fengshitong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Medicinal liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To treat low back pain and numbness in the feet and hands, and relieve rheumatoid arthritis pain.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Shiquan Dabu Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Medicinal liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To treat dizziness, palpitation, fatigue, and weakness, and ease menstrual flow.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Fengtong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Medicinal liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To treat low back pain and numbness in the feet and hands, and relieve symptoms of arthritis.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Shenrong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Medicinal liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To improve blood circulation and relieve symptoms of fatigue, low back pain and leg pain.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Qishe Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Medicinal liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To treat blood stasis, arthritis, and numbness in the feet and hands.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">Cold and Flu Medicines Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Qiangli Pipa Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Relieve cough and reduce mucus and phlegm.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Paracetamol Granule for Children</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Granules</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To relieve children&rsquo;s headaches, muscle aches, toothaches, colds and fevers.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Isatis Root Granule</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Granules</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">To treat common colds and other infections of the upper respiratory tract.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Among the 13 TCMD products we manufacture,
Guben Yanlin Pill is our signature product. For the fiscal years ended September 30, 2019 and 2018, the revenue derived from the
sale of Guben Yanlin Pill represented 32.4% and 25.9% of our total revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Manufacturing Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following chart illustrates our main manufacturing
process from raw material purchase to marketing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_008.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Our Raw Materials and Suppliers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We select our raw materials for the manufacturing
of our products strictly in accordance with the guidance in Pharmacopoeia of the People&rsquo;s Republic of China (&#12298;&#20013;&#21326;&#33647;&#20856;&#12299;)
(the &ldquo;PPRC&rdquo;), an official compendium of drugs covering both TCM and western medications complied by the Pharmacopoeia
Commission of the Ministry of Health of People&rsquo;s Republic of China. The PPRC specifies the standards of description, dosage,
purity, storage, and other material information for each drug. In the manufacturing of our TCMD products, a total of more than
110 raw materials are regularly used, among which angelica, codonopsis, poria mushroom, isatis root, loquat leaves, safflower,
and Baijiu liquor represent our main raw materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Currently, we have stable access to all the
raw materials necessary for our production. There are many suppliers in the industry for the regularly used raw materials, and
therefore we are not relying on a single supplier for any of our raw materials. If we are unable to purchase any of the raw materials
from one supplier, we do not expect to face material difficulties in locating another supplier at substantially the same price.
While the prices of such raw materials may vary greatly from time to time due to market forces beyond our control, we believe we
can hedge such risk by adjusting our price, or absorbing higher costs if and when necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To source the raw materials required for our
products, we regularly contract with our suppliers by placing bulk orders with them at below market prices. Our raw material suppliers
include mostly traditional Chinese medicine manufacturers and pharmaceutical trading companies. After years of business cooperation,
we believe that our relationships with our current suppliers are strong and stable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consider our raw materials suppliers whose
sales to us accounted for more than 10% of our overall purchases in any given period to be our major suppliers for such period.
We had one such supplier during the fiscal year ended September 30, 2019, Jiangxi Hongjing Pharmaceutical Co., Ltd., whose sales
to us accounted for approximately 14.1% of our overall purchases in that fiscal year. We had one such supplier during the fiscal
year ended September 30, 2018, Jiangxi Boyuantang Pharmaceutical Co., Ltd., whose sales to us accounted for approximately 15.2%
of our overall purchases in that fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Manufacturing Process </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a brief description of the
manufacturing process of the TCMD products we currently produce by dosage forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Pill Products </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To make our pill products, the raw materials
first go through a preparation process, during which such materials are dried, roughly ground and sterilized. Processed raw materials
are then finely ground, mixed with honey, and made into pills before they are finally packaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Granule Products </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The raw materials of our granule products typically
go through a purifying process, during which such materials are stewed, filtered, condensed, and let stand. Processed raw materials
are then mixed with supplemental ingredients before they are made into granules, dried, and finally packaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Syrup Products</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The raw materials of our syrup products are
first stewed together and condensed. Condensed liquid is then filtered and mixed with supplemental ingredients before it is bottled
and packaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Oral Liquid Products</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The raw materials of our oral liquid products
are first filtered, condensed, and fixed with other supplemental ingredients. The processed materials are then further filtered
and sterilized before being bottled and packaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Medicinal Liquor Products</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The raw materials of our medicinal liquor products
first go through a purifying process, during which such materials are selected, cut, rinsed, stewed, and refrigerated. Processed
raw materials then go through an extraction process that involves mixing with solvents and filtering. Then, the liquor products
are bottled and packaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Quality Control and Assurance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In China, each pharmaceutical manufacturer
is required to comply with the Good Manufacturing Practice (the &ldquo;GMP&rdquo;) standards and obtain Pharmaceutical Manufacturing
Permits and GMP Certificates granted by National Medical Products Administration (the &ldquo;NMPA&rdquo;) or its local branches
before it engages in any pharmaceutical manufacturing and distribution. The GMP standards regulate whole processes and procedures
adopted to manufacture pharmaceutical products to ensure their high quality. We are a GMP-certified company and have obtained the
Pharmaceutical Manufacturing Permit with the product manufacturing scopes covering our pharmaceutical products in the forms of
tablets, pills, granules, syrup, oral liquid, and medicinal liquor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We seek to ensure the high quality of our products
through our quality control system and by conducting product testing and review. Our entire manufacturing process is strictly supervised
pursuant to internal quality control standards that have been set up in strict adherence to the guidelines provided in PPRC. We
conduct our quality testing by examining the quality of each and every type of raw materials. If the raw materials meet our quality
standards, we start the manufacturing process, during which we continue our quality testing for every substantial procedure, including
filtering, grinding, mixing, and pill making. After our products are packaged, we will examine various features of our final products
thoroughly, including appearance, weight, taste, water content, and microorganism content.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Third-party Product Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to manufacturing our own products,
we also distribute and sell, through our subsidiary Universe Trade, biomedical drugs, medical instruments, TCMP products and dietary
supplements manufactured by third-party pharmaceutical companies. For the year ended September 30, 2019, we had distributed roughly
3,590 third-party products, of which approximately 71.55% are biochemical drugs, such as liquid glucose, prednisolone, and citicoline,
approximately 18.68% are medical instruments, such as drug-eluting stents, surgical tubes and syringes, approximately 9.05% are
TCMP products, such as red sage tables, Longdan Xiegan pills, and Chinese skullcap capsules and approximately 0.72% are dietary
supplements, such as vitamins, probiotic powder, and calcium tablets. We distribute these products to hospitals, drugstore chains,
clinics, and pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our Suppliers of Third-party Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We source third-party pharmaceutical products
from their manufacturers in China. Our third-party product suppliers include mostly medical instrument manufacturers, pharmaceutical
product manufacturers and dietary supplement manufacturers. For all of the products that we source and sell, we can generally find
similar replacements in the market from the competitors of our current suppliers. Accordingly, we do not have any continuous or
long-term supply agreements with any of these suppliers. We purchase third-party medical products from our suppliers on a per purchase
order basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the fiscal year ended September 30, 2019
and 2018, we purchased products from over 650 and over 500 suppliers, respectively. For the fiscal years ended September 30, 2019
and 2018, we did not have any supplier of third-party products whose sales to us accounted for more than 10% of our overall purchases
of that fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our Customers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our customers are mostly pharmaceutical companies,
hospitals, clinics and drugstore chains with pharmaceutical business qualification certificates, awarded and authorized by the
National Medical Products Association (the &ldquo;NMPA&rdquo;) and are authorized to sell and deliver our products to end consumers.
As of March 31, 2020, our customers are scattered over 280 cities of 31 provinces in China. We determine whether to establish long-term
business relationships with our customers primarily based on two factors, their ability to promote our products and their ability
to make payments on time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, we generated
revenues from a total of 2,603 customers, of which 1,341 were pharmaceutical companies, 573 were clinics, 449 were drug
stores, and 240 were hospitals. For the fiscal year ended September 30, 2019, our revenues generated from sales to
pharmaceutical distributors, hospitals, clinics and drugstore chains represented 58.89%, 21.22%, 19.40%, and 0.48% our of
total revenues, respectively. For the fiscal year ended September 30, 2018, our revenues generated from sales to
pharmaceutical distributors, hospitals, clinics and drugstore chains represented 69.47%, 20.19%, 8.65% and 1.7% of our total
revenues, respectively. None of our customers generated more than 10% of our revenue for the fiscal years ended September 30,
2019 and 2018. However, our top 10 customers aggregately accounted for 34.5% and 31.6% of our total revenue for the years
ended September 30, 2019 and 2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Marketing and Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that marketing activities are crucial
to our success in the competitive Chinese patent medicine industry. As of March 31, 2020, we had a total of 57 employees in our
marketing department. Employees in our marketing department are mainly responsible for performing various marketing activities,
including researching the most updated industry and market information, analyzing market trends and consumer preferences, setting
up marketing strategies, executing sales contracts, communicating with existing customers and networking with potential customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our marketing and sales initiatives for the
next several years will focus on three objectives: developing a strong brand image, building a successful marketing team, and expanding
retail channels. To develop our brand image as a producer of TCMD products aiming at addressing the physical conditions of the
elderly during the aging process and promoting their general well-being, we seek to promote our brand &ldquo;Bai Nian Dan (&#30334;&#24180;&#20025;)&rdquo;
utilizing both online marketing channels such as WeChat official account and other social media and traditional platforms such
as television, newspapers, and live radio stations. As part of the efforts to build a successful marketing team, we intend to hire
additional sales talents and provide monetary and equity incentives to sales employees. For purposes of expanding our retail channels,
we plan to open an online retail store, and according to the preferences of online shoppers, we may adjust the sizes, packaging,
or prices of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We established a research and development
department in 1998. Our research and development team has been focusing on the upgrade of current products and the
development of production techniques to increase productivity. After years of continued development, our research and
development department has become the core of our technological innovation efforts. As of March 31, 2020, we had 9 employees
dedicated to research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>R&amp;D Achievements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development team has invented
patented technologies to enhance the quality of our products and our manufacturing efficiency. For instance, our patented TCM mixer
is able to mix powders more evenly and thoroughly compared to a traditional mixing machine, thereby increasing the quality of the
mixed medicine powder. The special design of our patented TCM concentration device is able to increase the contact area of the
liquid medicine as compared to a regular concentration device, thereby increasing the manufacturing efficiency of our products
in liquid dosage form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of our efforts, our subsidiary,
Jiangxi Universe, became certified as a National High-Tech Enterprise by the Science and Technology Department of Jiangxi Province
in December 2013, with a term of three years. We successfully renewed the certificate in December 2019. This certification entitles
us to a favorable corporate income tax of 15%, rather than the unified tax rate of 25% we would pay if we were not certified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>R&amp;D Development Plan </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To further our strong brand image, we plan
to develop products designed to address the physical conditions of the elderly during the aging process and promoting their general
well-being, including TCMD products and dietary supplements. In the upcoming years, we intend to focus on the development of immunity
boost products and sleep aids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to our own efforts, our research
and development team also intends to collaborate with other industry professionals and TCM experts with respect to the development
of products we plan to launch in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We compete with pharmaceutical companies in
China that manufacture and sell products similar to ours. Furthermore, many of these companies are more established than we are,
and have significantly greater financial, technical, and other resources than we presently possess. Some of our competitors may
be able to respond more quickly to new opportunities, market changes or changes of customer preferences, and may be able to undertake
more extensive promotional activities, offer more attractive terms to distributors, and adopt more aggressive pricing strategies
than we are. Despite that, we believe we are well-positioned to compete in this market with our diversified product portfolio,
recognized brand name, established sales and marketing network and experienced management team with a proven track record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Competitors of products manufactured
by us</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the competitors
of products manufactured by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; width: 47%; font-weight: bold; text-align: center">Products</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 51%; font-weight: bold; text-align: center">Competitors</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Guben Yanling Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Taiyuan Daningtang Pharmaceuticals Co., Ltd.; <BR>Shenyang Dongxin Pharmaceutical Industry Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Shenrong Weisheng Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">China Beijing Tong Ren Tang Group Co., Ltd.; <BR>Jiangxi Zhongyuan Pharmaceutical Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Quanlu Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Renhe Pharmaceuticals Co.; <BR>Guangzhou Pharmaceutical Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Fuzi Lizhong Pill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">China Beijing Tong Ren Tang Group Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Yangxue Danggui Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Sichuan Tiancheng Pharmaceuticals Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Qiangli Pipa Syrup</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Jiangzhong Pharmaceuticals Co., Ltd.; <BR>China Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.; <BR>Jiangxi Tengwangge Pharmaceuticals Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Paracetamol and Chlorpheniramine Maleate<BR>
 Granules for Children</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">China Resources Sanjiu Medical &amp; Pharmaceuticals Co., Ltd.; Sunflower Pharmaceutical Group Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Isatis Root Granules</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Guangzhou Pharmaceuticals Co., Ltd.; <BR>China Resources Sanjiu Medicine &amp; Pharmaceuticals Co., Ltd.; <BR>China Beijing Tong Ren Tang Group Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Wuzi Yanzong Oral Liquid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">China Beijing Tong Ren Tang Group Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Shuquan Dabu Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Jiangxi Puzheng Pharmaceuticals Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Shenrong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Jiangxi Puzheng Pharmaceuticals Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Qishe Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Jiangxi Zhongyuan Pharmaceuticals Co., Ltd.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">Fengtong Medicinal Liquor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Jiangxi Zhongyuan Pharmaceuticals Co., Ltd.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Competitors of Third-party Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors of pharmaceutical products,
including biochemical drugs and TCMP products, are many internationally and nationally well-known manufacturers and distributors,
including China Beijing Tong Ren Tang Group Co., Ltd., Yunnan Baiyao Group, China Resources Sanjiu Medicine &amp; Pharmaceuticals
Co., Ltd., and Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors in the medical instrument market
include many well-known manufacturers and distributors of medical instruments, including Shinva Medical Instrument Co., Ltd., Jiangsu
Yuyue Medical Equipment &amp; Supply Co., Ltd., Lepu Medical Technology (Beijing) Co., Ltd., and Shanghai Runda Medical Technology
Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competitors in the dietary supplement market
include internationally and nationally well-known manufacturers and distributors of dietary supplements, such as By-health Co.,
Ltd., Amway (China) Co., Ltd., and Perfect (China) Co., Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to compete with these larger companies
by appealing to the specific needs and preferences of our customers and offering competitive prices. For details regarding competitive
landscape of the Chinese patent medicine industry, see &ldquo;Industry.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2020, we had a total of 176
employees, all of which are located in China. The following table sets forth the number of our employees by function as of March
31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Function</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.7pt; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.85pt; text-align: center"><B>Employees</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 12.95pt 0 13.95pt; text-align: center"><B>% of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 12.1pt 0 13.1pt; text-align: center"><B>Total</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Purchasing Department</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.11</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Warehouse Department</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.95</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Manufacturing Department</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34.09</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Quality Control Department</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.25</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Research and Development Department</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.11</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Marketing Department</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26.70</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Finance Department </TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.55</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Administration Department</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.23</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends on our ability to attract,
retain and motivate qualified personnel. As part of our human resources strategy, we offer employees competitive salaries and other
bonuses and incentives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We primarily recruit our employees in China
through direct hiring. We provide training to new employees that we hire. We also conduct regular and specialized internal training
to meet the need of our employees in different departments. We believe that such training is effective in equipping our employees
with the skill set and worth ethics we require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As required under PRC regulations, we participate
in various employee social security plans that are organized by applicable local municipal and provincial governments, including
housing, pension, medical, work-related injury, maternity and unemployment benefit plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We enter into standard contracts and agreements
regarding confidentiality, intellectual property, employment, ethic policies and non-competition with most of our executive officers,
managers and employees. These contracts typically include a non-competition provision effective during and up to one year after
termination of their employment with us and a confidentiality provision effective during and up to one year after their employment
with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our employees have not formed any employee
union or association. We believe that we maintain a good working relationship with our employees and we have not experienced any
difficulty in recruiting staff for our operations as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Properties and Facilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our corporate headquarter is located in Jinggangshan,
Jiangxi Province, China. We own properties in Jingggangshan as office spaces, storage facilities and manufacturing facilities with
an aggregate gross floor area of approximately 825,563 square feet. We believe that our existing facilities are generally adequate
to meet our current needs, but we expect to seek additional space as needed to accommodate future growth. Following is a list of
our properties all of which we own the land use rights to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">No.</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Land Use Right Holder</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Property Address</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Use of Property</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Area in <BR>
Square Feet</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Terms of Use</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 6%; text-align: center">1</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 39%; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center">Manufacturing</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center">173,467</TD><TD STYLE="text-align: center; width: 1%; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 13%; text-align: center">October 2053</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">2</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Manufacturing</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">470,921</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">October 2053</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">3</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Manufacturing</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">57,010</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">October 2053</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">4</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Storage</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">27,426</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">October 2053</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">5</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Manufacturing</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">29,276</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">October 2053</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">6</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Storage</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">57,083</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">October 2053</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">7</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Jiangxi Universe</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">265 Jingjiu Avenue, Economy and Technology Development District, Jinggangshan, Ji&rsquo;an, Jiangxi, China</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Manufacturing</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">10,380</TD><TD STYLE="text-align: center; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">October 2053</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We manufacture all of our products at the properties
listed above. Currently, we are capable of producing a maximum of approximately 12 million bottles of liquid products, 13 million
boxes of pill products, and 10 million boxes of solid products annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intellectual Property </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We regard our patents, trademarks, domain names
and other intellectual property critical to our business operations. We rely on laws and regulations on patents, trademarks and
domain names to protect our intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 30, 2020, we had 11 effective patents
in China. The following table sets forth the title, patent number, application date, and the category of each patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">No.</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Patent Title</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Patent Number</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Application Date</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration Date</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Patent Category</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 4%; text-align: center">1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: left">A Coarse Grinder for Chinese Medicine</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; text-align: justify">&nbsp;&nbsp;CN201520922379.1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">11/18/2015</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">11/17/2025</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">An Automatic Chinese Medicine Pill Maker</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821790286.8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">A Chinese Medicine Boiler</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821787013.8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">A Chinese Medicine Extractor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821789886.2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">A Chinese Medicine Distiller</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821787483.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">An Automatic Grinder for Chinese Medicine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821789843.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">An Intelligent Traditional Chinese Medicine Sterilizer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821787111.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">An Efficient Traditional Chinese Medicine Mixer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821786741.7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">A Traditional Chinese Medicine Concentration Device</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821795987.0</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">11/01/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5/6/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: center">10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">A Temperature-controlled Traditional Chinese Medicine Dryer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821786955.4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">6/18/2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/30/2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: center">11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">A Chinese Medicine Pill Intelligent Bottling Machine</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">CN201821791526.6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/31/2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4/30/2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Utility Model</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through Jiangxi Universe, we currently have
25 Chinese trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Trademark Number</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Trademark Class</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issue Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expiration Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Trademark Title</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 15%; text-align: center">1456583</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; padding-left: 13.9pt">5</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center; padding-left: 13.9pt">October 14, 2000</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 13, 2020<SUP>*</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: center">&#27704;&#21644;&#21452;&#20964;(Yong He Shuang Feng)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">1715278</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">33</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">February 14, 2002</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 13, 2022<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#32993;&#21331;&#20154;(Hu Zhuo Ren)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1728438</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">March 14, 2002</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 13. 2022<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#40845;&#31278;(Long Zhong)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">1770559</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">May 21, 2002</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2022<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#30334;&#24180;&#20025;(Bai Nian Dan)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3222662</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">April 7, 2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 6, 2026<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#33298;&#20799;&#24247;(Shu Er Kang)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3226175</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">September 21, 2003</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 20, 2023<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#30410;&#20811;&#20572; (Yi Ke Ting)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3226176</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">January 21, 2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 20, 2026<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#34880;&#21147;(Xue Li)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3265593</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">30</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">February 28, 2004</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 27, 2024<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#34880;&#21147;(Xue Li)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3279793</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">30</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">March 7, 2004</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 6, 2014<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="image_009.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3279794</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">January 14, 2004</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 13, 2024<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="image_010.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3279795</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">January 14, 2004</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 13, 2024<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><IMG SRC="image_011.jpg" ALT=""></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3362654</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">June 7, 2004</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 6, 2024<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#32993;&#21331;&#20161;(Hu Zhuo Ren)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3824261</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">30</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">September 21, 2005</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 20, 2025<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#26421;&#26469;&#32654;(Duo Lai Mei)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">3829764</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">May 14, 2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2026<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#26421;&#26469;&#32654;(Duo Lai Mei)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3829765</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">May 14, 2006</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2026<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#29233;&#24517;&#27427;(Ai Bi Xin)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">4324589</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">November 28, 2007</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 27, 2027<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">UPC</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">4361774</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">January 14, 2008</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 13, 2028<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#19975;&#21659;(Wan Ning)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">4892932</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">January 14, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 13, 2029<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#23567;&#30410;&#20811;&#20572;(Xiao Yi Ke Ting)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">5597261</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">November 7, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 6, 2029<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#30334;&#24180;&#20025;(Bai Nian Dan)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">5597262</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">November 7, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 6, 2029<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#40857;&#31181; (Long Zhong)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">5597263</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">November 7, 2009</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 6, 2029<SUP>*</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#30410;&#20811;&#20572; (Yi Ke Ting)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">10664817</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 13.9pt">May 21, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 20, 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&#24917;&#20848;&#38745; (Mu Lan Jing)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duration of this trademark has been extended for additional 10 years.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp; &nbsp; &nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We implement a set of comprehensive measures
to protect our intellectual property, in addition to making trademark and patent registration application. Key measures include
: (i) timely registration, filing and application for ownership of our intellectual property, (ii) actively tracking the registration
and authorization status of our intellectual property and take action in a timely manner if any potential conflicts with our intellectual
property are identified, (iii) clearly stating all rights and obligations regarding the ownership and protection of our intellectual
property in all employment contracts and commercial contracts we enter into.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of the date of this prospectus, we have
not been subject to any material dispute or claims for infringement upon third parties&rsquo; trademarks, licenses and other intellectual
property rights in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Seasonality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently do not experience seasonality
in our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Environmental Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We comply with the Environmental Protection
Law of China as well as applicable local regulations. In addition to statutory and regulatory compliance, we actively ensure the
environmental sustainability of our operations. Parties may be levied upon us if we fail to adhere to and maintain certain standards.
Such failure has not occurred in the past, and we generally do not anticipate that it will occur in the future, but no assurance
can be given in this regard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Insurance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain certain insurance policies to safeguard
us against risks and unexpected events. For example, we provide social security insurance including pension insurance, unemployment
insurance, work-related injury insurance and medical insurance for our employees in compliance with applicable PRC laws. We do
not maintain business interruption insurance or product liability insurance, which are not mandatory under PRC laws. We do not
maintain key man insurance, insurance policies covering damages to our network infrastructures or information technology systems
nor any insurance policies for our properties. During the fiscal years ended September 30, 2019 and 2018, we did not make any material
insurance claims in relation to our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may from time to time become a party to
various legal administrative proceedings arising in our ordinary course of our business. As of the date of this prospectus, neither
we nor any of our subsidiaries is a party of any pending legal proceedings, nor are we aware of any such proceedings threatened
against us or our subsidiaries.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="c15"></A>REGULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">This section sets forth a summary of the principal
PRC laws and regulations relevant to our business and operations in China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a pharmaceutical manufacturer in China.
This section sets forth a summary of applicable laws, rules, regulations, government and industry policies and requirement that
have a significant impact on our operations and business in China. This summary does not purport to be a complete description of
all laws and regulations, which apply to our business and operations. Investors should note that the following summary is based
on relevant laws and regulations in force as of the date of this prospectus, which may be subject to change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Major Regulatory Authorities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
pharmaceutical industry in the PRC is mainly administered by four governmental agencies: (i) the NMPA, a department under the State
Administration for Market Regulation (the &ldquo;SAMR&rdquo;) (</FONT>&#22269;&#23478;&#24066;&#22330;&#30417;&#30563;&#31649;&#29702;&#24635;&#23616;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
(ii) the National Health Commission (the &ldquo;NHC&rdquo;) (</FONT>&#22269;&#23478;&#21355;&#29983;&#20581;&#24247;&#22996;&#21592;&#20250;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
(iii) the National Administration of Traditional Chinese Medicine (the &ldquo;NATCM&rdquo;) (</FONT>&#22269;&#23478;&#20013;&#21307;&#33647;&#31649;&#29702;&#23616;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
and (iv) the National Healthcare Bureau (the &ldquo;NHB&rdquo;) (</FONT>&#22269;&#23478;&#21307;&#30103;&#20445;&#38556;&#23616;<FONT STYLE="font-family: Times New Roman, Times, Serif">).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NMPA, whose predecessor is the China Food
and Drug Administration, or the CFDA, is the primary regulator of almost all key stages of the life-cycle of pharmaceutical products,
including non-clinical researches, clinical trials, marketing approvals, manufacturing, advertising and promotion, distribution
and pharmacovigilance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NHC, formerly known as the National Health
and Family Planning Commission, is the principal regulator of healthcare in China. It is primarily responsible for drafting national
healthcare policies and regulating public health, medical services and health contingency system, coordinating the healthcare reform
and overseeing the operation of medical institutions and professional practice of medical personnel. The NHC is responsible for
(1) the research, production, circulation and use of Chinese medicines, including traditional Chinese medicine; (2) the preparation
and publication of the Chinese Pharmacopoeia; and (3) the supervision of the selection, approval, distribution and revision of
the National OTC Drug Catalogue. In addition, the CFDA and its local administrative authorities may take a number of enforcement
actions to enforce their regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NATCM is an agency under the NHC that oversees
China&rsquo;s traditional Chinese medicine industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NHB, a new authority established in May
2018, is responsible for (1) drafting and implementing policies, plans and standards on medical insurance, maternity insurance
and medical assistance; (2) administering healthcare fund; (3) formulating a uniform medical insurance catalogue and payment standards
on drugs, medical disposables and healthcare services; and (4) formulating and administering the bidding and tendering policies
for drugs and medical disposables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Regulations Related to Pharmaceutical Manufacture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Manufacturing License</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Pharmaceutical Administration Law of the People&rsquo;s Republic of China (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated in 1984 by the SCNPC and last amended in April 2015, a pharmaceutical manufacturer is required to obtain
its manufacturing license from the NMPA before it starts to manufacture pharmaceutical products. Prior to granting such permit,
the relevant government authority will inspect the applicant&rsquo;s production facilities, and assess whether the sanitary conditions,
quality assurance system, management structure and equipment at the production facilities have met the required standards. A manufacturing
license is valid for a period of five years and the manufacturer is required to apply for renewal within six months prior to its
expiration date. The manufacturer will be subject to reassessment by the authority in accordance with then prevailing legal and
regulatory requirements for the purposes of such renewal. Currently, our subsidiary Jiangxi Universe holds a valid manufacturing
license from the NMPA issued on January 1, 2016 and valid until December 31, 2020. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Good Manufacturing Practice (GMP)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
manufacturing process of a pharmaceutical manufacturer must be compliant with the Good Manufacturing Practice for Drugs (</FONT>&#33647;&#21697;&#29983;&#20135;&#36136;&#37327;&#31649;&#29702;&#35268;&#33539;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(2010 version) issued by the Ministry of Health in January 2011, which sets forth the requirements on the manufacturer&rsquo;s
organization and employee qualifications, manufacture premises and facilities, equipment, hygiene conditions, manufacture management,
product management, maintenance of sales records and the procedure of handling customer complaints and adverse reaction reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Notice of the State Food and Drug Administration, the Ministry of Health and the State Administration of Traditional Chinese
Medicine on strengthening the supervision and administration of ready-to-use slices of traditional Chinese medicine (</FONT>&#12298;&#22269;&#23478;&#39135;&#21697;&#33647;&#21697;&#30417;&#30563;&#31649;&#29702;&#23616;&#12289;&#21355;&#29983;&#37096;&#12289;&#22269;&#23478;&#20013;&#21307;&#33647;&#31649;&#29702;&#23616;&#20851;&#20110;&#21152;&#24378;&#20013;&#33647;&#39278;&#29255;&#30417;&#30563;&#31649;&#29702;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
issued on January 5, 2011, a manufacturer of ready-to-use slices of traditional Chinese medicine is required to obtain manufacturing
license and a Good Manufacturing Permit certificate (&ldquo;GMP Certificate&rdquo;). Our subsidiary Jiangxi Universe obtained its
GMP Certificate on January 2015, which was valid until January 2020. In September 2019, Jiangxi Universe successfully renewed its
GMP Certificate for additional five years. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Certification Measures for Good Manufacturing Practice for Drugs (</FONT>&#12298;&#33647;&#21697;&#29983;&#20135;&#36136;&#37327;&#31649;&#29702;&#35268;&#33539;&#35748;&#35777;&#31649;&#29702;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
issued by the NMPA in August 2011, in any of the following cases, the Drug Supervision and Administration Department (the &ldquo;DSAD&rdquo;)
will recall a manufacturer&rsquo;s GMP Certificate: (1) the manufacturer does not meet the GMP requirements; (2) the manufacturer
is ordered to suspend manufacturing to rectify a violation of drug management regulations; and (3) other circumstances where the
GMP shall be recalled. Such manufacturer is required to correct the practices that have resulted in the recall of its GMP Certificate.
After the manufacturer corrects its practices, it shall inform the DSAD of its correction. If, through an on-site inspection, the
DSAD determines that the manufacturer meets the GMP requirements, it shall return the original GMP Certificate to the manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In any of the following circumstances, the
original license-issuing authority shall revoke the GMP Certificate of a manufacturer: (1) the manufacturer&rsquo;s manufacturing license
is revoked, cancelled, or withdrawn according to applicable laws; (2) the manufacturing scope of the manufacturer is revoked or
withdrawn according to applicable laws; (3) the manufacturer&rsquo;s GMP Certificate has expired and has not been renewed; and
(4) others circumstances where the GMP Certificate shall be cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
revised Drug Administration Law of the People&rsquo;s Republic of China (</FONT>&#12298;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(&ldquo;Drug Administration Law&rdquo;), which became effective on December 1, 2019, states that the pharmaceutical supervisory
and administrative department shall, in accordance with relevant provisions, certify whether a pharmaceutical manufacturer meets
the requirements set forth in the regulations on the quality of pharmaceuticals. The GMP certification shall be issued to manufacturers
who meet the requirements. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Notice of the State Food and Drug Administration on the Implementation of the Drug Administration Law of the People&rsquo;s Republic
of China (</FONT>&#12298;&#22269;&#23478;&#33647;&#30417;&#23616;&#20851;&#20110;&#36143;&#24443;&#23454;&#26045;<FONT STYLE="font-family: Times New Roman, Times, Serif">&lt;</FONT>&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#33647;&#21697;&#31649;&#29702;&#27861;<FONT STYLE="font-family: Times New Roman, Times, Serif">&gt;</FONT>&#26377;&#20851;&#20107;&#39033;&#30340;&#20844;&#21578;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
starting from December 1, 2019, GMP Certificates are cancelled and will no longer be issued. Certification applications received
before December 1, 2019 shall be handled in accordance with the original GMP certification provisions. GMP certificates shall be
issued to those manufacturers who complete on-site inspections and meet the requirements before December 1, 2019. Where on-site
inspections are required by existing regulations, they shall continue to be conducted after December 1, 2019, and the results of
on-site inspections shall be notified to the manufacturers. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Contract Manufacturing of Drugs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Administrative Regulations for the Contract Manufacturing of Drugs (</FONT>&#12298;&#33647;&#21697;&#22996;&#25176;&#29983;&#20135;&#30417;&#30563;&#31649;&#29702;&#35268;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Contract Manufacturing Regulations&rdquo;) issued by the NMPA in August 2014, in the event that a drug manufacturer
in China with drug marketing authorization temporarily lacks manufacturing capability as a result of technology upgrade or is unable
to meet market demand due to insufficient manufacturing capacity, it may use contract manufacturer for its drug manufacturing.
Contract manufacturing arrangements need to be approved by the provincial branch of the NMPA. The Contract Manufacturing Regulations
prohibit contract manufacturing arrangements for certain special drugs, including narcotic drugs, psychoactive drugs, biochemical
drugs and active pharmaceutical ingredients.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Regulations in relation to the
Pharmaceutical Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&ldquo;Two-vote system&rdquo; for
drug sales</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
NHC and other six ministries and commissions issued the Notice on the Opinions on the Implementation of the
&ldquo;Two-Invoice System&rdquo; in Drug Procurement by Public Medical Institutions (for Trial Implementation)
(</FONT>&#12298;&#20851;&#20110;&#22312;&#20844;&#31435;&#21307;&#30103;&#26426;&#26500;&#33647;&#21697;&#37319;&#36141;&#20013;&#25512;&#34892;<FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;</FONT>&#20004;&#31080;&#21046;<FONT STYLE="font-family: Times New Roman, Times, Serif">&rdquo;</FONT>&#30340;&#23454;&#26045;&#24847;&#35265;
(&#35797;&#34892;) &#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">) (the
&ldquo;Notice on Two-Invoice System&rdquo;) on January 11, 2017. &ldquo;Two-invoice system&rdquo; means that one invoice
shall be issued by a pharmaceutical manufacturer to a distributor, and another invoice shall be issued by the distributor to
a hospital. An internal transfer of drugs from a group pharmaceutical distributor to its wholly owned or controlled
subsidiary or a transfer of drugs between such wholly owned subsidiaries may not be deemed as &ldquo;one invoice&rdquo;
however, the invoicing for the whole group can be done only once. Pharmaceutical manufacturers and distributors shall
reasonably determine the markup level in the spirit of fairness, legality, legitimacy and integrity. Public medical
institutions is encouraged to settle the payment for drugs directly with pharmaceutical manufacturers, and pharmaceutical
manufacturers and are encouraged to settle the delivery cost with distributors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the sale of drugs, drug manufacturers and distributors shall issue value-added tax (&ldquo;VAT&rdquo;) special invoices or normal
VAT invoices in accordance with the regulations regarding invoice control. The sold drug shall also be delivered in a way that
confirms to the requirements of the Good Supply Practice for Pharmaceutical Products (2013) (</FONT>&#12298;&#33647;&#21697;&#32463;&#33829;&#36136;&#37327;&#31649;&#29702;&#35268;&#33539;<FONT STYLE="font-family: Times New Roman, Times, Serif">(2013)</FONT>&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
, and the names of the purchaser and seller on the invoices shall be consistent with the delivery form, payment flow and amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Drug Advertisements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Provisions for Drug Advertisement Examination (</FONT>&#12298;&#33647;&#21697;&#24191;&#21578;&#23457;&#26597;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated on March 13, 2007 and effective on May 1, 2007, an enterprise seeking to advertise its drugs must apply for an advertising
approval code. An advertisement approval code is valid for one year. The contents of an approved advertisement shall not be altered
without prior approval. Where an advertisement needs to be edited, the enterprise shall submit an application for a new advertisement
approval code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Insert Sheet, Labels and Packaging
of Pharmaceutical Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Measures for the Administration of the Insert Sheets and Labels of Drugs (</FONT>&#12298;&#33647;&#21697;&#35828;&#26126;&#20070;&#21644;&#26631;&#31614;&#31649;&#29702;&#35268;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
effective on June 1, 2006, the insert sheets and labels of a pharmaceutical product shall be reviewed and approved by the NMPA.
A drug insert sheet should include the scientific data, conclusions and information concerning drug safety and efficacy in order
to direct the safe and reasonable use of pharmaceutical products. The inner label of a pharmaceutical product shall indicate the
product name, indication or function, strength, dose and usage, production date, batch number, expiration date and drug manufacturer,
and the outer label of a pharmaceutical product shall indicate the product name, ingredients, description, indication or function,
strength, dose and usage and adverse reactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Measures for the Administration of Pharmaceutical Packaging (</FONT>&#12298;&#33647;&#21697;&#21253;&#35013;&#31649;&#29702;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
effective on September 1, 1988, pharmaceutical packaging must comply with national and professional standards. If no national or
professional standards are available, a manufacturer can formulate and implement its own standards after it receives approval from
the provincial food and drug administration or bureau of standards. The company shall reapply for approval if it were to change
its own packaging standards. Pharmaceutical products with no approved packing standards shall not be sold or traded in the PRC,
except for drugs for military use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Drug Technology Transfer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
August 19, 2009, the NMPA promulgated the Administrative Regulations for Technology Transfer Registration of Drugs (</FONT>&#12298;&#33647;&#21697;&#25216;&#26415;&#36716;&#35753;&#27880;&#20876;&#31649;&#29702;&#35268;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Technology Transfer Regulations&rdquo;) to regulate the drug technology transfer process, including the application,
evaluation, examination, approval and monitoring of, drug technology transfer. Drug technology transfer means that the owner transfers
its pharmaceutical manufacturing technology to a pharmaceutical manufacturer and that the transferee applies for drug registration
pursuant to the Technology Transfer Regulations. Drug technology transfer includes the transfer of new drug technology and drug
manufacturing technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Applications for drug technology transfer
shall be submitted to the provincial drug regulatory authority where the transferee is located. The drug regulatory authority examines
application materials and conducts on-site inspections of the transferee&rsquo;s manufacturing facilities. If the transferor and
the transferee are located in different provinces, the provincial drug regulatory authority where the transferor is located shall
issue examination opinions as well. The Center for Drug Evaluation (the &ldquo;CDE&rdquo;), a branch of the NMPA, shall further
review the application materials, provide technical evaluation opinions and form a comprehensive evaluation opinion based on the
on-site inspection reports and the testing results of the samples. The NMPA shall determine whether to approve the application
according to the comprehensive evaluation opinion of the CDE. An approval letter of supplementary application and a drug approval
number will be issued for qualified applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Price of drugs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Drug Administration Law (</FONT>&#12298;&#33647;&#21697;&#31649;&#29702;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
for those drugs whose prices are determined by market, manufacturers and distributors of pharmaceutical products and medical institutions
shall set the prices in accordance with the principles of fairness, rationality, and good faith, and provide consumers with drugs
at reasonable prices. Pharmaceutical product manufacturers, distributors and medical institutions shall determine and indicate
their products&rsquo; retail prices in accordance with the regulations over drug prices promulgated by the pricing department of
the State Council of the People&rsquo;s Republic of China (the &ldquo;State Council&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 4, 2015, the National Development and Reform Commission, the National Health and Family Planning Commission, the Ministry of
Human Resources and Social Security, the Ministry of Industry and Information Technology, the Ministry of Finance, the MOFCOM and
the NMPA jointly issued the Notice Regarding Reforms to the Price of Medical Products (</FONT>&#12298;&#20851;&#20110;&#21360;&#21457;&#25512;&#36827;&#33647;&#21697;&#20215;&#26684;&#25913;&#38761;&#24847;&#35265;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
pursuant to which, since June 1, 2015, other than anesthetics and Class 1 psychotropic drugs, the actual price of pharmaceutical
products shall be decided by market instead of by the government. As of the date of this prospectus, the actual price of all products
we sell, including TCMD products and third-party products, are determined by market. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation in relation to medical device
registration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Regulations on Supervision and Administration of Medical Devices (</FONT>&#12298;&#21307;&#30103;&#22120;&#26800;&#30417;&#30563;&#31649;&#29702;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the State Council of China with the last amendment effective on May 4, 2017, medical devices are classified based
on the invasiveness of, and risks associated with, each medical device. Class I medical devices have relatively low risks, whose
safety and effectiveness can be guaranteed through routine administration. Class II medical devices have moderate risks and require
strict control and administration to ensure their safety and effectiveness. Class III medical devices have relatively high risks
and require especially strict control and administration measures to ensure their safety and effectiveness. Pursuant to the Administrative
Measures for the Medical Devices Registration (</FONT>&#12298;&#21307;&#30103;&#22120;&#26800;&#27880;&#20876;&#31649;&#29702;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which became effective on October 1, 2014, manufacturers of Class I medical devices are required to file with the local food and
drug administrative authority at the city level. Manufacturers of Class II medical devices shall obtain product registration certificates
from and be subject to the inspection and approval of the drug administrative authority at the provincial level. Manufacturers
of Class III medical devices shall obtain product registration certificates from the NMPA and be subject to its inspection and
approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to Regulation on Supervision and Administration of Medical Device Business (amended in 2017) (</FONT>&#12298;&#21307;&#30103;&#22120;&#26800;&#32463;&#33829;&#30417;&#30563;&#31649;&#29702;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
the medical device business shall be subject to classified regulations determined by the degree of risks associated with a medical
device. No license or registration is required for the selling of Class I medical devices. Sellers of Class II medical devices
shall keep records of their purchases and sales, while sellers of Class III medical devices shall obtain licenses from the local
branch of NMPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of the date of this prospectus, we are
engaged in the business of selling medical devices. We sell medical devices categorized as Class I, Class II and Class III under
the Regulation on Supervision and Administration of Medical Devices in the PRC, and we obtained our medical device selling license
in May 2015 in compliance with the applicable PRC laws and regulations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation relating to Company Establishment
and Foreign Investment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PRC Company Law applies to the establishment, operation and management of both PRC domestic companies and foreign-invested enterprises.
Foreign investment in the PRC corporate entities are also regulated by the oreign-Owned Enterprise Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Foreign-Owned Enterprise Law&rdquo;) promulgated on April 12, 1986 and amended on October 31, 2000 and September 3,
2016, the Implementing Rules for the Foreign-Owned Enterprise Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#36164;&#20225;&#19994;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated on December 12, 1990 and amended on April 12, 2001 and February 19, 2014, and the Interim Administrative Measures for
the Record-filing of the Incorporation and Change of Foreign-invested Enterprises (</FONT>&#12298;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#35774;&#31435;&#21450;&#21464;&#26356;&#22791;&#26696;&#31649;&#29702;&#26242;&#34892;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Record-filing Measures&rdquo;) promulgated on October 8, 2016 and amended on July 30, 2017 and June 29, 2018. Under
these laws and regulations, the establishment of a wholly foreign-owned enterprise is subject to the approval of, or the filing
with the MOFCOM or its local counterpart, and such wholly foreign-owned enterprises must register and file with the appropriate
administrative bureau of industry and commerce.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Foreign Investment Law of the People&rsquo;s Republic of China (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Foreign Investment Law&rdquo;), which was promulgated by the National People&rsquo;s Congress On March 15, 2019, and came
into effect on January 1, 2020, provides that foreign investment refers to the investment activities in China carried out directly
or indirectly by foreign natural persons, enterprises or other organizations (the &ldquo;Foreign Investors&rdquo;), including the
following: (1) Foreign Investors establishing foreign-invested enterprises in China alone or collectively with other investors;
(2) Foreign Investors acquiring shares, equities, properties or other similar rights of Chinese domestic enterprises; (3) Foreign
Investors investing in new projects in China alone or collectively with other investors; and (4) Foreign Investors investing through
other ways prescribed by laws and regulations or the State Council. The State adopts the management system of pre-establishment
national treatment and negative list for foreign investment. The pre-entry national treatment means the treatment given to Foreign
Investors and their investments at the stage of investment access is not lower than that of domestic investors and their investments.
The negative list management system means that the state implements special administrative measures for access of foreign investment
in specific fields. Foreign investors shall not invest in any forbidden fields stipulated in the negative list and shall mean the
conditions stipulated in the negative list before investing in any restricted fields. The negative list is released upon approval
of the State Council. After the Foreign Investment Law came into effect, it replaced the Foreign-Owned Enterprise Law. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Implementation Regulations for the Foreign Investment Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#21830;&#25237;&#36164;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Implementation Regulations for the FIL&rdquo;) was adopted at the 74th executive meeting of the State Council on December
12, 2019 and came into effect on January 1, 2020. The purpose of the Implementation Regulations for the FIL is to encourage and
promote foreign investment, protect the legitimate rights and interests of investors, regulate the administration of foreign investment,
and continuously optimize the foreign investment environment. For those foreign-invested enterprises established prior to the implementation
of the Foreign Investment Law and established in accordance with the Law of the People&rsquo;s Republic of China on Sino-foreign Joint
Ventures (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20013;&#22806;&#21512;&#36164;&#32463;&#33829;&#20225;&#19994;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
the Law of the People&rsquo;s Republic of China on Foreign-invested Enterprises, and the Law of the People&rsquo;s Republic of China on Sino-Foreign
Cooperative Enterprises, they can modify or retain their organizational forms and organizational structures in accordance with
the PRC Company Law, Partnership Law of the People&rsquo;s Republic of China and other applicable laws within 5 years since the implementation
of the Foreign Investment Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
investment in China shall comply with the Catalogue for the Guidance of Foreign Investment Industries (2017 Revision) (</FONT>&#12298;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#25351;&#23548;&#30446;&#24405;<FONT STYLE="font-family: Times New Roman, Times, Serif">(2017</FONT>&#24180;&#20462;&#35746;<FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT>&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;2017 Catalogue&rdquo;), which was promulgated on June 28, 2017 and became effective on July 28, 2017, and the Special
Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2018) (</FONT>&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;<FONT STYLE="font-family: Times New Roman, Times, Serif">(</FONT>&#36127;&#38754;&#28165;&#21333;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(2018</FONT>&#24180;&#29256;<FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT>&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;2018 Negative List&rdquo;) which were promulgated on June 28, 2018 and became effective on July 28, 2018. The Catalogue
classifies foreign-invested industries into two categories, (1) encouraged foreign-invested industries; and (2) foreign-invested
industries that are subject to the 2018 Negative List. The 2018 Negative List set out restrictions such as shareholding requirements
and qualifications of the senior management. According to the Record-filing Measures, foreign investments that are not subject
to special access administrative measures are only required to complete an online filing with the MOFCOM or its local counterpart.
The Catalogue for Encouraged Foreign Investment (2019 Revision) (</FONT>&#12298;&#40723;&#21169;&#22806;&#21830;&#25237;&#36164;&#20135;&#19994;&#30446;&#24405;<FONT STYLE="font-family: Times New Roman, Times, Serif">(2019</FONT>&#24180;&#29256;<FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT>&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
or the 2019 Catalogue, and the Special Administrative Measures for the Access of Foreign Investment (Negative List) (Edition 2019)
(</FONT>&#12298;&#22806;&#21830;&#25237;&#36164;&#20934;&#20837;&#29305;&#21035;&#31649;&#29702;&#25514;&#26045;<FONT STYLE="font-family: Times New Roman, Times, Serif">(</FONT>&#36127;&#38754;&#28165;&#21333;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(2019</FONT>&#24180;&#29256;<FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT>&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
or the 2019 Negative List, which were issued on June 30, 2019 and came into effect on July 30, 2019, further reduced restrictions
on foreign investment. The 2019 Catalogue and the 2019 Negative List replaced the 2017 Catalogue and the 2018 Negative List. The
scope of our business as approved by the licensing authority and the actual scope of our business are not subject to the restrictions
set forth in the 2019 Negative List. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The M&amp;A Rules were jointly promulgated
by the MOFCOM, the State-Owned Assets Supervision and Administration Commission of the State Council, the SAT, the SAIC, the CSRC,
and the SAFE on August 8, 2006 and was amended by MOFCOM on June 22, 2009. The M&amp;A Rules provides that a foreign investor is
required to obtain necessary approvals when it: (1) acquires equity interests in a domestic enterprise or subscribes to additional
shares in a domestic enterprise; (2) purchases the assets of a domestic enterprise through establishment of a foreign-invested
enterprise; or (3) establishes a foreign-invested enterprise through which it purchases the assets of a domestic enterprise and
operates these assets. In particular, any PRC company, enterprise or individual is required to obtain approval from the MOFCOM
and comply with applicable laws and regulations if it establishes an offshore company and attempts to acquire a domestic enterprise
related to such offshore company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation in relation to Intellectual
Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
terms of international conventions, China has entered into (including but not limited to) the Agreement on Trade-Related Aspects
of Intellectual Property Rights (</FONT>&#12298;&#19982;&#36152;&#26131;&#26377;&#20851;&#30340;&#30693;&#35782;&#20135;&#26435;&#21327;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
the Paris Convention for the Protection of Industrial Property (</FONT>&#12298;&#20445;&#25252;&#24037;&#19994;&#20135;&#26435;&#24052;&#40654;&#20844;&#32422;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
the Madrid Agreement Concerning the International Registration of Marks (</FONT>&#12298;&#21830;&#26631;&#22269;&#38469;&#27880;&#20876;&#39532;&#24503;&#37324;&#21327;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
and the Patent Cooperation Treaty (</FONT>&#12298;&#19987;&#21033;&#21512;&#20316;&#21327;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Patent Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
or the Patent Law, promulgated by the SCNPC on March 12, 1984 and last amended on December 27, 2008 and effective from October
1, 2009 and the Implementation Rules of the Patent Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#19987;&#21033;&#27861;&#23454;&#26045;&#32454;&#21017;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated by the State Council on June 15, 2001 and amended on December 28, 2002 and January 9, 2010, respectively, patents in
China fall into three categories: invention patents, utility model patents and design patents. The term of patent protection starts
from the date of application and lasts 20 years for invention patents and 10 years for utility model patents and design patents.
Any individual or entity that utilizes a patent or conducts any other activity that infringes a patent without the patent holder&rsquo;s
authorization shall pay compensation to the patent holder and be subject to a fine imposed by regulatory authorities and, if such
behavior constitutes a crime, shall be held criminally liable in accordance with applicable laws. According to the Patent Law,
for public health purposes, the State Intellectual Property Office of the PRC, or SIPO, may grant a compulsory license for manufacturing
patented drugs and exporting them to countries or regions covered under relevant international treaties to which PRC has acceded.
In addition, under the Patent Law, any organization or individual that applies for a patent in a foreign country for an invention
or utility model patent established in China is required to report to the SIPO for confidentiality examination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trade Secrets</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the PRC Anti-Unfair Competition Law (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21453;&#19981;&#27491;&#24403;&#31454;&#20105;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SCNPC in September 1993, as amended in November 4, 2017 and April 23, 2019 respectively, the term &ldquo;trade
secrets&rdquo; refers to technical and business information that is unknown to the public, has utility, may create business interests
or profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair
Competition Law, business persons are prohibited from infringing others&rsquo; trade secrets by: (1) obtaining trade secrets from
the legal owners or holders by any unfair methods, such as theft, bribery, fraud, coercion, electronic intrusion, or any other
illicit means; (2) disclosing, using or permitting others to use the trade secrets obtained illegally under item (1) above; or
(3) disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements
of the legal owners or holders to keep such trade secrets in confidence. If a third party knows or should have known of the above-
mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to
have committed a misappropriation of the others&rsquo; trade secrets. The parties whose trade secrets are being misappropriated
may petition for administrative corrections, and regulatory authorities may stop any illegal activities and impose fines on the
infringing parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
accordance with the Trademark Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21830;&#26631;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Trademark Law&rdquo;), which was promulgated by the SCNPC on August 23, 1982, and was last amended on April 23, 2019
and came into effect on November 1, 2019, any trademark which is registered with the approval of the Trademark Office is a registered
trademark, including commodity trademark, service trademark, collective trademark, certification trademark, and the trademark registrant
has the exclusive right to use a registered trademark and such right is protected by law. A registered trademark is valid for a
period of 10 years commencing from the date on which the registration is approved. Upon expiration of the trademark, the registrant
shall apply for renewal within twelve months prior to the expiration date if it intends to maintain exclusive use of the trademark.
If the registrant fails to apply for renewal, a grace period of six months may be granted. In the absence of a renewal upon the
expiration of a trademark registration, the registered trademark shall be canceled. Use of a trademark that is identical with or
similar to a registered trademark, for the same kind of or similar commodities, without authorization of the trademark registrant,
constitutes infringement of the exclusive right to use a registered trademark. Industrial and commercial administrative authorities
have the authority to investigate any behavior that may constitute an infringement of the exclusive right under a registered trademark.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Domain names</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Domain
names are protected under the Administrative Measures on the Internet Domain Names (</FONT>&#12298;&#20114;&#32852;&#32593;&#22495;&#21517;&#31649;&#29702;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated by the Ministry of Industry and Information Technology, or the MIIT, on August 24, 2017 and came into effect
on November 1, 2017, and the Implementing Rules of China Internet Network Information Center on the Registration of Domain Names
(</FONT>&#12298;&#20013;&#22269;&#20114;&#32852;&#32593;&#32476;&#20449;&#24687;&#20013;&#24515;&#22495;&#21517;&#27880;&#20876;&#23454;&#26045;&#32454;&#21017;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
issued by China Internet Network Information Center (the &ldquo;CNNIC&rdquo;) on May 28, 2012 and came into effect on May 29, 2012.
Domain name registrations are handled through domain name service agencies established under the relevant regulations, and the
applicant becomes domain name holder upon successful registration. Domain name disputes shall be submitted to an organization authorized
by CNNIC for resolution. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Product Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Product Quality Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20135;&#21697;&#36136;&#37327;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated by the SCNPC on February 22, 1993 and last amended on December 29, 2018, governs the supervision and administration
of product quality and specifies the liabilities of manufacturers and sellers. A manufacture shall be liable for compensating for
any bodily injuries or property damages, other than the defective product itself, resulting from the defects in the product, unless
the manufacturer is able to prove that: (1) the product has never been distributed; (2) the defects causing injuries or damage
did not exist at the time when the product was distributed; or (3) the science and technology at the time when the product was
distributed was at a level incapable of detecting the defects. A seller shall pay compensation if it fails to indicate either the
manufacturer or the supplier of the defective product. A person who is injured or whose property is damaged by the defects in the
product may claim for compensation from the manufacturer or the seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Tort Liability Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20405;&#26435;&#36131;&#20219;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated by the SCNPC on December 26, 2009 and effective from July 1, 2010, manufacturers shall assume tort liabilities where
the defects in products cause damage to others. Sellers shall assume tort liability where the defects in products that have caused
damage to others are attributable to the sellers. The aggrieved party may claim for compensation from the manufacturer or the seller
of the defected product that has caused damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Environmental Protection</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Environmental Protection Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#20445;&#25252;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SCNPC on December 26, 1989 and amended on April 24, 2014, the Environmental Impact Assessment Law of the PRC
(</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#24433;&#21709;&#35780;&#20215;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated by the SCNPC on October 28, 2002 and amended on July 2, 2016 and December 29, 2018 respectively, the Administrative
Regulations on the Environmental Protection of Construction Project (</FONT>&#12298;&#24314;&#35774;&#39033;&#30446;&#29615;&#22659;&#20445;&#25252;&#31649;&#29702;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the State Council on November 29, 1998 and amended on July 16, 2017, and other applicable environmental laws and
regulations, an enterprise with a project construction plan shall submit an environmental impact assessment report, stating the
environmental impacts the project is likely to have, to the administrative authority of environmental protection for approval.
Enterprises shall engage qualified institutions to issue the environmental impact assessment reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Law of the PRC on the Prevention and Control of Water Pollution (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27700;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SCNPC on May 11, 1984 and last amended on June 27, 2017, and effective on January 1, 2018, the Law of the PRC
on the Prevention and Control of Atmospheric Pollution (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22823;&#27668;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SCNPC on September 5, 1987 and last amended on October 26, 2018, the Law of the PRC on the Prevention and Control
of Pollution from Environmental Noise (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#29615;&#22659;&#22122;&#22768;&#27745;&#26579;&#38450;&#27835;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SCNPC on October 29, 1996 and amended on December 29, 2018, and the Law of the PRC on the Prevention and Control
of Environmental Pollution of Solid Waste (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22266;&#20307;&#24223;&#29289;&#27745;&#26579;&#29615;&#22659;&#38450;&#27835;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated by the SCNPC on October 30, 1995 and last amended on November 7, 2016, all the enterprises that may cause environmental
pollution in the course of their business operation shall implement preventive and curative environmental protection measures in
their plants and establish a reliable environmental protection system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We strictly complied with the applicable
environmental laws and regulations in constructing our factory. On December 8, 2004, the environmental protection bureau of local
government determined that the environmental protection facilities we constructed for our factory satisfied the relevant standards.
According to the certificate issued by the ecological environment bureau of local government (the &ldquo;Bureau&rdquo;), our factory
has not been assessed on its environmental impacts since its establishment in 2004. Although there were certain procedural defects
in the original construction process, we constructed our environmental protection facilities for our factory in strict compliance
with the requirements of applicable PRC environmental laws and regulations. Our environmental protection facilities were approved
by the Bureau in December 2004 and have since been under normal operations. As of the date of the date of this prospectus, we have
not been found in violation of applicable environmental laws or regulations, or imposed of administrative penalties by environmental
protection authorities in the past three years. No environmental pollution incident has occurred on our manufacturing facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Foreign Exchange Control</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Foreign Exchange Administration Regulations of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22806;&#27719;&#31649;&#29702;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
as amended on August 5, 2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment (</FONT>&#12298;&#32467;&#27719;&#12289;&#21806;&#27719;&#21450;&#20184;&#27719;&#31649;&#29702;&#35268;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
or the Settlement Regulations, promulgated by the People&rsquo;s Bank of China on June 20, 1996 and came into effect on July 1,
1996, foreign exchanges required for profit distributions and dividend payments may be purchased from designated foreign exchange
banks in the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Notice of SAFE on Further Improving and Adjusting Foreign Exchange Administration Policies on Direct Investment (</FONT>&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#36827;&#19968;&#27493;&#25913;&#36827;&#21644;&#35843;&#25972;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;Circular No. 59&rdquo;) and its appendix, the Operating Rules for Foreign Exchange Issues with Regard to Direct Investment
under Capital Account (</FONT>&#12298;&#36164;&#26412;&#39033;&#30446;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#19994;&#21153;&#25805;&#20316;&#35268;&#31243;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated on November 19, 2012 and amended on May 4, 2015 and October 10, 2018 by the State Administration of Exchange Control,
or the SAFE, (1) the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject
to approval by the SAFE; (2) reinvestment with legal income of foreign investors in China is no longer subject to approval by SAFE;
(3) the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified;
(4) purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE;
(5) domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6) the
administration over the conversion of foreign exchange capital of foreign-invested enterprises is improved. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Circular on Further Simplifying and Improving the Direct Investment-related Foreign Exchange Administration Policies (</FONT>&#12298;&#20851;&#20110;&#36827;&#19968;&#27493;&#31616;&#21270;&#21644;&#25913;&#36827;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(the &ldquo;SAFE Circular No. 13&rdquo;), which was promulgated on February 13, 2015 and became effective on June 1, 2015, the
foreign exchange registration under domestic direct investment and the foreign exchange registration under foreign direct investment
is directly reviewed and handled by banks in accordance with the Circular No. 13, and the SAFE and its branches shall perform indirect
regulation over the foreign exchange registration via banks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors (</FONT>&#12298;&#22806;&#22269;&#25237;&#36164;&#32773;&#22659;&#20869;&#30452;&#25509;&#25237;&#36164;&#22806;&#27719;&#31649;&#29702;&#35268;&#23450;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
or the FDI Provisions, which were promulgated by the SAFE on May 11, 2013 and became effective on May 13, 2013, and last amended
on October 10, 2018, regulate and clarify the administration over foreign exchange administration in foreign direct investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises
(</FONT>&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#22806;&#21830;&#25237;&#36164;&#20225;&#19994;&#22806;&#27719;&#36164;&#26412;&#37329;&#32467;&#27719;&#31649;&#29702;&#26041;&#24335;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SAFE on March 30, 2015 and became effective on June 1, 2015, and the Circular on the Reform and Standardization
of the Management Policy of the Settlement of Capital Projects (</FONT>&#12298;&#22269;&#23478;&#22806;&#27719;&#31649;&#29702;&#23616;&#20851;&#20110;&#25913;&#38761;&#21644;&#35268;&#33539;&#36164;&#26412;&#39033;&#30446;&#32467;&#27719;&#31649;&#29702;&#25919;&#31574;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the SAFE on June 9, 2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by
the policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used
for its own operation purposes within the business scope of the foreign invested enterprises in accordance with the principle of
authenticity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Pursuant to the Circular 37, a PRC resident
shall register with the local SAFE branch before he or she contributes assets or equity interests in an overseas special purpose
vehicle (&ldquo;Overseas SPV&rdquo;) , that is directly established or controlled by the PRC Resident for the purpose of conducting
investment for financing. Failure to comply with the SAFE registration requirements could result in penalties for evasion of foreign
exchange controls. The Circular No. 13 provides that banks can directly handle the initial foreign exchange registration and amendment
registration under the Circular 37. Mr. Gang Lai has completed the initial foreign registration on June 3, 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Labor and Social Insurance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the PRC Labor Contract Law (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated by the SCNPC on June 29, 2007 and became effective on January 1, 2008, and amended on December 28, 2012 and
became effective on July 1, 2013, and the Implementing Regulations of the Labor Contracts Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#21512;&#21516;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated by the State Council on September 18, 2008, labor contracts shall be concluded in writing if employment relationships
are to be or have been established between employers and employees. In addition, employee wages cannot be lower than local standards
on minimum wages. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Labor Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#21171;&#21160;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated by the SCNPC on July 5, 1994 and last amended and came into effect on December 29, 2018, employers shall
establish and improve their system of workplace safety and sanitation, strictly abide by state rules and standards on workplace
safety, educate employees in occupational safety and sanitation in the PRC. Occupational safety and sanitation facilities shall
comply with state-fixed standards. Enterprises and institutions shall provide employees whose work involves occupational hazards
with health examinations on a regular basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the Social Insurance Law, the Interim Regulations on the Collection and Payment of Social Security Funds (</FONT>&#12298;&#31038;&#20250;&#20445;&#38505;&#36153;&#24449;&#32564;&#26242;&#34892;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated by the State Council on January 22, 1999 and amended on March 24, 2019, and the Administrative Regulations
on the Housing Provident Funds (</FONT>&#12298;&#20303;&#25151;&#20844;&#31215;&#37329;&#31649;&#29702;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
which was promulgated by the State Council on April 3, 1999 and last amended on March 24, 2019, employers are required to make
contributions, on behalf of their employees, to a number of social security funds, including funds for basic pension insurance,
unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and to housing provident funds.
Any employer who fails to make contributions may be fined and ordered to make good the deficit within a stipulated time limit.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to April 2020, we only contributed
to the social insurance and housing provident funds for some, but not all, of our employees. There is a risk that the labor security
administration authority may take enforcement action to collect from us all the outstanding contributions of the social insurance
and housing provident funds required to be made for the employees in the past, and we may be subject to a late charge at the rate
of 0.2% per day on the total outstanding contribution. We started to contribute to the social insurance and housing provident funds
for all of our employees since April 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since April 2020, we have been contributing
to the social insurance and housing provident funds for our employees in accordance with the minimum contribution requirements.
Pursuant to the aforementioned applicable laws and regulations, the government or an employee has the right to demand us to contribute
to the employee&rsquo;s social insurance and housing provident funds calculated based on his or her actual salary, and an employee
who has not received contributions from us has the right to demand us to contribute to his or her social insurance and housing
provident funds. As confirmed in writing by the local government, our contributions of the social insurance and housing provident
funds are in compliance with the PRC laws and the local regulations and policies, and therefore the local government is very unlikely
to impose any penalty on us for our contributions since April 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Enterprise Income Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According
to the EIT Law, promulgated by the National People&rsquo;s Congress on March 16, 2007, effective on January 1, 2008 and last amended
on December 29, 2018, and the Implementation Regulations for the Enterprise Income Tax Law of the PRC (</FONT>&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#20225;&#19994;&#25152;&#24471;&#31246;&#27861;&#23454;&#26045;&#26465;&#20363;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
promulgated by the State Council on December 6, 2007 and became effective on January 1, 2008, other than a few exceptions, the
income tax rate for both domestic enterprises and foreign-invested enterprises is 25%. Enterprise taxpayers are classified as either
resident enterprises or non-resident enterprises. Resident enterprises are defined as enterprises that are established in China
in accordance with PRC laws, or that are established in accordance with the laws of foreign countries but whose actual or de facto
management bodies are located in China. Non-resident enterprise refers to an entity established under foreign law whose de facto
management bodies are not within the PRC but which have an establishment or place of business in the PRC, or which do not have
an establishment or place of business in the PRC but have income sourced within the PRC. An income tax rate of 10% will normally
be applicable to dividends declared to non-PRC resident enterprise investors that do not have an establishment or place of business
in the PRC, or that have such establishment or place of business but the relevant income is not effectively connected with the
establishment or place of business, to the extent such dividends are derived from sources within the PRC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Arrangement between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation
and Prevention of Fiscal Evasion with respect to Taxes on Incomes (</FONT>&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#23545;&#25152;&#24471;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
or the Double Tax Avoidance Arrangement, and other applicable PRC laws, 5% withholding tax rate shall apply to the dividends paid
by a PRC company to a Hong Kong resident, provided that such Hong Kong resident directly holds at least 25% of the equity interests
in the PRC company, and 10% of withholding tax rate shall apply if the Hong Kong resident holds less than 25% of the equity interests
in the PRC company. However, pursuant to the Circular on Certain Issues Relating to the Implementation of Dividend Provisions in
Tax Treaties (</FONT>&#12298;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
issued on February 20, 2009 by the State Administration of Taxation, or the SAT, if a PRC tax authority determines, in its discretion,
that a company benefits from such reduced income tax rate as a result of an arrangement that is primarily tax-driven, such PRC
tax authority may adjust the preferential tax treatment of the company. Based on the Announcement on Certain Issues with Respect
to the Beneficial Owner in Tax Treaties (</FONT>&#12298;&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#31246;&#25910;&#21327;&#23450;&#20013;&#21463;&#30410;&#25152;&#26377;&#20154;&#26377;&#20851;&#38382;&#39064;&#30340;&#20844;&#21578;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
issued by the SAT on February 3, 2018 and effective on April 1, 2018, if an applicant&rsquo;s business activities do not constitute substantive
business activities, it could result in the negative determination of the applicant&rsquo;s status as a beneficial owner, and consequently,
the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance
Arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c16"></A>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following individuals are the members
of the board of directors and the executive management as of the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 29%; border-bottom: black 1.5pt solid; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT> </TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 63%; border-bottom: black 1.5pt solid; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT> </TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang
    Lai</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board of Directors and Chief Executive Officer</FONT> </TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lin
    Yang</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT> </TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiawen
    Pang*</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director Nominee</FONT> </TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yongping
    Yu*</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director Nominee</FONT> </TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ding
    Zheng*</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT> </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director Nominee</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This individual has indicated his or her assent to occupy such position upon closing of this offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following is a brief biography of each
of our executive officers and directors or director nominees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mr. Gang Lai </I>is our chief executive
officer and chairman of the board. Mr. Lai has served as the chief executive officer of Jiangxi Universe since 2004 and founded
Universe Trade in 2010. Before joining us, Mr. Lai was a successful entrepreneur. He founded Jiangxi Lvzhouyuan Timber Joint Stock
Co., Ltd. in 2001, a company listed on PRC National Equities Exchange and Quotations (NEEQ: 838893), and has since served as its
chairman of the board. Mr. Lai graduated from Jingdezhen Ceramic Institute with a bachelor&rsquo;s degree in mechanical engineering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Ms. Lin Yang</I> has served as the financial
director of Jiangxi Universe since April 2006. Before joining us, Ms. Yang served as an accountant at Jiangxi Automobile Engineering
Plastic Co., Ltd. from 1998 to March 2006. Ms. Yang graduated from Jiangxi University of Finance and Economics with a bachelor&rsquo;s
degree in accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <I>Mr. Jiawen Pang</I> will serve as our
independent director immediately upon the closing of this offering. Mr. Jiawen Pang has served as the marketing director at Shanghai
Raas Blood Products Co., Ltd. since September 2014, a company listed on the Shenzhen Stock Exchange (SZSE: 002252). Mr. Xiao served
as the business and marketing director at Shandong Bausch &amp; Lomb Freda Pharmaceutical Co., Ltd. from May 2011 to August 2014.
Prior to that, Mr. Xiao served as the marketing director at Guangdong Bangmin Pharmaceutical Co., Ltd. from July 2001 to April
2011. Mr. Xiao graduated from Sun Yat-sen University with a master of business administration in healthcare and medicine. We believe
Mr. Pang is qualified to serve on our board of directors as one of our independent directors due to his over substantial work
experience and expertise in the pharmaceutical industry, and his significant management experience. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <I>Mr. Yongping Yu </I>will serve as our
independent director immediately upon the closing of this offering. Mr. Yongping Yu has served as the general manager at Qidi
Boda Investment Management Co., Ltd. since August 2019. Mr. Yu served as the director and vice general manager of Xinhua Kangmei
Healthcare Thinktank Co., Ltd. from May 2017 to July 2019. Mr. Yu also served as the manager of the big data division at Xinhuanet
Co., Ltd. (SHA: 603888) from July 2015 to May 2017. Before that, Mr. Yu served as the editor-in-chief of <I>Xinhua Cyber Health</I>,
a WeChat official account, at Xinhua News Agency from July 2014 to July 2015. Prior to that, Mr. Yu served as a chief physician
at Avian General Hospital of China Medical University from February 2011 to July 2014. From April 2004 to February 2011, Mr. Yu
served as the deputy secretary of the Pharmaceutical Association of Jiangxi Province. Mr. Yu received a bachelor&rsquo;s degree
in medicine from the Medical College of Nanchang University and a bachelor&rsquo;s degree in Chinese language and literature from
Tsinghua University. We believe Mr. Yu is qualified to serve on our board of directors as one of our independent directors due
to his deep knowledge and extensive expertise in the healthcare and medical industries and his significant management experience
in both public and private sectors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <I>Mr. Ding Zheng </I>will serve as our
independent director immediately upon the closing of this offering. Mr. Ding Zheng has served as the chairman of the board at
Guangzhou Roujing Sunshade Energy-saving Technology Co., Ltd. since 2019. Mr. Zheng has also served as the general manager at
Hande Manufacturing (China) Co., Ltd., since 2015. From 2007 to 2015, Mr. Zheng served as the financial director at Hunter Douglas
(China) Holdings Co., Ltd. Prior to that, Mr. Zheng served as the manager of finance at Esquel Group from 2005 to 2007. Mr. Zheng
obtained a bachelor&rsquo;s degree in technology economics from Shanghai Jiao Tong University and a master of business administration
degree from Tsinghua University. Mr. Zheng is a member of the China Institute of Certified Public Accountants (CICPA). We believe
Mr. Zheng is qualified to serve on our board of directors as one of our independent directors due to his deep financial expertise
and his substantial experience in the financial industry. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our articles of association
as we expect them to be amended and become effective on or before the completion of this offering, the minimum number of directors
shall consist of not less than one person unless otherwise determined by the shareholders in a general meeting. Unless removed
or re-appointed, each director shall be appointed for a term expiring at the next-following annual general meeting, if any is held.
At any annual general meeting held, our directors will be elected by a majority vote of shareholders eligible to vote at that meeting.
At each annual general meeting, each director so elected shall hold office for a one-year term and until the election of their
respective successors in office or removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional information, see &ldquo;Description
of Share Capital&mdash;Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment Agreements and Indemnification
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will enter into employment agreements
with each of our executive officers. Pursuant to employment agreements, the form of which is filed as Exhibit 10.1 to this Registration
Statement, we agreed to employ each of our executive officers for a specified time period, which may be renewed upon both parties&rsquo;
agreement 30 days before the end of the current employment term, and payment of cash compensation and benefits shall become payable
when the Company becomes a public reporting company in the US. We may terminate the employment for cause, at any time, without
notice or remuneration, for certain acts of the executive officer, including but not limited to the commitments of any serious
or persistent breach or non-observance of the terms and conditions of the employment, conviction of a criminal offense, willful
disobedience of a lawful and reasonable order, fraud or dishonesty, receipt of bribery, or severe neglect of his or her duties.
An executive officer may terminate his or her employment at any time with a one-month prior written notice. Each executive officer
has agreed to hold, both during and after the employment agreement expires, in strict confidence and not to use or disclose to
any person, corporation or other entity without written consent, any confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will also enter into indemnification
agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive
officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being
a director or officer of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors will consist of
[&#9679;] directors upon closing of this offering, including three independent directors. A director is not required to hold any
shares in our company to qualify to serve as a director. A director may vote with respect to any contract, proposed contract or
arrangement in which he is materially interested, provided that (a) such director, if his or her interest in such contract or arrangement
is material, has declared the nature of his or her interest at the earliest meeting of the board at which it is practicable for
him or her to do so, either specifically or by way of a general notice and (b) if such contract or arrangement is a transaction
with a related party, such transaction has been approved by the audit committee. The directors may exercise all the powers of the
company to borrow money, mortgage its undertaking, property and uncalled capital, and issue debentures or other securities whenever
money is borrowed or as security for any obligation of the company or of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Committees of the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will establish three committees under
the board of directors prior to the closing of this offering: an audit committee, a compensation committee, and a nominating and
corporate governance committee. We will adopt a charter for each of the three committees. Each committee&rsquo;s members and functions
are described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Audit Committee</I>. Our audit committee
will consist of Jiawen Pang, Yongping Xu, and Ding Zheng. Ding Zheng will be the chairman of our audit committee. We have determined
that Jiawen Pang, Yongping Xu, and Ding Zheng will satisfy the &ldquo;independence&rdquo; requirements of <FONT STYLE="background-color: white">[Section
303A of the Corporate Governance Rules of the New York Stock Exchange/Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock
Market]</FONT> and Rule 10A-3 under the Securities Exchange Act. Our board also has determined that Ding Zheng qualifies as an
audit committee financial expert within the meaning of the SEC rules or possesses financial sophistication within the meaning of
the NASDAQ corporate governance rules. The audit committee will oversee our accounting and financial reporting processes and the
audits of the financial statements of our company. The audit committee will be responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing the independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with the independent auditors any audit problems or difficulties and management&rsquo;s response;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing the annual audited financial statements with management and the independent auditors;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any steps taken to monitor and control major financial risk exposures;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving all proposed related party transactions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting separately and periodically with management and the independent auditors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation Committee.</I> Our compensation
committee will consist of Jiawen Pang, Yongping Yu, and Ding Zheng. Jiawen Pang will be the chairperson of our compensation committee.
We have determined that Jiawen Pang, Yongping Yu, and Ding Zheng will satisfy the &ldquo;independence&rdquo; requirements of <FONT STYLE="background-color: white">[Section
303A of the Corporate Governance Rules of the New York Stock Exchange/Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock
Market]</FONT> and Rule 10C-1 under the Securities Exchange Act. The compensation committee will assist the board in reviewing
and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers.
Our chief executive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation
committee will be responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the total compensation package for our most senior executive officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and overseeing the total compensation package for our executives other than the most senior executive officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board with respect to the compensation of our directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodically and approving any long-term incentive compensation or equity plans;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">selecting compensation consultants, legal counsel or other advisors after taking into consideration all factors relevant to that person&rsquo;s independence from management; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Nominating and Corporate Governance
Committee.</I> Our nominating and corporate governance committee will consist of Jiawen Pang, Yongping Yu and Ding Zheng. Yongping
Yu will be the chairperson of our nominating and corporate governance committee. Jiawen Pang, Yongping Yu, and Ding Zheng satisfy
the &ldquo;independence&rdquo; requirements of <FONT STYLE="background-color: white">[Section 303A of the Corporate Governance
Rules of the New York Stock Exchange/Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market]</FONT>. The nominating and
corporate governance committee will assist the board of directors in selecting individuals qualified to become our directors and
in determining the composition of the board and its committees. The nominating and corporate governance committee will be responsible
for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending nominees for election or re-election to our board of directors or for appointment to fill any vacancy;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing annually with our board of directors its current composition in light of the characteristics of independence, age, skills, experience and availability of service to us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying and recommending to our board the directors to serve as members of committees;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">advising the board periodically with respect to significant developments in the law and practice of corporate governance as well as our compliance with applicable laws and regulations, and making recommendations to our board of directors on all matters of corporate governance and on any corrective action to be taken; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Controlled Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of this offering, our chairman,
Gang Lai, may beneficially own approximately [&#9679;]% of the aggregate voting power of our outstanding ordinary shares. As a
result, we may be deemed a &ldquo;controlled company&rdquo; within the meaning of the [New York Stock Exchange listing rules/Nasdaq
listing standards]. If we are deemed a controlled company, we are permitted to elect to rely on certain exemptions from the obligations
to comply with certain corporate governance requirements, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that a majority of the board of directors consist of independent directors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that our director nominees be selected or recommended solely by independent directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the requirement that we have a nominating and corporate governance committee and a compensation committee that are composed entirely of independent directors with a written charter addressing the purposes and responsibilities of the committees.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we do not intend to rely on the
controlled company exemptions under the [New York Stock Exchange listing rules/Nasdaq listing standards] even if we are deemed
a controlled company, we could elect to rely on these exemptions in the future, and if so, you would not have the same protection
afforded to shareholders of companies that are subject to all of the corporate governance requirements of [the New York Stock Exchange/Nasdaq
Capital Market].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Duties of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Cayman Islands law, all of our directors
owe three types of duties to us: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Companies Law (2020
Revision) of the Cayman Islands imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary
duties are not codified, however, the courts of the Cayman Islands have held that a director owes the following fiduciary duties:
(a) a duty to act in what the director <I>bona fide</I> considers to be in the best interests of the company, (b) a duty to exercise
their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a
duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and
diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation
to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular
skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of
care to us, our directors must ensure compliance with our articles of association expected to be amended and effective on or before
the completion of this offering. We have the right to seek damages if a duty owed by any of our directors is breached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors has all powers necessary
for managing, and for directing and supervising, our business affairs. The functions and powers of our board of directors include,
among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convening shareholders&rsquo; annual general meetings and reporting its work to shareholders at such meetings;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">declaring dividends and distributions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing officers and determining the terms of office of the officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercising the borrowing powers of our company and mortgaging the property of our Company; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the transfer of shares in our Company, including the registration of such shares in our share register. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Terms of Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors may be elected by a resolution
of our board of directors or by an ordinary resolution of our shareholders. Our directors are not subject to a term of office and
hold office until such time as they are removed from office by ordinary resolution of the shareholders. A director will cease to
be a director if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditors;
(ii) dies or is found by our company to be or becomes of unsound mind; (iii) resigned his or her office by notice in writing to
the company; or (iv) without special leave of absence from our board, is absent from three consecutive board meetings and our directors
resolve that his office be vacated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our officers are elected by and serve at
the discretion of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="c27"></A>Compensation of Directors and Executive
Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the fiscal year ended September 30,
2019, we paid an aggregate of $30,205.59 as compensation to our executive officers, and we did not compensate our non-executive
directors for their services other than to reimburse them for out-of-pocket expenses incurred in connection with their attendance
at meetings of the board of directors. We have not set aside or accrued any amount to provide pension, retirement, or other similar
benefits to our directors and executive officers. Our PRC subsidiaries are required by law to make contributions equal to certain
percentages of each employee&rsquo;s salary for his or her pension insurance, medical insurance, unemployment insurance, and other
statutory benefits and a housing provident fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Insider Participation Concerning Executive
Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our director has been making all determinations
regarding executive officer compensation from the inception of the Company. When our Compensation Committee is set up, it will
be making all determination regarding executive officer compensation (please see below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">None of our directors or executive officers
has a family relationship as defined in Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Involvement in Certain Legal Proceedings
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the best of our knowledge, none of our
directors or executive officers has, during the past 10 years, been involved in any legal proceedings described in subparagraph
(f) of Item 401 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Qualification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is currently no shareholding qualification
for directors, although a shareholding qualification for directors may be fixed by our shareholders by ordinary resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors will adopt a code
of business conduct and ethics, which is to be filed as Exhibit 99.1 of this registration statement and applicable to all of our
directors, officers and employees. We will make our code of business conduct and ethics publicly available on our website prior
to the initial closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c28"></A>PRINCIPAL SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our Ordinary Shares as of
the date of this prospectus, and as adjusted to reflect the sale of the Ordinary Shares offered in this offering for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our directors and executive officers who beneficially own our Ordinary Shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our directors and executive officers as a group; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known to us to own beneficially more than 5% of our Ordinary Shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beneficial ownership includes voting or
investment power with respect to the securities. Except as indicated below, and subject to applicable community property laws,
the persons named in the table have sole voting and investment power with respect to all Ordinary Shares shown as beneficially
owned by them. Percentage of beneficial ownership of each listed person prior to this offering is based on 50,000 Ordinary Shares
outstanding as of the date of this prospectus immediately prior to the effectiveness of the registration statement of which this
prospectus is a part. Percentage of beneficial ownership of each listed person after this offering includes Ordinary Shares outstanding
immediately after the completion of this offering, assuming the underwriter does not exercise its over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information with respect to beneficial
ownership has been furnished by each director, officer, or beneficial owner of 5% or more of our Ordinary Shares. Beneficial ownership
is determined in accordance with the rules of the SEC and generally requires that such person have voting or investment power with
respect to securities. In computing the number of Ordinary Shares beneficially owned by a person listed below and the percentage
ownership of such person, Ordinary Shares underlying options, warrants, or convertible securities held by each such person that
are exercisable or convertible within 60 days of the date of this prospectus are deemed outstanding, but are not deemed outstanding
for computing the percentage ownership of any other person. Except as otherwise indicated in the footnotes to this table, or as
required by applicable community property laws, all persons listed have sole voting and investment power for all Ordinary Shares
shown as beneficially owned by them. As of the date of the prospectus, we have 5 shareholders of record, none of whom are located
in the United States. We will be required to have at least [400 shareholders at closing in order to satisfy the New York Stock
Exchange listing rules/300 shareholders at closing in order to satisfy the Nasdaq listing standards].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares<BR> Beneficially Owned<BR> Prior to this Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary Shares<BR> Beneficially Owned<BR> After this Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage&nbsp;of<BR> Votes Held<BR> After this<BR> Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors and Executive Officers <SUP>*</SUP>:</B></FONT></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gang Lai <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">39,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">78.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Lin Yang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiawen Pang <SUP>&dagger;</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yongping Yu <SUP>&dagger;</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ding Zheng <SUP>&dagger;</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">All directors and executive officers as a group:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -10pt; padding-left: 10pt">5% Shareholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greatest Group (China) Financial Management Limited <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">True Ample Holdings Limited <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Xingrui Investment Company Limited <SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bliss International Investment Company Limited <SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Notes:</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">*</TD><TD STYLE="text-align: justify">The business address for our directors and executive officers
is 265 Jingjiu Avenue, Jingji Jishu Kaifa District, Jinggangshan, Ji&rsquo;an, Jiangxi, People&rsquo;s Republic of China.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">&dagger;</TD><TD STYLE="text-align: justify">Expected to become a director immediately upon closing
of this offering.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Represents 39,000 ordinary shares owned by Sununion Holding
Group Limited, a business company incorporated under the laws of the BVI, which is owned as to 100% by Mr. Gang Lai.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Hongji Lin exercises voting and dispositive power over
the shares held by such entity.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Yat Ho Tsang exercises voting and dispositive power over
the shares held by such entity.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Tianpai Hong exercises voting and dispositive power over
the shares held by such entity.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Yung Yung Cheung exercises voting and dispositive power
over the shares held by such entity.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>History of Share Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated in the Cayman Islands
as an exempted company with limited liability on December 11, 2019. We have issued the following Ordinary Shares to certain founding
shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Purchaser</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date of Issuance</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Ordinary Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Sununion Holding Group Limited</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">December 11, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 24%; text-align: right">39,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Greatest Group (China) Financial Management Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">True Ample Holdings Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Xingrui Investment Company Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Bliss International Investment Company Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, our
authorized share capital consists of $50,000 divided into 50,000 Ordinary Shares, par value $1.00 per share. Holders of Ordinary
Shares are entitled to one vote per share. We will issue Ordinary Shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, none
of our outstanding Ordinary Shares are held by shareholders in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not aware of any arrangement that
may, at a subsequent date, result in a change of control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c17"></A>RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of this offering, [&#9679;]
and [&#9679;] will hold [&#9679;]% of the combined total of our issued Ordinary Shares, assuming the underwriter does not exercise
its over-allotment option. Following the completion of this offering, they will continue to have the power to act alone in approving
any action requiring a vote of the majority of our Ordinary Shares and to elect all of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Material Transactions with Related Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Due to related party</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2019 and 2018, the
balances due to related party were $54,705 and $55,709, respectively, which mainly consisted of advances from our principal shareholder
for working capital purposes in our normal course of business. These advances are non-interest bearing and due on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Loan guarantee provided by Foshan
Shangyu</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In connection with our borrowings from
LRC Bank, our controlling shareholder, Mr. Gang Lai, and Foshan Shangyu jointly signed a guarantee agreement with LRC Bank to
provide credit guarantee to safeguard our borrowings. For details, see &ldquo;Notes to the Financial Statements &ndash; Note 8.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">See &ldquo;Management&mdash;Employment Agreements
and Indemnification Agreements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c18"></A>DESCRIPTION OF SHARE CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of our share
capital and provisions of our memorandum and articles of association, as amended from time to time, are summaries and do not purport
to be complete. Reference is made to our amended and restated memorandum and articles of association, copies of which are filed
as an exhibit to the registration statement of which this prospectus is a part (and which is referred to in this section as, respectively,
the &ldquo;memorandum&rdquo; and the &ldquo;articles&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated as an exempted company
with limited liability under the Companies Law (2020 Revision) of the Cayman Islands, or the &ldquo;Cayman Companies Law,&rdquo;
on December 11, 2019. A Cayman Islands exempted company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 18pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is a company that conducts its business mainly outside the Cayman Islands;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is prohibited from trading in the Cayman Islands with any person, firm or corporation except in furtherance of the business of the exempted company carried on outside the Cayman Islands (and for this purpose can effect and conclude contracts in the Cayman Islands and exercise in the Cayman Islands all of its powers necessary for the carrying on of its business outside the Cayman Islands);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to hold an annual general meeting;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have to make its register of members open to inspection by shareholders of that company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may obtain an undertaking against the imposition of any future taxation;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a limited duration company; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register as a segregated portfolio company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our issued and outstanding Ordinary
Shares are fully paid and non-assessable. Our Ordinary Shares are issued in registered form, and are issued when registered in
our register of members. Unless the board of directors determine otherwise, each holder of our Ordinary Shares will not receive
a certificate in respect of such Ordinary Shares. Our shareholders who are non-residents of the Cayman Islands may freely hold
and vote their Ordinary Shares. We may not issue shares or warrants to bearer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized share capital is $50,000
divided into 50,000 Ordinary Shares, par value $1.00 per share. Subject to the provisions of the Cayman Companies Law and our articles
regarding redemption and purchase of the shares, the directors have general and unconditional authority to allot (with or without
confirming rights of renunciation), grant options over or otherwise deal with any unissued shares to such persons, at such times
and on such terms and conditions as they may decide. Such authority could be exercised by the directors to allot shares which carry
rights and privileges that are preferential to the rights attaching to Ordinary Shares. No share may be issued at a discount except
in accordance with the provisions of the Cayman Companies Law. The directors may refuse to accept any application for shares, and
may accept any application in whole or in part, for any reason or for no reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the completion of this offering, there
will be [&#9679;] Ordinary Shares issued and outstanding held by at least 400 shareholders and beneficial owners which is the minimum
requirement by Nasdaq and above the minimum requirement by the New York Stock Exchange. Shares sold in this offering will be delivered
against payment from the underwriter upon the closing of the offering in New York, New York, on or about [&#9679;], 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will apply to list the Ordinary Shares
on [the New York Stock Exchange/Nasdaq Capital Market] under the symbol &ldquo;[&#9679;]&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for the
Ordinary Shares is [&#9679;], [&#9679;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Cayman
Companies Law and any rights attaching to any class or classes of shares under and in accordance with the articles:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the directors may declare dividends or distributions out of our funds which are lawfully available for that purpose; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Company&rsquo;s shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended by the directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirements of the Cayman
Companies Law regarding the application of a company&rsquo;s share premium account and with the sanction of an ordinary resolution,
dividends may also be declared and paid out of any share premium account. The directors when paying dividends to shareholders may
make such payment either in cash or in specie.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless provided by the rights attached
to a share, no dividend shall bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to any rights or restrictions as
to voting attached to any shares, unless any share carries special voting rights, on a show of hands every shareholder who is present
in person and every person representing a shareholder by proxy shall have one vote per Ordinary Share. On a poll, every shareholder
who is present in person and every person representing a shareholder by proxy shall have one vote for each share of which he or
the person represented by proxy is the holder. In addition, all shareholders holding shares of a particular class are entitled
to vote at a meeting of the holders of that class of shares. Votes may be given either personally or by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Variation of Rights of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever our capital is divided into different
classes of shares, the rights attaching to any class of share (unless otherwise provided by the terms of issue of the shares of
that class) may be varied either with the consent in writing of the holders of not less than two-thirds of the issued shares of
that class, or with the sanction of a resolution passed by a majority of not less than two-thirds of the holders of shares of the
class present in person or by proxy at a separate general meeting of the holders of shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the terms on which a class of shares
was issued state otherwise, the rights conferred on the shareholder holding shares of any class shall not be deemed to be varied
by the creation or issue of further shares ranking pari passu with the existing shares of that class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Alteration of Share Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Law, our
shareholders may, by ordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our share capital by new shares of the amount fixed by that ordinary resolution and with the attached rights, priorities and privileges set out in that ordinary resolution;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and divide all or any of our share capital into shares of larger amount than our existing shares;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convert all or any of our paid up shares into stock, and reconvert that stock into paid up shares of any denomination;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sub-divide our shares or any of them into shares of an amount smaller than that fixed, so, however, that in the sub-division, the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel shares which, at the date of the passing of that ordinary resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so cancelled or, in the case of shares without nominal par value, diminish the number of shares into which our capital is divided.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Law and
to any rights for the time being conferred on the shareholders holding a particular class of shares, our shareholders may, by special
resolution, reduce its share capital in any way.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Calls on Shares and Forfeiture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms of allotment, the
directors may make calls on the shareholders in respect of any monies unpaid on their shares including any premium and each shareholder
shall (subject to receiving at least 14 clear days&rsquo; notice specifying when and where payment is to be made), pay to us the
amount called on his shares. Shareholders registered as the joint holders of a share shall be jointly and severally liable to pay
all calls in respect of the share. If a call remains unpaid after it has become due and payable the person from whom it is due
and payable shall pay interest on the amount unpaid from the day it became due and payable until it is paid at the rate fixed by
the terms of allotment of the share or in the notice of the call or if no rate is fixed, at the rate of ten percent per annum.
The directors may, at their discretion, waive payment of the interest wholly or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a first and paramount lien on all
shares (whether fully paid up or not) registered in the name of a shareholder (whether solely or jointly with others). The lien
is for all monies payable to us by the shareholder or the shareholder&rsquo;s estate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">either alone or jointly with any other person, whether or not that other person is a shareholder; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether or not those monies are presently payable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any time the directors may declare any
share to be wholly or partly exempt from the lien on shares provisions of the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may sell, in such manner as the directors
may determine, any share on which the sum in respect of which the lien exists is presently payable, if due notice that such sum
is payable has been given (as prescribed by the articles) and, within 14 days of the date on which the notice is deemed to be given
under the articles, such notice has not been complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Unclaimed Dividend</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A dividend that remains unclaimed for a
period of six years after it became due for payment shall be forfeited to, and shall cease to remain owing by, the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forfeiture or Surrender of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder fails to pay any capital
call, the directors may give to such shareholder not less than 14 clear days&rsquo; notice requiring payment and specifying the
amount unpaid including any interest which may have accrued, any expenses which have been incurred by us due to that person&rsquo;s
default and the place where payment is to be made. The notice shall also contain a warning that if the notice is not complied with,
the shares in respect of which the call is made will be liable to be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If such notice is not complied with, the
directors may, before the payment required by the notice has been received, resolve that any share the subject of that notice be
forfeited (which forfeiture shall include all dividends or other monies payable in respect of the forfeited share and not paid
before such forfeiture).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A forfeited share may be sold, re-allotted
or otherwise disposed of on such terms and in such manner as the directors determine and at any time before a sale, re-allotment
or disposition the forfeiture may be cancelled on such terms as the directors think fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person whose shares have been forfeited
shall cease to be a shareholder in respect of the forfeited shares, but shall, notwithstanding such forfeiture, remain liable to
pay to us all monies which at the date of forfeiture were payable by him to us in respect of the shares, together with all expenses
and interest from the date of forfeiture or surrender until payment, but his liability shall cease if and when we receive payment
in full of the unpaid amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A declaration, whether statutory or under
oath, made by a director or the secretary shall be conclusive evidence that the person making the declaration is our director or
secretary and that the particular shares have been forfeited or surrendered on a particular date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Subject to the execution of an instrument
of transfer, if necessary, the declaration shall constitute good title to the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Share Premium Account</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors shall establish a share premium
account and shall carry the credit of such account from time to time to a sum equal to the amount or value of the premium paid
on the issue of any share or capital contributed or such other amounts required by the Cayman Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Redemption and Purchase of Own Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Law and
any rights for the time being conferred on the shareholders holding a particular class of shares, we may by action of our directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue shares that are to be redeemed or liable to be redeemed, at our option or the shareholder holding those redeemable shares, on the terms and in the manner our directors determine before the issue of those shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the consent by special resolution of the shareholders holding shares of a particular class, vary the rights attaching to that class of shares so as to provide that those shares are to be redeemed or are liable to be redeemed at our option on the terms and in the manner which the directors determine at the time of such variation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchase all or any of our own shares of any class including any redeemable shares on the terms and in the manner which the directors determine at the time of such purchase.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may make a payment in respect of the
redemption or purchase of its own shares in any manner authorized by the Cayman Companies Law, including out of any combination
of capital, our profits and the proceeds of a fresh issue of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When making a payment in respect of the
redemption or purchase of shares, the directors may make the payment in cash or in specie (or partly in one and partly in the other)
if so authorized by the terms of the allotment of those shares or by the terms applying to those shares, or otherwise by agreement
with the shareholder holding those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Provided that a transfer of Ordinary Shares
complies with applicable rules of [the NYSE/Nasdaq], a shareholder may transfer Ordinary Shares to another person by completing
an instrument of transfer in a common form or in a form prescribed by [the NYSE/Nasdaq] or in any other form approved by the directors,
executed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the Ordinary Shares are fully paid, by or on behalf of that shareholder; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where the Ordinary Shares are partly paid, by or on behalf of that shareholder and the transferee.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transferor shall be deemed to remain
the holder of an Ordinary Share until the name of the transferee is entered into the register of members of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors may, in its absolute
discretion, decline to register any transfer of any Ordinary Share that has not been fully paid up or is subject to a company lien.
Our board of directors may also decline to register any transfer of such Ordinary Share unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is lodged with the Company, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is in respect of only one class of Ordinary Shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument of transfer is properly stamped, if required;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Ordinary Share transferred is fully paid and free of any lien in favor of us;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fee related to the transfer has been paid to us; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the transfer is not to more than four joint holders.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our directors refuse to register a transfer,
they are required, within [three months] after the date on which the instrument of transfer was lodged, to send to each of the
transferor and the transferee notice of such refusal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This, however, is unlikely to affect market
transactions of the Ordinary Shares purchased by investors in the public offering. Once the Ordinary Shares have been listed, the
legal title to such Ordinary Shares and the registration details of those Ordinary Shares in the Company&rsquo;s register of members
will remain with Depository Trust Company (&ldquo;DTC&rdquo;). All market transactions with respect to those Ordinary Shares will
then be carried out without the need for any kind of registration by the directors, as the market transactions will all be conducted
through the DTC systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration of transfers may, on 14
calendar days&rsquo; notice being given by advertisement in such one or more newspapers or by electronic means, be suspended and
our register of members closed at such times and for such periods as our board of directors may from time to time determine. The
registration of transfers, however, may not be suspended, and the register may not be closed, for more than 30 days in any year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Inspection of Books and Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of our Ordinary Shares will have
no general right under the Cayman Companies Law to inspect or obtain copies of our register of members or our corporate records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a Cayman Islands exempted company, we
are not obligated by the Cayman Companies Law to call shareholders&rsquo; annual general meetings; accordingly, we may, but shall
not be obliged to, in each year hold a general meeting as an annual general meeting. Any annual general meeting held shall be held
at such time and place as may be determined by our board of directors. All general meetings other than annual general meetings
shall be called extraordinary general meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may convene general meetings
whenever they think fit. General meetings shall also be convened on the written requisition of one or more of the shareholders
entitled to attend and vote at our general meetings who (together) hold not less than ten percent of the rights to vote at such
general meeting in accordance with the notice provisions in the articles, specifying the purpose of the meeting and signed by each
of the shareholders making the requisition. If the directors do not convene such meeting for a date not later than 21 clear days&rsquo;
after the date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting
themselves within three months after the end of such period of 21 clear days in which case reasonable expenses incurred by them
as a result of the directors failing to convene a meeting shall be reimbursed by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At least 14 days&rsquo; notice of an extraordinary
general meeting and 21 days&rsquo; notice of an annual general meeting shall be given to shareholders entitled to attend and vote
at such meeting. The notice shall specify the place, the day and the hour of the meeting and the general nature of that business.
In addition, if a resolution is proposed as a special resolution, the text of that resolution shall be given to all shareholders.
Notice of every general meeting shall also be given to the directors and our auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the Cayman Companies Law and
with the consent of the shareholders who, individually or collectively, hold at least 90 percent of the voting rights of all those
who have a right to vote at a general meeting, a general meeting may be convened on shorter notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A quorum shall consist of the presence
(whether in person or represented by proxy) of one or more shareholders holding shares that represent not less than one-third of
the outstanding shares carrying the right to vote at such general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, within 15 minutes from the time appointed
for the general meeting, or at any time during the meeting, a quorum is not present, the meeting, if convened upon the requisition
of shareholders, shall be cancelled. In any other case it shall stand adjourned to the same time and place seven days or to such
other time or place as is determined by the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The chairman may, with the consent of a
meeting at which a quorum is present, adjourn the meeting. When a meeting is adjourned for seven days or more, notice of the adjourned
meeting shall be given in accordance with the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At any general meeting a resolution put
to the vote of the meeting shall be decided on a show of hands, unless a poll is (before, or on, the declaration of the result
of the show of hands) demanded by the chairman of the meeting or by at least two shareholders having the right to vote on the resolutions
or one or more shareholders present who together hold not less than ten percent of the voting rights of all those who are entitled
to vote on the resolution. Unless a poll is so demanded, a declaration by the chairman as to the result of a resolution and an
entry to that effect in the minutes of the meeting, shall be conclusive evidence of the outcome of a show of hands, without proof
of the number or proportion of the votes recorded in favor of, or against, that resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a poll is duly demanded it shall be
taken in such manner as the chairman directs and the result of the poll shall be deemed to be the resolution of the meeting at
which the poll was demanded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the case of an equality of votes, whether
on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded,
shall not be entitled to a second or casting vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may by ordinary resolution, from time
to time, fix the maximum and minimum number of directors to be appointed. Under the articles, we are required to have a minimum
of one director and the maximum number of Directors shall be unlimited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may be appointed by ordinary
resolution or by the directors. Any appointment may be to fill a vacancy or as an additional director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the remuneration of the directors
is determined by the shareholders by ordinary resolution, the directors shall be entitled to such remuneration as the directors
may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shareholding qualification for directors
may be fixed by our shareholders by ordinary resolution and unless and until so fixed no share qualification shall be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless removed or re-appointed, each director
shall be appointed for a term expiring at the next-following annual general meeting, if one is held. At any annual general meeting
held, our directors will be elected by an ordinary resolution of our shareholders. At each annual general meeting, each director
so elected shall hold office for a [one-year] term and until the election of their respective successors in office or removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may be removed by ordinary resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may at any time resign or retire
from office by giving us notice in writing. Unless the notice specifies a different date, the director shall be deemed to have
resigned on the date that the notice is delivered to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the articles,
the office of a director may be terminated forthwith if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is prohibited by the law of the Cayman Islands from acting as a director;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made bankrupt or makes an arrangement or composition with his creditors generally;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he resigns his office by notice to us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he only held office as a director for a fixed term and such term expires;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the opinion of a registered medical practitioner by whom he is being treated he becomes physically or mentally incapable of acting as a director;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is given notice by the majority of the other directors (not being less than two in number) to vacate office (without prejudice to any claim for damages for breach of any agreement relating to the provision of the services of such director);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">he is made subject to any law relating to mental health or incompetence, whether by court order or otherwise; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">without the consent of the other directors, he is absent from meetings of directors for continuous period of six months.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the compensation committee and
the nominating and corporate governance committee shall consist of at least three directors and the majority of the committee members
shall be independent within the meaning of <FONT STYLE="background-color: white">[Section 303A of the Corporate Governance Rules
of the New York Stock Exchange/Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock Market]</FONT>. The audit committee shall
consist of at least three directors, all of whom shall be independent within the meaning of <FONT STYLE="background-color: white">[Section
303A of the Corporate Governance Rules of the New York Stock Exchange/Rule 5605(a)(2) of the Listing Rules of the Nasdaq Stock
Market] </FONT>and will meet the criteria for independence set forth in Rule 10A-3 or Rule 10C-1 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Powers and Duties of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the provisions of the Cayman
Companies Law and our memorandum and articles of association, our business shall be managed by the directors, who may exercise
all our powers. No prior act of the directors shall be invalidated by any subsequent alteration of our memorandum or articles of
association. To the extent allowed by the Cayman Companies Law, however, shareholders may by special resolution validate any prior
or future act of the directors which would otherwise be in breach of their duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may delegate any of their
powers to any committee consisting of one or more persons who need not be shareholders and may include non-directors so long as
the majority of those persons are directors; any committee so formed shall in the exercise of the powers so delegated conform to
any regulations that may be imposed on it by the directors. Upon the initial closing of this offering, our board of directors will
have established an audit committee, compensation committee, and nomination and corporate governance committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors may establish any
local or divisional board of directors or agency and delegate to it its powers and authorities (with power to sub-delegate) for
managing any of our affairs whether in the Cayman Islands or elsewhere and may appoint any persons to be members of a local or
divisional board of directors, or to be managers or agents, and may fix their remuneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may from time to time and
at any time by power of attorney or in any other manner they determine appoint any person, either generally or in respect of any
specific matter, to be our agent with or without authority for that person to delegate all or any of that person&rsquo;s powers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may from time to time and
at any time by power of attorney or in any other manner they determine appoint any person, whether nominated directly or indirectly
by the directors, to be our attorney or our authorized signatory and for such period and subject to such conditions as they may
think fit. The powers, authorities and discretions, however, must not exceed those vested in, or exercisable, by the directors
under the articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The board of directors may remove any person
so appointed and may revoke or vary the delegation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors may exercise all of our powers
to borrow money and to mortgage or charge its undertaking, property and assets both present and future and uncalled capital or
any part thereof, to issue debentures and other securities whether outright or as collateral security for any debt, liability or
obligation of ours or our parent undertaking (if any) or any subsidiary undertaking of us or of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director shall not, as a director, vote
in respect of any contract, transaction, arrangement or proposal in which he has an interest which (together with any interest
of any person connected with him) is a material interest (otherwise than by virtue of his interests, direct or indirect, in shares
or debentures or other securities of, or otherwise in or through, us) and if he shall do so his vote shall not be counted, nor
in relation thereto shall he be counted in the quorum present at the meeting, but (in the absence of some other material interest
than is mentioned below) none of these prohibitions shall apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the giving of any security, guarantee or indemnity in respect of:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">money lent or obligations incurred by him or by any other person for our benefit or any of our subsidiaries; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a debt or obligation of ours or any of our subsidiaries for which the director himself has assumed responsibility in whole or in part and whether alone or jointly with others under a guarantee or indemnity or by the giving of security;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where we or any of our subsidiaries is offering securities in which offer the director is or may be entitled to participate as a holder of securities or in the underwriting or sub-underwriting of which the director is to or may participate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any contract, transaction, arrangement or proposal affecting any other body corporate in which he is interested, directly or indirectly and whether as an officer, shareholder, creditor or otherwise howsoever, provided that he (together with persons connected with him) does not to his knowledge hold an interest representing one percent or more of any class of the equity share capital of such body corporate (or of any third body corporate through which his interest is derived) or of the voting rights available to shareholders of the relevant body corporate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any act or thing done or to be done in respect of any arrangement for the benefit of the employees of us or any of our subsidiaries under which he is not accorded as a director any privilege or advantage not generally accorded to the employees to whom such arrangement relates; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any matter connected with the purchase or maintenance for any director of insurance against any liability or (to the extent permitted by the Cayman Companies Law) indemnities in favor of directors, the funding of expenditure by one or more directors in defending proceedings against him or them or the doing of anything to enable such director or directors to avoid incurring such expenditure.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A director may, as a director, vote (and
be counted in the quorum) in respect of any contract, transaction, arrangement or proposal in which he has an interest which is
not a material interest or as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Capitalization of Profits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The directors may resolve to capitalize:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 18pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any part of our profits not required for paying any preferential dividend (whether or not those profits are available for distribution); or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sum standing to the credit of our share premium account or capital redemption reserve, if any.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount resolved to be capitalized must
be appropriated to the shareholders who would have been entitled to it had it been distributed by way of dividend and in the same
proportions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidation Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are wound up, the shareholders may,
subject to the articles and any other sanction required by the Cayman Companies Law, pass a special resolution allowing the liquidator
to do either or both of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to divide in specie among the shareholders the whole or any part of our assets and, for that purpose, to value any assets and to determine how the division shall be carried out as between the shareholders or different classes of shareholders; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to vest the whole or any part of the assets in trustees for the benefit of shareholders and those liable to contribute to the winding up.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The directors have the authority to present
a petition for our winding up to the Grand Court of the Cayman Islands on our behalf without the sanction of a resolution passed
at a general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Register of Members</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Cayman Companies Law, we must
keep a register of members and there should be entered therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names and addresses of our shareholders, a statement of the shares held by each shareholder, and of the amount paid or agreed to be considered as paid, on the shares of each shareholder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the name of any person was entered on the register as a shareholder; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which any person ceased to be a shareholder.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Cayman Companies Law, the register
of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a
presumption of fact on the matters referred to above unless rebutted) and a shareholder registered in the register of members is
deemed as a matter of the Cayman Companies Law to have legal title to the shares as set against its name in the register of members.
Upon the completion of this offering, the register of members will be immediately updated to record and give effect to the issuance
of shares by us to the custodian or its nominee. Once our register of members has been updated, the shareholders recorded in the
register of members will be deemed to have legal title to the shares set against their name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the name of any person is incorrectly
entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register
the fact of any person having ceased to be a shareholder of our company, the person or shareholder aggrieved (or any shareholder
of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified,
and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification
of the register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Differences in Corporate Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Law is derived, to
a large extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments,
and accordingly there are significant differences between the Cayman Companies Law and the current Companies Act of the United
Kingdom. In addition, the Cayman Companies Law differs from laws applicable to United States corporations and their shareholders.
Set forth below is a summary of certain significant differences between the provisions of the Cayman Companies Law applicable to
us and the comparable laws applicable to companies incorporated in the State of Delaware in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 41%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware </B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman Islands</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Title of Organizational Documents </I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Bylaws</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation and Memorandum and Articles of Association</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Duties of Directors</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, the business and affairs of a corporation are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the corporation and a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that directors act in an informed and deliberative manner and inform themselves, prior to making a business decision, of all material information reasonably available to them. The duty of care also requires that directors exercise care in overseeing and investigating the conduct of the corporation&rsquo;s employees. The duty of loyalty may be summarized as the duty to act in good faith, not out of self-interest, and in a manner which the director reasonably believes to be in the best interests of the shareholders.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a matter of Cayman Islands law, a director owes three types of duties to the company: (i) statutory duties, (ii) fiduciary duties, and (iii) common law duties. The Cayman Companies Law imposes a number of statutory duties on a director. A Cayman Islands director&rsquo;s fiduciary duties are not codified, however the courts of the Cayman Islands have held that a director owes the following fiduciary duties (a) a duty to act in what the director bona fide considers to be in the best interests of the company, (b) a duty to exercise their powers for the purposes they were conferred, (c) a duty to avoid fettering his or her discretion in the future and (d) a duty to avoid conflicts of interest and of duty. The common law duties owed by a director are those to act with skill, care and diligence that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and, also, to act with the skill, care and diligence in keeping with a standard of care commensurate with any particular skill they have which enables them to meet a higher standard than a director without those skills. In fulfilling their duty of care to us, our directors must ensure compliance with our amended articles of association, as amended and restated from time to time. We have the right to seek damages if a duty owed by any of our directors is breached.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Limitations on Personal Liability of Directors</I></FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the limitations described below, a certificate of incorporation may provide for the elimination or limitation of the personal liability of a director to the corporation or its shareholders for monetary damages for a breach of fiduciary duty as a director. Such provision cannot limit liability for breach of loyalty, bad faith, intentional misconduct, unlawful payment of dividends or unlawful share purchase or redemption. In addition, the certificate of incorporation cannot limit liability for any act or omission occurring prior to the date when such provision becomes effective.</FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Islands law does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification of Officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification of Directors, Officers, Agents, and Others</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A corporation has the power to indemnify any director, officer, employee, or agent of corporation who was, is, or is threatened to be made a party who acted in good faith and in a manner he believed to be in the best interests of the corporation, and if with respect to a criminal proceeding, had no reasonable cause to believe his conduct would be unlawful, against amounts actually and reasonably incurred.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cayman Islands law does not limit the extent
        to which a company&rsquo;s memorandum and articles of association may provide for indemnification of directors and officers, except
        to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification
        against the consequences of committing a crime, or against the indemnified person&rsquo;s own fraud or dishonesty.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated articles
of association provide to the extent permitted by law, we shall indemnify each existing or former secretary, director (including
alternate director), and any of our other officers (including an investment adviser or an administrator or liquidator) and their
personal representatives against: (a) all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred
or sustained by the existing or former director (including alternate director), secretary or officer in or about the conduct of
our business or affairs or in the execution or discharge of the existing or former director (including alternate director), secretary&rsquo;s
or officer&rsquo;s duties, powers, authorities or discretions; and (b) without limitation to paragraph (a) above, all costs, expenses,
losses or liabilities incurred by the existing or former director (including alternate director), secretary or officer in defending
(whether successfully or otherwise) any civil, criminal, administrative or investigative proceedings (whether threatened, pending
or completed) concerning us or our affairs in any court or tribunal, whether in the Cayman Islands or elsewhere.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No such existing or former director (including
        alternate director), secretary or officer, however, shall be indemnified in respect of any matter arising out of his own dishonesty.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent permitted by law, we may
        make a payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred by an existing
        or former director (including alternate director), secretary or any of our officers in respect of any matter identified in above
        on condition that the director (including alternate director), secretary or officer must repay the amount paid by us to the extent
        that it is ultimately found not liable to indemnify the director (including alternate director), the secretary or that officer
        for those legal costs.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interested Directors</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, a transaction in which a director who has an interest in such transaction would not be voidable if (i) the material facts as to such interested director&rsquo;s relationship or interests are disclosed or are known to the board of directors and the board in good faith authorizes the transaction by the affirmative vote of a majority of the disinterested directors, even though the disinterested directors are less than a quorum, (ii) such material facts are disclosed or are known to the shareholders entitled to vote on such transaction and the transaction is specifically approved in good faith by vote of the shareholders, or (iii) the transaction is fair as to the corporation as of the time it is authorized, approved or ratified. Under Delaware law, a director could be held liable for any transaction in which such director derived an improper personal benefit.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interested director transactions are governed by the terms of a company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting Requirements</I></FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The certificate of incorporation may include
        a provision requiring supermajority approval by the directors or shareholders for any corporate action.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, under Delaware law, certain
        business combinations involving interested shareholders require approval by a supermajority of the non-interested shareholders.</P></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the protection of shareholders, certain
        matters must be approved by special resolution of the shareholders as a matter of Cayman Islands law, including alteration of the
        memorandum or articles of association, appointment of inspectors to examine company affairs, reduction of share capital (subject,
        in relevant circumstances, to court approval), change of name, authorization of a plan of merger or transfer by way of continuation
        to another jurisdiction or consolidation or voluntary winding up of the company.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Companies Law requires that
        a special resolution be passed by a majority of at least two-thirds or such higher percentage as set forth in the memorandum and
        articles of association, of shareholders being entitled to vote and do vote in person or by proxy at a general meeting, or by unanimous
        written consent of shareholders entitled to vote at a general meeting.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting for Directors</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, unless otherwise specified in the certificate of incorporation or bylaws of the corporation, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Law defines &ldquo;special resolutions&rdquo; only. A company&rsquo;s memorandum and articles of association can therefore tailor the definition of &ldquo;ordinary resolutions&rdquo; as a whole, or with respect to specific provisions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative Voting</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the certificate of incorporation.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No cumulative voting for the election of directors unless so provided in the memorandum and articles of association.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors&rsquo; Powers Regarding Bylaws</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certificate of incorporation may grant the directors the power to adopt, amend or repeal bylaws.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The memorandum and articles of association may only be amended by a special resolution of the shareholders.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination and Removal of Directors and Filling Vacancies on Board</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders may generally nominate directors if they comply with advance notice provisions and other procedural requirements in company bylaws. Holders of a majority of the shares may remove a director with or without cause, except in certain cases involving a classified board or if the company uses cumulative voting. Unless otherwise provided for in the certificate of incorporation, directorship vacancies are filled by a majority of the directors elected or then in office.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination and removal of directors and filling of board vacancies are governed by the terms of the memorandum and articles of association.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mergers and Similar Arrangements</I></FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law, with certain exceptions,
        a merger, consolidation, exchange or sale of all or substantially all the assets of a corporation must be approved by the board
        of directors and a majority of the outstanding shares entitled to vote thereon. Under Delaware law, a shareholder of a corporation
        participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant
        to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined
        by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delaware law also provides that a parent
        corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90% of each class
        of capital stock without a vote by shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary
        would have appraisal rights.</P></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify">The Cayman Companies Law permits
        mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies.
        For these purposes, (a) &ldquo;merger&rdquo; means the merging of two or more constituent companies and the vesting of their undertaking,
        property and liabilities in one of such companies as the surviving company, and (b) a &ldquo;consolidation&rdquo; means the combination
        of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of
        such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent
        company must approve a written plan of merger or consolidation, which must then be authorized by (a) a special resolution of the
        shareholders of each constituent company, and (b) such other authorization, if any, as may be specified in such constituent company&rsquo;s
        articles of association. The plan must be filed with the Registrar of Companies together with a declaration as to the solvency
        of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking that
        a copy of the certificate of merger or consolidation will be given to the shareholders and creditors of each constituent company
        and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required
        for a merger or consolidation which is effected in compliance with these statutory procedures.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A merger between a Cayman Islands parent
        company and its Cayman Islands subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this
        purpose a subsidiary is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consent of each holder of a fixed or
        floating security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except in certain limited circumstances,
a dissenting shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares
upon dissenting from a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting
shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right
to seek relief on the grounds that the merger or consolidation is void or unlawful.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, there are statutory provisions
that facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number
of each class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths
in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by
proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must
be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the
view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that:
(a) the statutory provisions as to the required majority vote have been met; (b) the shareholders have been fairly represented
at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests
adverse to those of the class; (c) the arrangement is such that may be reasonably approved by an intelligent and honest man of
that class acting in respect of his interest; and (d) the arrangement is not one that would more properly be sanctioned under some
other provision of the Cayman Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a takeover offer is made and accepted
by holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration
of such four month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection
can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so
approved unless there is evidence of fraud, bad faith or collusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">If an arrangement and reconstruction is thus approved, or if
a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would
otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash
for the judicially determined value of the shares.</P>



</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Suits</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class actions and derivative actions generally are available to shareholders under Delaware law for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court generally has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in Foss v. Harbottle and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge: (a) an act which is illegal or ultra vires with respect to the company and is therefore incapable of ratification by the shareholders; (b) an act which, although not ultra vires, requires authorization by a qualified (or special) majority (that is, more than a simple majority) which has not been obtained; and (c) an act which constitutes a &ldquo;fraud on the minority&rdquo; where the wrongdoers are themselves in control of the company.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inspection of Corporate Records</I></FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Delaware law, shareholders of a Delaware corporation have the right during normal business hours to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders of a Cayman Islands exempted company have no general right under Cayman Islands law to inspect or obtain copies of a list of shareholders or other corporate records (other than the register of mortgages or charges) of the company. However, these rights may be provided in the company&rsquo;s memorandum and articles of association.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder Proposals</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless provided in the corporation&rsquo;s certificate of incorporation or bylaws, Delaware law does not include a provision restricting the manner in which shareholders may bring business before a meeting.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Law provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&rsquo;s articles of association. Our articles provide that general meetings shall be convened on the written requisition of one or more of the shareholders entitled to attend and vote at our general meetings who (together) hold not less than 10 percent of the rights to vote at such general meeting in accordance with the notice provisions in the articles, specifying the purpose of the meeting and signed by each of the shareholders making the requisition. If the directors do not convene such meeting for a date not later than twenty-one clear days&rsquo; after the date of receipt of the written requisition, those shareholders who requested the meeting may convene the general meeting themselves within three months after the end of such period of twenty-one clear days in which case reasonable expenses incurred by them as a result of the directors failing to convene a meeting shall be reimbursed by us. Our articles provide no other right to put any proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated by law to call shareholders&rsquo; annual general meetings. However, our corporate governance guidelines require us to call such meetings every year.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval of Corporate Matters by Written Consent</I></FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits shareholders to take action by written consent signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting of shareholders.</FONT></TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Law allows a special resolution to be passed in writing if signed by all the voting shareholders (if authorized by the memorandum and articles of association).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Calling of Special Shareholders Meetings</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware law permits the board of directors or any person who is authorized under a corporation&rsquo;s certificate of incorporation or bylaws to call a special meeting of shareholders.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Cayman Companies Law does not have provisions governing the proceedings of shareholders meetings which are usually provided in the memorandum and articles of association. Please see above.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dissolution; Winding Up</I></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="padding-left: 2.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Cayman Companies Law and our amended and restated articles, the Company may be wound up by a special resolution of our shareholders, or if the winding up is initiated by our board of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-money Laundering&mdash;Cayman Islands</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to comply with legislation or
regulations aimed at the prevention of money laundering, we may be required to adopt and maintain anti-money laundering procedures,
and may require subscribers to provide evidence to verify their identity. Where permitted, and subject to certain conditions, we
may also delegate the maintenance of our anti-money laundering procedures (including the acquisition of due diligence information)
to a suitable person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reserve the right to request such information
as is necessary to verify the identity of a subscriber. In the event of delay or failure on the part of the subscriber in producing
any information required for verification purposes, we may refuse to accept the application, in which case any funds received will
be returned without interest to the account from which they were originally debited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also reserve the right to refuse to
make any redemption payment to a shareholder if our directors or officers suspect or are advised that the payment of redemption
proceeds to such shareholder might result in a breach of applicable anti-money laundering or other laws or regulations by any person
in any relevant jurisdiction, or if such refusal is considered necessary or appropriate to ensure our compliance with any such
laws or regulations in any applicable jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any person resident in the Cayman Islands
knows or suspects or has reason for knowing or suspecting that another person is engaged in criminal conduct or is involved with
terrorism or terrorist property and the information for that knowledge or suspicion came to their attention in the course of their
business in the regulated sector, or other trade, profession, business or employment, the person will be required to report such
knowledge or suspicion to (i) a nominated officer (appointed in accordance with the Proceeds of Crime Law (Revised) of the Cayman
Islands) or the Financial Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Law (Revised), if the disclosure
relates to criminal conduct or money laundering or (ii) to a police constable or a nominated officer (pursuant to the Terrorism
Law (Revised) of the Cayman Islands) or the Financial Reporting Authority, pursuant to the Terrorism Law (Revised), if the disclosure
relates to involvement with terrorism or terrorist financing and terrorist property. Such a report shall not be treated as a breach
of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Data Protection in the Cayman Islands
&ndash; Privacy Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This privacy notice explains the manner
in which the Company collects, processes and maintains personal data about investors of the Company pursuant to the Data Protection
Law, 2017 of the Cayman Islands, as amended from time to time and any regulations, codes of practice or orders promulgated pursuant
thereto (the &ldquo;DPL&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is committed to processing
personal data in accordance with the DPL. In its use of personal data, the Company will be characterized under the DPL as a &lsquo;data
controller&rsquo;, whilst certain of the Company&rsquo;s service providers, affiliates and delegates may act as &lsquo;data processors&rsquo; under the
DPL. These service providers may process personal information for their own lawful purposes in connection with services provided
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By virtue of making an investment in the
Company, the Company and certain of the Company&rsquo;s service providers may collect, record, store, transfer and otherwise process
personal data by which individuals may be directly or indirectly identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Your personal data will be processed fairly
and for lawful purposes, including (a) where the processing is necessary for the Company to perform a contract to which you are
a party or for taking pre-contractual steps at your request (b) where the processing is necessary for compliance with any legal,
tax or regulatory obligation to which the Company is subject or (c) where the processing is for the purposes of legitimate interests
pursued by the Company or by a service provider to whom the data are disclosed. As a data controller, we will only use your personal
data for the purposes for which we collected it. If we need to use your personal data for an unrelated purpose, we will contact
you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We anticipate that we will share your personal
data with the Company&rsquo;s service providers for the purposes set out in this privacy notice. We may also share relevant personal
data where it is lawful to do so and necessary to comply with our contractual obligations or your instructions or where it is necessary
or desirable to do so in connection with any regulatory reporting obligations. In exceptional circumstances, we will share your
personal data with regulatory, prosecuting and other governmental agencies or departments, and parties to litigation (whether pending
or threatened), in any country or territory including to any other person where we have a public or legal duty to do so (e.g. to
assist with detecting and preventing fraud, tax evasion and financial crime or compliance with a court order).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Your personal data shall not be held by
the Company for longer than necessary with regard to the purposes of the data processing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not sell your personal data. Any
transfer of personal data outside of the Cayman Islands shall be in accordance with the requirements of the DPL. Where necessary,
we will ensure that separate and appropriate legal agreements are put in place with the recipient of that data. The Company will
only transfer personal data in accordance with the requirements of the DPL, and will apply appropriate technical and organizational
information security measures designed to protect against unauthorized or unlawful processing of the personal data and against
the accidental loss, destruction or damage to the personal data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are a natural person, this will
affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted
limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation to your investment
into the Company, this will be relevant for those individuals and you should inform such individuals of the content.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You have certain rights under the DPL,
including (a) the right to be informed as to how we collect and use your personal data (and this privacy notice fulfils the Company&rsquo;s
obligation in this respect) (b) the right to obtain a copy of your personal data (c) the right to require us to stop direct marketing
(d) the right to have inaccurate or incomplete personal data corrected (e) the right to withdraw your consent and require us to
stop processing or restrict the processing, or not begin the processing of your personal data (f) the right to be notified of a
data breach (unless the breach is unlikely to be prejudicial) (g) the right to obtain information as to any countries or territories
outside the Cayman Islands to which we, whether directly or indirectly, transfer, intend to transfer or wish to transfer your personal
data, general measures we take to ensure the security of personal data and any information available to us as to the source of
your personal data (h) the right to complain to the Office of the Ombudsman of the Cayman Islands and (i) the right to require
us to delete your personal data in some limited circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you consider that your personal data
has not been handled correctly, or you are not satisfied with the Company&rsquo;s responses to any requests you have made regarding the
use of your personal data, you have the right to complain to the Cayman Islands&rsquo; Ombudsman. The Ombudsman can be contacted by calling
+1 (345) 946-6283 or by email at info@ombudsman.ky.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c19"></A>SHARES ELIGIBLE FOR FUTURE SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before our initial public offering, there
has not been a public market for our Ordinary Shares, and although we expect to make an application for the Ordinary Shares to
be listed on [the New York Stock Exchange/Nasdaq Capital Market], a regular trading market for our Ordinary Shares may not develop.
Future sales of substantial amounts of shares of our Ordinary Shares in the public market after our initial public offering, or
the possibility of these sales occurring, could cause the prevailing market price for our Ordinary Shares to fall or impair our
ability to raise equity capital in the future. Upon completion of this offering, we will have outstanding Ordinary Shares held
by public shareholders representing approximately [&#9679;]% of our Ordinary Shares in issue. All of the Ordinary Shares sold in
this offering will be freely transferable by persons other than our &ldquo;affiliates&rdquo; without restriction or further registration
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed not to, for a period of
[180] days from the effective date of this registration statement, offer, issue, sell, contract to sell, encumber, grant any option
for the sale of, or otherwise dispose of, except in this offering, any of our Ordinary Shares or securities that are substantially
similar to our Ordinary Shares, including but not limited to any options or warrants to purchase our Ordinary Shares, or any securities
that are convertible into or exchangeable for, or that represent the right to receive, our Ordinary Shares or any such substantially
similar securities (other than pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible
or exchangeable securities outstanding as of, the date such lock-up agreement was executed), without the prior written consent
of the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, each of our directors, executive
officers, and principal shareholders ([5%] or more shareholders) of our Ordinary Shares has also entered into a similar lock-up
agreement for a period of [&#9679;] months from the effective date of this registration statement, subject to certain exceptions,
with respect to our Ordinary Shares and securities that are substantially similar to our Ordinary Shares. All of our other shareholders
have agreed with the underwriter, subject to certain exceptions, not to sell, transfer, or dispose of, directly or indirectly,
any our Ordinary Shares or securities convertible into or exercisable or exchangeable for our Ordinary Shares for a period of [&#9679;]
months after the effective date of this registration statement. These parties collectively own all of our outstanding Ordinary
Shares, without giving effect to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than this offering, we are not aware
of any plans by any significant shareholders to dispose of significant numbers of our Ordinary Shares. However, one or more existing
shareholders or owners of securities convertible or exchangeable into or exercisable for our Ordinary Shares may dispose of significant
numbers of our Ordinary Shares in the future. We cannot predict what effect, if any, future sales of our ordinary shares, or the
availability of Ordinary Shares for future sale, will have on the trading price of our Ordinary Shares from time to time. Sales
of substantial amounts of our Ordinary Shares in the public market, or the perception that these sales could occur, could adversely
affect the trading price of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our Ordinary Shares outstanding
prior to this offering are &ldquo;restricted securities&rdquo; as that term is defined in Rule 144 under the Securities Act and
may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities
Act or pursuant to an exemption from the registration requirement such as those provided by Rule 144 and Rule 701 promulgated under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, under Rule 144 as currently
in effect, beginning 90 days after the date of this prospectus, a person who is not deemed to have been our affiliate at any time
during the three months preceding a sale and who has beneficially owned restricted securities within the meaning of Rule 144 for
more than six months would be entitled to sell an unlimited number of those shares, subject only to the availability of current
public information about us. A non-affiliate who has beneficially owned restricted securities for at least one year from the later
of the date these shares were acquired from us or from our affiliate would be entitled to freely sell those shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A person who is deemed to be an affiliate
of ours and who has beneficially owned &ldquo;restricted securities&rdquo; for at least six months would be entitled to sell, within
any three-month period, a number of shares that is not more than the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of Ordinary Shares then outstanding, in the form of Ordinary Shares or otherwise, which will equal approximately [&#9679;] shares immediately after this offering, assuming the underwriter does not exercise their over-allotment option; or</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly trading volume of the Ordinary Shares on [the NYSE/Nasdaq] during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales under Rule 144 by our affiliates
or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements
and to the availability of current public information about us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 701</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, under Rule 701 of the Securities
Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection
with a compensatory stock or option plan or other written agreement relating to compensation is eligible to resell such ordinary
shares 90 days after we became a reporting company under the Exchange Act in reliance on Rule 144, but without compliance with
some of the restrictions, including the holding period, contained in Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation S</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulation S provides generally that sales
made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c20"></A>TAXATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion of material
PRC, Cayman Islands, and United States federal income tax consequences of an investment in our Ordinary Shares is based upon laws
and relevant interpretations thereof in effect as of the date of this prospectus, all of which are subject to change. This discussion
does not deal with all possible tax consequences relating to an investment in our Ordinary Shares, such as the tax consequences
under state, local, and other tax laws. To the extent that the discussion relates to matters of Cayman Islands tax law, it represents
the opinion of Ogier, our Cayman Islands counsel. To the extent that the discussion relates to matters of PRC tax law, it represents
the opinion of AllBright Law Offices, our PRC counsel. To the extent the discussion relates to the matters of U.S. tax law, it
represents the opinion of Hunter Taubman Fischer &amp; Li LLC.&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WE URGE POTENTIAL PURCHASERS OF OUR ORDINARY
SHARES TO CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES OF PURCHASING,
OWNING AND DISPOSING OF OUR ORDINARY SHARES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cayman Islands Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cayman Islands currently levies no
taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of
inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands
except for stamp duties which may be applicable on instruments executed in, or, after execution, brought within the jurisdiction
of the Cayman Islands. No stamp duty is payable in the Cayman Islands on the issue of shares by, or any transfers of shares of,
Cayman Islands companies (except those which hold interests in land in the Cayman Islands). There are no exchange control regulations
or currency restrictions in the Cayman Islands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments of dividends and capital in respect
of our Ordinary Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment
of a dividend or capital to any holder of our Ordinary Shares, as the case may be, nor will gains derived from the disposal of
our Ordinary Shares be subject to Cayman Islands income or corporation tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>People&rsquo;s Republic of China Enterprise
Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief description of Chinese
enterprise laws is designed to highlight the enterprise-level taxation on our earnings, which will affect the amount of dividends,
if any, we are ultimately able to pay to our shareholders. See &ldquo;Dividend Policy.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Enterprise Income Tax</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the Enterprise Income Tax
Law of the People&rsquo;s Republic of China, or the EIT Law, which was promulgated by the SCNPC on March 16, 2007, and became effective
on January 1, 2008, and then amended on February 24, 2017, and the Implementation Rules of the EIT Law, or the Implementation Rules,
which were promulgated by the State Council on December 6, 2007, and became effective on January 1, 2008, enterprises are divided
into resident enterprises and non-resident enterprises. Resident enterprises pay enterprise income tax on their incomes obtained
in and outside the PRC at the rate of 25%. Non-resident enterprises setting up institutions in the PRC pay enterprise income tax
on the incomes obtained by such institutions in and outside the PRC at the rate of 25%. Non-resident enterprises with no institutions
in the PRC, and non-resident enterprises with income having no substantial connection with their institutions in the PRC, pay enterprise
income tax on their income obtained in the PRC at a reduced rate of 10%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an exempted company incorporated
with limited liability in the Cayman Islands and we gain substantial income by way of dividends paid to us from our PRC subsidiaries,
Universe Technology, Jiangxi Universe, and Universe Trade. The EIT Law and its implementation rules provide that China-sourced
income of foreign enterprises, such as dividends paid by a PRC subsidiary to its equity holders that are non-resident enterprises,
will normally be subject to PRC withholding tax at a rate of 10%, unless any such foreign investor&rsquo;s jurisdiction of incorporation
has a tax treaty with China that provides for a preferential tax rate or a tax exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the EIT Law, an enterprise established
outside of China with a &ldquo;de facto management body&rdquo; within China is considered a &ldquo;resident enterprise,&rdquo;
which means that it is treated in a manner similar to a Chinese enterprise for enterprise income tax purposes. Although the implementation
rules of the EIT Law define &ldquo;de facto management body&rdquo; as a managing body that actually, comprehensively manage and
control the production and operation, staff, accounting, property and other aspects of an enterprise, the only official guidance
for this definition currently available is set forth in SAT Notice 82, which provides guidance on the determination of the tax
residence status of a Chinese-controlled offshore incorporated enterprise, defined as an enterprise that is incorporated under
the laws of a foreign country or territory and that has a PRC enterprise or enterprise group as its primary controlling shareholder.
Although Universe INC does not have a PRC enterprise or enterprise group as our primary controlling shareholder and is therefore
not a Chinese-controlled offshore incorporated enterprise within the meaning of SAT Notice 82, in the absence of guidance specifically
applicable to us, we have applied the guidance set forth in SAT Notice 82 to evaluate the tax residence status of Universe INC
and its subsidiaries organized outside the PRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to SAT Notice 82, a Chinese-controlled
offshore incorporated enterprise will be regarded as a PRC tax resident by virtue of having a &ldquo;de facto management body&rdquo;
in China and will be subject to PRC enterprise income tax on its worldwide income only if all of the following criteria are met:
(i) the places where senior management and senior management departments that are responsible for daily production, operation and
management of the enterprise perform their duties are mainly located within the territory of China; (ii) financial decisions (such
as money borrowing, lending, financing and financial risk management) and personnel decisions (such as appointment, dismissal and
salary and wages) are decided or need to be decided by organizations or persons located within the territory of China; (iii) main
property, accounting books, corporate seal, the board of directors and files of the minutes of shareholders&rsquo; meetings of
the enterprise are located or preserved within the territory of China; and (iv) one half (or more) of the directors or senior management
staff having the right to vote habitually reside within the territory of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we do not meet some of
the conditions outlined in the immediately preceding paragraph. For example, as a holding company, the key assets and records of
Universe INC, including the resolutions and meeting minutes of our board of directors and the resolutions and meeting minutes of
our shareholders, are located and maintained outside the PRC. In addition, we are not aware of any offshore holding companies with
a corporate structure similar to ours that has been deemed a PRC &ldquo;resident enterprise&rdquo; by the PRC tax authorities.
Accordingly, we believe that Universe INC and its offshore subsidiaries should not be treated as a &ldquo;resident enterprise&rdquo;
for PRC tax purposes if the criteria for &ldquo;de facto management body&rdquo; as set forth in SAT Notice 82 were deemed applicable
to us. However, as the tax residency status of an enterprise is subject to determination by the PRC tax authorities and uncertainties
remain with respect to the interpretation of the term &ldquo;de facto management body&rdquo; as applicable to our offshore entities,
we will continue to monitor our tax status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The implementation rules of the EIT law
provides that, (i) if the enterprise that distributes dividends is domiciled in the PRC or (ii) if gains are realized from transferring
equity interests of enterprises domiciled in the PRC, then such dividends or gains are treated as China-sourced income. It is not
clear how &ldquo;domicile&rdquo; may be interpreted under the EIT Law, and it may be interpreted as the jurisdiction where the
enterprise is a tax resident. Therefore, if we are considered as a PRC tax resident enterprise for PRC tax purposes, any dividends
we pay to our overseas shareholders which are non-resident enterprises as well as gains realized by such shareholders from the
transfer of our shares may be regarded as China-sourced income and as a result become subject to PRC withholding tax at a rate
of up to 10%. AllBright Law Offices, our PRC counsel, is unable to provide a &ldquo;will&rdquo; opinion because it believes that
it is more likely than not that we and our offshore subsidiaries would be treated as non-resident enterprises for PRC tax purposes
because we do not meet some of the conditions outlined in SAT Notice 82. In addition, AllBright Law Offices is not aware of any
offshore holding companies with a corporate structure similar to ours that has been deemed a PRC &ldquo;resident enterprise&rdquo;
by the PRC tax authorities as of the date of the prospectus. Therefore, AllBright Law Offices believes that it is possible but
highly unlikely that the income received by our overseas shareholders will be regarded as China-sourced income. See &ldquo;Risk
Factors&mdash;Risks Relating to Doing Business in the PRC&mdash;Under the PRC Enterprise Income Tax Law, or the EIT Law, we may
be classified as a &lsquo;resident enterprise&rsquo; of China, which could result in unfavorable tax consequences to us and our
non-PRC shareholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, as resident enterprises in the
PRC, Universe Technology as well as Jiangxi Universe and its subsidiary in PRC are subject to the enterprise income tax at the
rate of 25%, except that once an enterprise meets certain requirements and is identified as a small-scale minimal profit enterprise,
the part of its taxable income not more than RMB1 million is subject to a reduced rate of 5% and the part between RMB1 million
and 3 million is subject to a reduced rate of 10%. The EIT is calculated based on the entity&rsquo;s global income as determined under
PRC tax laws and accounting standards. If the PRC tax authorities determine that Jiangxi Universe is a PRC resident enterprise
for enterprise income tax purposes, we may be required to withhold a 10% withholding tax from dividends we pay to our shareholders
that are non-resident enterprises. In addition, non-resident enterprise shareholders may be subject to a 10% PRC withholding tax
on gains realized on the sale or other disposition of our Ordinary Shares, if such income is treated as sourced from within the
PRC. It is unclear whether our non-PRC individual shareholders would be subject to any PRC tax on dividends or gains obtained by
such non-PRC individual shareholders in the event we are determined to be a PRC resident enterprise. If any PRC tax were to apply
to dividends or gains realized by non-PRC individuals, it would generally apply at a rate of 20% unless a reduced rate is available
under an applicable tax treaty. However, it is also unclear whether our non-PRC shareholders would be able to claim the benefits
of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise.
There is no guidance from the PRC government to indicate whether or not any tax treaties between the PRC and other countries would
apply in circumstances where a non-PRC company was deemed to be a PRC tax resident, and thus there is no basis for expecting how
tax treaty between the PRC and other countries may impact non-resident enterprises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Value-added Tax</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Provisional Regulations
on Value-Added Tax of the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#12299;),
or the VAT Regulations, which were promulgated by the State Council on December 13, 1993, and amended on November 10, 2008, February
6, 2016, and November 19, 2017, respectively, and the Implementation Rules of the Provisional Regulations on Value Added Tax of
the PRC (&#12298;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#22686;&#20540;&#31246;&#26242;&#34892;&#26465;&#20363;&#23454;&#26045;&#32454;&#21017;&#12299;)
promulgated by the MOF on December 25, 1993 and amended on December 15, 2008 and October 28, 2011, respectively, entities and individuals
that sell goods or labor services of processing, repair or replacement, sell services, intangible assets, or immovables, or import
goods within the territory of the People&rsquo;s Republic of China are taxpayers of value-added tax.&nbsp;The VAT rate is 17% for taxpayers
selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise specified; 11%
for taxpayers selling goods, labor services, or tangible movable property leasing services or importing goods, except otherwise
specified; 6% for taxpayers selling services or intangible assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Provisions in the Notice on
Adjusting the Value added Tax Rates (Cai Shui [2018] No. 32), or the Notice, issued by the SAT and the MOF, where taxpayers make
VAT taxable sales or import goods, the applicable tax rates shall be adjusted from 17% to 16% and from 11% to 10%, respectively.
The Notice took effect on May 1, 2018, and the adjusted VAT rates took effect at the same time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 23, 2016, the MOF and the SAT
jointly issued the Circular of Full Implementation of Business Tax to VAT Reform (the &ldquo;Circular 36&rdquo;) (&#12298;&#20851;&#20110;&#20840;&#38754;&#25512;&#24320;&#33829;&#19994;&#31246;&#25913;&#24449;&#22686;&#20540;&#31246;&#35797;&#28857;&#30340;&#36890;&#30693;&#12299;),
which confirms that business tax will be completely replaced by VAT from May 1, 2016. The Notice of the MOF and the SAT on the
Adjustment to VAT Rates (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#12298;&#20851;&#20110;&#35843;&#25972;&#22686;&#20540;&#31246;&#31246;&#29575;&#30340;&#36890;&#30693;&#12299;</FONT>),
promulgated on April 4, 2018 and effective as of May 1, 2018, adjusted the applicative rate of VAT. The deduction rates of 17%
and 11% applicable to the taxpayers who have VAT taxable sales activities or imported goods are adjusted to 16% and 10%, respectively.
For the export goods to which a tax rate of 17% was originally applicable and the export rebate rate was 17%, the export rebate
rate is adjusted to 16%. For the export goods and cross-border taxable activities to which a tax rate of 11% was originally applicable
and the export rebate rate was 11%, the export rebate rate is adjusted to 10%. Pursuant to such circular, the Value Added Tax Pilot
Program has been applicable nationwide since May 1, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> According to the VAT Regulations and
the related rules, as of the date of this prospectus, as taxpayers selling goods, Jiangxi Universe and its consolidated affiliated
entities are generally subject to 16% VAT rate. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Dividend Withholding Tax</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Arrangement between Mainland
China and Hong Kong for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with respect to Taxes on Income (<FONT STYLE="font-family: Times New Roman, Times, Serif">&#12298;&#20869;&#22320;&#21644;&#39321;&#28207;&#29305;&#21035;&#34892;&#25919;&#21306;&#20851;&#20110;&#25152;&#24471;&#31246;&#36991;&#20813;&#21452;&#37325;&#24449;&#31246;&#21644;&#38450;&#27490;&#20599;&#31246;&#28431;&#31246;&#30340;&#23433;&#25490;&#12299;</FONT>)
effective on August 21, 2006, no more than 5% withholding tax rate applies to dividends paid by a PRC company to a Hong Kong resident,
provided that the recipient is a company that holds at least 25% of the capital of the PRC company. The 10% withholding tax rate
applies to dividends paid by a PRC company to a Hong Kong resident if the recipient is a company that holds less than 25% of the
capital of the PRC company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
pursuant to the Circular of the SAT on Relevant Issues Concerning the Implementation of Dividend Clauses in Tax Treaties (&#12298;</FONT>&#22269;&#23478;&#31246;&#21153;&#24635;&#23616;&#20851;&#20110;&#25191;&#34892;&#31246;&#25910;&#21327;&#23450;&#32929;&#24687;&#26465;&#27454;&#26377;&#20851;&#38382;&#39064;&#30340;&#36890;&#30693;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#12299;),
which was promulgated and effective on February 20, 2009, all of the following requirements should be satisfied where a fiscal
resident of the other party to the tax agreement needs to be entitled to such tax agreement treatment as being taxed at a tax rate
specified in the tax agreement for the dividends paid to it by a PRC resident company: (1) such a fiscal resident who obtains dividends
should be a company as provided in the tax agreement; (2) owner&rsquo;s equity interests and voting shares of the PRC resident
company directly owned by such a fiscal resident reaches a specified percentage; and (3) the equity interests of the PRC resident
company directly owned by such a fiscal resident, at any time during the 12 months prior to the acquisition of the dividends, reaches
a percentage specified in the tax agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, according to Administrative Measures on Entitlement of Non-residents to Treatment under Tax Treaties (</FONT>&#12298;&#38750;&#23621;&#27665;&#32435;&#31246;&#20154;&#20139;&#21463;&#31246;&#25910;&#21327;&#23450;&#24453;&#36935;&#31649;&#29702;&#21150;&#27861;&#12299;<FONT STYLE="font-family: Times New Roman, Times, Serif">),
promulgated by the SAT on August 27, 2015, which became effective on November 1, 2015 and was amended on June 15, 2018, where a
non-resident enterprise that receives dividends from a PRC resident enterprise wishes to enjoy the favorable tax benefits, it may
be entitled to the convention treatment itself when filing a tax return or making a withholding declaration through a withholding
agent, subject to the subsequent administration by the tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, when
considered as a non-PRC resident investor, which is much more likely to happen than not, Universe HK shall be subject to the dividend
withholding tax at the rate of 10%. Upon identified as the Hong Kong resident enterprise stipulated by the Double Tax Avoidance
Arrangement and other applicable laws, the withholding tax may be reduced to 5%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Hong Kong Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Entities incorporated in Hong Kong are
subject to profits tax in Hong Kong at the rate of 16.5%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>United States Federal Income Taxation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following does not address the tax
consequences to any particular investor or to persons in special tax situations such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial institutions;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulated investment companies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">real estate investment trusts;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that elect to mark their securities to market;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates or former long-term residents of the U.S.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">governments or agencies or instrumentalities thereof;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt entities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons liable for alternative minimum tax;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our Ordinary Shares as part of a straddle, hedging, conversion or integrated transaction;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons that actually or constructively own 10% or more of our voting power or value (including by reason of owning our Ordinary Shares);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who acquired our Ordinary Shares pursuant to the exercise of any employee share option or otherwise as compensation;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our Ordinary Shares through partnerships or other pass-through entities;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficiaries of a trust holding our Ordinary Shares; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons holding our Ordinary Shares through a trust.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discussion set forth below is addressed
only to U.S. Holders that purchase Ordinary Shares in this offering. Prospective purchasers are urged to consult their own tax
advisors about the application of the U.S. federal income tax rules to their particular circumstances as well as the state, local,
foreign and other tax consequences to them of the purchase, ownership and disposition of our Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Material Tax Consequences Applicable
to U.S. Holders of Our Ordinary Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following sets forth the material U.S.
federal income tax consequences related to the ownership and disposition of our Ordinary Shares. It is directed to U.S. Holders
(as defined below) of our Ordinary Shares and is based upon laws and relevant interpretations thereof in effect as of the date
of this prospectus, all of which are subject to change. This description does not deal with all possible tax consequences relating
to ownership and disposition of our Ordinary Shares or U.S. tax laws, other than the U.S. federal income tax laws, such as the
tax consequences under non-U.S. tax laws, state, local and other tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following brief description applies
only to U.S. Holders (defined below) that hold Ordinary Shares as capital assets and that have the U.S. dollar as their functional
currency. This brief description is based on the federal income tax laws of the United States in effect as of the date of this
prospectus and on U.S. Treasury regulations in effect or, in some cases, proposed, as of the date of this prospectus, as well as
judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject
to change, which change could apply retroactively and could affect the tax consequences described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The brief description below of the U.S.
federal income tax consequences to &ldquo;U.S. Holders&rdquo; will apply to you if you are a beneficial owner of Ordinary Shares
and you are, for U.S. federal income tax purposes,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof or the District of Columbia;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a partnership (or other entities treated
as a partnership for United States federal income tax purposes) is a beneficial owner of our Ordinary Shares, the tax treatment
of a partner in the partnership will depend upon the status of the partner and the activities of the partnership. Partnerships
and partners of a partnership holding our Ordinary Shares are urged to consult their tax advisors regarding an investment in our
Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taxation of Dividends and Other Distributions
on our Ordinary Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the PFIC (defined below) rules
discussed below, the gross amount of distributions made by us to you with respect to the Ordinary Shares (including the amount
of any taxes withheld therefrom) will generally be includable in your gross income as dividend income on the date of receipt by
you, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined
under U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends will not be eligible for the dividends-received
deduction allowed to corporations in respect of dividends received from other U.S. corporations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to non-corporate U.S. Holders,
including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend income,
provided that (1) the Ordinary Shares are readily tradable on an established securities market in the United States, or we are
eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange of information
program, (2) we are not a PFIC (defined below) for either our taxable year in which the dividend is paid or the preceding taxable
year, and (3) certain holding period requirements are met. Because there is not income tax treaty between the United States and
the Cayman Islands, clause (1) above can be satisfied only if the Ordinary Shares are readily tradable on an established securities
market in the United States. Under U.S. Internal Revenue Service authority, Ordinary Shares are considered for purpose of clause
(1) above to be readily tradable on an established securities market in the United States if they are listed on certain exchanges,
which presently include the NYSE and the Nasdaq Stock Market. You are urged to consult your tax advisors regarding the availability
of the lower rate for dividends paid with respect to our Ordinary Shares, including the effects of any change in law after the
date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends will constitute foreign source
income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed above),
the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will be limited to
the gross amount of the dividend, multiplied by the reduced rate divided by the highest rate of tax normally applicable to dividends.
The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this
purpose, dividends distributed by us with respect to our Ordinary Shares will constitute &ldquo;passive category income&rdquo;
but could, in the case of certain U.S. Holders, constitute &ldquo;general category income.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that the amount of the distribution
exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated
first as a tax-free return of your tax basis in your Ordinary Shares, and to the extent the amount of the distribution exceeds
your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal
income tax principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution
would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Taxation of Dispositions of Ordinary
Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the passive foreign investment
company rules discussed below, you will recognize taxable gain or loss on any sale, exchange or other taxable disposition of a
share equal to the difference between the amount realized (in U.S. dollars) for the share and your tax basis (in U.S. dollars)
in the Ordinary Shares. The gain or loss will be capital gain or loss. If you are a non-corporate U.S. Holder, including an individual
U.S. Holder, who has held the Ordinary Shares for more than one year, you will generally be eligible for reduced tax rates. The
deductibility of capital losses is subject to limitations. Any such gain or loss that you recognize will generally be treated as
United States source income or loss for foreign tax credit limitation purposes which will generally limit the availability of foreign
tax credits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Passive Foreign Investment Company
(&ldquo;PFIC&rdquo;)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-U.S. corporation is considered a
PFIC, as defined in Section 1297(a) of the US Internal Revenue Code, for any taxable year if either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 75% of its gross income for such taxable year is passive income; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the &ldquo;asset test&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Passive income generally includes dividends,
interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains
from the disposition of passive assets. We will be treated as owning our proportionate share of the assets and earning our proportionate
share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock. In
determining the value and composition of our assets for purposes of the PFIC asset test, (1) the cash we raise in this offering
will generally be considered to be held for the production of passive income and (2) the value of our assets must be determined
based on the market value of our Ordinary Shares from time to time, which could cause the value of our non-passive assets to be
less than 50% of the value of all of our assets (including the cash raised in this offering) on any particular quarterly testing
date for purposes of the asset test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our operations and the composition
of our assets we do not expect to be treated as a PFIC under the current PFIC rules. We must make a separate determination each
year as to whether we are a PFIC, however, and there can be no assurance with respect to our status as a PFIC for our current taxable
year or any future taxable year. Depending on the amount of cash we raise in this offering, together with any other assets held
for the production of passive income, it is possible that, for our current taxable year or for any subsequent taxable year, more
than 50% of our assets may be assets held for the production of passive income. We will make this determination following the end
of any particular tax year. Although the law in this regard is unclear, we are treating Jiangxi Universe as being owned by us for
United States federal income tax purposes, not only because we control their management decisions, but also because we are entitled
to the economic benefits associated with Jiangxi Universe, and as a result, we are treating Jiangxi Universe as our wholly-owned
subsidiary for U.S. federal income tax purposes. If we are not treated as owning Jiangxi Universe for United States federal income
tax purposes, we would likely be treated as a PFIC. In addition, because the value of our assets for purposes of the asset test
will generally be determined based on the market price of our Ordinary Shares and because cash is generally considered to be an
asset held for the production of passive income, our PFIC status will depend in large part on the market price of our Ordinary
Shares and the amount of cash we raise in this offering. Accordingly, fluctuations in the market price of the Ordinary Shares may
cause us to become a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in several respects and the
composition of our income and assets will be affected by how, and how quickly, we spend the cash we raise in this offering. We
are under no obligation to take steps to reduce the risk of our being classified as a PFIC, and as stated above, the determination
of the value of our assets will depend upon material facts (including the market price of our Ordinary Shares from time to time
and the amount of cash we raise in this offering) that may not be within our control. If we are a PFIC for any year during which
you hold Ordinary Shares, we will continue to be treated as a PFIC for all succeeding years during which you hold Ordinary Shares.
If we cease to be a PFIC and you did not previously make a timely &ldquo;mark-to-market&rdquo; election as described below, however,
you may avoid some of the adverse effects of the PFIC regime by making a &ldquo;purging election&rdquo; (as described below) with
respect to the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are a PFIC for your taxable year(s)
during which you hold Ordinary Shares, you will be subject to special tax rules with respect to any &ldquo;excess distribution&rdquo;
that you receive and any gain you realize from a sale or other disposition (including a pledge) of the Ordinary Shares, unless
you make a &ldquo;mark-to-market&rdquo; election as discussed below. Distributions you receive in a taxable year that are greater
than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding
period for the Ordinary Shares will be treated as an excess distribution. Under these special tax rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the excess distribution or gain will be allocated ratably over your holding period for the Ordinary Shares;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to your current taxable year, and any amount allocated to any of your taxable year(s) prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the amount allocated to each of your other taxable year(s) will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tax liability for amounts allocated
to years prior to the year of disposition or &ldquo;excess distribution&rdquo; cannot be offset by any net operating losses for
such years, and gains (but not losses) realized on the sale of the Ordinary Shares cannot be treated as capital, even if you hold
the Ordinary Shares as capital assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A U.S. Holder of &ldquo;marketable stock&rdquo;
(as defined below) in a PFIC may make a mark-to-market election under Section 1296 of the US Internal Revenue Code for such stock
to elect out of the tax treatment discussed above. If you make a mark-to-market election for first taxable year which you hold
(or are deemed to hold) Ordinary Shares and for which we are determined to be a PFIC, you will include in your income each year
an amount equal to the excess, if any, of the fair market value of the Ordinary Shares as of the close of such taxable year over
your adjusted basis in such Ordinary Shares, which excess will be treated as ordinary income and not capital gain. You are allowed
an ordinary loss for the excess, if any, of the adjusted basis of the Ordinary Shares over their fair market value as of the close
of the taxable year. Such ordinary loss, however, is allowable only to the extent of any net mark-to-market gains on the Ordinary
Shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well
as gain on the actual sale or other disposition of the Ordinary Shares, are treated as ordinary income. Ordinary loss treatment
also applies to any loss realized on the actual sale or disposition of the Ordinary Shares, to the extent that the amount of such
loss does not exceed the net mark-to-market gains previously included for such Ordinary Shares. Your basis in the Ordinary Shares
will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the tax rules that apply
to distributions by corporations which are not PFICs would apply to distributions by us, except that the lower applicable capital
gains rate for qualified dividend income discussed above under &ldquo;&mdash;Taxation of Dividends and Other Distributions on our
Ordinary Shares&rdquo; generally would not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The mark-to-market election is available
only for &ldquo;marketable stock&rdquo;, which is stock that is traded in other than de minimis quantities on at least 15 days
during each calendar quarter (&ldquo;regularly traded&rdquo;) on a qualified exchange or other market (as defined in applicable
U.S. Treasury regulations), including [the New York Stock Exchange/Nasdaq Capital Market]. If the Ordinary Shares are regularly
traded on [the New York Stock Exchange/Nasdaq Capital Market] and if you are a holder of Ordinary Shares, the mark-to-market election
would be available to you were we to be or become a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, a U.S. Holder of stock in
a PFIC may make a &ldquo;qualified electing fund&rdquo; election under Section 1295(b) of the US Internal Revenue Code with respect
to such PFIC to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund election
with respect to a PFIC will generally include in gross income for a taxable year such holder&rsquo;s pro rata share of the corporation&rsquo;s
earnings and profits for the taxable year. The qualified electing fund election, however, is available only if such PFIC provides
such U.S. Holder with certain information regarding its earnings and profits as required under applicable U.S. Treasury regulations.
We do not currently intend to prepare or provide the information that would enable you to make a qualified electing fund election.
If you hold Ordinary Shares in any taxable year in which we are a PFIC, you will be required to file U.S. Internal Revenue Service
Form 8621 in each such year and provide certain annual information regarding such Ordinary Shares, including regarding distributions
received on the Ordinary Shares and any gain realized on the disposition of the Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you do not make a timely &ldquo;mark-to-market&rdquo;
election (as described above), and if we were a PFIC at any time during the period you hold our Ordinary Shares, then such Ordinary
Shares will continue to be treated as stock of a PFIC with respect to you even if we cease to be a PFIC in a future year, unless
you make a &ldquo;purging election&rdquo; for the year we cease to be a PFIC. A &ldquo;purging election&rdquo; creates a deemed
sale of such Ordinary Shares at their fair market value on the last day of the last year in which we are treated as a PFIC. The
gain recognized by the purging election will be subject to the special tax and interest charge rules treating the gain as an excess
distribution, as described above. As a result of the purging election, you will have a new basis (equal to the fair market value
of the Ordinary Shares on the last day of the last year in which we are treated as a PFIC) and holding period (which new holding
period will begin the day after such last day) in your Ordinary Shares for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IRC Section 1014(a) provides for a step-up
in basis to the fair market value for our Ordinary Shares when inherited from a decedent that was previously a holder of our Ordinary
Shares. However, if we are determined to be a PFIC and a decedent that was a U.S. Holder did not make either a timely qualified
electing fund election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our Ordinary
Shares, or a mark-to-market election and ownership of those Ordinary Shares are inherited, a special provision in IRC Section 1291(e)
provides that the new U.S. Holder&rsquo;s basis should be reduced by an amount equal to the Section 1014 basis minus the decedent&rsquo;s
adjusted basis just before death. As such if we are determined to be a PFIC at any time prior to a decedent&rsquo;s passing, the
PFIC rules will cause any new U.S. Holder that inherits our Ordinary Shares from a U.S. Holder to not get a step-up in basis under
Section 1014 and instead will receive a carryover basis in those Ordinary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You are urged to consult your tax advisors
regarding the application of the PFIC rules to your investment in our Ordinary Shares and the elections discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Information Reporting and Backup
Withholding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividend payments with respect to our Ordinary
Shares and proceeds from the sale, exchange or redemption of our Ordinary Shares may be subject to information reporting to the
U.S. Internal Revenue Service and possible U.S. backup withholding under Section 3406 of the US Internal Revenue Code with at a
current flat rate of 24%. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification
number and makes any other required certification on U.S. Internal Revenue Service Form W-9 or who is otherwise exempt from backup
withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on U.S. Internal
Revenue Service Form W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the U.S. information
reporting and backup withholding rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Backup withholding is not an additional
tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain
a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the
U.S. Internal Revenue Service and furnishing any required information. We do not intend to withhold taxes for individual shareholders.
Transactions effected through certain brokers or other intermediaries, however, may be subject to withholding taxes (including
backup withholding), and such brokers or intermediaries may be required by law to withhold such taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Hiring Incentives to Restore
Employment Act of 2010, certain U.S. Holders are required to report information relating to our Ordinary Shares, subject to certain
exceptions (including an exception for Ordinary Shares held in accounts maintained by certain financial institutions), by attaching
a complete Internal Revenue Service Form 8938, Statement of Specified Foreign Financial Assets, with their tax return for each
year in which they hold Ordinary Shares. <FONT STYLE="background-color: white">Failure to report such information could result
in substantial penalties. You should consult your own tax advisor regarding your obligation to file a Form 8938.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="c21"></A>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms and subject to the conditions
of an underwriting agreement dated the date of this prospectus, the underwriter named below has agreed to purchase, and we have
agreed to sell to them, severally, the number of Ordinary Shares indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT> </TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 69%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of Ordinary Shares</B></FONT> </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Univest Securities,
    LLC</FONT> </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;[&#9679;]</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter is offering the Ordinary
Shares subject to its acceptance of the Ordinary Shares from us and subject to prior sale. The underwriting agreement provides
that the obligations of the underwriter to pay for and accept delivery of the Ordinary Shares offered by this prospectus are subject
to the approval of certain legal matters by its counsel and to other conditions. The underwriter is obligated to take and pay for
all of the Ordinary Shares offered by this prospectus if any such Ordinary Shares are taken. However, the underwriter is not required
to take or pay for the Ordinary Shares covered by the underwriter&rsquo;s option to purchase additional Ordinary Shares described
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have granted to the underwriter an option,
exercisable for 45 days from the effective date of this registration statement, to purchase up to [&#9679;] additional Ordinary
Shares at the initial public offering price listed on the cover page of this prospectus, less underwriting discounts. The underwriter
may exercise this option solely for the purpose of cover over-allotments, if any, made in connection with the offering contemplated
by this prospectus. To the extent the option is exercised, the underwriter will become obligated, subject to certain conditions,
to purchase about the same percentage of the additional Ordinary Shares as the number listed in the preceding table bears to the
total number of Ordinary Shares listed in the preceding table. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter will offer the Ordinary
Shares to the public at the initial public offering price set forth on the cover of this prospectus and to selected dealers at
the initial public offering price less a selling concession not in excess of $[&#9679;] per Ordinary Share. After this offering,
the initial public offering price, concession, and reallowance to dealers may be reduced by the representative. No change in those
terms will change the amount of proceeds to be received by us as set forth on the cover of this prospectus. The securities are
offered by the underwriter as stated herein, subject to receipt and acceptance by them and subject to their right to reject any
order in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Discounts and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The underwriting discounts are equal to
the following percentages of the initial public offering price set forth on the cover of this prospectus. (i) 7% for all investors
introduced by the underwriter; and (ii) 4% for securities offered through the Company&rsquo;s direct placement program. If the
total purchase amount of Company&rsquo;s direct placement program exceeds $10 million, the underwriting discounts shall be 3.5%. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table shows the per Ordinary
Share and total initial public offering price, underwriting discounts, and proceeds before expenses to us. These amounts are shown
assuming both no exercise and full exercise of the underwriter&rsquo;s option to purchase up to an additional [&#9679;] Ordinary
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 40%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Without Exercise of Over-Allotment Option</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 20%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total With Full Exercise of Over-Allotment Option</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial public offering price</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts to be paid by us</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We have agreed to reimburse the underwriter
up to a maximum of $230,000 for out-of-pocket accountable expenses, including: (i) all reasonable travel and lodging expenses
incurred by the underwriter and its counsel in connection with visits to, and examinations of, our company; (ii) background check
on the Company&rsquo;s principal shareholders, directors and officers; (iii) the costs of all mailing and printing of the placement
documents, registration statements, prospectuses and all amendments, supplements and exhibits thereto, and as many preliminary
and final prospectuses as the underwriter may reasonably deem necessary; (iv) the fees and expenses of the transfer agent for
such Ordinary Shares; and (v) the reasonable cost for road show meetings and preparation of a power point presentation. In addition,
at the closing of the offering, the Company shall reimburse the underwriter one percent (1%) of the gross proceeds of the offering
as non-accountable expenses. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We paid an expense deposit of $50,000 to
the underwriter upon the execution of the engagement letter between us and the underwriter dated May 26, 2020 (the &ldquo;Engagement
Letter&rdquo;), and an additional $30,000 upon the Company&rsquo;s receipt of the acceptance of the Company&rsquo;s filing by
the SEC, for the underwriter&rsquo;s anticipated out-of-pocket expenses; any expense deposits will be returned to us to the extent
the underwriter&rsquo;s out-of-pocket accountable expenses are not actually incurred in accordance with FINRA Rule 5110(f)(2)(C). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to list our Ordinary Shares on [the New York Stock Exchange/Nasdaq Capital Market] under the symbol &ldquo;[&#9679;].&rdquo;
There is no assurance that such application will be approved, and if our application is not approved, this offering may not be
completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In addition, we have agreed to issue
warrants to the underwriter of the underwriter, for a nominal consideration of $0.001 per warrant, to purchase a number of
Ordinary Shares equal to 6% of the total number of Ordinary Shares sold in this offering (not including any over-allotment
Ordinary Shares sold in the over-allotment option) (the &ldquo;Underwriter Warrants&rdquo;). Such warrants shall have an exercise price equal to 110% of the offering
price of the Ordinary Shares sold in this offering. The Underwriter Warrants may be purchased in cash or via cashless
exercise, will be exercisable for five (5) years from the effective date of the registration statement of which this
prospectus forms a part, and will terminate on the fifth anniversary of the date thereafter. The Underwriter Warrants and the
underlying Ordinary Shares will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 5110(g)(1). In
accordance with FINRA Rule 5110(g)(1), and except as otherwise permitted by FINRA rules, neither the Underwriter Warrants nor
any of our Ordinary Shares issued upon exercise of the Underwriter Warrants may be sold, transferred, assigned, pledged, or
hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the
effective economic disposition of such securities by any person, for a period of 180 days immediately following the effective
date of the registration statement of which this prospectus forms a part. In addition, although the Underwriter Warrants and
the underlying Ordinary Shares are registered in the registration statement of which this prospectus forms a part, we have
also agreed that the Underwriter Warrants will provide for registration rights in certain cases. These registration rights
apply to all of the securities directly and indirectly issuable upon exercise of the Underwriter Warrants. The piggyback
registration right provided will not be greater than five years from the effective date of the offering in compliance with
FINRA Rule 5110(f)(2)(G)(v). </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>Right of First Refusal</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In addition, the Company agrees that it
shall provide the underwriter the right of first refusal (the &ldquo;Right of First Refusal&rdquo;), exercisable at the sole discretion
of the underwriter, for twelve (12) months from the date of the Engagement Letter to provide investment banking service to the
Company on an exclusive basis, including acting as leading manager for any underwritten public offering, as exclusive placement
agent for any private financing by the Company, and as financial advisor in connection with any merger, business combination,
recapitalization or sale of a majority or controlling portion of the equity or assets of the Company. The Right of First Refusal
shall be subject to FINRA Rule 5110(f)(2), including that it may be terminated by the Company for cause, which shall be a breach
by the underwriter of the Engagement Letter or a material failure by the underwriter to provide the services as contemplated by
the Engagement Letter. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act and liabilities
arising from breaches of representations and warranties contained in the underwriting agreement, or to contribute to payments
that the underwriter may be required to make in respect of those liabilities.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Each of our directors, executive officers,
and principal shareholders (5% or more shareholders) of our Ordinary Shares will enter into an identical lock-up agreement for
a period of [&#9679;] months from the effective date of this registration statement, subject to certain exceptions, with respect
to our Ordinary Shares. All of our other shareholders have agreed with the underwriter, subject to certain exceptions, not to
sell, transfer, or dispose of, directly or indirectly, any our Ordinary Shares or securities convertible into or exercisable or
exchangeable for our Ordinary Shares for a period of [&#9679;] months after the effective date of this registration statement.
These parties collectively own all of our outstanding ordinary shares, without giving effect to this offering. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our Ordinary Shares. The initial public offering price of the Ordinary Shares
has been negotiated between us and the underwriter. Among the factors considered in determining the initial public offering price
of the Ordinary Shares, in addition to the prevailing market conditions, are our historical performance, estimates of our business
potential and earnings prospects, an assessment of our management, and the consideration of the above factors in relation to market
valuation of companies in related businesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale, and Distribution of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the underwriter or selling group members,
if any, participating in this offering and the underwriter may distribute prospectuses electronically. The underwriter may agree
to allocate a number of Ordinary Shares to selling group members for sale to its online brokerage account holders. The Ordinary
Shares to be sold pursuant to internet distributions will be allocated on the same basis as other allocations. Other than the
prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus
or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the underwriter,
and should not be relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
Stabilization, Short Positions, and Penalty Bids</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter may engage in transactions that stabilize, maintain, or otherwise affect the price
of our Ordinary Shares. Specifically, the underwriter may sell more Ordinary Shares than it is obligated to purchase under the
underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number
of Ordinary Shares available for purchase by the underwriter under option to purchase additional Ordinary Shares. The underwriter
can close out a covered short sale by exercising the option to purchase additional Ordinary Shares or purchasing Ordinary Shares
in the open market. In determining the source of Ordinary Shares to close out a covered short sale, the underwriter will consider,
among other things, the open market price of Ordinary Shares compared to the price available under the option to purchase additional
Ordinary Shares. The underwriter may also sell Ordinary Shares in excess of the option to purchase additional Ordinary Shares,
creating a naked short position. The underwriter must close out any naked short position by purchasing Ordinary Shares in the
open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure
on the price of the Ordinary Shares in the open market after pricing that could adversely affect investors who purchase in the
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter may also impose a penalty bid. This occurs when a particular underwriter or dealer repays selling concessions allowed
to it for distributing our Ordinary Shares in this offering because such underwriter repurchases those Ordinary Shares in stabilizing
or short covering transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
the underwriter may bid for, and purchase, our Ordinary Shares in market making transactions, including &ldquo;passive&rdquo;
market making transactions as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
activities may stabilize or maintain the market price of our Ordinary Shares at a price that is higher than the price that might
otherwise exist in the absence of these activities. The underwriter is not required to engage in these activities, and may discontinue
any of these activities at any time without notice. These transactions may be effected on [the New York Stock Exchange/Nasdaq
Capital Market], in the over-the-counter market, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriter may engage in passive market making transactions in our Ordinary Shares on [the
New York Stock Exchange/Nasdaq Capital Market] in accordance with Rule 103 of Regulation M under the Exchange Act, during a period
before the commencement of offers or sales of the Ordinary Shares and extending through the completion of the distribution. A
passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if
all independent bids are lowered below the passive market maker&rsquo;s bid, then that bid must then be lowered when specified
purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Potential
Conflicts of Interest</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriter and its affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary
course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their
various business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade
debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts
and for the accounts of their customers and such investment and securities activities may involve securities and/or instruments
of our Company. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent
research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
Restrictions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action has been taken in any jurisdiction (except in the United States) that would permit a public offering of the Ordinary Shares,
or the possession, circulation or distribution of this prospectus or any other material relating to us or the Ordinary Shares,
where action for that purpose is required. Accordingly, the Ordinary Shares may not be offered or sold, directly or indirectly,
and neither this prospectus nor any other offering material or advertisements in connection with the Ordinary Shares may be distributed
or published, in or from any country or jurisdiction except in compliance with any applicable rules and regulations of any such
country or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stamp
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you purchase Ordinary Shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws
and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c22"></A>EXPENSES
RELATING TO THIS OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is an itemization of the total expenses, excluding underwriting discounts and non-accountable expense allowance that
we expect to incur in connection with this offering. With the exception of the SEC registration fee, the FINRA filing fee and
the [NYSE/Nasdaq] listing fee, all amounts are estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities and Exchange
    Commission Registration Fee</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[NYSE/NASDAQ] Listing Fee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FINRA Filing Fee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal Fees and Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting Fees and Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printing and Engraving Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Transfer Agent Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">]</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
expenses will be borne by us. Underwriting discounts will be borne by us in proportion to the numbers of Ordinary Shares sold
in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="c23"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The validity of the Ordinary Shares and
certain other legal matters as to United States Federal and New York State law in connection with this offering will be passed
upon for us by Hunter Taubman Fischer &amp; Li LLC. The validity of the Ordinary Shares offered in this offering and certain other
legal matters as to Cayman Islands law will be passed upon for us by Ogier, our counsel as to Cayman Islands law. Legal matters
as to PRC law will be passed upon for us by AllBright Law Offices. Pryor Cashman LLP and [Underwriter Counsel]&nbsp;are acting
as counsel to the underwriter. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c24"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements for the years ended September 30, 2019 and 2018, included in this prospectus have been so included
in reliance on the report of Friedman LLP, an independent registered public accounting firm, given on the authority of said firm
as experts in auditing and accounting. The office of Friedman LLP is located at One Liberty Plaza, 165 Broadway, Floor 21, New
York, NY 10006.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c25"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form F-1, including relevant exhibits and schedules under the Securities Act,
covering the Ordinary Shares offered by this prospectus. You should refer to our registration statements and their exhibits and
schedules if you would like to find out more about us and about the Ordinary Shares. This prospectus summarizes material provisions
of contracts and other documents that we refer you to. Since the prospectus may not contain all the information that you may find
important, you should review the full text of these documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediately
upon the completion of this offering, we will be subject to periodic reporting and other informational requirements of the Exchange
Act, as applicable to foreign private issuers. Accordingly, we will be required to file reports, including annual reports on Form
20-F, and other information with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing
the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b)
and (c) of the Exchange Act, and our executive officers, directors and principal shareholders are exempt from the reporting and
short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration statements, reports and other information so filed can be inspected and copied at the public reference facilities
maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents upon payment of
a duplicating fee, by writing to the SEC. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the
public reference rooms. The SEC also maintains a website that contains reports, proxy statements and other information about issuers,
such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov. The information on that website
is not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dealers, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus.
You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this
prospectus is current only as of its date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="c26"></A>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; padding-left: 9pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
    Financial Statements</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><A HREF="#f_01"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><A HREF="#f_02"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of September 30, 2019 and 2018</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><A HREF="#f_03"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Income and Comprehensive Income for the years ended September 30, 2019 and 2018</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><A HREF="#f_04"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo; Equity for the years ended September 30, 2019 and 2018</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><A HREF="#f_05"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the years ended September 30, 2019 and 2018</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt; text-align: justify; text-indent: -9pt"><A HREF="#f_06"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7
    &ndash; F-26</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 131; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="f_01"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><IMG SRC="fimg_01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To
the Board of Directors and shareholders of </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Universe
Pharmaceuticals Inc. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Opinion
on the Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have audited the accompanying consolidated balance sheets of Universe Pharmaceuticals Inc. and its subsidiaries (collectively,
the &ldquo;Company&rdquo;) as of September 30, 2019 and 2018, and the related consolidated statements of income and comprehensive
income, changes in shareholders&rsquo; equity, and cash flows for each of the years in the two-year period ended September 30,
2019, and the related notes (collectively referred to as the &ldquo;consolidated financial statements&rdquo;). In our opinion,
the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September
30, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the two-year period ended September
30, 2019, in conformity with accounting principles generally accepted in the United States of America. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Basis
for Opinion</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">These
consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an
opinion on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits
to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting,
but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statement. We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">/s/
Friedman LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have served as the Company&rsquo;s auditor since 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">New
York, New York</FONT></P>

<P STYLE="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="background-color: white">April
24 , 2020, except Note 2 as to which the date is June 12, 2020</FONT> </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 132; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="f_02"></A><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">ASSETS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,177,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,190,176</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,420,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,637,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Inventories, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,615,155</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,120,436</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,300</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,484</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">TOTAL CURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,229,762</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,956,273</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 10pt">Property, plant and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,566,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,075,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 10pt">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,610</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,583</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 10pt">Investment in equity securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">700,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">728,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: 10pt">Deferred tax assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">168,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">135,021</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL NONCURRENT ASSETS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,607,117</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,122,299</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,836,879</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,078,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Short-term bank loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,521,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,620,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,937,095</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,938,221</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Taxes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">551,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">893,512</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Due to related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,709</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Dividend payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,648,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accrued expenses and other current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">388,171</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">240,758</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">TOTAL CURRENT LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,452,820</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,397,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 20pt">Ordinary shares, $1.00 par value, 50,000 shares authorized, issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Statutory reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,439,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,439,535</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Retained earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,180,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,832,292</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,767</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">680,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">TOTAL SHAREHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,384,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,681,572</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,836,879</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,078,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="f_03"></A><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the years ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: justify">REVENUE</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">33,229,316</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">28,514,180</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">COST OF REVENUE</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,821,831</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,105,265</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,407,485</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,408,915</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,578,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680,258</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,457,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282,946</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Research and development expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">618,437</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">789,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,654,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,752,586</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">INCOME FROM OPERATIONS</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,752,829</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,656,329</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OTHER INCOME(EXPENSES)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(129,268</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(164,922</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Other income, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,760</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Equity investment income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,741</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,630</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Total other expense</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(99,767</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(138,278</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">INCOME BEFORE INCOME TAX PROVISION</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,653,062</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,518,051</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">INCOME TAX PROVISION</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,101,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,915,118</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">NET INCOME</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,551,465</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">7,602,933</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">OTHER COMPREHENSIVE INCOME (LOSS)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(645,978</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(587,693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">COMPREHENSIVE INCOME</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,905,487</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,015,240</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">EARNINGS PER SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">151.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">152.1</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 134; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="f_04"></A><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED SEPTEMBER 30, 2019 AND 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ordinary&nbsp;shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional paid-in</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Statutory</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Retained earnings (Accumulated</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated other comprehensive</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total shareholders&rsquo;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares*</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; font-weight: bold; text-align: left; text-indent: -5pt; padding-left: 5pt">Balance at September 30, 2017</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">50,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">50,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">3,679,000</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">2,348,034</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(311,140</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">1,268,438</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">7,034,332</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Appropriation to statutory reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,501</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(91,501</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Dividend declared</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,368,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,368,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Net income for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,602,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,602,933</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(587,693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(587,693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -5pt; padding-left: 5pt">Balance at September 30, 2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">50,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">50,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,679,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,439,535</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,832,292</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">680,745</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">9,681,572</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Dividend declared</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,203,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,203,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Net income for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,551,465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,551,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Foreign currency translation adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(645,978</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(645,978</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -5pt; padding-left: 5pt">Balance at September 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">50,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">50,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,679,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,439,535</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,180,757</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">34,767</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,384,059</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 135; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="f_05"></A><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the years ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 10pt">Net income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,551,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,602,933</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Adjustments to reconcile net income to cash provided by operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">418,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">452,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt">Loss from disposal of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,085</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Allowance for doubtful accounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,972</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt">Inventory reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(187,271</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(188,641</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Deferred income tax provision (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,625</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,538</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">665,485</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,815,443</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,586,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(327,259</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,449</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,348</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(924,444</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,173</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Taxes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(320,611</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,790</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Accrued expenses and other current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">162,540</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,129,019</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Net cash provided by operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,203,755</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,455,599</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">Cash flows from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86,324</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(145,095</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Proceeds from disposal of fixed assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">291</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(86,033</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(145,095</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Cash flows from financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Proceeds from short-term bank loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,055,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,641,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 20pt">Repayment of bank loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,055,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,508,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 20pt">Dividend payment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,005,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,060,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Proceeds from related party borrowings</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,143</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Net cash used in financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,003,857</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,914,580</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Effect of changes of foreign exchange rates on cash</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(126,720</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(189,162</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,012,855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(793,238</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Cash, beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,190,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,983,414</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">Cash, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,177,321</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,190,176</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Supplemental disclosure of cash flow information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 20pt">Cash paid for interest expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">135,717</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">183,069</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 20pt">Cash paid for income tax</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,257,893</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,703,420</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="f_06"></A>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &mdash; ORGANIZATION AND BUSINESS DESCRIPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
Pharmaceuticals Inc. (&ldquo;Universe INC&rdquo; or the &ldquo;Company&rdquo;) was incorporated under the laws of the Cayman Islands
on December 11, 2019 as an exempted company with limited liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC. owns 100% equity interest of Universe Pharmaceuticals (International) Group (&ldquo;Universe HK&rdquo;), an entity incorporated
on May 21, 2018 in accordance with the laws and regulations in Hong Kong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
Universe Pharmaceuticals Technology Co., Ltd. (&ldquo;Universe Technology&rdquo;) was formed on April 8, 2019, as a Wholly Foreign-Owned
Enterprise (&ldquo;WOFE&rdquo;) in the People&rsquo;s Republic of China (&ldquo;PRC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC, Universe HK and Universe Technology are currently not engaging in any active business operations and merely acting as holding
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jiangxi
Universe Pharmaceuticals Co., Ltd. (&ldquo;Jiangxi Universe&rdquo;) was incorporated on March 2, 1998 in accordance with PRC laws
and is engaged in research and development and manufacturing of modernized traditional Chinese medicines. Jiangxi Universe owns
100% of the equity of Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd. (&ldquo;Universe Trade&rdquo;) which was incorporated
on March 10, 2010 to handle the sales and distribution of the pharmaceutical products manufactured by Jiangxi Universe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Reorganization</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reorganization of our legal structure (&ldquo;Reorganization&rdquo;) was completed on December 11, 2019. The reorganization involved
the incorporation of Universe INC and Universe Technology, and the transfer of the 100% equity interest of Jiangxi Universe to
Universe Technology. Consequently, Universe INC, through its subsidiary Universe HK, directly controls Universe Technology and
Jiangxi Universe, and became the ultimate holding company of all other entities mentioned above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Reorganization has been accounted for as a recapitalization among entities under common control since the same controlling shareholders
controlled all these entities before and after the Reorganization. The consolidation of the Company and its subsidiaries has been
accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the
beginning of the first period presented in the accompanying consolidated financial statements. Results of operations for the periods
presented comprise those of the previously separate entities combined from the beginning of the period to the end of the period,
eliminating the effects of intra-entity transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &mdash; ORGANIZATION AND BUSINESS DESCRIPTION (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of the Reorganization, the Company has subsidiaries in countries and jurisdictions in the PRC, and Hong Kong. Details
of the subsidiaries of the Company as of September 30, 2019 were set out below:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name of Entity</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Date of<BR> Incorporation</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Place of<BR> Incorporation</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">% of&nbsp;<BR> Ownership</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal Activities</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">Universe INC</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">December&nbsp;11,&nbsp;2019</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Cayman&nbsp;Islands</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">Parent, 100%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Investment holding</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">Universe HK</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 18%; text-align: center">May 21, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center">Hong Kong</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center">100%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%; text-align: center">Investment holding</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">Universe Technology</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;&nbsp;April 18, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">PRC</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">100%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">WOFE, Investment holding</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">Jiangxi Universe</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">March 2, 1998</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">PRC</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">100%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Research and development and manufacturing of modernized traditional Chinese medicines</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left; text-indent: -5pt; padding-left: 5pt">Universe Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">March 10, 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;PRC</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">100%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Sales of modernized traditional Chinese medicines</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, through its wholly-owned subsidiaries, is primarily engaged in the development, manufacturing and sale of traditional
Chinese medicines derivatives (&ldquo;TCMD&rdquo;) products targeted to the elderly to address their physical conditions in the
aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments,
traditional Chinese medicine pieces products and dietary supplements (together &ldquo;third-party products&rdquo;). All of these
TCMD and third-party products are currently sold to customers including pharmaceutical companies, hospitals, clinics and drugstore
chains throughout China. .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of consolidation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the financial statements of Universe INC, Universe HK, Universe Technology,
Jiangxi Universe and Universe Trade. All inter-company balances and transactions are eliminated upon consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Uses
of estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America (&ldquo;US GAAP&rdquo;), management makes estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. These estimates are based on information as of the date of the consolidated
financial statements. Significant estimates required to be made by management include, but are not limited to, the allowance for
estimated uncollectible receivables, inventory valuations, useful lives of property, plant and equipment, intangible assets, the
recoverability of long-lived assets, provision necessary for contingent liabilities, revenue recognition and realization of deferred
tax assets. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
and Uncertainties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main operation of the Company is located in the PRC. Accordingly, the Company&rsquo;s business, financial condition, and results
of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of
the PRC economy. The Company&rsquo;s results may be adversely affected by changes in the political, regulatory and social conditions
in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing
laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s business, financial condition and results of operations may also be negatively impacted by risks related to natural
disasters, extreme weather conditions, health epidemics and other catastrophic incidents, which could significantly disrupt the
Company&rsquo;s operations (see Note 14- <I>Subsequent Events</I>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new pharmaceutical products is highly competitive, and the industry currently is characterized
by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. The Company may face
competition with respect to our current and future pharmaceutical product candidates from major pharmaceutical companies in China.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
includes currency on hand and deposits held by banks that can be added or withdrawn without limitation. The Company maintains
most of its bank accounts in the PRC. Cash balances in bank accounts in PRC are not insured by the Federal Deposit Insurance Corporation
or other programs.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accounts
receivable, net</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable are presented net of allowance for doubtful accounts. The Company determines the adequacy of reserves for doubtful
accounts based on individual account analysis and historical collection trend. The Company establishes a provision for doubtful
receivables when there is objective evidence that the Company may not be able to collect amounts due. The allowance is based on
management&rsquo;s best estimate of specific losses on individual exposures, as well as a provision on historical trends of collections.
Actual amounts received may differ from management&rsquo;s estimate of credit worthiness and the economic environment. Delinquent
account balances are written-off against the allowance for doubtful accounts after management has determined that the collection
is not probable. Allowance for uncollectable balances amounted to $517,754 and $239,904 as of September 30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Inventories,
net</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at net realizable value using weighted average method. Costs include the cost of raw materials, freight, direct labor
and related production overhead. Any excess of the cost over the net realizable value of each item of inventories is recognized
as a provision for diminution in the value of inventories. Net realizable value is the estimated selling price in the normal course
of business less any costs to complete and sell products. The Company evaluates inventories on a quarterly basis for its net realizable
value adjustments, and reduces the carrying value of those inventories that are obsolete or in excess of the forecasted usage
to their estimated net realizable value based on various factors including aging, expiration dates, as applicable, taking into
consideration historical and expected future product sales. The Company recorded inventory reserve of $179,412 and $373,855 as
of September 30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
value of financial instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure
fair value. The hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs.
The three levels of inputs used to measure fair value are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="padding: 0; width: 0.25in; text-align: right; text-indent: 0"></TD><TD STYLE="padding: 0; width: 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1&thinsp;&mdash;&thinsp;inputs
to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2&thinsp;&mdash;&thinsp;inputs
to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted market prices
for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable and inputs
derived from or corroborated by observable market data.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: right"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3&thinsp;&mdash;&thinsp;inputs
to the valuation methodology are unobservable.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise disclosed, the fair value of the Company&rsquo;s financial instruments, including cash, accounts receivable, inventories,
prepaid expenses and other current assets, accounts payable, short-term bank loans, accrued expenses and other current liabilities,
taxes payable and due to related parties, approximate the fair value of the respective assets and liabilities as of September
30, 2019 and 2018 based upon the short-term nature of the assets and liabilities. The Company&rsquo;s investment in equity securities
is accounted for using the measurement alternative in accordance with ASC 321, which also approximate its recorded value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Property,
plant and equipment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization of property
and equipment is provided using the straight-line method over their expected useful lives, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-bottom: 1.5pt">Useful life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">Buildings</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">20 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5&ndash;10 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Automobiles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3&ndash;5 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Office and electric equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3&ndash;5 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures
for maintenance and repairs, which do not materially extend the useful lives of the assets, are charged to expense as incurred.
Expenditures for major renewals and betterments which substantially extend the useful life of assets are capitalized. The cost
and related accumulated depreciation of assets retired or sold are removed from the respective accounts, and any gain or loss
is recognized in the consolidated statements of income and other comprehensive income in other income or expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intangible
Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist primarily of land use rights and software. Under the PRC law, all land in the PRC is owned by the government and
cannot be sold to an individual or company. The government grants individuals and companies the right to use parcels of land for
specified periods of time. Land use rights are stated at cost less accumulated amortization. Intangible assets are amortized using
the straight-line method with the following estimated useful lives:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; padding-bottom: 1.5pt">Useful life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">Land use rights</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">50 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Software</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of long-lived Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets with finite lives, primarily property, plant and equipment and intangible assets, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the estimated cash
flows from the use of the asset and its eventual disposition below are the asset&rsquo;s carrying value, then the asset is deemed
to be impaired and written down to its fair value. There were no impairments of these assets as of September 30, 2019 and 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investments
in Equity Securities </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its equity investments in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 321 &ldquo;Investments&mdash;Equity
Securities&rdquo; (&ldquo;ASC 321&rdquo;). In accordance with ASC 321, equity investment which the Company has no significant
influence (generally less than a 20% ownership interest) with readily determinable fair values are accounted for at fair value
based on quoted market prices with the changes in fair value recognized as unrealized gains or losses in earnings. Equity investment
without readily determinable fair values are accounted for either at fair value or using the measurement alternative. Under the
measurement alternative, the equity investments are measured at cost, less any impairment, if any, plus or minus changes resulting
from observable price changes in orderly transactions for the identical or a similar investment .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March 2009 to September 2017, the Company invested approximately $0.7 million (RMB 5 million) in Jiangxi Jian Rural Commercial
Bank (&ldquo;JX RCB Bank&rdquo;) in exchange for 5% ownership interest in the bank. The purpose of entering into these equity
investment agreements with JX RCB Bank was to earn investment income as the bank continues to grow. The Company determined that
this investment in equity securities does not have a readily determinable fair value and, accordingly, elected the measurement
alternative noted above .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">The
Company initially recorded the investments at historical cost and subsequently records any dividends received from the net accumulated
earnings of the investee as income As of September 30, 2019 and 2018, this investment amounted to $700,500 (RMB 5 million)and
$728,000 (RMB 5 million), respectively, and was reported as long-term investment in equity investee on the consolidated balance
sheets. Investment income amounted to $26,741 and $21,630 for the years ended September 31, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investments in equity securities are evaluated for impairment when facts or circumstances indicate that the fair value of the
investment is less than its carrying value. An impairment is recognized when a decline in fair value is determined to be other-than-temporary.
The Company reviews several factors to determine whether a loss is other-than-temporary. These factors include, but are not limited
to, the: (i) nature of the investment; (ii) cause and duration of the impairment; (iii) extent to which fair value is less than
cost; (iv) financial condition and near term prospects of the investments; and (v) ability to hold the investment for a period
of time sufficient to allow for any anticipated recovery in fair value. There was no impairment for the Company&rsquo;s investments
in equity securities for the years ended September 30, 2019 and 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 141; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company early adopted Accounting Standards Codification (&ldquo;ASC&rdquo;) 606 using the modified retrospective approach. The
adoption of this standard did not have a material impact on the Company&rsquo;s consolidated financial statements. Therefore,
no adjustments to opening retained earnings were necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606, Revenue from Contracts with customers, establishes principles for reporting information about the nature, amount, timing
and uncertainty of revenue and cash flows arising from the entity&rsquo;s contracts to provide goods or services to customers.
The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount
that reflects the consideration that it expects to be entitled to receive in exchange for those goods or services recognized as
performance obligations are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
606 requires the use of a <I>five</I>-step model to recognize revenue from customer contracts. The <I>five</I>-step model requires
that the Company (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii)
determine the transaction price, including variable consideration to the extent that it is probable that a significant future
reversal will <I>not</I> occur, (iv) allocate the transaction price to the respective performance obligations in the contract,
and (v) recognize revenue when (or as) the Company satisfies the performance obligation. The application of the <I>five</I>-step
model to the revenue streams compared to the prior guidance did <I>not</I> result in significant changes in the way the Company
records its revenue. The Company has assessed the impact of the guidance by reviewing its existing customer contracts and current
accounting policies and practices to identify differences that would result from applying the new requirements, including the
evaluation of its performance obligations, transaction price, customer payments, transfer of control and principal versus agent
considerations. Based on the assessment, the Company concluded that there was no change to the timing and pattern of revenue recognition
for its current revenue streams.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance to ASC 606, the Company recognizes revenue when it transfers its goods and services to customers in an amount that
reflects the consideration to which the Company expects to be entitled in such exchange. The Company accounts for the revenue
generated from sales of its TCMD and third-party products on a gross basis as the Company is acting as a principal in these transactions,
is subject to inventory risk, has latitude in establishing prices, and is responsible for fulfilling the promise to provide customers
the specified goods, which the Company has control of the goods and has the ability to direct the use of goods to obtain substantially
all the benefits. All of the Company&rsquo;s contracts have one single performance obligation as the promise is to transfer the
individual goods to customers, and there is no separately identifiable other promises in the contracts. The Company&rsquo;s revenue
streams are recognized at a point in time when title and risk of loss passes and the customer accepts the goods, which generally
occurs at delivery. The Company&rsquo;s products are sold with no right of return and the Company does not provide other credits
or sales incentive to customers. Revenue is reported net of all value added taxes (&ldquo;VAT&rdquo;).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Contract
Assets and Liabilities </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
terms are established on the Company&rsquo;s pre-established credit requirements based upon an evaluation of customers&rsquo;
credit quality. Contract assets are recognized for in related accounts receivable. Contract liabilities are recognized for contracts
where payment has been received in advance of delivery. The contract liability balance can vary significantly depending on the
timing when an order is placed and when shipment or delivery occurs. As of September 30, 2019 and 2018, other than accounts receivable
and advances from customers, the Company had no other material contract assets, contract liabilities or deferred contract costs
recorded on its consolidated balance sheet. Costs of fulfilling customers&rsquo; purchase orders, such as shipping, handling and
delivery, which occur prior to the transfer of control, are recognized in selling, general and administrative expense when incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 142; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disaggregation
of Revenues</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company disaggregates its revenue from contracts by product types, as the Company believes it best depicts how the nature, amount,
timing and uncertainty of the revenue and cash flows are affected by economic factors. The Company&rsquo;s disaggregation of revenues
for the years ended September 30, 2019 and 2018 are disclosed in Note 13 of this consolidation financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and development expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expenses all internal research and development costs as incurred, which primarily comprise employee costs, internal and
external costs related to execution of studies, including manufacturing costs, facility costs of the research center, and amortization
and depreciation to intangible assets and property, plant and equipment used in the research and development activities. For the
years ended September 30, 2019 and 2018, total research and development expense were approximately $618,437 and $789,382, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Advertising
expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
expenses primarily relate to promotion of the Company&rsquo;s brand name and products through outdoor billboards and social media
such as Weibo and WeChat. Advertising expenses are included in selling expenses in the consolidated statements of income and comprehensive
income. Advertising expenses amounted to $367,513 and $488,423 for the years ended September 30, 2019 and 2018, respectively.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for current income taxes in accordance with the laws of the relevant tax authorities. Deferred income taxes are
recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the
consolidated financial statements. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date. Valuation
allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
uncertain tax position is recognized only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained
in a tax examination. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized
on examination. For tax positions not meeting the &ldquo;more likely than not&rdquo; test, no tax benefit is recorded. Penalties
and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred. No significant
penalties or interest relating to income taxes have been incurred during the years ended September 30, 2019 and 2018. The Company
does not believe there was any uncertain tax provision at September 30, 2019 and 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s operating subsidiary in China is subject to the income tax laws of the PRC. No significant income was generated
outside the PRC for the fiscal years ended September 30, 2019 and 2018. As of September 30, 2019, all of the Company&rsquo;s tax
returns of its PRC Subsidiaries remain open for statutory examination by PRC tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Value
added tax (&ldquo;VAT&rdquo;)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23.1pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
revenue represents the invoiced value of goods, net of VAT. The VAT is based on gross sales price and VAT rates range up to 17%
(starting from May 1, 2018, VAT rate was lowered to 16%, and starting from April 1, 2019, VAT rate was further lowered to 13%),
depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials
included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable or receivable net of
payments in the accompanying consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 143; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Earnings
per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company computes earnings per share (&ldquo;EPS&rdquo;) in accordance with ASC 260, &ldquo;Earnings per Share&rdquo; (&ldquo;ASC
260&rdquo;). ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured
as net income divided by the weighted average common shares outstanding for the period. Diluted presents the dilutive effect on
a per share basis of potential common shares (e.g., convertible securities, options and warrants) as if they had been converted
at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect
(i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of
September 30, 2019 and 2018, there were no dilutive shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Foreign
currency translation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional currency for Universe INC is the U.S Dollar (&ldquo;US$&rdquo;). Universe HK uses Hong Kong dollar as its functional
currency. However, Universe INC and Universe HK currently only serve as the holding companies and did not have active operation
as of the date of this prospectus. The Company operates only in the PRC, the Company&rsquo;s functional currency is the Chinese
Yuan (&ldquo;RMB&rdquo;). The Company&rsquo;s consolidated financial statements have been translated into the reporting currency
U.S. Dollars (&ldquo;US$&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
and liabilities of the Company are translated at the exchange rate at each reporting period end date. Equity is translated at
historical rates. Income and expense accounts are translated at the average rate of exchange during the reporting period. The
resulting translation adjustments are reported under other comprehensive income (loss). Gains and losses resulting from the translations
of foreign currency transactions and balances are reflected in the results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions.
No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table outlines the currency exchange rates that were used in creating the consolidated financial statements in this
report:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&nbsp;30,<BR> 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September&nbsp;30,<BR> 2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: justify">Year-end spot rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">US$1=RMB&nbsp;7.1378</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">US$1=RMB&nbsp;6.8681</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Average rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">US$1=RMB 6.8729</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">US$1=RMB 6.5359</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comprehensive
income </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
income consists of two components, net income and other comprehensive income (loss). The foreign currency translation gain or
loss resulting from translation of the financial statements expressed in RMB to US$ is reported in other comprehensive income
(loss) in the consolidated statements of income and comprehensive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Statement
of Cash Flows</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 230, &ldquo;Statement of Cash Flows&rdquo;, cash flows from the Company&rsquo;s operations are formulated
based upon the local currencies. As a result, amounts related to assets and liabilities reported on the statements of cash flows
will not necessarily agree with changes in the corresponding balances on the balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Employee Defined Contribution Plan</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The Company&rsquo;s subsidiaries in the
PRC participate in a government-mandated multi-employer defined contribution plan pursuant to which pension, work-related injury
benefits, maternity insurance, medical insurance, unemployment benefit and housing fund are provided to eligible full-time employees.
The relevant labor regulations require the Company&rsquo;s subsidiaries in the PRC to pay the local labor and social welfare authorities
monthly contributions based on the applicable benchmarks and rates stipulated by the local government. The contributions to the
plan are expensed as incurred. Employee social security and welfare benefits included as expenses in the accompanying statements
of income and comprehensive income amounted to $274,091 and $256,635 for the years ended September 30, 2019 and 2018, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp;&nbsp; </P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 144; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Note
2 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers the applicability and impact of all accounting standards updates (&ldquo;ASUs&rdquo;). Management periodically
reviews new accounting standards that are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02,&nbsp;Leases (Topic 842), which requires lessees
to recognize a right-of-use asset and lease liability on the balance sheet for all leases, including operating leases, with a
term in excess of 12 months. The guidance also expands the quantitative and qualitative disclosure requirements. The new guidance
requires the lessee to record operating leases on the balance sheet with a right-of-use asset and corresponding liability for
future payment obligations. In July 2018, FASB issued ASU 2018-11 Leases (Topic 842) &ndash; Targeted Improvements&nbsp;that reduces
costs and eases implementation of the leases standard for financial statement preparers. The ASU simplifies transition requirements
and, for lessors, provides a practical expedient for the separation of non-lease components from lease components. . In November
2019, FASB released ASU No. 2019-10, <I>Financial Instruments&mdash;Credit Losses (Topic 326), Derivatives and Hedging (Topic
815), and Leases (Topic 842): Effective Dates</I>, which modified the implementation date of the standard. For public entities,
the guidance will be effective for fiscal year beginning after December 15, 2018 and interim periods therein. For all other entities,
the guidance is effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning
after December 15, 2021. As an emerging growth company, the Company will adopt this guidance effective October 1, 2021. The Company
does not expect the cumulative effect resulting from the adoption of this guidance will have a material impact on its consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB Accounting Standards Board issued ASU No. 2018-13, &ldquo;Fair Value Measurement (Topic 820): Disclosure
Framework Changes to the Disclosure Requirements for Fair Value Measurement&rdquo; (&ldquo;ASU 2018-13&rdquo;). ASU 2018-13 modifies
the disclosure requirements on fair value measurements. ASU 2018-13 is effective for all entities for fiscal years and interim
periods within those fiscal years beginning after December 15, 2019, with early adoption permitted for any removed or modified
disclosures. The removed and modified disclosures will be adopted on a retrospective basis and the new disclosures will be adopted
on a prospective basis. The Company does not expect this guidance will have a material impact on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all
expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and
reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit
losses on financial assets measured at amortized cost. ASU 2016-13 was subsequently amended by Accounting Standards Update 2018-19,
<I>Codification Improvements to Topic 326, Financial Instruments&mdash;Credit Losses, </I>Accounting Standards Update 2019-04
<I>Codification Improvements to Topic 326, Financial Instruments&mdash;Credit Losses, Topic 815, Derivatives and Hedging, and
Topic 825, Financial Instruments</I>, and Accounting Standards Update 2019-05, <I>Targeted Transition Relief.</I> For public entities,
ASU 2016-13 and its amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2019. For all other entities, this guidance and its amendments will be effective for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years. Early application will be permitted for all entities for
fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. As an emerging growth company,
the Company plans to adopt this guidance effective October 1, 2023. The Company is currently evaluating the impact of its pending
adoption of ASU 2016-13 on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)&mdash;Simplifying the Accounting for Income Taxes. ASU
2019-12 is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic
740 and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after
December 15, 2020 and interim periods within those fiscal years, which is fiscal 2021 for us, with early adoption permitted. The
Company does not expect adoption of the new guidance to have a significant impact on our financial statements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 145; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &mdash; ACCOUNTS RECEIVABLE, NET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
receivable consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Accounts receivable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,938,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,877,081</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: allowance for doubtful accounts</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(517,754</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(239,904</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Accounts receivable, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,420,986</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,637,177</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s accounts receivable primarily includes balance due from customers when the Company&rsquo;s pharmaceutical products
are sold and delivered to customers. As of date of this prospectus, approximately 98%, or $6.3 million, of the Company&rsquo;s
net account receivable balance at September 30, 2019 has been subsequently collected. The Company expects to collect the remaining
balance by June 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowance
for doubtful accounts movement is as follows:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Beginning balance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">239,904</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">146,029</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,972</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Reductions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,571</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Ending balance</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">517,754</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">239,904</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &mdash; INVENTORY, NET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.8pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of the following:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,175,310</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,953,513</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Work-in-progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">342,102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Finished goods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,619,257</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,198,676</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Inventory valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(179,412</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(373,855</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total inventory, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,615,155</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,120,436</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &mdash; PROPERTY, PLANT AND EQUIPMENT, NET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
plant and equipment, net, consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Buildings</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,066,548</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,343,964</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,413,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,443,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Automobiles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,758</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,909</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Office and electric equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">411,671</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">416,042</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Subtotal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,025,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,340,627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,458,231</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,264,932</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,566,932</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,075,695</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 146; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &mdash; PROPERTY, PLANT AND EQUIPMENT, NET (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $413,199 and $445,923 for the years ended September 30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-align: justify; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &mdash; INTANGIBLE ASSETS, NET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Land use rights</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">251,898</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">261,787</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Software</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,145</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,975</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">273,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,762</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Less: accumulated amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(101,433</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(100,179</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">171,610</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">183,583</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $5,232 and $6,810 for the years ended September 30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
future amortization expense for intangible assets is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Years ending September 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortization expense</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: justify">2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">146,420</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">171,610</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &mdash; SHORT-TERM BANK LOANS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
bank loans consist of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Short-term bank loans:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Loans payable to Jiangxi Luling Rural Commercial Bank (&ldquo;LRC Bank&rdquo;):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maturity date on June 26, 2019, interest rate 5.655% per annum</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,456,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maturity date on November 29, 2018, interest rate 5.655% per annum</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">436,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maturity date on September 25, 2019, interest rate 5.655% per annum</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">728,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maturity date on June 25, 2020, interest rate 5.655% per annum</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,401,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maturity date on September 25, 2020, interest rate 5.655% per annum</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">(5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,120,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total short-term bank loans</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,521,800</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,620,800</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2018,
    the Company&rsquo;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&ldquo;LRC
    Bank&rdquo;) to borrow RMB10 million (equivalent to $1,456,000) as working capital for one year, with the maturity date on
    June 26, 2019. The fixed interest rate of the loan was 5.655% per annum. Related parties including Mr. Gang Lai, the Company&rsquo;s
    controlling shareholder, and Foshan Shangyu Investment Holding Co., Ltd. (&ldquo;Foshan Shangyu&rdquo;), an affiliated entity
    controlled by Mr. Gang Lai, and two unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit
    guarantee to safeguard this loan. Foshan Shangyu has no other business transaction with the Company except providing loan
    guarantee. That loan was fully paid upon maturity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 147; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &mdash; SHORT-TERM BANK LOANS (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 30,
    2017, the Company&rsquo;s subsidiary Universe Trade signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&ldquo;LRC
    Bank&rdquo;) to borrow RMB3 million (equivalent to $436,800) as working capital for one year, with the maturity date on November
    29, 2018. The fixed interest rate of the loan was 5.655% per annum.&nbsp;Related parties including Mr. Gang Lai, the Company&rsquo;s
    controlling shareholder, Foshan Shangyu Investment Holding Co., Ltd., an affiliated entity controlled by Mr. Gang Lai, and
    Jiangxi Universe, and two unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit guarantee
    to safeguard this loan. The Company repaid this loan in full upon maturity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 26,
    2018, the Company&rsquo;s subsidiary Universe Trade signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&ldquo;LRC
    Bank&rdquo;) to borrow RMB5 million (equivalent to $728,000) as working capital for one year, with the maturity date on September
    25, 2019. The fixed interest rate of the loan was 5.655% per annum.&nbsp;Related parties including Mr. Gang Lai, the Company&rsquo;s
    controlling shareholder, and Foshan Shangyu Investment Holding Co., Ltd., an affiliated entity controlled by Mr. Gang Lai,
    and three unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit guarantee to safeguard
    this loan. The loan was fully repaid upon maturity.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 26, 2019,
    the Company&rsquo;s subsidiary Jiangxi Universe signed a loan agreement with Jiangxi Luling Rural Commercial Bank (&ldquo;LRC
    Bank&rdquo;) to borrow RMB 10 million (equivalent to $1,401,000) as working capital for one year, with the maturity date on
    June 25, 2020. The fixed interest rate of the loan was 5.655% per annum. Related parties including Mr. Gang Lai, the Company&rsquo;s
    controlling shareholder, and Foshan Shangyu Investment Holding Co., Ltd., an affiliated entity controlled by Mr. Gang Lai,
    and three unrelated individuals jointly signed a guarantee agreement with LRC Bank to provide credit guarantee to safeguard
    this loan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September
    26, 2019, the Company&rsquo;s subsidiary Universe Trade signed a loan agreement with Jiangxi Luling Rural Commercial Bank
    (&ldquo;LRC Bank&rdquo;) to borrow RMB 8 million (equivalent to $1,120,800) as working capital for one year, with the maturity
    date on September 25, 2020. The fixed interest rate of the loan was 5.655% per annum.&nbsp;Related parties including Mr. Gang
    Lai, the Company&rsquo;s controlling shareholder, Foshan Shangyu Investment Holding Co., Ltd., an affiliated entity controlled
    by Mr. Gang Lai, and the Company&rsquo;s subsidiaries Jiangxi Universe and Universe Technology, as well as three unrelated
    individuals jointly signed a guarantee agreement with LRC Bank to provide credit guarantee to safeguard this loan. &nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the above-mentioned loans, the Company recorded a total interest expense of $135,717 and $183,069 for the years ended September
30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &mdash; RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Due to related
    party</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2019 and 2018, the balance due to related party mainly consisted of advances from the Company&rsquo;s principal
shareholder for working capital purposes during the Company&rsquo;s normal course of business. These advances are non-interest
bearing and due on demand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 148; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &mdash; RELATED PARTY TRANSACTIONS (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Loan guarantee
    provided by related party</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&rsquo;s bank borrowings from LRC Bank, the Company&rsquo;s chief executive officer Mr. Gang Lai and
Foshan Shangyu Investment Holding Co., Ltd., an affiliated entity controlled by him, jointly signed a guarantee agreement with
LRC Bank to provide credit guarantee to safeguard the Company&rsquo;s loans from LRC Bank (see Note 7). &nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &mdash; TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate Income
    Taxes (&ldquo;CIT&rdquo;)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Cayman
Islands</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the current tax laws of the Cayman Islands, Universe INC is not subject to tax on its income or capital gains. In addition, no
Cayman Islands withholding tax will be imposed upon the payment of dividends by the Company to its shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hong
Kong</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
HK is incorporated in Hong Kong and is subject to profit taxes in Hong Kong at a rate of 16.5%. However, Universe HK did not generate
any assessable profits derived from Hong Kong sources for the fiscal years ended September 30, 2019 and 2018, and accordingly
no provision for Hong Kong profits tax has been made in these periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate Income
    Taxes (&ldquo;CIT&rdquo;) (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PRC</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Enterprise Income Tax (&ldquo;EIT&rdquo;) Law of PRC, domestic enterprises and Foreign Investment Enterprises (&ldquo;FIEs&rdquo;)
are usually subject to a unified 25% enterprise income tax rate while preferential tax rates, tax holidays and even tax exemption
may be granted on a case-by-case basis. EIT grants preferential tax treatment to High and New Technology Enterprises (&ldquo;HNTEs&rdquo;).
Under this preferential tax treatment, HNTEs are entitled to an income tax rate of 15%, subject to a requirement that they re-apply
for their HNTE status every three years. Jiangxi Universe, one of the Company&rsquo;s main operating subsidiaries in PRC, was
approved as a HNTE and is entitled to a reduced income tax rate of 15% beginning November&nbsp;2016 with a term of three years.
EIT is typically governed by the local tax authority in PRC. Each local tax authority at times may grant tax holidays to local
enterprises as a way to encourage entrepreneurship and stimulate local economy. The corporate income taxes for the years ended
September 30, 2019 and 2018 were reported at a blended reduced rate as a result of Jiangxi Universe being approved as a HNTE and
enjoying a 15% reduced income tax rate. Universe Trade is subject to a standard 25% income tax rate. The impact of the tax holidays
noted above decreased PRC corporate income taxes by $312,357 and $471,275 for the years ended September 30, 2019 and 2018, respectively.
The benefit of the tax holidays on net income per share (basic and diluted) $6.25 and $9.43 for the years ended September 30,
2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 149; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &mdash; TAXES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
components of the income tax provision (benefit) are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Current tax provision</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cayman Islands</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Hong Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-bottom: 1.5pt">PRC</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2,141,222</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1,897,580</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,141,222</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,897,580</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Deferred tax provision (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Cayman</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Hong Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">PRC</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(39,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,538</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(39,625</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,538</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Income tax provision</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,101,597</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,915,118</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table reconciles the China statutory rates to the Company&rsquo;s effective tax rate for the years ended September 30,
2019 and 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">China Income tax statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25.0</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">25.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Effect of income tax holiday</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3.3</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5.0</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Permanent difference</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Effective tax rate</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">21.8</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20.1</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative
rulings. As of September 30, 2019, all of the Company&rsquo;s tax returns of its PRC Subsidiaries remain open for statutory examination
by PRC tax authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Taxes payable</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes
payable consist of the following:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2019</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September&nbsp;30, </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2018</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Income tax payable</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">385,092</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">513,348</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Value added tax payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">307,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Other taxes payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,767</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,790</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total taxes payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">551,049</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">893,512</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 150; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
10 &mdash; CONCENTRATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
majority of the Company&rsquo;s revenue and expense transactions are denominated in RMB and a significant portion of the Company
and its subsidiaries&rsquo; assets and liabilities are denominated in RMB. RMB is not freely convertible into foreign currencies.
In the PRC, certain foreign exchange transactions are required by law to be transacted only by authorized financial institutions
at exchange rates set by the People&rsquo;s Bank of China (&ldquo;PBOC&rdquo;). Remittances in currencies other than RMB by the
Company in China must be processed through the PBOC or other China foreign exchange regulatory bodies which require certain supporting
documentation in order to affect the remittance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2019 and 2018, $3,171,961 and $6,180,199 of the Company&rsquo;s cash was on deposit at financial institutions
in the PRC where there currently is no rule or regulation requiring such financial institutions to maintain insurance to cover
bank deposits in the event of bank failure. For the years ended September 30, 2019 and 2018, the Company&rsquo;s substantial assets
were located in the PRC and the Company&rsquo;s substantial revenues were derived from its subsidiaries located in the PRC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended September 30, 2019 and 2018, no single customer accounted for more than 10% of the Company&rsquo;s total revenue.
The Company&rsquo;s top 10 customers aggregately accounted for 34.5% and 31.6% of the total revenue for the years ended September
30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of one of the Company&rsquo;s major product, Guben Yanling Pill, accounted for 32.4% and 25.9% of the Company&rsquo;s total revenue
for the years ended September 30, 2019 and 2018, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2019, three customers accounted for 12.6%, 11.8% and 10.8% of the total accounts receivable balance, respectively.
As of September 30, 2018, two customers accounted for 13.3% and 10.2% of the total outstanding accounts receivable balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended September 30, 2019 and 2018, one supplier accounted for approximately 14.1% and 15.2% of the total purchases,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
11 &mdash; SHAREHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ordinary
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
INC was incorporated under the laws of the Cayman Islands on December 11, 2019. The authorized number of ordinary shares was 50,000
shares with par value of US$1.00 per share and 50,000 shares were issued. The issuance of these 50,000 shares is considered as
a part of the Reorganization of the Company, which was retroactively applied as if the transaction occurred at the beginning of
the period presented (see Note 1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
dividends </I></B></FONT></P>

<P STYLE="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 21, 2016, September 13, 2017, February 2, 2018, September 20, 2018 and February 21, 2019, the board of directors of
Jiangxi Universe approved resolutions to pay cash dividend of RMB40 million, RMB30 million, RMB20 million, RMB10 million and RMB30
million, respectively, to its shareholders at the time of record out of the retained earnings balance of Jiangxi Universe, to
be paid to these shareholders when there are sufficient available earnings and the Company has sufficient funds. A total of RMB130
million (approximately $19.1 million) cash dividend was declared from September 2016 to February 2019, among which approximately
RMB20 million ($3.1 million) was paid in cash to its shareholders in 2018 and the remaining RMB 110 million ($16 million) was
paid to its shareholders in 2019.</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 151; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
11 &mdash; SHAREHOLDERS&rsquo; EQUITY (continued)</B></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the dividends declared mentioned above, the Company has not declared or paid dividends to its shareholders in the past, and
may not choose to make additional distributions in the future. Any decision as to the payment of dividends will depend on the
available earnings, the capital requirements of the Company, the Company&rsquo;s general financial condition and other factors
deemed pertinent by the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;<I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Statutory
reserve and restricted net assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. The
payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the
PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards
and regulations in China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary
surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC
(&ldquo;PRC GAAP&rdquo;). Appropriations to the statutory surplus reserve are required to be at least 10% of the after-tax net
income determined in accordance with PRC GAAP until the reserve is equal to 50% of the entity&rsquo;s registered capital. Appropriations
to the discretionary surplus reserve are made at the discretion of the board of directors. The statutory reserve may be applied
against prior year losses, if any, and may be used for general business expansion and production or increase in registered capital,
but are not distributable as cash dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relevant
PRC laws and regulations restrict the Company&rsquo;s PRC subsidiaries from transferring a portion of their net assets, equivalent
to its statutory reserves and their share capital, to the Company in the form of loans, advances or cash dividends. Only PRC entities&rsquo;
accumulated profits may be distributed as dividends to the Company without the consent of a third party. As of September 30, 2019
and 2018, the restricted amounts as determined pursuant to PRC statutory laws totalled $2,439,535, and total restricted net assets
amounted to $6,168,535.<B>&nbsp;</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
12 &mdash; CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company is a party to various legal actions arising in the ordinary course of business. The Company accrues
costs associated with these matters when they become probable and the amount can be reasonably estimated. Legal costs incurred
in connection with loss contingencies are expensed as incurred. For the years ended September 30, 2019 and 2018, the Company did
not have any material legal claims or litigation that, individually or in aggregate, could have a material adverse impact on the
Company&rsquo;s consolidated financial position, results of operations and cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
13 &mdash; SEGMENT REPORTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur
expenses, and is identified on the basis of the internal financial reports that are provided to and regularly reviewed by the
Company&rsquo;s chief operating decision maker in order to allocate resources and assess performance of the segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
management of the Company concludes that it has only one reporting segment. The Company develops, manufactures and sells traditional
Chinese medicine derivatives (&ldquo;TCMD&rdquo;) products targeted to the elderly to address their physical conditions in the
aging process and to promote their general well-being. In addition, the Company also sells biochemical drugs, medical instruments,
Traditional Chinese Medicine Pieces products and dietary supplements manufactured by third-party pharmaceutical companies (&ldquo;third-party
products&rdquo;). All of these products are currently sold in China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 152; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
13 &mdash; SEGMENT REPORTING (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s products have similar economic characteristics with respect to raw materials, vendors, marketing and promotions,
customers and methods of distribution. The Company&rsquo;s chief operating decision maker has been identified as the Chief Executive
Officer, who reviews consolidated results when making decisions about allocating resources and assessing performance of the Company,
rather than by product types or geographic area; hence the Company has only one reporting segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Revenue
by product source </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For&nbsp;the&nbsp;year ended<BR> September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Sales of TCMD products manufactured by the Company</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,895,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">17,620,823</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Sales of third-party products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,893,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Total revenue</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,229,316</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,514,180</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Revenue
by product categories </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of our total revenues by product categories for the years ended September 30, 2019 and 2018 was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended<BR>
 September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Sales of TCMD products:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Medicinal liquor products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,356,015</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,857,283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Other chronic condition treatment products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,056,228</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,529,642</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Cold and flu medicines</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,483,299</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,233,898</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Sub-total of TCMD products sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,895,542</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,620,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Sales of third-party products:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Biochemical drugs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,508,816</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,226,228</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Traditional Chinese medicine pieces</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,503</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Medical instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,668,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,483,052</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Dietary supplements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,127</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,574</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Subtotal of third-party products sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,333,774</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,893,357</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total revenue</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">33,229,316</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28,514,180</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
14 &mdash; SUBSEQUENT EVENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s subsidiary, Universe Technology, was formed on April 18, 2019 as a WFOE in the PRC, with registered capital of
approximately $4.3 million (RMB 30.5 million). In December 2019, the Company made capital contribution of $500,000 to Universe
Technology. Pursuant to the article of incorporation, the Company is required to complete the capital contribution before 2038.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed in Note 9, Jiangxi Universe, the Company&rsquo;s main operating subsidiary in PRC, was approved as a HNTE and is entitled
to a reduced income tax rate of 15% beginning December&nbsp;2016 with a term of three years. In December 2019, Jiangxi Universe
successfully renewed its HNTE certification with local government and will continue to enjoy the reduced income tax rate of 15%
for another three years through December 2022.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, a novel strain of coronavirus was reported
in Wuhan, China. On March 11, 2020, the World Health Organization categorized it as a pandemic. To reduce the spread of the COVID-19,
the Chinese government has employed measures including city lockdowns, quarantines, travel restrictions, suspension of business
activities and school closures. Due to difficulties resulting from the COVID-19 outbreak, including, but not limited to, the
temporary closure of the Company&rsquo;s factory and operations beginning in early February, limited support from the Company&rsquo;s
employees, delayed access to raw material supplies and inability to deliver products to customers on a timely basis, the Company&rsquo;s
business was negatively impacted and is expected to generate lower revenue and net income during the period from February to April
2020. The Company resumed operations on March 2, 2020 and, as such, the extent of the impact of COVID-19 on the Company&rsquo;s
results of operations and financial condition will depend on future developments, including the duration and spread of the outbreak
and the impact on the Company&rsquo;s customers, which are still uncertain and cannot be reasonably estimated at this point of
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 153; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
15 &mdash; CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent
company shall be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets
as of the end of the most recently completed fiscal year. The Company performed a test on the restricted net assets of consolidated
subsidiaries in accordance with such requirement and concluded that it was applicable to the Company as the restricted net assets
of the Company&rsquo;s PRC subsidiary exceeded 25% of the consolidated net assets of the Company. Therefore, the condensed financial
statements for the parent company are included herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company&rsquo;s proportionate
share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal
year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the
consent of a third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed financial information of the parent company has been prepared using the same accounting policies as set out in the Company&rsquo;s
consolidated financial statements except that the parent company used the equity method to account for investment in its subsidiaries.
Such investment is presented on the condensed balance sheets as &ldquo;Investment in subsidiaries&rdquo; and the respective profit
or loss as &ldquo;Equity in earnings of subsidiaries&rdquo; on the condensed statements of income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements
should be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and
footnote disclosures normally included in financial statements prepared in accordance with U.S GAAP have been condensed or omitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2019 and 2018, there were no material contingencies, significant provisions for long-term obligations, or guarantees
of the Company, except for those which have been separately disclosed in the consolidated financial statements, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 154; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARENT
COMPANY BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30, 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30, 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify">Non-current assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Investment in subsidiaries</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">12,384,059</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">9,681,572</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 10pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,384,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,681,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">LIABILITIES AND SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">SHAREHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Ordinary shares, $1.00 par value, 50,000 shares authorized, issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,679,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Retained earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,620,292</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,271,827</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,767</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">680,745</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Total shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,384,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,681,572</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 20pt">Total liabilities and shareholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,384,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,681,572</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 155; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARENT
COMPANY STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-bottom: 1.5pt">EQUITY IN EARNINGS OF SUBSIDIARIES</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,551,465</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">7,602,933</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">NET INCOME</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,551,465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,602,933</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">FOREIGN CURRENCY TRANSLATION ADJUSTMENTS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(645,978</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(587,693</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">COMPREHENSIVE INCOME ATTRIBUTABLE TO THE COMPANY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,905,487</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,015,240</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNIVERSE
PHARMACEUTICALS INC. AND SUBSIDIARIES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PARENT
COMPANY STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 10pt">Net income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,551,465</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,602,933</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 10pt">Adjustments to reconcile net cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 20pt">Equity in earnings of subsidiary</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,551,465</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,602,933</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 30pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">CHANGES IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">CASH, beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">CASH, end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 156; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ], 2020, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required
to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters
and with respect to their unsold allotments or subscriptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ordinary
Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="logo_001.jpg" ALT="" STYLE="width: 650px; height: 213px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
Pharmaceuticals INC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated [&#9679;], 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cayman Islands law does not limit the extent to which a company&rsquo;s articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to
public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our amended and
restated articles of association, which will become effective upon or before completion of this offering, provide that, to the
extent permitted by law, we shall indemnify each existing or former secretary, director (including alternate director), and any
of our other officers (including an investment adviser or an administrator or liquidator) and their personal representatives against:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all actions, proceedings, costs, charges, expenses, losses, damages, or liabilities incurred or sustained by the existing or former
director (including alternate director), secretary, or officer in or about the conduct of our business or affairs or in the execution
or discharge of the existing or former director (including alternate director)&rsquo;s, secretary&rsquo;s, or officer&rsquo;s
duties, powers, authorities or discretions; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
without limitation to paragraph (a) above, all costs, expenses, losses, or liabilities incurred by the existing or former director
(including alternate director), secretary, or officer in defending (whether successfully or otherwise) any civil, criminal, administrative
or investigative proceedings (whether threatened, pending or completed) concerning us or our affairs in any court or tribunal,
whether in the Cayman Islands or elsewhere.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
such existing or former director (including alternate director), secretary, or officer, however, shall be indemnified in respect
of any matter arising out of his own dishonesty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted by law, we may make a payment, or agree to make a payment, whether by way of advance, loan or otherwise,
for any legal costs incurred by an existing secretary, or any of our officers in respect of any matter identified in above on
condition that the secretary, or officer must repay the amount paid by us to the extent that it is ultimately found not liable
to indemnify the secretary or that officer for those legal costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to indemnification agreements, the form of which will be filed as Exhibit 10.2 to this registration statement, we will agree to
indemnify our directors and officers against certain liabilities and expenses incurred by such persons in connection with claims
made by reason of their being such a director or officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement, the form of which will be filed as Exhibit 1.1 to this registration statement, will also provide for indemnification
of us and our officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933, as amended may be permitted to directors, officers
or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 158; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
7. RECENT SALES OF UNREGISTERED SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2019, we issued 50,000 Ordinary Shares (bringing our total issued and outstanding shares to 50,000 Ordinary Shares)
in connection with the incorporation of the Company without registering the securities under the Securities Act, including 39,000
Ordinary Shares issued to Sununion Holding Group Limited, an entity owned as to 100% by Mr. Gang Lai, our chief executive officer
and chairman of the board. We believe that each of the following issuance was exempt from registration under the Securities Act
pursuant to Section 4(2) of the Securities Act regarding transactions not involving a public offering or in reliance on Regulation
S under the Securities Act regarding sales by an issuer in offshore transactions. No underwriters were involved in these issuances
of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Purchaser</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date of Issuance</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Ordinary Shares</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Consideration</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Sununion Holding Group Limited</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">December&nbsp;11,&nbsp;2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">39,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">39,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Greatest Group (China) Financial Management Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">True Ample Holdings Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Xingrui Investment Company Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Bliss International Investment Company Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 11, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
8. <I>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Exhibit Index beginning on page II-7 of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial
Statements or the Notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM
9. <I>UNDERTAKINGS.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each
purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the provisions described in Item 6, or otherwise, the registrant has been advised that in the opinion
of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and
is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Securities Act and will be governed by the final adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant
under Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of
the time it was declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
For the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b)
as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as
of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus
that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior
to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of
the registration statement or made in any such document immediately prior to such date of first use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
For the purpose of determining any liability of the registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if
the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of [&#9679;], People&rsquo;s Republic of China, on [&#9679;], 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Universe
    Pharmaceuticals INC</FONT></TD></TR>
<TR>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive
    Officer and Director</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
    Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities
and on [&#9679;], 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/</FONT></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Gang Lai</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Lin Yang</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: [&#9679;]</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: [&#9679;]</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></P></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: [&#9679;]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Power
Of Attorney</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below constitutes and appoints each of [&#9679;] as&nbsp;attorneys-in-fact&nbsp;with full power
of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments
which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;), and any rules, regulations, and requirements of the Securities and Exchange Commission
thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant (the &ldquo;Shares&rdquo;),
including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated
below to the Registration Statement on Form&nbsp;F-1&nbsp;(the &ldquo;Registration Statement&rdquo;) to be filed with the Securities
and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement,
whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related
Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed
as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed
before or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all
that such attorney and agent shall do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 44%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
and Chairman of the Board</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;], 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Gang Lai</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
    Officer)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;], 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Lin Yang</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Accounting
    and Financial Officer)</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left">Director </TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;], 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: [&#9679;]</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;], 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: [&#9679;]</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;], 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: [&#9679;]</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America,
has signed this registration statement thereto in New York, NY on [&#9679;], 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hunter
Taubman Fischer &amp; Li LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Ying Li</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Partner and
    Member</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting
    Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated
    Memorandum of Association</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated
    Articles of Association</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen
    Certificate for Ordinary Shares</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Opinion
    of Ogier regarding the validity of the Ordinary Shares being registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Opinion
    of AllBright Law Offices regarding certain PRC tax matters (included in Exhibit 99.2)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Employment Agreement by and between executive officers and the Registrant</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement with the Registrant&rsquo;s directors and officers</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">English
    Translation of the Working Capital Loan Contract between Jiangxi Universe and Jiangxi Liuling Rural Commercial Bank Co., Ltd.,
    dated June 26, 2019</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">English
    Translation of the Working Capital Loan Contract between Universe Trade and Jiangxi Liuling Rural Commercial Bank Co., Ltd.,
    dated September 26, 2019</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">English
    Translation of the Loan Guarantee Contract among Jiangxi Universe, Xing Wu, Universe Trade, and Jiangxi Liuling Rural Commercial
    Bank Co., Ltd., dated September 26, 2019</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">English
    Translation of the Loan Guarantee Contract among Gang Lai, Lin Yang, Jiangxi Universe, Foshan Shangyu Investment Holding Co.,
    Ltd., Fujing Wang, Universe Trade, and Jiangxi Liuling Rural Commercial Bank Co., Ltd., dated September 26, 2019</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> 10.7* </TD>
    <TD STYLE="text-align: justify"> &nbsp; </TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0"><A HREF="ea122948drsa1ex10-7_universe.htm"> Form of Sales and Distribution Agreement by and between Universe Trade and customers </A></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT>&dagger; </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Friedman
    LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ogier
    (included in Exhibit 5.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of AllBright
    Law Offices (included in Exhibit 99.2)</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business
    Conduct and Ethics of the Registrant</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Opinion
    of AllBright Law Offices, People&rsquo;s Republic of China counsel to the Registrant, regarding certain PRC law matters</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Frost and Sullivan</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry
    Report by Frost and Sullivan</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Jiawen Pang</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Yongping Yu</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.7&dagger;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Ding Zheng</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be filed by amendment.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"> &dagger; </TD>
    <TD STYLE="text-align: justify"> Previously filed. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">II-7</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font-size: 10pt"><IMG SRC="ex10-7_001.jpg" ALT=""></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jiangxi Universe Pharmaceuticals Commerce
        and Trade Co., Ltd.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Product Sales Agreement (the &ldquo;Agreement&rdquo;)</B></P></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 0; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Party A: Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd.</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: </FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 0; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Party B: </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Location: Ji&rsquo;an City, Jiangxi Province</FONT></TD></TR>
<TR>
    <TD STYLE="width: 18%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <U>Product name, quantity, price and
manufacturer</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 20%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product Name</FONT></TD>
    <TD STYLE="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specification</FONT></TD>
    <TD STYLE="width: 8%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unit</FONT></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qty.</FONT></TD>
    <TD STYLE="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unit Price</FONT></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD>
    <TD STYLE="width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturer</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 20%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total Amount (RMB in words):</FONT></TD>
    <TD STYLE="width: 46%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Page 1 of 2</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <U>Delivery Method</U>: Products sold
shall be sent to the premise designated by Party B. Delivery costs shall be borne by Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <U>Transportation Method</U>: Automobile
transportation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <U>Payment Method and Deadline</U>:
Payment shall be made through bank transfer and within 90 days after Party B receives the products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>Acceptance Standard and Deadline
for Raising an Objection</U>: Party B shall accept the products according to different product types. An objection shall be raised
within three days after Party B receives the products; otherwise, it is deemed as no objection to product quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>Returns and Exchanges</U>: Returns
shall be accepted if the reason of return is based on product quality and the return request is made within the allotted time frame.
Returns and exchanges based on other reasons may be made if Party B obtains consent from Party A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>Breach of Contract</U>: If Party
A fails to perform the Agreement, it shall compensate for the actual economic losses to Party B. If Party B fails to perform or
breaches the Agreement, it shall bear the actual economic losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <U>Dispute Resolution</U>: The Parties
agree to settle any disputes that arise from this Agreement through good faith negotiations. If the Parties are unable to settle
the matter between themselves, the matter shall thereafter be resolved by filing a proceeding at Ji&rsquo;an County People&rsquo;s
Court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <U>Force Majeure</U>: If either of the
Parties is unable to perform the Agreement arising out of or caused, directly or indirectly, by circumstances such Party&rsquo;s
reasonable control, it shall notify the other party within 24 hours. The nonperforming party receives proof of force majeure from
a competent authority, it may delay its performance, partially perform, or not perform the Agreement, and be exempted from bearing
some or all of the damages caused, depending on the actual circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <U>Other Matters</U>: The Agreement
has been executed in two (2) duplicate originals in Chinese. Each Party shall receive one (1) original copy, all of which shall
be equally valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Party A: Jiangxi Universe Pharmaceuticals Commerce and Trade Co., Ltd.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 0; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Party B: </FONT></TD></TR>
<TR>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Add.: Jingjiu Avenue, Jingkai District, Jiangxi</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Add.: </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel.: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel.:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Page 2 of 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #+ FL# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH) ZD#ZT %%)D=,
MC/ID9JG>WD-C!/>75Q%:V5E;RWE]<S$+';VMNC332R.2!'%'#'(\DC<(J@CK
M19[):NR2[M[*V^M].X=+W^?3_+0F6X1FV .&[Y P#SP<$\X!/&>!]*G]?;_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8@*$U& +K^F1;P&NXM66-2URAD^)?^#HCX^-I_P^_9L_9DTV];[1XP\4:_\
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MR>,?B5J3W][%80@-9Z;9:'X0\,+I.EZ;I0BLM(TG45LK=%BN)!+_ &21H$7
MZ$D]N,]ACC Z#VQU/)[^+<BI<,YQ_84<1];Q6"PF'EF>)BFJ<LQKP56M1I;7
MIX:$Z=)2DHSG+FG*$6U&/L95C9YEA7C91]G"M6J2H0^TZ*]R$Y]I2Y7*VRO9
M-J[;Z***^:/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.Z[XVDN#'@/+OSCE/V<?#"Z)X#;69H1%>>*=0DO\J2=NEVN;73E(Z[909;E
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MZ&^\%^#;I9M-UCX^W]E*IR^[R+W3/A9;SQLNHZM&(+GQ:ZMIFBRIIBWNI/\
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MEYI<UUOV:OUUU-:=&E*C[:MS6Y^2/*D]=7K?R_X8_ __ (*@?M@?L<?M]_\
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M%KT^%3-I'BCPOJ:6^JZ+J,!5H[B 07 FLKB[MIONK_@A!8?L"Z5^POINB_\
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MAI=UH?BCPEXHTVUUKP]XAT>]79=:9K&E7L<MI?V%PGRS6UQ&T<@&&%?&2_\
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M?&'B+3[_ $^72-.^'&O:5;"ZU^TU?4O+AU74%9;U9&=&D:)/W8_X.IYH(_\
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M ,'AS%?V*_V8?FPG_#3;;\DX_P"2;>+0I9 P$B%B(V5E8 2%AM8*:_KK4!4
M7H!QGC\\ #ZX&*_C9_X/(KHC]FS]B:R6<H]U^T'X]N#&"WE/':?"G4HI&D0'
M9((6O$<!RIVLQC='VYUQ%HT9WV25^_Q1_$,$_P#:J+5U[S:MT]R?^9X+^PU_
MP:T_LI?M3_L<_LT?M)>,_P!HK]H3PWXJ^./P9\"?$_7] \.1^ ET#1=4\8:'
M;:U<:7I(O_#MY?O86+W1MH);JZEN)T032.KR,J_+O_!-#]CSP7^Q?_P<RR?L
MK> ?$?B7Q5X;^"7A3XLVWA#QCXP33I-??4?$/[.,6LMJVH6FE"QTNY&G3^*=
M0L8H5@C2>&)5N$624;/H_P#88_X.H?V8?V6/V1OV;_V:?&7[,OQXU_6/@5\%
M_ 'PNU/Q/X:U[X=2:9KVK>#=!L]%O-2L++6-<TF[M-.NVM6N;0WC&?9(L,R"
M568_.7_!)W]ISPY^VU_P<NZQ^U5X%\,^)_#'A3XN^'_C9XKTK0/%;Z;<^(-!
MT^W^"ECX;2'5Y='O+[3 QGL/W LKNXMUCO+:&617"EN63@XT7#_GY"^_51WN
MEK<ZOWW/B75;Y73J<G,UM=VVVO&W1=#[Q^$W_!!C]I'XY_\ !6SXK?M+_P#!
M2WX_>%OCQ\(?A7\0O#_C3P-K::]HD&L?'_[!.^L_#WP!?_#^UOW3X/?#[X7R
M6UI:>+/!HBBM-6U"TDTOPW)J&CZKJNN-_9_;&&Z03VDL,T+[/*N+26*6%DB(
M"B-XF,;+\J"1,!1AU0X( _S=/^#EC]@[6/V4_P!M[1/VH+GXF^-M7^%O[;_C
MKQ/XJ\275C =)/PP\0>'+[PU%K_A+2+B#5#:ZO$G@ZZ7Q-I$VL"T2[OK74K5
M[>'3[.:8_J;HW_!I%\+?%GAGPOXI\#_\%*_V@KOP[XFT/3/$>B7LO@C0[JRU
M+1-=TZWU32KRR.G^+[)4BO+:ZANPX,HDCE4(!D-6R<U*48497YY2YG):\U]>
M_+VMMWN<]6$)1HSG7BHNG&$5R.T906J:3TE?J]]6E8]G_;M_X-;F_:-_:W^(
M_P"U?^SK^U_J7P!U?XK>,]2^)?B#PSK'@C5/$%QX7^(&L;9M9UGP)XP\,>,_
M">N:59:KJ)N-4&GSK)-I5Q=W$%A?"RD^RI]\_P#!'W_@D;\;/^"=7CSXY?$'
M]H/]K;6OVK/$'Q!\-^%?!O@&?4[[XB20>!M"L-2U/6?%:_V;XV\6>);2VO?%
M%Z?#@:;33'+#;:&\)N'6YE0_PR?MH_\ !.?7O@)_P4T\&?\ !-;]G?\ :-^)
M7Q[\;>)]9^$'@^^\77DVI>%KSPWX]^)LZ:EJ.EO9Z3XGOK=(/ _A"[TSQ7J=
M\+I9+6%YXYV@N;=UB_U1OA?\/])^&7PX\ ?#+1;B^O-'^'G@?PMX'TZ^U"YF
MN]1O;/PKHMEHEK>ZC>7,DT][>7D5FMY=75Q)--<W<EQ//)))*Y8HQA-R7).#
MIRL_>NFY7O:VFFOITZ6*[G"G3C[2%2%2',GR6DDFDDVWS+_(_FO_ .#DW_@K
M-:_LC_ F\_8Y^!GB??\ M3_M(^'3I>NSZ!+)<ZM\(_@UKQDTS5]:D%J)9;+Q
MI\0XVF\*^!M*!746M+K4_$%M;+]DTZ>X_FV_X-WOA7X[^!/_  7*^'7PC^*'
MA^?PAX_\!^ /C9HGBSPO>M&VI:+JUU\*K36QIFH>6Q6.^L]/U*R-]9DF2QN3
M+:3A+JWFC7^SGXA?\$./V._B-_P4J\+_ /!2+Q%I^LW_ (STF.#Q%XC^%&I2
M-J_P]\:_&'05TZ#P%\5]534)IKFTOO!]C9-)#X6M@/#6HZY9:#KDMI%<Z=<Q
M7O\ -I^QYI>J:U_P=J?M;Q:!JEMIFI1^)OVK9K#63:Q:B='OE^$VA:5;:@-,
MD>"WU$Z;JEY;7$NFW,\,>H_998)9T3YTBM2FZL)\U[-1C'=66M_\5TO^ :4)
MQ]C5I4[*U'VE24EJYW2:NG\-GHK=O,_<+_@X(_X*ZZ%_P3]_9WU7X-?"#Q'!
M-^V%\>_#6I:/X.M--F1]3^$7@+48;C3]?^+VM1 .UC?1Q;](^'=G<QPW.I^)
MY1JEN9++0[L/X9_P;&?\$^?#?[*'[-6K?M2?%#4_#3_M&?M7Z-IVM164VO:3
M>Z_\/O@<;B+5_"OAW4FCO9YH-=\:ZE*OCGQBK,&6>3PUIMX%U'1[E:^0/V?_
M /@V\_:(^+O[>?[3/Q^_X*<?&33/C?X9@O-<F^%WC4-#?S?M ^+/&/A74++P
MQXS\2>#C>&7P'X)^#L&HVD%I\-$FMM/N_$>D66CZ1/-X0TDS:K^+G_!9K_@B
MAHG_  2(^$7P/\?^'/VK/'_QGU7XK>--?\%S:)JOA2+P-%86OASPNNO7>L6M
MQHOB34S-YEY);P7-K+'&(_M2SEYY%E=6_:*?MI4^:*332=K>=M;M_EY(5.-"
M5.6&IUDJDIJ<I-.S44WRI[I+=W6NV[T_TZ?[<T-0W_$ZTA1MZC4;,#C')_?#
ML.2?Y5_*#_P="_\ !-?6?VB/@=X6_;X^!6D37_QD_9;TJ6V^(</A5R^N^*_@
M9;ZBNO+XATN;3P]S/KOP@\0-<^*-/>W66]@\.ZCXAN8ID;38(S\<? [_ (-,
M]+^*_P #_@_\5M:_;Z^,?A37?B;\*/A_\0M6\+0?#^RU.Q\,ZQXS\(:3XCO?
M#\.HR^-;6ZU"ST:]U*73DO98+6YNX+<3/#!(^Q?Q,_;_ /\ @F5K7_!//_@H
M'^RG^Q_;?M'>*?C\GQFN_@WXCU::]@U_PBMCIOC+XPR^"KKPM?:#;>*O$2:C
MINJ:;I-Z6G:6-IH;F6(VSB-Z<ZDI0:=&48V5I-Q;5TN5Z=7I?;?6PJ%&G[7F
MCB$I1O=.#Y7%7YD]4KM;*^NGD?VR_P#!!W_@K!X=_P""D/[,6D>%/'_B2QC_
M &N/@-HFC^&_C3X<FNHH-3\<:99"'3M ^-FAV9:.6]T;Q7'# /%+6*S0>'O&
M7]H:7>>5;ZAI)N?WNK^3;X%_\&VQ_9Q_X*NC]K7X+?'SQ#\&_P!E3P?<)\0O
MAKX!^&FI7&G_ !,L_%>MWLUOXG^ NLZCJ5K?Z;<? DVZ27$QO%U34-7\.ZC;
M^#98+2;2T\0'^LFMZ2G&"C4MSK>ST:Z-?):_?U.>O[+G<J,N:$M=59I]4_G]
MVW8****U,0HHHH YGQEIWB/5O#.L:=X1\26_@_Q+=V<D.C>)[O0H/$UOHEZW
M$=]+H%S?:;;ZL(QN M)KZVC9F#M(=FQOYF?VY?V!?^"Y_P 1O[8N/ /[>>E_
M%OPA<M,(O 7@J<?LMZQ):9D>&VD@\-P2:1?N+=C:LTWC*!K^8A[A$C9P?ZBV
M4,,'IU_*HVA0CG/3KDYP.V1AL'N 1G'->WD/$&+X=QD<;@\)E6+J*WN9KE>"
MS*@TK:*&*A.4'UO!Q=[-/>_%CL#2Q]%T:M7$4X/?V%:5)M>?+\6MM'H[?=_E
MD_M _L5?ME? 35+S5/VA_P!G[XR^'+DRRFY\:>(M!U?Q=H]\0HEGN5\>Z4WB
M'1KP(Q!GG_MSR$3:<*=P'R=%)%(H>%T?DJ3&P.TX+-EA\GW<D@,6.< %CBO]
M=J>*.:"6"YCBN8959)H+E4FMYHB"K1S1.&0QD$A@R88 !P17X.?\%*/A]_P1
M\T:#4XOCW\"_AOXN^,NH6TKV&A_!BRB\'_%26>0O,EYKWB#P1/HL6BI)<+&T
MFH>*9I9I0 T5K>!!&/W[AOQRQ.*KT<'F'"<:U6;C'GR!.E%0]U2DL(Z<:2LM
M5:O%)*T4]#\JXQP/#G".5XC/\\XHR[)<JP475KXC/Z].A348J;Y*2J5/;5<1
M4MRTHX>C6JR=U&#1_ 9G<<*49VVHB-\YD9EW)$%7)RP.U6QM#G;P< ^^^$_!
M/QW'AQV\,SZ[I&BW)22'37U>WTNZN@,;1:Z?>,LT2L3@2HUF[  ^85"FOL\?
M"3X1>&?%VL:YX%\%ZEH^E7>H2W/AK2_%?B<^-M6\.6!Y2V&NR:7I2W=T"?WE
MTUA%=#.$GGMU#GM!)(/[V<%2,K@@GHRE=I _A&.#D]22?U'&\5T\5%/ X)3B
MU&;CFT%5]C-I.5&=#GYHRAU]YZ[/0_S4\4_I;Y;C:ZRC@SA7),[R[#XR%>6;
M<482GF%#$/#5)QI5,IPE2T\+&IRN3Q590Q"4HNC3@^:_Y>>)O"WQ*M92?%.B
M^+9)<GS)M0CU#4(A@\8N4EO(&!.>3*!UQTK@@BAWC^1)5^5XVPK\=0RX^7'7
MY]H'UK]9_$GB/2O"FCW6LZ]J<6G6$ 8;92&>1\?\>MI"R*UU<R9VI&J %F7<
MRH"P_.CXG?$N?XA:HLMOIUKH^C64DG]GVL=O:KJ,JMD&?5;F)"\DT@.3;!VM
MHL#R]^2[>QD6;XC,IN'U"G2HPC+FQ%*W(Y1224?=CHW=:.R22UL?K_@-XQ\5
M^(\YK$^'.5Y/DN#<H5^(LOQ.(PF6U)TTO]DPN!JY<EC:[<]9T,3*%"S?.W*Q
MY?1117TQ_4UE&\%M!M)*[MS-U$M==%-770*3OCM@_P!/_KTM% )I.+:;5U=)
M7;75)=6Q& *;V7Y.Q8?=).!S@[7'!'0XQZUTN@Z_XQT^6-/#6LZ_%/&"(X=)
MFOY>>N3:0K/"SYP-QCWE<#H!5WP-XGTWPGKL.I:QX>TOQ'I;E(M0M-0LX;BX
MCA)VM=6$LJL([N,'<!(&BE V-Y>=X_27P?JWAC6]%M-8\)QZ>VF3KULK2WM7
MMYDPDUM<10)&\%Q"<(T<P\Q1@AW0JU>#GF:?V="*J9;'%4YQ356I:,$]=.=J
M5DK+6_71'\W^.OBU+PXI4(8[PSI<3Y3F4)4Z.:XNGETLKI8J+FI8+$3Q>58Z
MK0Q7+RSIJ2A&MSJ-"<Y*27Q==>,_VB8?#5U+>1^);?2#%MFUF;08X-0@B8C?
M(+U+6*2,E3Q,44Q@EGE0Y<?/;S/<R27$DDL\TCAI9II#--/+(>9))9&:9I9<
M[Y//D8G.58Q%17Z]LQ?<64.7#!F<%BRG@J025Q@D, ,,#A@02#X?XM_9[\#^
M,M3M[]+FZ\%SS7MNVLZCH>FVVH1RZ<TR+J$Z:#-<:=:3WT,#%[=%OK)+F4JD
MLD8!EKPLNXGR^G4J.M@Z>"C*\E*A:M)<J>BY4I>]HNCV/PSPF^D[P%@,VQ>#
MSO@/).!:.95HJ.<\+X/VM)7DKRSN-6G/'U(WE[U;"<M*DHRE+ QIQ]W\\&C2
M5=CHCJS*H4F)U8L2W(+%'0,N)5W>Q'<>[?!C]J3]HW]GK4K>?X%_'7XL?"^\
M\Y%M]-\&^,]7MM)NI)"%2(^%)+BYT34I)ES##:7^BW3;)9(X(SN6OZL/V"O^
M"*G_  2P^-'AFW\7/\9OBC^TGKMI##)XD\%ZUKUG\*I= F94:6V\1^ _"B0>
M)HX1)MBM[[_A)+S3;J$>7#<W2,[5_0=\$OV%_P!CO]G2.!?@M^S=\(O EW =
MR:WI_@W2;_Q.6( =V\4ZQ#J'B-FD(WRYU(+)*3(R[BQ/P7$WC+PK2^L8*/#^
M,SBK:5*K3S+ X+!T%RN2NIX^GCL0T]TXX9)K6$KM-?Z4\,92L_RW"9YDW$&"
MQ&6XZG&M@LRR?'4,PP]>E*,6I0K86M*C[1)I5*4I1K4I)TZE.G.+@OYJ?V'?
M^"F/_!=+X@'2K=_V/;S]I_P>[6T#^*O&OP^NO@1,ML"BO,/B#='PWX5NYXX?
MG/F^'M0NYBWFR/(T@4?U:_!?Q3\4O&/@73M;^,/PGM?@QXXG)74O ]EX_P!'
M^)5K8@*I62'Q1HFG:59W0<LP:/[%&T3*1ND4AV]3,*,%W9(   X 'T&/E(XQ
MC&,#'04Y$5,[<\G)R2><8[^U?SAQ#G>"SK$NM@>',HR&FY.3AE\\=.<M_B]O
M6="[O[WLZ%-7^!1C:*_4LOP5;!4E3K8_%8Z5OXF(<-'9:)*/-;1VO)CZ***^
M>/0$)P"<$X[#J?I7S-^U3^UM^SQ^QE\*M:^-G[27Q/\ #_PP\":);W"P7.L7
M2-K/BC4%1'A\-^#/#L#OK'B[Q'J3M%#8:-HEE=WK,QDF%M:>;=1_FC_P70_;
M2_;X_88_9;D^.G[&_P ,_A7XQ\+:--<6/QI\>^,;;7O$?B7X+:3?7%K:Z'X[
MTKP)9RV.B>(O#QN9GL-<U;6M2-EX5NYM/U'4]'U+1I+V2R_CD_90_P""7W_!
M4?\ X+J?%+3OVC?VI?B7\1O#OP8NSYDW[1?QQMKN4WNB7%S+)/X?_9T^$[_V
M/I\]AL5_LUYI.G>'/ 5H'$DVJ:O=1_86QJU&FH0ASU&KQOI%6U=Y=++6W78Z
M:6&]I'VDZD*=).TFY+G?=1CNV^RUZG??M2?M2?MA_P#!S'^VQX#_ &9_V;_"
M.M?#S]F7X?ZW_;VB:3K3&72/A_X4-S-I>K?M%?'F\L))]/7Q?)I,MWIW@GP;
M:75X;>XD'AS1'N]1U/7-5/\ H"?L;_LF?"3]B#]G'X8_LR?!/23IO@3X:Z##
MI\5_<)&=:\5Z]=,;SQ-XV\37:J'OO$OBS69KO5]5N'9DC>>.RM%AL;2UMXN#
M_80_X)]_LS?\$[O@Q:?!S]F_P6-$LKV2UU3QUXWUAXM2^(/Q0\30VHMF\3>.
M_$7DQ2ZE=A#*FG:9;1V>@Z%;RR6NB:780R2K)]LK$J@@9Y.2>,D\\DXR>O?I
M@8Q4PHN_/4?-.2N^T7_+'R7W-KMNJU=34:5*/+1IW4>CF_YY+N_G9'\_/_!?
MG_@D8O\ P4D_9RB\<?"C2K$?M;_ #3M;U7X4S2^3;)\2_"=\R7OBKX.:Y>;4
M=AK)MO[4\#7%Q.MOI'BU%MR]I8:[JMROY#_\$&?^"_;Z$?#G_!/K_@HIXFG\
M(^(_"%P/AS\$_CM\0;B?2)8+S1IVT2#X+?'JZU62.;0_$FA36L>A>$_&FK-!
M#>?95\.>*9;35[2RU'5O[?R@*%-S*#_$K88>X/8U_*W_ ,%S/^#>GPU^V_>:
M_P#M3_LB6WASP%^UA/9R7/CWP)>FRT3P%^T=):P*D-WJ5X8UM/"WQ7:WBCLH
M/%5PJ:-XN\NPM/%[V]S;0Z[&JE.<)^UHJ+FW::;LG'RTNVOO?1WT=49PG3EA
MZ^L6[TJFMZ<NS[1EL^BZZ;?U/V]Q#/'&\4BR*Z(RNC*ZNCH'C=)$)1TD1E>-
MT8JZ$,I(JQ7^>1_P17_X*5?\%;/V>?VLO G_  3!\7_"#Q9\=K*RUE_#.J_!
M?XYR:IX'^(W[.GA'1/LTOB#Q5I?Q+O[#5[NV^''AC24DN;72M>LO%/AZ_1K#
M3/!&JV[:EIT$W^A=;3/,'+@+M( &T@@XR<DLP((PRXQA6 ;Y@<:TYJ:;2::=
MI)JWO+?UW_X!C5I2I249.+37-%Q::Y;V5[;/3;[K[G\UW_!UR ?^"3VI]!C]
MI7X%D'G@_;M?Y&T$YY., DDX )(%?7O_  0#_L>Y_P"".O[!EA<G2[FX;X0Z
MD&LY6LYY75/B'XU&3 Q9F4$-U7@Y!P0P'PU_P=I^(8](_P""6FD:;-=65LWB
M+]JCX1:?&MTV'G.GZ-XZU_RK3YU#SJFEF>5"'#VD5R"%&67\F/V ?^#9#P/^
MU]^QQ^SQ^T]=_MT_'CX:7WQH^'6G>-KKP3X6\*:'<:#X8DU"[OX7TS2+R7Q#
M8SR6B2VS3*\EM S22RYB7=Q@^;ZQ5:CS>Y!6;LM^]GM_6QT+DEA*7--P3JU&
MG%7>RM>-T]=K_(_O2_X1_02.=#TCH.#IMEQ[?ZDCC\JK7'A+PK=E3=^&?#]T
M4!"&XT739B@8Y(4R6S;02 2!C)'-?QN2?\&@6EB1Q#_P4L^/31;V\LS?#V!I
M60,=GFM'\1%C:3;@LR(J%LE5 .!>M/\ @TEUW0+6\_X1/_@J3^T%HEW<A"1#
MX,O+.RFFC!$;WD.G?%"TFG,:LZQL)0R!V (R<Z<T_P#GRO\ P-?_ ")E[*C_
M -!;7DX33_-G]@5WX*\&Q6MU-%X,\*&6&WGEB#>'M((:1(F9 P%H#C< #@CO
M@]#7\+/_  :7RO<_MW_\%*KF6...6X\'Z3.\<:!(XGF^//Q"DDB@11MA@1SL
MC@7'E*BJ0%$=?2-S_P &I/QIBMYYI?\ @K3\;BD5O/*V?"?C'RR(XF=@Y'QF
M9O*.TA\98H3@,3BOE/\ X-!M-.C?MD?\% ]#:X>\?0_A/X%T62^D5D?4'T?X
MN^-=.&H.DDDLJRWR6J7<RR/(RR3,C2RNC2&.:;K4TXV5I/=/ITLNFVNYT1IP
MAAZ[C7]IK3NHQE:W,K-RE9]]+:/0_OQ(+)@$@D#!'7L>Q&,],YXS7\W?_!?[
M_@FW^U5^VY\,=#\0?"O]M6V^#WP3\$+;:E\<O@C\4=73P;\ K?P-H_GZAXG^
M,VO^)O"NDGQ/K=WX'TN.?5]0\)^+7U_1-0TZ"Z;0CHVJQ1"]_I"D=DA9U&YE
M4$*,9.,9 R5&2,XR0,XSZ5_%C_P= ?\ !3C4M2M-#_X)2?LUWU]XI^)WQ/U/
MPO\ \-%CP5%<7VJ+I^NW]I_PKW]G^PBL_.ENO$/C_6)]*UOQ7IMI-]JM-#MM
M$TF\*VWB2_MUUK-*G)N[2W2O=]M%YV_$Y,+"4JZ4;)I\[;M915VWKU2V7>W2
MY^U7_!'G_@EE^QO_ ,$^_@MH?CKX!>)]#_: ^(?Q@\+Z=J?B?]J]I-'U:?XA
M>'[Q8+RVTCX<S:1/?Z5X9^&ZW$:7%OH>D7]W=:C>(M]XEU35+V&U-I[+_P %
M6/V<?CE^V1^S%XO_ &>?V8OVM;_]F'XT:YH.J>(8-+TN\TJPD^*W@^"W.FZE
MX)\4:C;;?B'X0\&:Q=WEKI^H^,/ UW9O97-PEAK$>J:==S6#\#_P16_X)R7_
M /P34_8H\+?";Q?X@U37/B_X[OT^*?Q?MWU^_P!6\)^$_&NN:?9I)X'\"Z7)
M.VC:7H7A*RAM]&OM1T6RMI/%6N17^O7LUV;JU$'\H?[<NN^/_P#@CO\ \'%_
MA']I:;Q)XJU/X,_'37=)\>ZA)X@UG5-=27X&?&344\(_&CP%#>ZM>W0BTKX?
M^*K*\\3>'M.B=(--@T_PJL44ALXF.<E:FGRV4DD[732E:]TM=+O3>^[NK&L%
M*M7J-U.:2YG3NDU)T[V3>B2:6FEG9))7N?LC_P $7?\ @AU\.?\ @E[X6O/V
MT_VY=?\ AQ_PT?I7AV^OA<:GK>CM\+/V7?"]W&Z:S-9>+=0:STG5O'^I6SO9
M:WXXC^S66EV<\^@^&A-%?:AJNJ_T]?#_ .('@?XJ^"?"_P 1OAKXKT/QQX"\
M;:%IWB;PEXO\-:A;ZMH/B+P_JUNMSIVK:3J5J[V]Y97<#!XIHW8#E6"LI4?$
MO_!2K]A+X??\%)_V,OB7^SAXDU);*Z\5Z7:>+OA5XUCGGDM_"GQ,T&VN+[P)
MXFEBM9(X]5T*6XN&T_Q!IMPMQ;ZEX>U74HXD2[-I<P?R]_\ !LE^WQ\1/@3\
M9/BG_P $>/VH)Y]"\1>%/%/Q!D^!.FZ_=1I-X1^(7@O4;^3XO?!2TDNO+N)]
M+U(VFH^/O!$;8RT/B?[';FUU&R6*8_N90C%6A.ZC>]V^M[]_YFWTZ:#<77I5
M*SE>K3DN>&B]VSM*/>VVB77J?J=_P6>_98_X)L_\%&?B'\,OV0O'O[0?PQ^#
MW_!1K5K#Q /V<?$>F7-IJ_C&%=*L9]:N/AU\4K&PE19O"GBL1W,VA>&-;O\
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MOX*_^"?8'_$6W^U]Q_S-?[7?_I@\,U_>H.YR#D]OH/?]/\C^"+_@F[=)K?\
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M_9+_ &K?$L-O\>;"VBT;X5_%#6+A+>T^-.GV,9C@\,Z_=3&"&#XJ6,,16*Y
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M6JM<306"3S11LT\L:Q*7(FW>_=KY#[>E_P 6G^*.DJ":5(\!QE<$GY2W'48
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MQ%S_ &BD[VK0-YZR"%6>CV=/^2'_ (#'_(:JU5_R\G?RG+Y_:/RHE_X(,_\
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M6RTVZT>S\+SVNGWOFZAHNCQ62Z3'I^F17USK6ISV/V)_P56^#OQ:^)/[9O\
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MIZ*+DK][;:'X<?\ !3S]JC]FOXB_\%F?C+X+_;Z_9T_:H_;#_9K_ &0?AO\
M#SP7\$OV=_@'X5O_ !=X$L/BKXXT.T\7>/\ XD_%S1++Q)X;^T7&HVNIVVE>
M&MUXXU"'3(8;N*2WT6);K&_84_:(_9I\'?\ !7G]DS7_ /@FE^Q7^V=^QQ\)
MOC_!XN^"/[77PJ^*7PSU[PO\#=?TNZ\-W6M?#CXBZ#;KX@\7V6A^*/"WB;2F
M75KB^FTG3WM+NW?3W2:]UNWU#]<?VS_A5^WI_P $_O\ @I#X\_X*:?L2?L]W
MO[9/P5_:6^%W@KX=_M<?LU^#M4CTCXG:9X@^%MK/!X0^(?@:$6U[=:H\FEQ&
M$3:9I/B*[AO+[7=-U+0FMM1TO4=.])_9$_:$_P""N_[='[9W@'XP?$/]GKQG
M_P $WOV#/A1X-\40>*?@S\78O#^O?%C]I+QIKMM]CTJTO+;6?#>G^(?"^E>'
M+R&+5X]7L=(\-+96-O<V,=UKMQKJMI^=FW97^._P[I/^;>UM']UM31R7+HDU
M[/EUG9)\MG[EM7?5/YW2T7R?^V9^R#\,/VV/^#CCX5_![XVZ0?%?P2T__@G9
MI_Q*^)7PVDU'4--T+XI)X+^*OC.U\#>&?&4>E7=E-K?AC1O%_B*T\4/HUS*U
MK/?:;:N\6(Q(NE_P7&_8DA^"'['/[$_P[_9I_95\8_%/]@/]FO\ :5U+X@_M
M0_L=_!'6/$EGJ?C/X::NFJZ[8&1K!-:\2W_AO1?%>I^(+K4;N0:A_8RZMI\E
MQ]GT^T&HZ9]T3_"'XL/_ ,'#^B_'%?AGX[?X+1_\$R;OX>O\6T\-:D?ARGCM
M_C2VLQ^#)?%BVYTF/Q2VD^9J2Z&]PEXUAMNUC:,$U[#_ ,%8[W_@I;X(\,_
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M_P""-/[#?[%O_!-7Q#^TS^S;\-M1^'/[2O[+OC;X*^.]#_: L_%OB:]^*WQ
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M).AWGQ_?6? 'Q!\-:KX2\8Z<NN?%_P"(.K:*][H&L6]OJ-LFK:9J%I?:<\L
M6\L[JVN;<21S(3;_ .#>_P"$_P 5O@=_P31\ ?#[XR_#;QM\)O'-G\9/VB-5
MO?!WQ%\.:EX4\4VFEZY\8/%.JZ/J%SH>JP6]]!::UIUW#J&ES2PHMSI]Q;W4
M9*R*&4*5N5O=1:>O5JS]=Y:Z[E5*C:K?#K6A)-):*,.72RT5TM%ILSY__P"#
M>9_%_B__ ((R/X#3XHZUX2N_"7CS]JWX1> ?B5>O;ZIJ7PO\.Z+XP\1:;X:U
MBTCU&]M[%XO!0O7U73K2>YLM,LQ:0VRK#90*U?B3X<L/^#7/]F?X5WGP&^,V
MMZA_P4<_:;U*Z\7V_P 3?CI\+_AE\6O'7Q*\>^.=5GU*YN-3\):MHFL#PKI,
MUF);9+"ZT77-:TV^U!5U*]U+4OM4SC]=?^"9G['/[1VK?\$(_P!J+]D_Q!X.
M\9? /XY?&+7?VVM \&Z9\3]#UKP)J]H_Q'UW7K?P7KEY;W\-IJ5CH7B2*Y@>
MVU:)&@:QO&NX9)84.[Y)_8P_:"_X*=_LZ?L^?#K]A[X#_P#!!"X^%O[2_P /
MO"6D_#M_VG?%4GA?PG^SRFOVL2Z7>?&7Q/XI3PRX\5W\A9_$VK1Z9\0=9?6-
M4,XLT?3Y8=/2&G"-.,M6HN^CFKWV5M+M;7Z?,K^(ZDH223JQ=G*--\JC?FN^
MB>EE>SUMJ>[?\$7/VC_%'P0_X-WOC;\;K"^US66_9IM_VS;_ .$]AXDN);K4
MM#T'P'+KFO\ P^\,72S-=K%#HEU=V\#V(_T/3R);**!;6W1JK_\ !,W_ ((5
M?L&_M(?\$]OAK\;_ -L/X7C]HG]I/]L?P-=_&;XK?'?Q?XH\1OX]TG7_ (IF
M_P!<@;P+J-KJ%O!H,^A6UU;7$%PUK=S7FLI<2W[W6G+;Z?#[]_P1/_9$^+%A
M_P $M_VIOV&_VQ?ASXQ^'7B/Q-\=?VM?A?XLNO$7A?5-"L_'7A?XK6$4%[\2
M_ %SJ%O8P>*?">MZCK>N77A_7=,6+3[N.R1+?"!9&^0OV=OVG_\ @LY_P3"^
M ^C?\$\M1_X)8?$+]KWQ-\(K?6OA]^S-^U#\+?$YN?@WXE\&?;+V?P#J?Q,:
MWTJ]72XM)M[RV2ZM-1\0>"[R#2K.+3;R*TNK.349Y@VG3;O:-*<7H_BE)-::
MWNMGW[#GK*JJ;BI.M&:::7N*#B[.]M'>Z3VN[,][_;ET7X_?\$=?^" OC/X*
MZ%^T7XL^+_Q'T'4O#_P!^''QLBT-O"_C+P1\/?B]\0X=&T_2M'A;5]:N;G5_
M G@J]U7P[X7U.34X;IF?2X].?2FM;(6WX!W7C+_@A:?V:6^#EG_P2._X*91_
M%:+PA]DM?VH!\']23XUI\2EM?/A^)3^*D^)301Z@/%7EZI)IL&C+I(MQY,.E
M; !7],S?\$M?VI_VA?\ @BQXP_8\_:Y^/&K>-?VT?B=>ZA\<X_'?BGQ1J'B[
M2/A7\9X?&=M\1?A[X"T;7I9+J7_A$/!4VE6/A=Y[#[78Z9+>ZM>:.M_:6]DU
MU\LVW_!37_@NUH?P@7]E>\_X(^?%W5?VQK/P@?AW9_M/V7BJUNOV=+K7+>P.
MA6WQ8N]4ELW\,37\L<0\1R6K?$E=)EUJ027,5M:[]*%2Y9/7F6C7P\WG:_1[
M?=OHT*+]RT&N=5N:;YU#F5E9VV<5[U^W9W-B?XV?%_\ :*_X-7/B_P",_P!H
M*T\4-\7K#]D?XH?#SQQ>^.M#U/1/$OB6Y^'/B:Z\(:5XBUS3-<M;74SJ&N:#
MI>F7M]>7T!EU2_ENM3ED<W98_KM\$5C'_!'7X:0!%6+_ (=P>'P(]JK$$/[.
M<"A"#A% 4D%3A0N>P-<MXM_9$_:@^-__  2*\<_L@?M(?%_2_BE^UG\3/V8O
M%'@GQQ\3VM=.T/PYJ/Q4UO3KN^TZQ/\ 8>EZ9:_V!H^K#2O#-UX@BTR"?6+.
MRN->FLTENG@3\4O@Q^T+_P %HO&?[%]M_P $N!_P3&\>?!WXJ^#_ (!7W[/7
MB[]LWXB>(2WP2TOX::#X'N_",_BKPKI&G:9<?\)[\2-8\*V\.F^&-'\(>+M=
ML;WQ1>PZBR6FG+<VUHU)0F[\UI4N5:/XOQL[+?R?8E0]KK%P3CB%4E>48KDY
MKMJ]FU=-66KNM-3K?V9_V9?@]^TU_P &I'PG\-_&+PQ<^(-&^%G[*_QY^/G@
MRVL=:U7P^=(^*GPEU3XZ^(_!&NS/HUW8S7T6E:QNNI]*NWGTK4</#?VMQ&RB
MOJG_ ((=?L>_ 3]GG_@D9IWQL^%7@^Z\/?$3]K[]EW2?B3\>=9N/$FO:W;>+
MO%^@^!_&EEIVHV>E:M?7.F^&H(K?7=2#:;H%KI]@[7/SPR&%)#Z=_P $W_V;
M/C*G_!O=X&_97\5> /%7PW^-OB3]CW]H[X5+\/\ XD:/?>$/$WA_Q5X\N_B[
MI7AG3O$FDZY%9WNCM<?V[I-QF_CAQ8W4-T3Y3JYXC_@BWX\_:EO?^"=?B?\
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MU'P%'>2>,K+X&_M]W/AZ.R'^EG4D\:?& PB +(C"7:[%'212F"=P(!K]!_\
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M43O/X4OKTZ%JCKY::[X2OTFO/"^NV\FU5D%WICQQW6TEH=2M[RU.&MG [_\
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MY+R9$.Z/PK\2K"?PQJ1E(!W0KX@M_"I <^2@>1F*Y+#^DD\C\1_,5\A?MY_
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MRY8I)7DVW9+:[;;LK7;LD+11161J%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !494DDX!]/PZ<'O_A]*DHJ7%2O?O&7H
MXVM;JMK/R;"VJ?;[OF(!T) S].YZTM%%4 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ +4# 2(  A$! Q$!_\0
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M?-T[47![#?O3_/YU!%KLMG<BUU:(1,?NRK]T_P"?6L*>[M&99-'CO(KH_P
MY!'YYK3U"X=_#DC:W;*DO2'! 9F['';WJX5EJZ6C6NEW!_?LRG3V4M;_ 'G3
M@AE#*001D$=Z6N>\)+>KI>ZY;]PQS"K?>Q_A70UZM&I[2FIM6N<TX\LFBIJ@
MSI=T<LI6)F4JQ!! .#D5E^$6>;23-++))(9"-TCEN./6M>^C:;3[F)!EGB90
M/<@UA^"YD;2)(<XDCE.Y3U&0,5,OXT?1G73UPD_5?J:-]&#J^GY=PK&3<H<@
M-A<C(J0ZWIH,H^UQGROOXR<>WN?84VY(DURQC0@M&LDCC^Z",#\R?T-96BJO
M_"5:NVT9!X..G-)R<9675_H$:<9T[S^S&_\ Y,;EIJ5I?6S3V\ZO&IPQZ8^N
M:S=)?3=/M+N:&^DGA\S,DC98*3]!^M5?"8 N-5 & )^GXM3/",23Z?J$4B[D
M>4JP]014QJ.;@[:NYK.A&FJB3=ER]NO^1T$5_:S637D<NZW4$E\'&!UI)-1M
MHUB)=F,HW1HJ%F8>N ,US.D+<1377AV0,567<7_Z9=3^?'_?1J0/_P 5K=17
M%Q);EX@L+(0,C ..1]?QIJNW%.V^GS)>#BIR5[I*Z\UI;\_P.CAU"TN+5KF.
M=#$F=['C;CUSTIL6I6LLB1AG5I 3'OC9=X SQD<\5F2Z180P7\"W4BR7(!E9
MV!VDMP3C'4G^=4[2ZU/2]0M-/U2-9X6?;!.O)!Z?U[^M-U91:4E_5R5AZ<U)
MP?R>CM:^G?\ R-*WU^&YU>2S17"1KRQC;);([8X'UK8KF-(('C#5LG^'/ZBN
MGJZ,G*+;[LRQ5.,)I171/[U<****U.8**** ,JT5;C4;J^D^[$3&F>V.I_+^
M9K$FN+DSKK#$B,3!%7OC&<?EQ^=:=K(Y\*SR-P[))G\R*HZE;2OX5M)(1E$'
MF.._/?\ 4UX-6,I4DUO9S^;>GW'5"W-KWL:VKZI%81PF6W$\$H/?Z=L<]:R3
MJ>BG+-I#Y]/*7!_6DU:0OX=TER?F+H,^ORG_  KK*[4IUZCU5K)ZQ3W1/NPB
MM._4Y[3M?M[C4(K&TT\PAL[B<+M !/0?2N<\9:D]SJQMH\E+88P/7J3_ $_"
MN@1@?'TBGM;9'Z5F>&]5B3Q9JNGRQ?OYYW*N!_=+$@UG.,ZD/93EO)K;MY>I
MI&T7SI=+_>:VFR6NN:#97MP67[(=S;#C#)[?0 _C6U9W45]9Q74))CE4,N>N
M*YSPD$:+7(E7]Q]ND"H>@'3'Y5;\%.S^$[+><D;Q_P"/FNRC+X5U:_+0QJ+?
MR?YZF_6%=6^BO?22'S%N5_UCVV_C_>*\ UNUQ6GZI/X9GFL]2MG,3R%Q,HZG
MIGW'%56DHVYMN_8VPE.4^9P>JZ)VOW^[L=/IB:>(';3V5T9L/(&+%CCNQY/6
MEM]*M+6XDN(8V663.]O,8[L_4U#;WFG6^G7&H6\BFV=C*VW^\0 1CL3Q^=49
MO$C6T-O=3);M!*0&2*7=)&",C([T<].*7-8%2K3E)0OKIKN^MC4M=*L[)I6M
MXVC:7[Y$C<_F?<TZRTRTT[?]EB,>_P"\-Y.?S-0SZF!J$-A;*LD\B^868_*B
M^I]?I44&I7DEU=VDEJ%EA4LDN#Y;CC\NOOW]*J]-.R1#C6DFV]]=7TV-);>)
M;A[@(!*ZA6;U SC^=5M0TFRU,+]J@#E>C D$?B*H6&N37^A7.H+#&KPEOD).
M"%4'^M+'KTC>'/[5^S!B"<H'QC#8ZTG4IR6NS5RE1KPE=:-/EWZEZ+2;&&R:
MS2W40/\ ?7GYOJ>IJK8?V9<WT@@>2:>T)4>:S-Y?8[<_3K4=EJVHW<EJXTW%
MM,FXR;^G'Z4FDZD;V\U*.*RAMY86 8YSO;)&20/:IYH-QM^7ST*=.JHSYG^*
M[VU_+_@%V31K"6_^VO!F?N0Q /U'0U);ZG:75Y/:PR;I8#AQ@^N#^M8_AN^O
MK^2[GF,3+YNU@,@C X"]L5:TS45N=7OH#9QV[Q ;W!!+GW.*(U(NSCI=_>%2
MC-<T9N_*EUVV_P ^ALT5S[^(R]K-=VXMC!$2 DDN)) .I [>U3R>(8##I[Q;
M5^VD@-*<*F.N??/%7[:'<R>$K+I_5K_D;-%5K:6X>26.XC12A&UT)(<'O[?2
MBM$[F$E9V(8+'99W%G(ZD2E]H!Z*:XF75=3$1T8XP'\O&/FZ_=S]:[6^6ULF
M?5I5<R11[?E)Y'88_&N:T2.34+VZUZ:+S3&24BCQDMCT]A7DXJFW*%*#L]5I
M_+Y_Y'52>CD]?\R_KFFWLECIUE8PF3R0-S9  P !U_&GE_%A&1%IX/H<_P"-
M9 \4:MK5X]GIYM;%QP/.<;CSVR.3]!45OH?C"[U#;>:G-;6XY,J39S[!0?\
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M]Z -F6:.!0TC8!..A-1?VA;?\]#_ -\G_"K-% %;^T+;_GH?^^3_ (459HH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (J H # 2(  A$! Q$!_\0
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MJE\NEZ9J.IO&TR:=87E\T2L%:5;2WDN&C5B"%9Q&4#$8!.2" *_/'X._'?\
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MY'_S84?\-W'_ *,T_;S_ /$>1_\ -A7WG10!\&?\-W'_ *,T_;S_ /$>1_\
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M (:4_:\_Z1Q_%3_Q(?\ 96_^>G1_PTI^UY_TCC^*G_B0_P"RM_\ /3K[NHH
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M6WF&5+*\N+FZN;JUM+2VMI99YU  ;P/_ (;N/_1FG[>?_B/(_P#FPIG[>/\
MS9E_V?M^SM_[N%?>U 'P9_PW<?\ HS3]O/\ \1Y'_P V%'_#=Q_Z,T_;S_\
M$>1_\V%?>=% 'P9_PW<?^C-/V\__ !'D?_-A1_PW<?\ HS3]O/\ \1Y'_P V
M%?>=% 'P9_PW<?\ HS3]O/\ \1Y'_P V%'_#=Q_Z,T_;S_\ $>1_\V%?>=%
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MNPUO3;JY +O_  W<?^C-/V\__$>1_P#-A1_PW<?^C-/V\_\ Q'D?_-A7T5\
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MHRW,.NV4FJ+9Z6IL[]-#D@?X>_8)_P""P'Q*\'_LS_LG^%OB5I?B3]H[Q_\
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MB?%']GJ\^.?@+2KG7_!/P2\0>)H?'GC"^TV]\":+I\?@&?P/97_DZQXK\?\
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MX4:#XYU/3XO WC33/%/QBN[NS\?Z3H/PY*O8_&75KK7M"UOP)?#QCXW\0/\
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M&L?AUIOC[PUK/C5X;'X:^$=&\$:9#X<U;Q1J6L:/+XBT+PYXL\>:!_PF]_\
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MO_F\H_X;LG_Z,N_;S_\ #!Z=_P#-Y7WG10!\&?\ #=D__1EW[>?_ (8/3O\
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M^B@#X2_X:1_:^_Z1S_$O_P 2*_9?_P#GCT?\-(_M??\ 2.?XE_\ B17[+_\
M\\>ONVB@#X2_X:1_:^_Z1S_$O_Q(K]E__P">/1_PTC^U]_TCG^)?_B17[+__
M ,\>ONVB@#\S_A]^W'^T;\4'\=)X/_X)Y?%FZ;X<?$/Q%\+?%8OOCW^S#8?9
M?&/A:'3;C6+2TW?$R7[9911:M9-;WZ^6ER)'*Q*$R?0_^&D?VOO^D<_Q+_\
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M/_PP>G?_ #>4?\-V3_\ 1EW[>?\ X8/3O_F\K[SHH ^#/^&[)_\ HR[]O/\
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M:W^"OA3Q5\(?"G[1W@CXA>&O$/BJ/2=8\)>/M?E^$5EX?\,:O9WD$3V^LZW
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M_P#AVK^Q]_T(_P 1O_$E/VG/_GQ4 ?=U%?"/_#M7]C[_ *$?XC?^)*?M.?\
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M?^&GQ&L/A]IJ>,##XIUF+Q1ID_B'2_#_ (J_X1\:_HFFV6KQ-Y]U;VZ?J?\
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ME'_#R#]E#_H._&G_ ,1'_:Z_^<97W.[K&C.YPJ*SL<$X5068X ). "< $G'
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M@\3:]\*V^!/[2_@WXKZQX$7]M7Q'^SMJWC+26\6>(!9_"CPQI'P/L-.^/_\
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M1?P1U?X/65A9:?X=^'WB_2)=!T=;^+5=9;5;H3:C;M<Z;%IVW;/+^5?[-?\
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M^-GAGP=I5C\4K[X3^)O"?B6TU:U\#QZGJOC'1_$/@+Q1H_C+PYJ%G;:/XO\
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MM2U^Q%SX?&DWFH:7JVH7UYI.JW%]ILMU<?91(WN] 'XO>%_^4+/[57_9'O\
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M??MJP?$WXU^*O!OA+PIJEEX4^'=I\#?BK\)K?5?'%_K&M:/?W=K!KWQ2\/\
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M+GXF?MM_'CXL:9\3[?PI\"OAYXO^,?C'5?V<OA5X _9:\;^-]/T348/"MO\
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M  40_P"CAOV-O_$/_C3_ /1MT?\ "'?\%$/^CAOV-O\ Q#_XT_\ T;=?:=%
M'Q9_PAW_  40_P"CAOV-O_$/_C3_ /1MT?\ "'?\%$/^CAOV-O\ Q#_XT_\
MT;=?:=% 'Q9_PAW_  40_P"CAOV-O_$/_C3_ /1MT?\ "'?\%$/^CAOV-O\
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MR>,M,_X1;1]?O-1\ >/]:O&T0:3J&IZ;XLOWETW6?$FM^(H]?F^$_P#P3/\
MV^?%W@WX;^(M#^.OQ9^#OAK1OV9OV@OA!#\)OC%^T9\4;KQE_P +4^)TGQGT
MN/XO^,]6TOP)J^K:SH_B#_A-_ VNZ3X9L[KX9>)/A6/AOX5A\+7$\=HL,X!^
MY_PK_8C^ OPBM?B!IOAC0=0.A^._AGX/^!EMH4FKW]K8>!/@+\/M$UC1?!?P
M:^']QID]CJ_AOP?H?_"2^*=7CFAU23Q!<:[XDU#49]9)@TJ+3LT_\$]_V-S\
M'_A+\ 1\"_#R_![X#^)7\8?![P-'K/B^/2_A[XD?3_$&DKJ?ANXC\1+J=I);
MZ;XI\065E;M?26FGV^J7$=C;VX\OR_P^^%7_  2/_P""I_@NW^+MA=_ML>'=
M#7QY\!/C/\+O"VL0?M!?M/?%:^\*>(O'WA;X)1^&+^'2_B%X<T[3[>"S\<?#
MGXE:SJ?BJRN!XLT:V^-FNS^'$)T"QTF_[SPA_P $G/\ @H)X>^.OP(\;W?[5
M\>H?#?X?^ ?AWX ^(.EZU^TO^T3X@\4^*-'\/^!_CUX.\6Q-I>G^ _!?P^\2
M7^IQ?%+P$NC>)=3T#0->CLOA3HDFISW.NNFMP@'TY\5/V'?^")_P)TSX._#3
MXE? ?X:Z'HO[0'Q:T7PQ\'=%MK+XQ^,M*\;?%FU\,6_A'0=&TS4O"UYXBL[#
M4;7P?IL6FZ=;:I?Z;IEOX?\ #LT\(2P\+7,^F>\6'_!/7_@F'-\7OC/\/[7X
M ^ [KXO?$CP OC3XQ:3=77Q"O-1UKP3\3/BO>^,H_$<U_?ZW+I=A=ZW\7_A]
M=>)X-0\.WMEXCTWQ/X=@U>%[!TM)Y/F&P_X)U?M7> ?V4O\ @EI\&_AW?_L\
MZK\0?V$?BWX:^+GQ.N?&7Q-^-47A3XCZSX0\ ?$/P)%%X6\1S_#SQGXKMW\8
MS_$.^\5:W/KND16WAN\M/[$T;3]2TZZ6XM.._:@_X)W_ /!1S]H7Q?>^.+?X
M\?"CPGJ7BCPM^R\OC#1/!_QT_:<^&WAX>)O@]\6_B3XO^)VC>'+?P7X>":9X
M8^(OPQ\;:'\*+K7K>TLM<UZR\*1:WXAT>*\O88]. /LCXS_\$[_^"8,NJ>'X
M?CC\!?!NMZQ\;/B/X)\+:3<>,-6^)OB?4/'?Q(\.?#O6O#7@NSU/49?$.ISW
M.H6/P\T75=,@O==N8[.:STV#[==37UOI[K]K? SX%?!#X&Z)XK3X%>$]'\+:
M%\4_'&M_%_Q5<:'JVJ:U:>+_ !SXSBLI-<\:S7^I:IJWVF]U^*SL99[FSG2U
MN5BBECCYW'^?_P"%/_!)O_@I;X?\!>$_!/Q&_:W\,^()=+^+OPS\:^(_$4/[
M1?[4GB'6]<\*Z#^RU\0_@%\2M,-_K?A[3;EKGQQXI\0>#?B!!H,LJ^'K.X\.
M&8RQ^(K>#7;RSX$_X) ?M^>!/#=MX9\-_MAZ=X*T+2OV#_ '[+_A?P7X.^*_
MQAA\!>%_'/A31]&L_&U_'IM]X.;Q+J&@_%77M"G\4_\ "?:/XL\&^._AE>>-
MO$>F:%H7B;2M(TB"Y /Z$?@Y\;?A;^T!X-D^('P?\7V?C;PC#XH\8^"KC6+*
MSU73UMO%GP^\3ZIX,\::!=66M6&FZE:ZCX<\4Z+JNB:E!<6<9BO;&=%+H [?
M-'_!23_DT;Q9_P!E5_9<_P#6J?@M6/\ \$S?V5OB-^QM^S"/@K\4+[P-?^(E
M^,?QX^(UJWP]\1>,_%N@V&@_%OXK^*?B1HNB2^)/B!HVA^+-=U;P_:>)AH>I
M:UJUFUUK4^GG5[B=KF^FCBV/^"DG_)HWBS_LJO[+G_K5/P6H U?%7_*1CX$_
M]F4_M8_^KT_8OK[6KXI\5?\ *1CX$_\ 9E/[6/\ ZO3]B^OM:@ HJAJMS>66
MEZE>:=ITFL:A:6%Y<V.D17-M92ZI>06\DMKIT=Y>O'9VDE].B6R7-W)';0-*
M)9W2)'8?CO\ L;_\%I_@/^U=XA\9Z3XB\#ZK^SSH/@;X<_\ "QO$OQ#^)GQ1
M^">I_#SP>O\ PM[6O@G#X%^)WBGPCX]U>P^%?Q,UCQAH5[>>%/!/C=],U/Q7
MX7\OQ!HWGVY,2@'[+U_/_P#&G]HS]GG]G?\ X+;>)/%WQG^/%C\/_!OA3_@F
M1)XUU7PUK_QA\1VGA=_BR/C9)H]J-,^%3^*O^$9UCXI:M\(X_)T30M+\*W7B
M_6M&D@O],LKJ6:*[;] KW_@I?^R-HWBW6- \1?&+X7Z+X=?Q9\-_ OPY^(8^
M+OPGUKP?\6?%GQ'\(>(/&-MI/A:?P]XTU74=(&A6'AN_@U:_\96'AS3YY3'/
MH]SJ5D7N5X/XB_\ !3S]G/X?_ KX<?&[Q#;Z%?:YXNU+]G!O&?PBTSXG?!+Q
M!\3/@[X9_:-\<>$? 'AKXA>.TT7Q[JN@?\(7X9U/QKH=[K7B70M<U32;G1Y6
MOM O]4B: S '\\_[>O\ P4K_ &N?$/[./[<?PB\:>-/AWX36_P#C+^W3X7\&
M>,M-LOB7\*O&_P ,M'_9K@^$%]\"_@OX+\1^#?B%HVO6OQL^+.G^+;_XC>%-
M>UJPN%UC2O"WBBPM_"GB73+U[[P[_6O^S=\;OAG\>OA=IWBGX7>.+'X@:7X<
MOKKX>>)=:L/M[);>._!D-IIGB[2)Y]0MK:2\N].U(LD]];&YL;TNMS97MW!*
MDS>*_M-_MK^!?V?O ?P$^+.C^";CXY_"?X[_ !O^$?P?B^)OPS\6_#R[\&>"
MW^,WB73O!G@7XDZ]KVK>(+33]5\!W&OZK8Z7<:UX;N-6FMI+VS"PO%=*ZMTO
M]N;X?Z%\0KSP!\;-(\/?L[6UMX<\>^+XO%OQ,^-7P)T[P]-X=\,?&#2?@WX0
MU*6SA^( \264/Q4UN_O;OP;=76@IIJ'1+WP_K.HZ?XIN-,T:^ /N>BOB?XJ?
M\%"?V2OASX*\5>)-(^/GP*^)'BCP_P"!Y?'VD_#+PI\?O@A9>,O&.A_9+6^L
MY] _X2KQ_H&B1V>HVE]9W-IK.K:MIVAFVN[6XEU*."YADD]X^'W[0?P*^*^O
MZ[X0^&GQF^$_C[QGX32[/B_P;X)^(_@SQ=XI\(RZ=JLV@:I!XFT+P[K6I:CH
MLNE>(+>YT'41J%O;BTUFVGTV8I=QM$ #V"BBB@#\7O"__*%G]JK_ +(]_P %
M,O\ U8W[3=?L#X2_Y%7PS_V+^C?^FZVK\?O"_P#RA9_:J_[(]_P4R_\ 5C?M
M-U^P/A+_ )%7PS_V+^C?^FZVH Z"BODS]H[]N7]EW]DK6O"_AW]H'XDW?@36
M/&GAWQEXM\,VD/P]^)_C$:GX:^'>F2:YX]UI;GP'X+\3VEK8^#-!BEU_Q/+?
M3VW]B:!#-KFHBWTJ*2\7U/6?C[\'=!^#>F_M":AX^T5O@OK.@>#_ !3H_P 0
M]-^VZWH&K>'/B!<:+:^#-:TQ]$M-0NK_ $[Q#-XBT3^S[FUM98VAU&&YD,=N
M)94 /8*_/[_@J=\7OBY^S]_P3\_:E^.OP*\:+X"^*GP@^%^K_$'PEK\WA?P]
MXQLOMWAV2WNWTW4_#_B>ROM,O-,U. 2V=\RQPWMO!(T]C=6]Q&D@^O[CXK?#
MRU^('AKX6R^*;!O'OB_1_&^N^'?#]NEW=RZAIGPWO/"VG^.)3?6EM-I=G<>&
M[SQKX6@O]/O[ZUU'=K%N8+69([AH?#_&-I^RA^WCX1^/O[-?C*+1/C1X0^'O
MCBT^%'[07PUO?^$LT:TTKQC;:)X;\?6OA+Q)Y!\/SZG;W&@>(?#6NF.PO+_0
MM4T[4K999;N)Y80 ?"O[</[:S?LN>&/V8/#_ ,1XM?\ CIH7BWX2?'OQC^T+
MX(L?!'P6UBY^,'A?X3?LR^(/B5K_ (9\8Z)XHU_PMIO@,^*K;3];\4Z4V@^'
M[_0-<N?"]YX&U"UTS3=<AO8?E&Y_X+;?"#0_@9\8?AY\&?V8_C)^S-KWPK^!
MW[0FM?#ZRM/!'P*N/#?@O7/@?\,OA/\ &#4M)\-^!=,\?V'@V]N](^%_QU\%
M?$6+0+VZT3PY<W\.L^!;_5;+7HP)?9[/X+?\$.?B;HFNQ+\/-*\<:;X-^-_Q
M&^!GBF]U?2/VI==U3P_\9+'X3'2/B1X$\3:QK27&NVD%K\'M(;0]236+T>#H
MO#3OHEK<#^UVM+WZ@\,?\$LO^"7GQ'\'Z;XT\-?LR?#_ ,0>$?BAX)O=1L=7
M&H?$"*/Q1X)^+'@'P+X<U66>.^\1VU^;7QI\//!7@'0]8AOH8;N]T3P_I.G:
MC$%MFAH ^5]#_P""W_AW0?&.N?#WXA_L[_&35=:@_:5UC]G'P$/AWHUCXY\7
M>/+'X6?"_P"&WC_XW_%C4_ _A*XU74= T[PA9_$71=<C\.V<%W-?:/J:065W
M)/I&K20=Q^P__P %$O'_ .V-^WI\2?#WAJ#Q)HW[)&L?LD:-\9/@KI'C3P_X
M&M=:U[6-)_:/^)?P+UGXB:%K7AFYN_$EMX2\6I\/KBXMO"/CV5/$>C:C'<S/
M:6%K<6UG#]1Z#^Q9_P $\-4^*GBCPMX?^#'@MOBO\,O&/P[^.7BB"SD\<6>K
MZ#XPUOP->?#OP?XPGU4ZG;VE]/XM^'_A"Y\*^*;&VOKVR\9:)H\=C\0-/U=!
M;B3)TWX:_P#!.']AS]IWP1JN@^!/#7P:_:1_:YE\4_#3P'/X=\-_$[4_^%@"
M;Q'=?%/Q1X*T>+1K/7/ ?A/3X?$%WJOCR;11'X:T^P\WQ!KUK!;V(UJX4 _2
M:BO*H/C=\++GXUZA^SI%XOLS\:=,^&MC\8;SP$]EJT.I)\--1\27'@^S\70W
MLM@FC7>FR>)K2XT9X[34I[R"\C*W%K$A5V]5H \Y\!?![X2?"N?Q#=?"_P"%
MOPY^'%SXMOEU/Q7<> O!'AGP?/XFU)'N94U#Q#+X>TS3I-:ODEO;R1;O4FN;
MA7N[EQ(&GE+^C5Y9\+?C7\+_ (U1>/)?AAXLM?%0^&'Q*\6?![Q_'!8ZOIUQ
MX7^)?@>6UA\4^$M2M=8T_3KD7^DM?6;R30136%S!=6]S8W=U;2I*?4Z /Q _
MX*E_\E@^&W_9OFH?^O&O^"8]?M_7X@?\%2_^2P?#;_LWS4/_ %XU_P $QZ_;
M^@#YH_:M_:I^'_['OPPM/BW\3?#OQ(\1>%;KQOX(^'WD_#'P?/XVURW\0_$7
MQ%8^$/!ZW6D6UY9S16.K^*]6T;P\E\&>*WU'5[ 7/DVTDMQ#X39_\$Y?^">G
M_"<^+_BO)\"? TWCWQ]K?COQ#XPUK7/%GBO5;R?QE\6_#5_X&\=^(CI^J^,+
M_2M"\<Z_X3OK_P &2>)-%M-/\2:?H(/A_1M2LM.M8+6+T']NS]E[Q=^U[\$=
M/^$/A#XFZ!\*+NV^+'P=^)]UXFU_X>WWQ(AG'P<^(_AWXH:5H<&AV/CSX?/;
M?VSX@\*:19:CJ+ZO<F'1I-2AMK(7MQ;7MG^46E?\$#K5_$W[8FN>*?V@_!EY
M;?M3Z=\3]5T:#PM^SN?#E_\ "SXL>+/VDI/VF/AQ\4K:ZU+XP>)M.\3:E\'?
M%++X?\/Z>NC>')-5\._:K:YU6R&I:C%<@'Z&>'_^"8?_  3=\*1[] _9\^'&
MFVT*>%-6FC3Q3XLFL)++X=:;I'A7PC)?VMUXOFL[S1?"VF^&M"T73[2^BFTB
MT30=*MV@\W3+3R-^X_9._P""?7C/X;>)?V29?!OP[UOX?^%?'FA_%?QC\*HO
M'WB)[C3O'_B"4^-O#7BKQ-<6_BY/$<VI7CV<'B30EU74YH8(M/TK4-/MX8-/
MTN2#X>^*7_!$?0?&_P :?B3\6/#OQITO1=)^('[.6@? *S^'.O?##5=5\$^$
M(M*TZP37=2TKPQX4^*?@/PEJ6@>-?%>FV_Q*UKPQK7AN\GT[XER7?C+1->L]
M5NII&\9^*_\ P;[VGQ%BU[^S_CI\)-(O?$GB_P" GCO5-6U7]E.+5M6?6_@S
M^R-X@_93OM&@U#1OC7X5N[?P/X@AU>P^(NC>&(IE3PSKFD#3+V\\3V]]<WP
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M/JWPLUO7;G3/"4?@M=7^+":9XRO-?L);J2YU'0KGP]<O#IVL0S_?]K_P3?\
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M '_0\^#_ /PIM%_^3: /Y]OVGOC'^TQ^Q+\;+>;]F?X%^,?&]_K_ .R]I'Q
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MSA\-VTEAK>H?9[[PV=.BTN:ZEN)/ZOO^%A^ /^AY\'_^%-HO_P FT?\ "P_
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M%AM+26"XMX\C_@I)_P FC>+/^RJ_LN?^M4_!:OKO_A8?@#_H>?!__A3:+_\
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MJWC;7/A1H MI]<^QZ/XC\.Z;KOV#3II=0U.^/YH>#?!'_!;;2]8_8\U'Q/\
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M[[5[>T\7!)?#&I6<.G74M^OS'K7_  2*_;'GT'XPW,'[5L^N_$I_A/\ L1>
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M"<L]OJ7Q"N$:RM;E%;4]2L9M2T.]_H9KX;_X>,?LL?\ 04^.7_B'_P"V#_\
M.(H_X>,?LL?]!3XY?^(?_M@__.(H ^)/^"I?_)8/AM_V;YJ'_KQK_@F/7[?U
M_/=^VY\7_#?[1WCJS\8?!OPM\;_%_AWX9?L\W[^-;Y_V:OVC/#<FFL_[=_\
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M<O\ Q#_]L'_YQ%'_  \8_98_Z"GQR_\ $/\ ]L'_ .<10!^*^I?"#X^? /\
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M'C'[+'_04^.7_B'_ .V#_P#.(H _+_\ X)4?M#?M9:5;?LJ_L_>/O!_CG4_
MGBNP_:GUKXA^-/B?\%/VG[#Q[I>O:1\:_B_JW@,6_COXKW5GIWA7P!J/@_\
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MA^'/BU\-OBCH6K6L]K/X:U[X9:/HWVQ-*COK8 _5RW_X)L?L6W=O!=6OP_\
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M1S+O16R!U% 'R=_PP3^PQ_T9?^R=_P"(Z?!__P"8ZC_A@G]AC_HR_P#9._\
M$=/@_P#_ #'5]8T4 ?)W_#!/[#'_ $9?^R=_XCI\'_\ YCJ/^&"?V&/^C+_V
M3O\ Q'3X/_\ S'5]8T4 ?&7B?]@_]AR#PWXAGA_8R_9/CFAT/5I8I%_9U^$
M:.2.PN'1U(\'9#*RA@1R" :^=?V&?V(/V+=?_8F_8\UW7?V0OV7M;US6OV6?
MV?=7UC6=7^ /PHU+5=7U74?A+X1O-1U/5-1O/"<UY?ZA?WDTUU>WMU-+<W5S
M-+//+)+(SG]-_%O_ "*OB;_L7]9_]-US7X,_&K]N#XM?L&_\$G_^">/Q7^%W
M@[P[XBL-2^ _P$TGXF>(]<\)>)OB=/\ #GP%H_[*=QXQD\7:=\(O WB[P/XU
M\>P2^)O#OAOPYXCN]!U](OA]X8UW6/B+KME>Z%X:OXU /U5_X8)_88_Z,O\
MV3O_ !'3X/\ _P QU'_#!/[#'_1E_P"R=_XCI\'_ /YCJ^2_VJ_VA/\ @H)H
MGPW_ &6_BI^RII_[%BZ!\3H?@QI_Q/TGXQ7GQ3^(.J>(O%WQNU[P7I&CZ'^S
MWJWPN\2>$_#VM:?X;L=7\0^(;SQ#XLNET[Q'HL.F7VC_ &>*WU(M\1Z/_P %
MP?'6B1_M*V/QA^%^B^#];^%W[1>B?#?PC:^%O!'COQ;K&@>!QXQU7PSXOT3Q
MMX/?Q-IE_P",/BYI4.E>')-$MO#6L^$]"US4OC'X#MX[**TT;4KK6P#]D/\
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M?G0!JQLCJHT4^*]'U8Z4-3.G:>=0%CY O/L%G]I\S[+!L\H_X8)_88_Z,O\
MV3O_ !'3X/\ _P QU?6-% 'R=_PP3^PQ_P!&7_LG?^(Z?!__ .8ZC_A@G]AC
M_HR_]D[_ ,1T^#__ ,QU?6-% 'R=_P ,$_L,?]&7_LG?^(Z?!_\ ^8ZC_A@G
M]AC_ *,O_9._\1T^#_\ \QU?6-% 'Y#?!/\ 8G_8QU+]K7]MO1KW]D7]F&[T
M;P[<?LY6^B:5=_ +X47&G:.VI?"N[U+4VTJRE\)O;6"ZC<3Q3WOV:.(W5S%Y
MTXD8*]?9'_#!/[#'_1E_[)W_ (CI\'__ )CJY#X G=^V)^WVQZQZY^S3;C'=
M%^!]E."?]HO<N"1@;57C()/P'^TI\=/C'X1_X*K?">?Q)\2/'_AG]CKX8^&/
M#F@^/M.^#'[2GP,A\,^%_&WB[PE\0_'5MX\_;7_9\\0^"K[XK^%/@HVBZ'>P
MZ?\ %G3_ (C^%]"TV?P]HUUJ6@OX?GUS7@ ?I7_PP3^PQ_T9?^R=_P"(Z?!_
M_P"8ZC_A@G]AC_HR_P#9._\ $=/@_P#_ #'5^ _B[]K+]O3XL?'7]IWP-^S;
M\0O%7BSQ%\08?VY_#7A/P9X5U?PS<6'P_P#AI^S9XH_9*'P3\??!:.]B33=
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MG=8\(_&.\^#3^*;+2M&T?XA^(O@GH.L-X(UK5I=-TO7KN;0O$,NFZ-JEZ$B
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MPWKWQ<\7/XFM?#6A7&E^-/!LMK#92I:P7# ']5=%?S(_'?\ X+$>./B/\?\
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M7PA\-V'CF31O#&M12ZOX)\8>&_AY\5M5FN6\<?#SPCXR\6:1J6MZU!X?O[T
M_J<KS?XF?!OX0_&G2;#0/C'\*OAO\6="TK4AK.EZ+\3/ WACQYI.FZNMK<6*
MZK8:=XITO5;.SU(65Y=V8OK>&.Z%K<W%N)?)GE1NA\$^+]#^(/@SPCX^\,SR
MW7AOQOX8T#Q?X>NIX)+6>YT/Q+I5IK.DSS6TP$MM+-87MO))!*!)$[&-P&4B
MNGH ^3O^&"?V&/\ HR_]D[_Q'3X/_P#S'4?\,$_L,?\ 1E_[)W_B.GP?_P#F
M.KZQHH ^3O\ A@G]AC_HR_\ 9._\1T^#_P#\QU9'B#]@O]AQ-!UMX?V,?V4$
ME32-2:)U_9U^#X9)%LYFC=3_ ,(=PRL 5.>" :^R*S]6C\W2M3B_YZ:?>Q_]
M]VTB_P!: /RT_86_8D_8M\1_L6_LG:UKO[(7[+NM:Y??LZ_!Q]9UC5?@!\)]
M1U75=5B\ Z#!J.HZGJ%YX2FN[_4;Z\BFN;Z]NYI;J[NI9;BXEDFD=S]5?\,$
M_L,?]&7_ +)W_B.GP?\ _F.KDOV%;^]L?V!_V?KO3;8WVHZ+\#]+@L+(<&ZO
M=!TRZL[6R]C+/8QV_;!/X5_-QH?[5W_!4'XK?LU>//$?PA^)_CS4K[PEX8_9
M%_:>^+7C)M:\'6FM?#?Q'\9?A9\:?%GQ5^'UI<^)X=-TSPY\#_A9\2O!GPUU
MGXD_#JZDF\0>$?A5?^(=%LDN9+PVS@'].G_#!/[#'_1E_P"R=_XCI\'_ /YC
MJ/\ A@G]AC_HR_\ 9._\1T^#_P#\QU?C5X=_X*A_&W7/CQ^TW^SCXI\%^)?
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M9:1/H\,<_AS4H;NX%=D/VB/VO>-W_!/;QR/7;^T9^SFV/S\9+G_/-2C]H?\
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M7Q,7[_["W[68_P!RR^#,G_H/Q>% '(Q?\$\OAWX(\<?LK^)/@5J>G?#'PO\
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M7]N-?K^S[.W_ *!XG?\ 3_&@#W+P5^SW\/?A_P#&?XS?'7PRWB>V\9?'NV\
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MM=1U3_A![&WM[>+PQ=:K>Q3W][HTBVL$MUI]U<2VMW<)]IN8I)B7/R[_ ,/
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M],2YG2RC@6:0-U5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+/$G_A\/C]_\]&C_ (=F_L6_]$L\2?\ A\/C]_\ /1K[RHH ^#?^'9O[%O\
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ME[?V^LZ%JOB*?3-=AU.'XW?%?2=4BU&WFBU#1_&^KV-VDJBS>U /AB+XR?\
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MXM^*?%'@OQKXU\-_!OQ%8:-IFI7&HZ?XB\6Z9+'8:C86GB+PU:W/B</[2O\
MP39UWXA?#OQ[X.^#WBW5_P!C_P 1_ ']H'QCXPN[KQ?^TU9_'OPU\9_@3\>_
MAO\ !34O"@BN/V@H/!4'A=[OX@QG4;K4+>/3;5K2+61XW73;AK2'ZF^&?PM_
MX(@^$=9MOV?OAS\?_'5EKGQ8\#6/[+^L>$M+^-G[1$$WQ-TGXD^+?BQ)X,\,
M>.=8MI+>UU;Q1X/\:^+OBCI'A34]>U2WU3X;Z_=W7A;4IM+NHK+2A]H>$_\
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M#9$OZ'5\$_L'?\WF_P#9^W[1/_NGU][4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q3XJ_P"4C'P)
M_P"S*?VL?_5Z?L7U]K5\4^*O^4C'P)_[,I_:Q_\ 5Z?L7T ?:U%%% !1110
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M/W_T--?=%% 'PO\ V]_P4O\ ^B5?L+_^'_\ C]_]#31_;W_!2_\ Z)5^PO\
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M_@I?_P!$J_87_P##_P#Q^_\ H::/[>_X*7_]$J_87_\ #_\ Q^_^AIK[HHH
M^%_[>_X*7_\ 1*OV%_\ P_\ \?O_ *&FC^WO^"E__1*OV%__  __ ,?O_H::
M^Z** /A?^WO^"E__ $2K]A?_ ,/_ /'[_P"AIH_M[_@I?_T2K]A?_P /_P#'
M[_Z&FONBB@#X7_M[_@I?_P!$J_87_P##_P#Q^_\ H::/[>_X*7_]$J_87_\
M#_\ Q^_^AIK[HHH ^1/V.?@U\5/@]X0^+$_QFN?A\_CWXN_M _$[XV:GIOPP
MU+Q)K7@_P];^.YM(6QT&QUKQ7H7AG6M6GLK?25DO+ZXT'3(WN+AXX+<11*[_
M %W110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'PI
M_P %)/\ DT;Q9_V57]ES_P!:I^"U?;>K1:G-I6IPZ)>V>FZS+I]['I.H:CI\
MVK:?8:G);2)87M_I5OJ&DW&IV=K=&*>ZT^#5=,FO8(WMH]0LGD6YB^)/^"DG
M_)HWBS_LJO[+G_K5/P6K[9UG3$UK2-5T>2\U+3X]6TV^TU[_ $:^GTO5[%+Z
MUEM6O-*U*V9+G3M2MEE,UC?6[)/:7217$3"2-2 #^<&7_@L[\>="_9<_9Y^,
MWB+P/\*KOQAJWPF_:3_:'^.5MHWAOQA%X=U[X;?LX_M3^#_V;[_P;\,--E\=
M7^K^$?&7BVS\<VWC"U\0^(-3\>:7I%WX>ET1_#VHQ:_%?Z/Q'C'_ (+C_M%6
MOP@^(?C_ ,'_  E^&EQ?Z]X0\%_&GX27^I>&O'>I>'?A7\'_ !)^T7\?/V?;
MFS^-UMI'B^/4?%_B-M3^"WAV:P\0>$[CP5I":Y\4X=)N]'%KX5CO/$?ZT>%O
M^"4W['GA7X:?##X20^'/B%KO@KX2>*/%?B'PK:>+?BQX]\3:C=:3X[\6:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\M]?T?2+[Q#8:9%=7&GW.IM?6$-]* 0R_P#!+;_@H5H?Q]^ VM>$M<\?:O\
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M\'_%FC?&BU^#7[*'[6_Q(\5^$[G]HF#0O#GBKQ7\%_#/P#U.S\+?%B:+X?\
MC:Z\4>)M2\+_ !$M-<\'^)M+\0VEYH^OW.L/XAT?5(]6A:R /D/XW_\ !-O_
M (*?>+_BQ^UGKWA_PKI&N_"[XN>'/@UX?\%?#SQ!^V1XO\7:/?:]\&?VC?@+
M\4_#_P 0M2?XDZ'JMUH^MO\ #3P)XU\%RM:0V036KR&6WTZ.PU.ZO7^UI_\
M@FG^T/\ &O\ 8(_X*&_LA_$77++X9ZK^TS\0-0\3?"3Q/XP^(NO?&[4H6>7P
M=XP*?$N\BEL])N_"=[XT\/W'AE;?PQH'AO5;[P"ZW'B70+[Q4+O5-;^/OB__
M ,%V_B!XJ^$G[3OA36/A5X9^$6O_  [\!_&&]L/%WPE_:ET\>,)M:^!G[1OP
M+^$WC%?"^NZE\)=1L_#ZW>A_&6SOM%U74-"U@7FK>&?$NG3Z=!HMW8:\OM'@
M/_@MM\=8/%/A[P;XG_9P\+_%+7?B#^V+^VG\+=#TSX5?$/3M.O/!/P%_9 ^(
MW@+X=^([O5KKQP-!TOQ;\69(O'5OXXT[0-)U*)?$/A'2[N:TBCU+5=&LY #M
MOVF_V:O^"I?[6.DZMK.I6=M\$= MO%'[(B^%?@%X"^-OP_T'Q/X;N?AW\6]&
M\7_M#>,O#7[2G@#X=^'?B#_PA.M?#[3;CPS\/_ /B#6IKJ\\4:KK.J^(]+MM
M%DTG3=,\4^.O_!*W]OK6-<_:L\,?!OXG:]:>"_$'@+XI:;\%O%^O_M/?%--7
M\4^&[ZQ_9]G_ &=O@C>VLVHWVL^ K[X#^(OAS\2]2_X6D]]?7OB2/QE#;ZC<
M:G;ZKKD-M]#?\$COVVOBK^V;^UQ^VGXP\8>(AIOPY\2?L]_L)_&KX4_!+3_B
MM)\3M ^$UE\6[#X^C6((X[S1="OO!WC;6-/\*>%1\3?"<-K-H^E>*;#;I=U/
M!*)IOZ Z /XB-5_9=_;>@_:B^$7[+5_<:[X._:<\=>"OVH?C?\.K\?MF>/+O
MP[\!O">M?M]?#/XJ_##QM>2VVH)9?$_7OA?\'E^(W@'3OAK'HUZ^J:6VOI:.
M?"=C/]D_MU7(503N8 !CC&3@9..V>N.V:=10 4444 %?%/BK_E(Q\"?^S*?V
ML?\ U>G[%]?:U?%/BK_E(Q\"?^S*?VL?_5Z?L7T ?:U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?"G_!-O_DT;PG_ -E5_:C_ /6J?C37W77PI_P3;_Y-&\)_]E5_:C_]
M:I^--?== !1110 4444 %?. _9"_9FE\5>*O&6J_!'X;^)==\7^)-2\8:E/X
MN\(Z'XM@L/$VNZ;9Z7XGUGPW:^(['4X/"UWXOM]/LI?%X\/IIT/B74+?^U-8
MBN]1FN;J;Z/HH \+TS]FC]FOPQ;YT']GKX(Z)#:ZIX=\21PZ'\)? >G;-=\$
MF[F\(:U!%8Z! !K7A5[R]?PSJ* 7NB27ER=+FM6N)2_XMI_P4[_8O2Z^'/B3
MX#_L0Z=XZU36OBQ\(OAY9:C#X!\ _!W7/!^N_MG^/?'?P[T'Q'!=^/\ PIX<
MDGMO%.K>![RV^+#:!>S:Q8WSWVF:]9ZH-,:ZN_Z&*^1/VT_V5[;]K3X6>$_"
M$/Q N?A=XK^&'QK^#_[0OPZ\<KX?M/%VE:+\0/@GXRL/&7A]?%/A&\U308_$
M_A/4Q:7>DZ_H\/B'P]>R6-\]S8:WIU[;07"@'RYX5\;?\$]-(U[Q?\.OCM\#
MOV*OV8_$4?Q5U+X:^ /!/Q#O/V:K?6/C%I?A'5M/\-:#XR\-^'8K.QNAIUQX
MA\5_\(_H^CW=K/JFEZIJ36+QV\^J117&O\)_C[_P3?\ B'KFM:AJ^A?L??#K
MXD?#_P >:SX<T+3=8U_]FK7/&[Z%\&/'5Q\%? OQ%T2Y\(:MK5[H.A1:Q<0^
M%O!]K>7&FZ_X)O-5B\&ZAIV@:U+)I%?)G[6?_!+K3/VQ=9^&GB/4/VY?AOX=
M\;:)X2^+_AJ_U;2O@[X7\11^(_'/QJ^)'P<^(GB#Q!X*TV;XTVUWX1L=-G^$
M'@KP_HOA1-4\5:D^DZCJO]K>*-5O-3MY[?VGX'?\$B-'^$_CGX;^/M>^/&I^
M+=8\%?%W]N/X@>)(= ^'EIX"M?B-X+_;;\5Q_$;5_A;XD:'QCXCO4TKX8_$Z
MSTOQKX0UF&[DFFN]+MX9]-M;EYM2< ^@=:\6?\$H[?P_X<T+Q%K/[ 4'A73]
M6^)GA_PEH^M2_L_1>'K+6]'O=#N/B]HWARPO@NF6VI6=]?\ AR\\?6&F1)<F
M6ZT>\UR)O,M)CJV<W_!,3Q8MK=:2/V(=8E\<_$)OAGIFHZ99_ V\NO$WQ5TN
M/3M1C\(Z;>0VTSZQXYTP0:+J%KID#76K6LD6CW,,*L+%C\+?LZ_\$-OAU^SI
M+^R=#!\2?A[XO\*_LP>.?BAXR\1:;XD_9WTJXU#XXP^,?@_)\%?"=_\ $76-
M8^)FN:9!X[\!^"I9()?&EEX>?2=9-KIL6G>"_"=E9SV][R&A?\$=/@UJ'Q*^
M _Q+\5?M1_#SXD1?"OXJ^.=5\)?#:^^'&B'X0IHWC8?"/7AX-^&G@V#XO7<O
M@WQIH'C7X7:)\1M U6WUKQ-X0T;7O$6I0Z#\)='\.Q>&](T8 [K]I3]K3]G?
M]C^\^,/[&7B;]BW0OB=\*?V:_P!D^3]M,1^.?B!\%]2T3XC^'$\3>*;;63IV
M@_%F_N]9\0_&2_\ %NB^.-4O[W7XY=1UW4G756UB6\\2VZ-P/PR_:K_9F^(G
MC/Q_\ ='_P""6GP=TGXK> ] ^"6J^ _A!,/V9KFZ^)$7[3'A'3?B45\*6FC>
M'K^'0-"\-> +4^)OBIXLU^PTSPII<^D:?I%WJEWJ%_H@N?H#]M#_ ()*#]LG
MXX?'?XP>)_BS\*[2T^+_ .QVW[(?A?P[XV_9:T/XK:M\(K";7?$7B.?XI^#_
M !=KOQ0TEX_'Z:CXN\0"PNK+0M%CL;;^PU$DUUH[W>H>$2?\$1?B;#\=H/VI
M]"_;1\-^%/VE/#-_^S=)\-?BUX:_9:EL=4\(^&O@)\-1\(O$GPXUFRG_ &AK
MM/'/PS^.O@0FS^)G@[7+J*S76H--\1^')=)U72;"6$ ^B_V<?%W[/?[0?QL\
M5?!OQ%_P2_\ #GPE_LCPM\7]8U#XB^+?AQ^S?XD\!Z[)X+^.,GPPU+1;&\\)
MS:OK-]#\2+RVF\?^']5O='M]$\0V&F:Y:SW3^)O#>N6%A^ED'P'^!UM>6FH6
MWP9^%%O?V'B]/B%87T'P[\(17EEX^CL+?2D\<6ES'HZS6WB]-+M+334\2PR)
MK2V%M;V8O1;PQQKZ/I,.IV^EZ;!K5]::GK$.GV<.K:CI^G2:18:AJ<=M$E_?
M66E3:AJTVF6EW=++/;:?+JNIR64,B6SZA>-$;F30H \U\%_!GX/_  VUC7O$
M/PZ^%'PU\ Z_XJDDE\3ZYX+\"^%_"VL>(Y9KR;49I=>U+0]+L+W6))=0N+B^
MD?4)[AGO)YKIBT\KNWI5%% !1110 4444 %?%/BK_E(Q\"?^S*?VL?\ U>G[
M%]?:U?%/BK_E(Q\"?^S*?VL?_5Z?L7T ?:U%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"
MG_!-O_DT;PG_ -E5_:C_ /6J?C37W77YS?"[]EK]L'X(>%;CX>?"[]K;X(VW
M@&U\:?$WQ5X:LO&G['WB?Q3XGTRS^)/Q*\6_$F;2-7\1Z1^UGX/T[7)M(O?%
MUUID.J6WAC1!>6MI!/+80SO(#Z'_ ,*T_;__ .CN_P!FG_Q"#QS_ /1KT ?:
MU%?%/_"M/V__ /H[O]FG_P 0@\<__1KT?\*T_;__ .CN_P!FG_Q"#QS_ /1K
MT ?:U%?%/_"M/V__ /H[O]FG_P 0@\<__1KT?\*T_;__ .CN_P!FG_Q"#QS_
M /1KT ?:U%?%/_"M/V__ /H[O]FG_P 0@\<__1KT?\*T_;__ .CN_P!FG_Q"
M#QS_ /1KT ?:U5-0-H+"]-]#]IL1:7)O+?[))?\ VBT$+FXA^PPQ7$MZ)8=Z
M?9(H)Y+G=Y*0R,X1OC3_ (5I^W__ -'=_LT_^(0>.?\ Z->C_A6G[?\ _P!'
M=_LT_P#B$'CG_P"C7H _D_\ @5\$?CK\.[[]C7QOX*_99N-;U/X:?MC?\%/_
M (G?##X3:Q_P3Q^,/PXUGP7KWC#0_CG?_LV:W\5OC!JFFPZ./A_X^\4>(/A1
M8^%)YO"/P^A\)6MUHCR^(+1? UQ-I/TO\2?VV_\ @M7X<\$^$->\%Z;^TGXC
MM++2/CIK=EJ,G[!B7GC'XL:AX0^#W[/OB;POX3\:>#;/X-V$_P -F?X\^)/C
M3\)/!]_:Z1X5D\9>$/#4?B!'UF2SB\7S_P!%/_"M/V__ /H[O]FG_P 0@\<_
M_1KT?\*T_;__ .CN_P!FG_Q"#QS_ /1KT ?EU_P3Z_;G^-?[1/\ P4'_ &J/
M@Y\7?VHO!'BKP!\-/"WQ7ET']F_2_A'>^%];N)-*^+0TO3]6TQM<^".@>+FT
MCP!\-;WP[X7\9^&=9^*/CGQ+XC^(6MZIK6FZ?%X6M4L-._-K]@ _';]G6^\6
M:%X@_8:\4>.- \0:Q^WC\2?V [.?]C#XL>#-(^ 7[3Z_&7QSXE\ V7[0%EJG
MPWL(-'A_:"\*:[\*;7X,_'V*_P##EEX%\%:5X@^&U_\ \(K:VNJ:C;?L%\7?
M@3^T3^Q7X5\>?M-_#'Q_^QK#\0-=\:?#_0O$=Q9_L9?%;23JLOQH^-G@WP=X
MDU.V2;]N'6M(\.S2ZGXVN?%^JP>&M"TF/Q)J]FD>JN?M#74/W1_PK3]O_P#Z
M.[_9I_\ $(/'/_T:] '\ZWQ)_;;_ ."U?AOP5X0UWP7IG[2?B.TLM(^.FMV6
MI/\ L&)>^,/BQJ'A#X/?L^^)O"_A/QIX.LO@W8S?#=I/CSXC^-7PD\'W]KI/
MA9_&?@_PU'XA1]9>SB\7S_=__!.K]N?X[?M%?\%%OVF_@W\3OVJ/!'B'P;\-
M="^)TGA3]G?2_A;<>"=<^W:7\8(]*T?7=,U#Q%\%O#'BBTTCX=_#N]\-^&O&
M>B:]\6/&?B'6OB%K.I^(+"UM?"EFMGIGZ=?\*T_;_P#^CN_V:?\ Q"#QS_\
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M\4ZWXRT+QUHDOE75_:?MM0 4444 %%%% !1110 4444 %%%% !1110 4444
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M<GXCZ1X(CO/A5HOVBVN[CR-?\7'5XFT^Y@^R?9[B$:;.8[FYLX@6$Q=/::*
M/!_#WQU_X2#7_B3H+?!OX[Z$/AQ8:O?_ -M^(?AZ-.T#QZ-(FFA-G\-]076+
MA_%%_J7D^;I%L;>P-]#+"ZLF_ PK?]I6"X^%>H_%/_A1?[24$>G:_;Z WP^N
M/A/=Q?%*\-Q):QC6-/\ !W]J&6ZT&'[4'N-36\5(HX+EC&3"0?I6B@#Y[\1_
MM"VGANP^&E_/\'OC_JH^)D44L5IX?^%NHZS?^!C+-I\(A^)-M:7C-X1F3^T/
M-E6X:Y5(;+4'+_Z-M?H?^%R6O_"W_P#A3Q^''Q>6Z_L_^T1\1#X OS\)"O\
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M:?IW@&2VCU#0==^!_P 0-%\:ZZ;IU57\&>$+_2(=;\71Q;]UP^B6MTL"!F?
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MVW+6#6O#LFAR#5;N5-.M+G14M[^WU2")K":8^ '_ (*#_$F;]H7X._!/2?\
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M (5?_P % ?\ H\/]G#_Q"#QA_P#1G5PR^,OVO?A!^T;^S%\//BO\9O@E\7/
MGQ[\1?%/PIJUEX1_9T\4?"3Q)X>N?!'P@\7?$K2M7T[Q!>_M#_%&PNTGOO#,
M6EWVF77AQ/-M+R6>&_MYH463]%*^%/VD_P#D[G_@G-_V57]H3_UE;XJ4 ?==
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?"G[-G_)W/_!1G_LJO[/?_K*WPKK[KKX4_9L_
MY.Y_X*,_]E5_9[_]96^%=?== !1139"X1S&H>0(Q16;:K. 2JLV#M!; +8.
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M\:Z%KLFH6_BGPAH,.B:Y<:;E_&OXZ_MS>$O^"A/P._9D\(?$[]F[2_AI\=O
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MUSX]>"_V0O#7@,_LR?&+X-^ ?"OQB^-G[4NM_LZ?"+XG2?%+7?BUXTM?BO\
M#70].\)Z_P",?B3H?@C2[1EU6?3/!FE^-[#4OM<T !_4#17\U7[47_!43]L'
M]FGXF_$/]G'7/$?P9U+QW\'OCS^Q?H/B+XQ^&?V:_BAXZT_QI\"_VR;?X@6<
M5YHWP%\+?&BY\7:9\7OA9XA^&^O+;^'])\9^,=/^)&BWND7%C8Z!>1:I'!^A
M&D>.?^"F>I^*?@GJ?A1OV</B%\%/%.E?!KQ#XU\6ZE\)OB%\-/&6I:%XN\4>
M)-4\;2:=X>O/C-XCA\%:I8?"D^&)X[/4H_$_]@^.HY-,F3Q#8Z_GPV ?J;11
M10 5\*?M)_\ )W/_  3F_P"RJ_M"?^LK?%2ONNOA3]I/_D[G_@G-_P!E5_:$
M_P#65OBI0!]UT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU74[[5KM+F*[-NNFV]O#^R/_  \M_P""?O\ T>-^SS_X<[PS_P#)U %OX?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^2?V_?\ DQ']M;_LTG]H_P#]4YXRKZ7\*,S^%_#;L2S-H&CLS,269FTZV)8D
M\DDDDD\D\U\T?M^_\F(_MK?]FD_M'_\ JG/&5?2WA+_D5?#/_8OZ-_Z;K:@#
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !17R?^U[\;_B/\$?!_PR;X2^&/ _BCX@?%GXZ?#CX)^'H?B/K>
MOZ#X-TBX\=RZJ9=>UF[\,:-KNN3Q:?;Z3*L%C8V(:YN9X1+<V\*R2#S[[;_P
M4[_Z%K]@[_PM_P!H+_YWU 'WC17P=]M_X*=_]"U^P=_X6_[07_SOJ/MO_!3O
M_H6OV#O_  M_V@O_ )WU 'WC17P=]M_X*=_]"U^P=_X6_P"T%_\ .^H^V_\
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MVFM<FLO%7[-GAW5=)\0:G^U'X>^#NF>,I-:L%^)]M/MTC6O@_9>)- N=)O\
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M_P $Z'W_ +&OP<7C, ^(-F0!C!L?BGXWLR#V+ P$.P^5F!9?E(H _';XB_\
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M;Z3\0Y)KVZ3P%HG@2WU:SN+B+4X+JZFDO3\2_M ?LX?\%8!\3_VDG^&GQ/\
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M=7BCXE?'_3/VM?VA/C#JGQ/^%GB3X*>+_$OA3XT_#/Q5:Z5X0^(W@7P)X?\
M%N@6 O/A?KEUX,G\1Z5X,\/>*3X522PT7P]K>J:MK7A?PQX=@\27D%S9^-O[
M)O[5WC7]C_\ 8!N+FX^(_P"T/\2OV1OVJ_A+^TE\4/A9\9]5^'?AWXI_'SP%
MX*U+QE&G@[Q)>VWCGQA\,+KXF_#ZQ\5Z'XM\(1Z_\3-:TK7O$_P\T8Z[X\FU
MZ]DUXY?[4'PW_;^^(OQ/^'?Q1_95^$GCG]G'1O&L[ZKXC\.Z-X\^%?@CQ)%\
M;[#XK_!.UA^,'[7NF>$/&UYH'Q/\ 7G[.GA7XG>";#P;HVO?%?4(=1N?#,M]
MI<=])I=WX: /T%^#O[ 7P8^$L'[0-IJ6O?$7XQ6/[3GA?1_!7Q=TWXNZKX7U
M32O$?A72-"\2^&WTNYTKP;X.\#Z;?76LZ'XLU72-?\1ZY:ZOXKU;1H=#T"XU
M[^P?#7A[3-,\OM/^"7/PGC^"VA? '5OCG^T_XG^&_P -Y_AK<_L^Z=XC\>^"
M;Z__ &;[KX/>+-(\7?#&\^&.HP?#.TE\0W_@NY\/>'M$T/4OC:GQ=U&T\+Z0
MF@_:VM-5\0_VS^(G@CX&_P#!</PS\4O"OB9[C]M74_"UC\7/!WB35O#WBO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^%/VD_\ D[G_ ()S?]E5_:$_]96^
M*E?==?!_[7>D_$S3/BY^QO\ &+P#\&O'WQMT?X.?$SXJ:CX[\,_#+4?AM9^+
M[#2/&_P'^('@32-8L[3XH?$#X;:#J5G%XCUK3+74(;;Q$=1MX;H7<5A<0PSM
M%L?\-;_%'_I'Q^VQ_P!_?V.__HO: /MBBOB?_AK?XH_](^/VV/\ O[^QW_\
M1>T?\-;_ !1_Z1\?ML?]_?V._P#Z+V@#[8HKXG_X:W^*/_2/C]MC_O[^QW_]
M%[1_PUO\4?\ I'Q^VQ_W]_8[_P#HO: /MBBOB?\ X:W^*/\ TCX_;8_[^_L=
M_P#T7M'_  UO\4?^D?'[;'_?W]CO_P"B]H ^V**^)_\ AK?XH_\ 2/C]MC_O
M[^QW_P#1>T?\-;_%'_I'Q^VQ_P!_?V.__HO: /MBBOB?_AK?XH_](^/VV/\
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M (:W^*/_ $CX_;8_[^_L=_\ T7M 'VQ17Q/_ ,-;_%'_ *1\?ML?]_?V._\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (5 G # 2(  A$! Q$!_\0
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M_P#\UM'_  W#^Q7_ -'?_LN_^'_^$_\ \UM>Y_\ "OO 7_0D>$/_  FM&_\
MD*C_ (5]X"_Z$CPA_P"$UHW_ ,A4 >&?\-P_L5_]'?\ [+O_ (?_ .$__P U
MM'_#</[%?_1W_P"R[_X?_P"$_P#\UM>Y_P#"OO 7_0D>$/\ PFM&_P#D*C_A
M7W@+_H2/"'_A-:-_\A4 >&?\-P_L5_\ 1W_[+O\ X?\ ^$__ ,UM'_#</[%?
M_1W_ .R[_P"'_P#A/_\ -;7N?_"OO 7_ $)'A#_PFM&_^0J/^%?> O\ H2/"
M'_A-:-_\A4 >&?\ #</[%?\ T=_^R[_X?_X3_P#S6T?\-P_L5_\ 1W_[+O\
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M  G_ /FMH_X;A_8K_P"CO_V7?_#_ /PG_P#FMKW/_A7W@+_H2/"'_A-:-_\
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MB/6)(=(T_6_$ATK03JES:V,VIPW-U;QR@'E?_#Q_]C7_ **U?_\ AJ_C)_\
M.^H_X>/_ +&O_16K_P#\-7\9/_G?5]1^ /B3X=^)5KXFO/#MOXEM8?"?CKQ;
M\.]3_P"$G\)^(_",MQX@\%:I+HVMW&B1>)--TR3Q!X=:_@GCTGQ3HRWOA[6T
M@FFTG4;N**1E[PN@4L74* "6+ * >A)S@ Y&#GG- 'Q!_P /'_V-?^BM7_\
MX:OXR?\ SOJ/^'C_ .QK_P!%:O\ _P -7\9/_G?5]P @C(((]0<CT_G2T >;
M_";XO?#?XY^"-/\ B/\ "?Q78>,_!>IZAK^DVFMZ?#?6J?VMX6UW4?#'B32K
MJRU.TL=2T_4]#\0Z1J>CZG87]G;7=G?V5Q!-"C)7I%?&O[#Y)^''Q@)))_X;
M+_;=&3SP/VJOBP /H  !Z  #@5]E4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'S?\ MD?\FA_M4_\ 9M_QQ_\ 58^**]$^"O\ R1SX3?\ 9,_ ?_J+
M:57G?[9'_)H?[5/_ &;?\<?_ %6/BBO1/@K_ ,D<^$W_ &3/P'_ZBVE4 >F5
M^+?P7_X*0^//B9J7@[XH^+_&'[-OPC^#?Q0_:Y^.W[,OPS^#'C>S\?I\??&6
MF? C7_&'@.\U3PEXETG5]1T#Q-\9?%WC3PO'JL'P7E\ :%:^'O %W>:E)XXU
MK4]%NH;C]I*^5U_8E_9:3XEZQ\7(OA!HL'C?7=:\3>*=2FMM6\46WAF3QGXT
M\*WO@?Q=\0+;X?V^NQ_#_3OB/XF\(ZGJOA[7?B-IWABT\<:KIFKZQ;WNOS+J
MVH_:0#X O?\ @N[^QY8> _#WQ#G\!_M+?V)K'Q,^,?PHUFUB^&/AZ75O ?BK
MX%:!X+\6>/V\:VB>/S%8Z3:>&/'.F:W9ZCI%SK:S0V.KZ?=1V6MV]KI=[]7?
M W_@H1\)/VE_V@_C=^S#\*O#?Q3L/'?P3TGQ)<^)?'/BSP;HMM\.(+[0_&^I
M?#=;>-8/&R^,1>WGB?2=7O-%T;Q'X<\(W7B;PQI%QXETBX;P_J&C:OJ'"G_@
MCE_P37/@NR^'8_9>T!/!.G7&OW5EX<B\=_%F+3[>X\4^$?"/@+Q',BQ>/DEW
MZSX-\!^$O#>H%I6^T:5HT-LXVSWAN6_LO_\ !.>Y_9P_:0_:/^.LG[17Q4\<
M^&/V@5\8Q2_!S4/$WQ*B\$>'$\5>+H/$=AJ%OIVO_%3Q?H-CXD\':5#/X3\/
M>(O 'AOX=7<VF:SKUYK,>HW][9R:: <7^SA_P4.\0K_P3<L/VY/VJM.T[6M7
MCOOBE>Z[X4_9]\"WVFW">&O 7QKU_P"$,-SHGAGQO\2-=GNOLB:/9^(/$FKZ
MCXOT_3K)-3:VCBBDALTU#VW]D/\ ;=\-_M>_$SXJVO@"Y>7X9:#\&OV4_B]X
M!&K>!=9\+^*I]#_:/\#>)_'=IJ.LZS=^*=6TK6()['3['3H=(L_#WAO4_#&L
M:1X@MM2FU^ROM&U*LS2/^"47[ 6B>"KOX<V7P!AG\"W4%K;1>%M8^)GQC\0Z
M/H\=I\0-,^*RMX7M-?\ B%J:^$9[GXCZ/IGC/4KKPL='N=7UZRAOM5EO'#;O
M=?@'^QQ^S7^R_J6L:O\  ?X867P]O]>\#_#?X;:K)8^(?%^K17/@;X0Z9?:-
M\-/#BVGB+Q#K%G;67@_2M3O[#2GM+>"Y6VNI8[B><,, 'TU7Q[^TM_R6G]@/
M_LZKQE_ZQ?\ M:5]A5\>_M+?\EI_8#_[.J\9?^L7_M:4 ?85%%% !7P[\>O^
M3SOV!_\ KX_:A_\ 50V-?<5?#OQZ_P"3SOV!_P#KX_:A_P#50V- 'W%7S7^V
M1\:_$_[-G[*7[1'[0W@[PUH'C/Q!\#/@_P"//BY:^$O$^M:EX<T;Q+:_#OP_
M?>+-6T.;7=)T;Q!?:7=ZGH^DW]GI5XFCWT$6K36)O8X[(W$T?TI7D'[0'P2\
M'_M)?!3XG_ +XA7?B:S\ _%_P;K7P_\ &Y\'Z_=>%_$5YX1\2VK:=XCT>QU^
MQ5KW3(M=T>:\T749[0QW+:9?WD,$T$LB31@'Y,?LY_\ !9#PS\1O&'QD/Q7M
M_A;H7PH^$_PM_9.UVW\8?"'4/C#\3/%WC/XP?M2VGBY[#X1^%_AO)\)M'\3Z
MY?\ A>Z^'WB=WN-!M-7O]5TJ[TG5/[,L+>P\1G3/JF/_ (*U_P#!/^7Q3XB\
M(K\?+<:AX8^&DGQ@O]2?P%\38_"MW\.T^$VF_')/$.A>,7\&KX7\1"Y^%FJ6
M_BNSTS0]6O\ 6+RWBO;"VT^35;"\L8<.[_X).?LTZEJ/BG7=6\7?M"ZMXD\4
M>%/@#X6'B>_^-/B"37_#3?LQPZO;?!OQ1X0OX[>(Z!XP\-6OBCQQ:7.N6T;O
MKMOX]\7QZU!??VG$;3R?XA?\$6_V:TL_&WBKX#W_ ,0/AC\5Y/@_XE^&GPK$
MWQ(\27OPM\%S7?[-#?LN>&C<>"+J'5["YTK2_AQ%;:?<+=V6LM)?37VOW5CJ
MVI3/%, 2_$O_ (+$_ W3/#&N^-?A/=:;X@\,>'/@G^U#\2=7N?BIX5_:#^%6
MIV?B?]FSQ?\ #7P%KF@2Z&_P(\1:HWA[2?%WC\Z3\1-:AMI=>\*?9(+W1O"G
MBNR&LSZ+]0>)OVIOB+HW[<W[._[+%AX(\ WO@+XU_L\_%?XY:MX\G\6^)(O%
MF@3_  JUGP%H%YX>T?PQ'X2DT76+76[WXF^&[JQU6^\1Z1-;V.EZ^+G3C</I
MD<_YB?!'_@C!\8+JTTKX7?M>_'#PI\3/V>]"_9Q^/OP(TG2?AS:+X&^,":3^
MT/XZ^%WBSQ=X6U+QK\/_ (??!_P+/X4TN?X8OJ^A:]X;^&/@_P 6_:?&>L>'
MM;_MN#2[3Q)??IS\:?\ @GU\*OCA\0? WQ1UWXG?M&^#_&WP^^#7B/X"Z#K'
MPR^,FM>!YG^'/C2YT.[\;65__9MHQGUCQ=<>%_#,VL>(X6MM;CET#3)M)O=,
MFA>20 \@C_X*V?LJ^$/B#XR^&_QI\=67@3Q!8_M#_$;X%>"%T/P=\:?%=CJ<
MGPXU7X3^%M;N/'.M+\*=-T'P+KUAXN^+?ANRU2RFU34_#-OH>KZ#XBL?%VI6
M%_>G3/U-K\CO&_\ P13_ &,_'_B'Q#XEUW4/C_'>^)O'OC7XE:E;:7\<?%NG
M:<OBOX@^(?A'XG\575I:0DBVM=0U3X&_#,K9*[06UOH#6]NL:ZAJ!N?UP4;5
M5<EMH W,<L<#&6/&2>I.!DT +7P]^Q']_P#:^_[/A^//_HCP=7W#7P]^Q']_
M]K[_ +/A^//_ *(\'4 ?<-%%% 'P]\ ?^3QOV_/^PS^S/_ZI*WKZM^(>@^*_
M%'@W6M!\$>/+SX8^)]2CLXM-\=Z?X?T#Q3J'AY4U&TGU"XT_0_%-K?>';R^N
M=,BO+"SDUG3]1L+&YNXM0GTW45M?L4_RE\ ?^3QOV_/^PS^S/_ZI*WK[8O;*
MSU*SN].U"U@O;"_MI[*^LKJ))[6[L[J)X+FUN8)5:.:"XAD>*:*1622-V1U*
MDB@#^<[]GG]O_P#:*\*_LZ_L1_''X_\ QLU?XJR?M/?&G]H[1-=MK/P%\ /A
M]H.A:#^SQX+_ &H-8/A*\UN9_!%CH>B^,;/X0Z1KUWXVN;R:[\,^(='>SOKJ
MW\):_>OH_>Z%_P %[O .L:1^SCK\G[,7Q+L='^.OB+QYX6\0W<OCSP )/A9J
M?P[_ &EOAK^S5KL^HV=S<6=WXJTJXUOXK^$/$^DWVB0Q27ND37]N]K;S6L<U
MS^M<7[&W[(T'@_P[\/8?V7OV?(_ 7A#4O$NL^%/!*_!SX?#PEX9U;QGIESHO
MB_4] \._\(__ &1H]_XJT>]O=*\1W>GV=O/K>G7MY9:E)<VUU<1R8Q_84_8F
M,6E0']D+]F7R-!N+F\T.#_A1?PR\G1[N\U?2O$%Y=:7%_P (SLT^XN]>T'0]
M<NI[18I;C6-&TK4YF>^T^TGA /RL\1?\%Z/"'A+P-\=/%OB/]ESQU8ZE\(T\
M=7_ASP[%\5_A=/+\2]#^%O[1/Q'_ &;?B%=Z9=/>V]SH^LZ=XN^&.O:OX:\*
M/I6JZ]XQ\/RP7VEVT45IJ\NF^HP?M\^-_C)\&_\ @J1X^^$WBKQ)X"O?V<?V
M=_AA\9/@M<^(/"/PXU.W\*'XA?L9:5^T[X;O OF:[_PD\6K_ -L:?%XKTKQE
M8(VC77]HZ=X>O+FP^Q:FGT[^S[_P3#_91^!_P\^(?P_\0?#?P+\>5^*7QC\<
M_&KQMXG^-'PJ^$GB'Q+XA\2>-/B%XF^)MK8:[=Z?X'TNVUW3/ WB;QCXC7P"
MVLVM]J/AK2-0&EVU\\,*LWTQ8_LL_LS:7H7CSPOIG[/?P3T[PU\4]&T#P[\3
M/#]C\+O!5IHOQ#\/^%=*BT'PQH7C?2[?18[+Q5H_AW0H8=$T/3-<@OK+2M'B
MCTRQ@@L46  'X'_LW_\ !4+]IK2?'-[J/QSC^*'C?3+W]DS_ ()V:K\/O@[X
MN\*?LX_#2^\??M"_MH>-O%_@>3QQ'X_^'=_KVF^%/A+?W_A:SNM#E\5:GIEU
MH5K>:ZFK^&YKH:#;+]"^%O\ @N]\-/%_Q#TKP?H?[,_QEU31?$OP8T/XM^$-
M>TO6?!-]KOB:]\0?LN?$[]J:P^']EX".IV^OKXE?PM\'_'.@+<^9)I,VI6FF
MZA;W<NEZFDT/ZDVG[%?['MA!K%K8_LK_ +.]I;>(?!NE?#K78+;X-?#R&'6/
M &A3V5UH7@G4XX_#RK>^$]#NM.L+G1?#]P)-*TFXLK:?3[6VEAC=>=^)?["'
M[)?Q,TWQ8+WX _![P]XR\3^";_P+;_%'PW\*_AY8_$GPOIEQX!U#X8Z;<>&/
M%,OAJXOM,N?#W@;4[OPQH*JSVNG^'YIM"BMQI$\]E( 4?V&OVKM?_;*^#5[\
M8]8^!WB[X%Z>WCGQ+X4\,Z3XOU:WUF3QIH?AS[%;_P#"?^';V#2M',_A/6=3
MEU&PT6ZFLHI+Y=)N+M5$,L0K/_X*0?\ )B_[3G_9+]6_]*K*KW[#7[$?PQ_8
M)^#U[\&?A3JWB35O#VI>+M3\:7;Z_=(8(-7U/3]*TJ9-%TBV"Z=H5D]EHM@]
MU::?''#>:H;W5IE^UW\Y-'_@I!_R8O\ M.?]DOU;_P!*K*@#[:HHHH *^'O@
M=_R>U^W9_P!@3]D__P!0+QU7W#7P]\#O^3VOV[/^P)^R?_Z@7CJ@#V+]J;Q]
M\8_A5^SW\6OB7\ ?AAHOQJ^+/@'P9K'B_P )_"?7?$NH>$(/B#/X>MGU2^\*
MZ=X@TW0?$MQ9>(=7TVUO+3PU&^CSVM[KTFGV-Y-96MS+>V_Q1X-_X*F?""P_
M9TT+]LKXY>)?!'@7]E/X@:%\(C\-_B=X0MOBEXYN;KQ=XJ\$OKGQ1TSQIHVG
M?#PMX0\._#OQ/!>^%U\3WD[61U#3=5TKQ$N@:]8IIMW^I.I6?]HZ=?Z>+N]L
M#?V5U9B^TV<6VHV7VJ"2#[787)246][;;_.M9S'((ITCD*.%VG\S/%/_  2+
M_9-\:_LF>"/V*?%-_P#''5_@1X \5>*O%>BZ1)\9_%MMKUY-XR@\71:WHOB'
MQ!8RVMWXA\.-<^-]>U73]*U5;E=)UF2RU/39K:ZTZR>$ [3Q)^WYX8U[X+_M
M_?$3X$^%]3\6^)?V"Y_B'H/B6T^(.E^)O O@/QQXR^&WPFT;XO:YHOAKQE%H
M>K-?V0T75H](EU'3--U"6QU"33]0N+%M$U?2+[4/C7]F'_@LWH/Q=\4^*)?B
M9IWPK\._"_PC^SC^RS\5M1\1_"W5_B]\1_&M_P#%[]J;7M?\,^&/@/X:^'K_
M  FTC7?%?B+2]:\,W=G%<>&HM5O=?;6=%-CI$ M]9^P?H%;_ +!GP1LO '[6
M/PTL-4^*-AX5_;1U#4-8^-\%M\0M6%]=ZYK_ ,./#OPH\8:UX3U"6.6Y\(ZE
MXW\%>%=%L/%,NDO'%>7-L^H6<-A>3RRMXU!_P2:_9DBN'OI_%/[06H:K!\+O
M@'\*/#^L7_QI\1S:KX-T;]E_Q#<>*O@1XA\(7B11/HOC?X>:]J&N7^F^)XQ+
M>7S^(]>CUI-2AOS'& 3?ME?MT^,?A#^R1X4_;)_9=\._!WX[?"36H_AWJ4^J
M^,?'WC#P6FKZ#\6O'O@'X>^![_P@OA_P!XNGNY5U'QPVK>(;;7H=$GTRPT:>
MP6&75;@P6O?WO[?'PG^%%C\1_#7[2&MVOA7XM? 3P'H7COX^Z1\+?!OQC^)G
M@3PAI?BK5X;#PG-HOBNS^&UI/K=QXDT^_P!*URWT*/3_ .WM-T^XU&XU"T6P
MT'5M2M^B^(W[!'[/WQ&_9+\,?L3/:^-? _P"\(VGP]L-%T/X<>--5\)Z]%8_
M##6M+\3>$[6X\3P&YU>Y2#Q+HFD^(-0>68S:KJEC%/?2S))<13<Q\</^"<'[
M/O[0WB7QCXM^)>L_&:\UOQOX!\+?#?5;G1/BWXH\-K:^&_#'B+PAXF>'2X]&
MFM!;#Q1?^"-%B\8:?*;G0=>M9M;$VCQ7/B#6;F] ,+3_ /@K#^P/J7C#PWX)
M@^.T4.I^+_A3X=^-WAO5+[P#\3;#P?JOPQ\6?"WQC\:/#_B:#QQ>>#H?"*KJ
M/PW^'OCCQ#%I<VLQ:RA\+:QI4NGQZS:_V>WT%^S%^UM\#_VPO"7B?QQ\"-=\
M2>(/#O@[QA/X"\0W/B7X>^/_ (<W=EXJM="T+Q+/IB:5\0O#?AG5+P1Z)XFT
M.^:\L[.XL2FHPQK<F998X_A.Y_X(O?LO^'W\->*/AEKOQDT#XB_"WX8^&_A[
M\';_ %SXN^*M8\*^&D^''PE^*OP?^%W]N>'I \.O:=X:\*_&+QKIUY#=K-/J
M=MJTDMT\]Y:V4T'KG_!+K]CCXP_L._L\:A\%_B[\7=*^*\P\:W_B'PK_ &1H
M'@O2K3PEHVH:3H]M?:.FI>"/A7\&+#7AJ6O66I^(C<:CX$BU>QDU:2PN]>U]
M8HKM #U;_@HK_P F)?M:_P#9!?B/_P"H[>5]G5\8_P#!17_DQ+]K7_L@OQ'_
M /4=O*^SJ "BBB@#XX_:-_Y.#_X)^_\ 9Q?Q2_\ 6,OVG:^QZ^./VC?^3@_^
M"?O_ &<7\4O_ %C+]IVOL>@#Q[]H7X86WQL^!'QD^#UYHOA7Q':_%'X9>-_
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M%+]ESQ+X,LM69O"GCBQUGPAX%O/A)XYUSQ?X7B^''C+2O%&C>/?%MM=>!_$
MUGQ!I^N?H-\)/V+?&?Q<_P""([?L63?"71?V?_B/XT^#_B[P=I7A[XF>(_%7
MBBT\#^/;OQQJGB#PS\8;S6K;P%\-/&L?B#2O$:Z9\7?"VG2_#SP-J?AKQ+::
M+H(T;1;'2H9(OC#X]?M0^+?V3/VU/V/?&'[,OQ%^,OQF_9]^(WP]\4:;XO\
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M\)>!_B_9^!X-*C^$/C;3;6]\-:)J<.A:5'#9ZOX=^D?$_P#P6K_:C\*?$?\
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MMO?^M5_%FOLNOC3]A[_DG'Q@_P"SR_VWO_6J_BS7V70 4444 %%%% !1110
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MQI]9\/V?B1-0D\/76KV"? HSV,&N)I6J/I<LZ(MZNGWAA+""3&]_PW#\'/\
MH2?VL/\ Q!G]L[_YQ%5?A/$L7[;?[8C<A[KX8_LES@$DAEBA^.UN649*K@H
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M!XU_Z,6_;7_\)CX ?_1$U]KT4 ?%'_#8'C7_ *,6_;7_ /"8^ '_ -$37'>
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M9['X)>"-+^'7PN_X)X_MG^%/!^CR7UQ9Z7#HGP3U.9[O5+V?4=3U#4=7UO\
M:6U+6M8U34;ZYGN[[5-7U&^U"[GD+W%S(0,?HW10!\4?\-@>-?\ HQ;]M?\
M\)CX ?\ T1-'_#8'C7_HQ;]M?_PF/@!_]$37VO10!\A?L2Z!XUT3X0^*K_QY
MX$\2_#36?'/[0_[4'Q/L?!?C&3PZ_BK2/"_Q+_:!^(GC;PB=>C\*Z_XHT*TU
M&_\ #>M:9J,UC9Z]J#68NTM[J2*[CGMXOKVBB@ HHHH **** "BBB@ HHHH
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MS?#7_P  =0_^6-'_  [=_87_ .C9OAK_ . .H?\ RQH ^W**^(_^';O["_\
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MR?\ #;J?]&D?MP?^(_7'_P TU'_#;J?]&D?MP?\ B/UQ_P#--7!_#G_@JO\
ML1>,=(C@\2?'[X7^"_B'HOP:T;XT_$KP(_B6^UF#P'X>O_ASX/\ BAJ'E>+_
M /A']*T7Q9:V?A3QSX<UC2+[0D:?Q7HNJZ=K.A:9<6M[&J_6_P "?V@O@]^T
MSX#_ .%F_ WQK:^/O P\1^)?"+Z]9Z9KND1Q>)_!NKW&@>*]#GL?$6EZ/JEO
MJ/A[7;.\T;5K>>RC:RU6RO-/FVW5I<11 '@G_#;J?]&D?MP?^(_7'_S35I>&
M?VUO"FN^/OAY\.O$/P1_:<^%VH_%3Q)J'@WP9K_Q1^#E_P"&/"-]XIL/!?BS
MQ\=#NM>BU74X=.N[OPUX)\275B]Y##:W$]@MD+A;FYMHY?LZOCG]J?\ Y*9^
MP9_V>-/_ .LD?M84 6?^"?O_ "8M^QY_V;1\%/\ U7GA^OKVOD+_ ()^_P#)
MBW['G_9M'P4_]5YX?KZ]H ^+?^"BWPE^-?QW_8>_::^#_P"SKKTGASXS_$#X
M7:SX?\#WL/B"7PG/?7=Q+:RZKX9M_%4,L#^&;CQEH$.K>$+?Q"+BV719M<34
MY+JVCM6GC_([4/"W[8N@7/B'7?V*?V2=2_8D\#:U\0OV%/A-::_X,^$G@S_A
M>VH?#NR\5:W'^T3+X]^$OBWQ/XB^#]YX-^"OA#Q#XBU+3?B9X<TRS\3?$C7?
M$&A6%GJFH6G@Z]CU3ZY_X*+?\%'_ !]^R/KOQ-T/X<>$?"&LW'PD^ _PE^)N
MN7OCJ74;?0+[Q3^TO^T5:_LR_".'5M0T^ZM)O#_@'P#K4/B3XC?$_68DO+[4
M],T[0?"VC2Z/<:GJ&K6GFG[6/[<W[4O_  3P^)G[.<OQ[\4?#_\ :!^!WBS4
MOBW:_$Z?X.?""3PK\7$T#P9\'6\>OXMO]*\0?%J7PEX3A\*^(8)YUL+'4M9F
M\2^!R\4<0\406YU$ ^9?C=XL_P""ZOA/X?\ [8EGX&O?B=XS\?Z+\;K?P-^S
M+_PA7P6^ (BNOAQX<T3Q;<^"?BW?>)?$6LSZ+XD\._%>RL_!T'Q8\+V'A&PU
M_P "_$>XU#^SK[P]X,OI].L]FXU#_@L?8?'[5M5\,/\ &'1_ GQ'_:A^&FJ^
M*[_Q'\./AMX_\-^#OA#_ ,,N?"SQ#X?\'^ O!X\3>'[S1? VI?&YOC#\/OC+
MJ[^)8]9\'ZU'X1UP77V*?5=7U/Z6TO\ X+)^!?!'Q.UKX;?%/X?_ !<\3KK?
M[57QL^"WAGQEX+^'W@G1/"GP[\/_  O^-GP=^!+1>.WOOC/K6N^(A9>)_C+X
M/UA?%_AS0X9/$>@ZRXM_!FE:SH]UI,_:>'O^"LW@_P")'Q&L-(\ ^!O&>AZ)
MX!_;,\!_L7?&_P ,?$30M"MO$$NN_'?2;V3X/?$[X=^(?"/C7Q/HEWH%IKND
M0P^(=$U./^U)-!U^]N+FWT;5=#MK:^ /)?V:(O\ @H[KW[7O[.NO?'^^_:3_
M .%+:"?VS=#\3S:AHGPB\+>"O$&M73?!Z^^"NK_$+P=X5TR+7="\-#0V^(VA
M^$!+?^)9H/%VB7=SI_C*]\/>(K1;CP;X:_LZ?M4?"WQ;JGA74/V4-.^('[0<
MO[<7[4'Q[^)'[:7BO3)=8OK_ ."OBG_A.?$WP*^(7P6^(NE^*H+K5?'/@KP?
M>> O@5HO[-WC[0KCPY8ZQI<&NR: WAKPNEUK?N7Q-_;=_:U\%_M;?\%!O T?
MB^,?!K]C;X9:7\:M&BT/]E27QAI>I^$[G]GR_P#B_K_@OQ?\5[GXV^#]*TWX
M@VUU 9/ >F&PTJ/Q7IVFWMM?RV1D.HVWI'PV_P""S/PKUBY\5> _%'PC^.M]
MX^^&?P/E^)NL>(K'PI\-O#WA+XKZEX>^%7P(^*.O6'PVL;WXQ:I=:)>ZMX<^
M/G@_7-/TKQIJ.EV&BQ'5='U3Q))?Z=;OJ8!\Z> +_P#X+36VC_L6S>)_%/Q1
M\4:W\2O!GPTUWXV0ZW\+OV>?"%E\.OB'J'C'P3X>^/\ X%^, T32KF30/"/A
M+X06?C;QU\%_$/@TW6H^(?B[JD>GZS<:EX=ATGPW#\'ZW^U9_P %EOA]X"^'
MOA?X[>*?VHOAU\6_B-\7? _PL^'VF:+\)/V3[OQQ\5_&0_8H^-'BOQWHOP]T
MR7PQJ7AC5O#L'[2G@3P;J/\ :UZNCR6OA'4=4:WNWT>^@AM/UR\+_P#!=?\
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MQKJ%SHGV+Q%J]Q\5?%MWXQL+>]MTF\+:K^P] 'Q]^W+_ ,D0\-_]G0_L/?\
MK:7P"IOB?_D__P""'_9GG[4W_JZOV.Z=^W+_ ,D0\-_]G0_L/?\ K:7P"IOB
M?_D__P""'_9GG[4W_JZOV.Z /KC4-0L-)L+[5=5O;33=,TRSN=0U'4;^YAL[
M'3["RA>YO+V]N[AX[>UM+6WCDGN;F>1(8(8WEE=45F'B?PI_:D_9H^.VL:EX
M>^"7[0OP2^+^O:/8/JFKZ)\,?BGX(\=ZMI>FQ7%I:2W^HZ=X8US5+RRM(;G4
M+"WFGN88HX9K^QCD97O+82^XW-M;WEO/:7<$-U:74,MM<VUS$D]O<V\Z-%-!
M/#*K1S0S1LT<L4BLDB,R.I4D'^?>;]EC]MW1?@9^WCIOPG^&GC7X,?&;XM?\
M%)K/XY_!3Q9\//BW\'/#GBV?]G?Q/XO^ =KX^DL_$$'B34-(T-+SP+\*_$<>
MK?#_ ,4QFUUI;SPS:2:;?S07$6F ']!U8?B;Q/X;\%^']9\6>,?$.A^$_"OA
MW3[G5_$'B;Q-JUAH7A_0M*LHFFO-3UG6=4N+73M,T^TA5I;F]O;F"V@B5I)9
M44$C^;7XG?LL?\%FO!OQJ_:5T+]GGXO?&3Q+\+;OX9?'&Q_9[^(_Q6_:4\+^
M)M.EUKQ-\+_@1+X TO5O">KWUAXCTOQM8^./#'QOT30_&#^'[#3/"6K^-] U
MJ'5(="@GO],^[_BO^S-^T1\;/V#/AG^Q9\1KKXD^-+CXP>#O$_@7]HWXR?$#
M_A2WC#QKX2\&G0==O[#3O'?AB/XBZ-H/CCQ/K]U<Z'X*AUCP-XH\4/I%_IP\
M7ZMKFJ31/J=^ ?KI')'-''+%(DL4J+)%+&RO')&ZADDC=25='4AE92592""0
M0:IZKJFF:'IFHZWK6H6.D:-H]A>:IJVK:G=06.FZ9IFGV\EW?ZAJ%[=/%;6=
MC96L,MS=W5Q+'!;P1232ND:,P_E?D_9]_P""X'B#PY^QS:SVWQQ^&6I?"'X#
M?!'X1_''2_AK^U;\&]&\+^/_ !%\.OV@-*T?QE\1/[(D\6ZK#=>)/&W[+<.O
MSW<H>$6_C'7;2W:6_P!;\+^&O$&F<AX)B_X*<^+/VLO@?^S9XD^(WQ9U+XS_
M  Q_87_9(\:?M3>"+[]H?P???"4WLWB_]J?P+\=&\5^$_P"W9](^)GC/XR>!
M]'^#NE:9J&@64D?A_P 2WVC^/?$FK^$I;^?4M2 /ZO/#/B_PGXT\+Z-XW\'>
M)_#_ (L\%^(](M/$'A[Q=X:UG3M=\,Z]H-_;+>6.MZ-KVEW-UI>J:3>VCI=6
MFHV5U/9W%NZS0S/&P8^)^&/VQ/V2?&VL^%?#O@W]I_\ 9\\6:_XZUC6/#W@G
M0_#?QD^'FN:OXPU_P]Y7_"0:'X7T[3/$-S>:_K&@^=#_ &WIFE0W=[I)D0:A
M!;EA7Y._\$L_V7_^"BWP \<^!M,_:0\1>)/#OP&^''['_P '/A3X&^">@>+/
MACXB^&>D^*/"W@OPOI'BG3]6ATK6[K7?^%DZ=XZT;Q+K6G>,]%TW_A'O$/@K
MQ19:=JOBH7&E6OA72/CSX3_L#?\ !1_P1XK^#7B[PUX(\9>"_%?A'XC?\%8_
M&'AU?&?Q'_9>U[X6_ /7OVNV\?ZI^S_XY\.Z=X,#?$;Q%.^K^*M'E^(VFZKK
MGCJ/1[BPU)](TFXM!9QW(!_4)>_$'P%IOC+3?AUJ/C;PE8?$'6?#NJ^+]'\"
MWGB/1[7QCJWA/0;NSL-<\3Z9X9GO$UJ_\/Z-?:CI]GJVLVEE+IVG75_96]Y<
M0RW4"2<]X#^-_P %_BD^G1_#+XN_#'XB2ZOH%[XKTJ+P-X\\+>+)=2\+Z;XC
MO/!^I>(["/0=5OWN]"T_Q=IVH>%K[5H%DL+3Q'87NB7%Q'J=K/:Q_P UWB']
MC/\ X*X:MJOPP^(>GP^+O^$X\#_"7]J?P)X=\2^*/C_X UWXY>!O GQ8^*?[
M'/B6;X83?%A_$$TNI^//'GAGX.?'F+P1\0;#5+JP^&I\:_#RSO\ Q!I3:5<M
MH'F'@G]A'_@K#\-_"&A>%/AKX/\ C)\-=.@T?3K6XG\'_M2?!C1_%UA=:K_P
M43^+?QS\?22^)K/Q0LMS=>+/V9?&FAZ)XE%O,^E:_P".XYY[BR_M*U37W /Z
M\**_CKLO'W_!027]K7X)?LM_&#XP_MLZ+\;H?V._#_A[7O#7PD\>_#&^\&CX
M\W/[/WQ"T^"\\5^*K;XNV&CWZ7>LV=O\2[CXF:U\*O$UI)\0X_#>AZY\0?#F
MCS30Z5_47^R7HOQ;\.?LW_"#0OCO!?6_Q<TKPA:V7CF/5/&-QX_U0ZM!<W2I
M-JOBZZU37IM8U2XL1:3ZDY\0>(X[2]DGT^#Q)XA@M(]9O@#P7]LK7;SPO\9/
MV+O$VGI!)?\ AWQO^TEKMC'<JSVTEYI'[''QVU"V2X1'1V@::W1951T9HRP5
MU)!'(_ _PC^W/\6?@M\(/BI?_ML^$M(O_B9\+O 'Q O=)L/V4/"$ECI=WXS\
M)Z3XCN=.LI+KXCS7+VEE-J3VUN]Q++.T,2--(\A9CJ?MW?\ )0_V3/\ L._M
M3?\ K%7Q]KZ+_8T_Y- _93_[-M^!G_JL/"] 'F/_  I']MS_ */I\._^(F^"
M?_GAT?\ "D?VW/\ H^GP[_XB;X)_^>'7W!7\HG[<W[3/Q=^'G_!6C5?!'@#]
MI?XLZ%X-TCQC_P $XUU/X9^"OC=J_B&_M9_BM\0OBOX4^+_A3P9^RK<@^'/B
M-IOBKP=9?#S4OBGJ3Z]H=W\#_"C'XNZ;H^J7UZT.H@'[M_\ "D?VW/\ H^GP
M[_XB;X)_^>'1_P *1_;<_P"CZ?#O_B)O@G_YX=?SO?L2?\%7OCGX5^'?P_\
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MZ< KRWUS<7<[7$45MT'_  3?_P"3-?A-_P!A+XL?^KG^(=:7PO\ ^3[?VO\
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MK4[2Y\,QVGAS4G\+:'X0&N:Q+<]1X<_8X_8U\0_LD_LW_#?P+^U[XIU7X$?
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M59]$U2\LY?!OC6?6;.^N-82*2T4 XSP_\&/^"5GA31?V./C9K'[(/PU^%/\
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M7D"QW$G5U^-'A;_@I7XH^%WQB\1?LZ_'7P;\0?CE\6;3XM>#_@'H5O\ LW_
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M+K5-+^5_A#_P62TS1I_VSO#7[0G@;Q?XI\1_LR>/OBYKOA?6_@EX'T6#PO\
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ML;C2=$M/'.N^)=2M+C[5;SKKEOHA\-0NTVD76M6WB&UGT=*G_!0O_DUO7_\
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ML?$OB>.QGNO W]J?9=5UG3=.N5L]2U/4[328;&TT[08-*TRWBLU /+_V5O\
M@JSX@_;J_9C_ &\+WQ?:_#_X!^)O@9\!F\>Z)XQ^#OQJFUUM-TSQ5HOQATW1
M_$$OB;6O#WAW_A%=:TOQ)\*+C4[5VAO;)-.UW2+:XE>[@NQ/\9ZU_P %-OBU
MIW[,'[(7@*Q^-]E;Z[J'AK_@F+\1=<^/L7Q=LO%7Q1^).J_%;X]_LYZ/^TAX
M:\?_ &;2)_"?AG0SH/Q2U_1M5T'Q+<Z!?G2)H;OPL-4M=%UZ/PM^[,'[?O\
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MT?\ X3[5/"EUX4FM[/1#8>*]=8SS:OJFKPR_HG=P_L2^+O#_ (&^ NH:_P#
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M_P $KOV^?"=_\4=.\(ZKI\'A[QA/^U9JU[J&B_MF?&3P]>>/O%GQ6_;*\/\
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M@G4/B+^S_P"-8?!]C;7WAWQM#\*IM UZP>2"VN]3_?[_ (73^W%_T8[X*_\
M$NO#?_SHZ/\ A=/[<7_1CO@K_P 2Z\-__.CH \ _X)W?LJ?M)?LY^,O&E]\8
MKS1CX3U?X%?LX>!-,TRR^,'C3XD1V/CGX4>!K?P3XD/A'0M2T+PIX5\&> ;B
MQTK3[RRT^'09_$;ZU>:I)+KMSHDFGZ5I'ZO5\0?\+I_;B_Z,=\%?^)=>&_\
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MA>%?'-SJFJ36/[2_PCU>]$$9\,)&D5GIFGWNH7ES/)%:V=E:7%W=30VT$LJ
M'Z^4444 ?%GQ/_X*#_LI?!CXYP_LZ_%#Q[X@\'_$N6+X7W$HU+X6_%9_ NGV
MGQJ\63> /A1>ZO\ %.S\%W/PTT:Q\=_$&VN/ &@7NJ>*[2UG\:PR>&998=6
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MIG]A^,+[1M6MO&/Q8?4;J[U'P9X!\-IXAO+MO#>GVR1@'[?45_&?\)?^"?\
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MQ?M,_P# ].^ ;_\ O&%H ^RJ*^-/^&8OC"/N?MQ_M(?\#T/X!/\ ^\=44?\
M#,WQJ'W?VY?VA?\ @?A?X O_ .\B6@#[+HKXT_X9J^.0^[^W-\>_^!^#/@ _
M_O)UH_X9N^/0^Y^W1\<?^!^ /V?Y/S_XM:N: +'[+G_)4/V]/^SP['_UC_\
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M_P#LPS>G^Q\9E[T ?9-%?&__  K;]N!>G[4GP:?_ '_V8]0&?KL^-R_I2_\
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M_95;_?\ V:OBE_[)^TXOX_H!2_\ "+_M]#I\;/V2F_W_ -FOXN?KL_:D7_\
M50!]7Z/H6B>'K1M/T#1]*T.P>ZNKU[+1]/M-,M&O+Z9[F]NVMK*&"%KJ\N)'
MGNK@H9;B9WEE=W8L5T;0]$\.6$>E>'M'TK0M+BDN)HM-T;3[32["*:ZGDN;J
M6.SL88+=)+FYEEN+AUC#33R22R%I'9C\G_\ "-_M_@?+\9/V/F]W_9L^,_7_
M (!^U6HX^E,;PY_P4$_A^,7[''_ OV;/C9_3]JV@#['HKXT_X1W_ (*%#_FL
M'[&C#T_X9O\ C<GZ_P##54G\J3^P?^"A8_YJO^QF_P#W;[\;H_\ WYF7'ZT
M?9E%?&?]B?\ !0H?\U._8S;_ +H7\;H__?B9,?KCWI?['_X*$C_FHG[&C_\
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M_P#X>S]D[_Y]U 'VK17Q5_PT7^T[_P!(^?C/_P"'L_9._P#GW4?\-%_M._\
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M*^*O^&B_VG?^D?/QG_\ #V?LG?\ S[J/^&B_VG?^D?/QG_\ #V?LG?\ S[J
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MMM2M-?75VO=&3\G/A1\!_C9K_P"Q/\"?'G[-VE_'F/\ ;6^"7[,_QZU?XC_
M#XJZ?^TOX2\-_M7?"KQ5\9/'GA_QU\!?B7?_ !"M-*TRW^(VI>#]0M_%'P*\
M16^JQ^-_#/C'2?#US:PR>$]3^T6G]F%% '\]_P )OAG;3_M2_'WP#^T]X<_:
MB\/:L/$'[..D_P#!/N\^'3_&VU\*^%OV:-+^$O@9[_PSX<\8>%I+OP+X<\36
M7Q)TCXDV?[1\'Q0U*RU/Q)H,VE6VJQZKH=[HT$G]"%%% !1110 4444 ?$NC
M_P#*1WXB?]F2_!K_ -7M\=Z^VJ^)='_Y2._$3_LR7X-?^KV^.]?;5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!\/?'G_D\[]@G_KK^U#_ZJ33J^X:_.W]K3XB?#_X6_M6?L'>+_B=X
MZ\&_#GPG!J'[2VGS>*/'GB?1/!_AV+4+_P"$UBMA82:WXAOM.TU+Z],4WV2T
M:Y%Q<B&8PQN(9"ON/_#;_P"Q;_T=[^R]_P"'_P#A1_\ -90!]0T5\O?\-O\
M[%O_ $=[^R]_X?\ ^%'_ ,UE'_#;_P"Q;_T=[^R]_P"'_P#A1_\ -90!]0T5
M\O?\-O\ [%O_ $=[^R]_X?\ ^%'_ ,UE'_#;_P"Q;_T=[^R]_P"'_P#A1_\
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M+#]'* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#,U71=&UR!+76])TS6+:.03);ZK86NH0)* 5$J0W<
M4T:R!690X4, Q .":P/^%=?#[_H1/!O_ (3&B?\ R#7944 <;_PKKX??]")X
M-_\ "8T3_P"0:/\ A77P^_Z$3P;_ .$QHG_R#7944 <;_P *Z^'W_0B>#?\
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M&_\ A,:)_P#(-=E10!QO_"NOA]_T(G@W_P )C1/_ )!H_P"%=?#[_H1/!O\
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M,7_9F7[-G_J[_P!JZOLTG )YX&> 2>/0#))]@"3VK\7_  #_ ,%'OV!?$O\
MP4K^(/A/P_\ MC?LYZQXL\6_ #]GSX+>&/"^G?%;PG=>(==^+>D?'3]I6'5_
MAOIFD1:BU[=>-M*E\1:#'J7AF.(ZQ9'6-/:XLXTN$8@'T;^WC\&?CA\7?'G[
M!FK_  @\#Z'XNT;X$?MC>%_CU\4I]:\?V7@Q],\&>'?AY\0O ;QZ'I]UHFK'
MQ+KL]Q\23J]M9^?I<$5GX=U"U>]6ZU2Q*?CA/_P1Q_:VTS2M3U/3-:\)ZOK7
MP_M;GX1>!O#<WQ"GTZP^*'@C6?#'[;WA&[^+^KZ@^@747@[6-+C_ &R=/U@>
M#+R#6M1OD^&>L6<>LP3ZYH\B?U144 ?SK_%G_@C/X^L[?X@:_P# WXH^)(?B
M#JG[,'P_\-I?ZIXX;POI7B[XX?#JS^%.D10Z5?:)H0\6^#-(\6V?P>TKQ%JO
MB/5M?\1'1/'%QX/U?PSI^DP^'=<CU7]HOV3/!/Q<^&_[-/P1\!_'KQ=_PG7Q
MB\*?#OP[HWQ"\5'4;K6GU3Q%:6:I<B;7K^.*_P#$5Q81F'3+GQ)?QI?>(;BS
MEUJ]'VJ^EKZ&HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^(]3
M_;=TL>-OB3X+\$_LW_M3?%@?"KQM<_#OQ5XL^'7@'P7>>$/^$NL=#T'Q!J6E
M:5J'B;XD^%]0U'^SK+Q)ID=U=QZ4MG]K>>W@GG-O(P^W*^(OV,O^1@_;9_[/
M=^)7_JLO@U0 ?\-F>(_^C(_VW?\ PW7PJ_\ GUT?\-F>(_\ HR/]MW_PW7PJ
M_P#GUU]NT4 ?$7_#9GB/_HR/]MW_ ,-U\*O_ )]='_#9GB/_ *,C_;=_\-U\
M*O\ Y]=?;M?E/_P5(\0>)O DO["'Q%LO'WQ.^&_PT\-?MV?"[3_VB/$W@;X@
M>.? GA.U^!_B+P9\1H-13XOS>#]8TNRN/AY<_$:R^&EE?7OB9)=(T^[N[:SN
MKFSTS6=66[ />_\ ALSQ'_T9'^V[_P"&Z^%7_P ^NC_ALSQ'_P!&1_MN_P#A
MNOA5_P#/KK\G_%?_  4I^)_[*7[0W[,/[/OAJS\-^/O@I\<(/!/Q!\2^.?C!
MXC^.7BWXPZ;I?QU_:B\4?"O1Y-!UWQ-KFJV4?AC3?#%WX>\;Z!!JZ6]AIGA+
M2+NVLK-M+U:QU72><_9+_P""DW[9!^!VF:Q<?"72OB?H>F?L2>-_VQO":N/C
M5XZ^(WQ&G^&/C_XS>"_C+\%;KXC^+M?G,/C_ $[QOIGPHE^'T6IZ1J6H'P#X
MTN].AT+6[CPG]K< _8/_ (;,\1_]&1_MN_\ ANOA5_\ /KH_X;,\1_\ 1D?[
M;O\ X;KX5?\ SZZ_*7P!_P %6OVV_'\=S%;?#/\ 8[T6Z\._L2_\-:>*;[4_
M'/Q*O/#LAE^*?C[X=Z9IVB^(O#@U[04L-3T_2?"7B75K;4]7B'@5FUO2_$?B
M22WNDUKP_P#2G[&G_!2/X]?M-?M5Z1\$M;^"_@WPU\,(?V9OAM\6=9^(-]=^
M(/!?C+Q7XJ\>Z)<:TOB?X;?#W7[_ %NYU?X16FIV6J?#_4+J+4=831?$VE0:
MHWCO6=/\2Z!I\P!]C?\ #9GB/_HR/]MW_P -U\*O_GUT?\-F>(_^C(_VW?\
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MS/$?_1D?[;O_ (;KX5?_ #ZZ/^&S/$?_ $9'^V[_ .&Z^%7_ ,^NOQ2^+/\
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M7K[=KXA_;4_Y"/[&O_9[WP>_]17XET ?;U%%% !1110 4444 %%%% !1110
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M%WC*74]07QQJRRV<GAE[*RFN-5U&VT3XL/\ P2B_9O\ V=/#6E>(]/\ B?\
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M#_A_XH?![XA^!?VBM5\4?$G1/ &@^!?"WBK6M%U/5X&^)?PY^''C37K?5(/
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MVUGP_K,>FZG9:SIZZAIUVCP7 LM6TZPU&V+J3#>6EO.A62)6'?44 ?DQXO\
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M$[4O"WQ&/AC5/"GQC\2:UKGPZU'3?!'B+2_^$2\"?#[P]??V?&UTFFWO%/\
MP2__ &D-5\.?M,ZK#XU?6?B?\1?VK] ^)'PKFUS]K#X]Q> H/@II.B^ 9[K1
M/''A*S\)#1K34]?^(?A77O&'BWPOX2TFP?58_%NJ-X>^(GA'5A;7$'DFI?\
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M33+NVO;27:OF6\\;X&ZNHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO*_BA\1O$
M'P[M]!GT#X,_%/XQ-K.I/87EM\+W^&:W'AJ!4C8:KKP^)/Q)^',3:;(79$_L
M*76]0#PR![! 8FE /5**\GN?B5XAM_BA8?#R/X*?%>[\/WNGQWTOQBMF^&(^
M&&G326EQ<G2[^.Y^)=O\2AJ$4D"64AM/AQ>6 NKJWV7[VWGW,'/Z-\9_%6JV
M/Q'N[O\ 9Q^._A^?P$DK:3IFLI\'&O?BB8[B^@5/AR^C?&'6-/E>9+.*ZB_X
M36^\$K]GU&P\QHY_MD%F >\45\]7_P <_%5A\//#_CM?V9OVA;_5-;UBYTJ\
M^&>GVOP;F^(?AB"![Q8]:\003?&2W\('1[P6L<EL^@^,-<U!4OK,76GVS_:D
MMNEU'XJZU8?$#PIX'B^"GQ@U33?$VFV6H7GQ(TZR\ -\/_"$MXEZSZ5XKGO/
MB%9^+(=2L39QI>KH?A'7;)'O[+R;V=6N6M@#V"BO$M'^,.N:KJGQ'TRX^ _Q
MMT)/A_97]YIVIZQIOP[&E_$TV4MW'%9_#B?2_B1JDU[>ZBEM'/81>*K?PDAB
MO;07<MI,;F&VQ)?CUKT7PRMOB,?V;_VB'U"X\0G0I/A=%H7PVD^)MG;".>3_
M (26YTU?BC_PC!\/$PK&);;Q;<ZJ9+B!?[)P96B /HBBO&-6^+VJ:7XG^'GA
MN/X*_&?5K?Q[8:5>WGBG2=$\'R^&/AV^IOLDL/B'<W?CBSU33+_21B358]"T
MGQ'#$A_T6XO&!4/TOXN:CJ7C#QWX3E^#7QDTFV\$Z?J%_:^,M4T'PLG@_P >
M&P,86Q\"7MEXROM7U'4+_>?[/M]9T705FV2&22$ ;@#V2OSMT3X0?MK_  C\
M??'N]^#FJ_LM:[X"^+_QIUKXPZ6/B7'\6M-\8:+/XA\(^"O#U_H>HCPNE]HM
MY':7?A.6XL[ZU-LTUI=Q1SVJ3PR22_0]K^T#JES\-+WXC-^SO^T7:W=GKD&B
M)\-;KPAX03XEWT<R0.=;LM&C\?RZ+)H<'GE)[J;Q%!<J\$X6S<*ADV-8^-MY
MI$_PSA'P3^.>JK\2+/3;NXN-'\(Z'>0?#AM1>R5[/XF;O%D,V@WFF_;"^I)I
MD.NQ1):7IMYKDP@2 'B&_P#X*3_\^W[#O_@=\>O_ )74;_\ @I/_ ,^W[#O_
M ('?'K_Y75]!V/Q;N+WXD>(_AVWPG^,%C!X>T^>_C^(=_P"%M+B^&_B%H+2S
MNOL'AS78O$,^HWVH3&[-M!!<Z)91R7=I>1"8")'EY72OVA)]4\ >*/'I^ O[
M1.FOX9U.UTU/!&J_#[3;7Q_XD%U]ESJ/A?0%\430ZEIEM]J_TJYGU&R>+[-=
M8A?RAO /)M__  4G_P"?;]AW_P #OCU_\KJ-_P#P4G_Y]OV'?_ [X]?_ "NK
MV76_CT^B:+\.-:?X*?'[4_\ A8N-^DZ)\/8=3UKP"3)9QD?$>P@UW_BF]HO/
M-)AEU)3':WA0LT&UNB3XL%_BO<?"L_#+XMH+?3CJ(^)+^#T'PHN -,AU+[%;
M^+EU1G?4<RG3A:MIB,=3AFMMVU5E< ^>-_\ P4G_ .?;]AW_ ,#OCU_\KJ-_
M_!2?_GV_8=_\#OCU_P#*ZO7M%_:#BUKPE\0/%J_!;]H32U^'\\,#>&]:^%]W
MIWBWQF)I&C\_X?Z')J+2^)X(MGF3/%-;-'&RML)8"H]:_:)MM#\%^!_&DOP7
M_:(U!/&]U=6J^%]%^$NK:OXT\)FUD9#<>./#ME=2W'AVUG"^9:SRR3K.A4J,
ML%H \EW_ /!2?_GV_8=_\#OCU_\ *ZC?_P %)_\ GV_8=_\  [X]?_*ZOH:Y
M^+L%M\5=.^%3?#KXN33:CIXU%/B#;> =1G^%5H#I]SJ'V/4?'$<IL;+4/]&-
MD;2>%7&H36UL3F97KG='_:"L-8T_XF:BGPF^/^GK\,8KN6YM-8^$/B73=0\;
M"TEO8C'\,[*X19O',MQ]B:2TCTD,;B*YLG3BZC! /%+B'_@H]>1^3=Z;^PM=
M0EE8Q7%S\=YX]RG*MLETQEW*>5.,@\@BJR:9_P %$HUD2/0OV#425H6E1#\<
ME65K>7S[=I%72@':";]]"6!,4O[Q-K\U['J?[2FEZ5\.-!^),WP=_:/NK37]
M7O-(3P?IGP1\8ZI\1])DLS= W^O>![&VGUK2=(N?LC&SU*XA^S3B>U(9?M$>
M>LU/XT:=I?Q$\)_#F7X>_&.[NO%VG6NHVWB[3/A=XHU+X=Z(MW'=2+9^+/&M
MI:2Z/X9U&$VICNK+598);:2>U$P5;A&H ^)?C+\#?VT_V@/AOXP^$GQ7\&?L
M,>(? GCVRBL/%&FVFL_M!Z'>ZA!;ZC9ZO!C5M+L8+V-H]3L+.ZEC=Y;2^6%K
M+4[6^TZYN[.?QKX!^$_VL?@)XEOOV*O@Y\*/V%/"'A+X7?##PE\9K$/K'QVU
M&QN_^%P>/OBSHFHK]FF\/JRZRVN?#_6M:UC41<107A\1P06FG6Z6T[/^EVC_
M !ZT?6=5^)NDP_#?XZ6,OPNM=6N[^\UCX->.M)TKQ@ND3W4$L/PRU.^TJ&S^
M(5U?-:-)I-MX:EO9=3@GM9K19([B,GX;T+]I3P_!^UM\6OBW)\+/VBSI=S^R
ME^SIX=_X0R'X _$VY^*T$]O\<OVKU.J7/PQMM!E\7P^'IL;K;73IATZ=3E)C
M@@ 'LZ:;_P %%(R&CT3]@Y&%Q'> HWQR4B[B1HXKH%=*!%Q'&S1QSC]ZB,R*
MP4D'PW]H3]EW]K/]J;X<W'PH^-O@']AOQ)X(N=<T/Q+)IVF:_P#M!^'K@ZUX
M;O1J&D74EUIVFA;R&WN=S2Z?J5O?:;<A]\UHT\5O-#][:Q\=-$T7Q7\._",_
M@#XVWMU\2=/TS4=-UK1_@S\0=7\*>&8]4D$45M\1/$VGZ'/I'P^U"T8@ZG8>
M++G2[K3H\RW<<42LZR:1\<M"UCQEX^\$Q>!?C38W_P /--U75-1UO5_@Q\1M
M+\&^(X-)EMHI;?P#XRO/#\7ASQYJ5X;E7TK2_"^HZEJ&IQQ7,EG;2I;S% #Y
M'^%?PP_;I^"7PY\&?"3X6>$OV$O"'PZ^'OA_3_"W@[PS8ZA\?WM=%T+2XA#9
M644DUB\LGEH,O+(Q>21G=L%L#O\ ?_P4G_Y]OV'?_ [X]?\ RNKU:V_:9\+7
M7PSU'XIK\-/VC8M)TW7X?#LOA:Y_9R^,5M\3+FYF6U9=1T[X9S>$4\:ZCH""
MZ03:_9Z--I4+172R72M;3A-;6?V@?#>B7?PULY_ 7QVO7^*-M87.D3:-\!OB
MOK5IX974;FRM8XOB5=:;X5N8/AG<V[WT<NH6WC=]$FT^V@O;F[2*&RNGB /$
M]_\ P4G_ .?;]AW_ ,#OCU_\KJ-__!2?_GV_8=_\#OCU_P#*ZOH/3OC3H&I?
M$?Q'\,8_"'Q=M=7\-:==:E<^(]2^#_Q&T[X=:K#:0V<TEOX:^)%YX=A\%>)-
M1D6]C6WTW1M:O+VYEAO(H('>SN5CY?3/VE?"6J_#_P 4?$:'X??M!VNE>$]3
MLM*OM U/]G;XRZ7X^U.>^GM(([CPS\/K_P &P>,/%&G0M>1O>:GH6CW]C9PQ
M74]S/%%:W#Q@'DF__@I/_P ^W[#O_@=\>O\ Y74;_P#@I/\ \^W[#O\ X'?'
MK_Y75[)K7[1G@_0M&^'6N7?@SXX7%I\33&NC6VE? ;XMZOJN@M)<6MMM^(&D
M:;X1NM2^'9C>[1YO^$SMM%$4$-W<.1#9W+Q]-#\8_#L_Q5N/A /#GQ.C\0V^
MGG4CXAG^%?Q @^&DL(LH[_R;;XI2^'U\ W%\8I/*6PAU][QKQ);(0FZB>( '
MSKO_ ."D_P#S[?L._P#@=\>O_E=1O_X*3_\ /M^P[_X'?'K_ .5U>OZ'^TIX
M%\0>$O'GC.Q\+_&F#3?AU/;P:YIVJ? GXN:/XGU%KF=[>.3PAX4U/P?:^(?&
MUNKQN\T_A73M6B@@7SYF2)E<IK'[2_P_T+P5X&\>:AX>^,7]C_$&\N;'1-/L
M_@;\6]1\56$UK<26TC>*_"%AX/N?$O@VW9XF>"Z\3Z9I5O<0-'/#(\,B.P!Y
M#O\ ^"D__/M^P[_X'?'K_P"5U<;X@^$'[;/Q>\;_  *F^,&J_LL:#X"^$_QK
M\,?&+5C\-H_BWJ7C#6)?">A^*-.LM#TQ?$ZV&BVBWUUX@B>[OKMKDP6EO,L%
MK)/)&\7UQ<?&KPC;?%/3_A ^E_$)_%.I:;%JD&I0?#'Q_<>!(K::SNKY([WX
MC0^'7\#6%Z(+219+"[UZ&\CN)+:U>%;BY@B? T3]I#X=^(+#XDZCI^F_$];?
MX4QM)XH6_P#@Y\4M+N;M$GU"W8^$+/4?"5K=>.R'TRZ;;X.AUMC$UK, 8KVT
M:8 ][HKYUU']J/X6Z3\.O#WQ1OK/XH1>&/$^LW&A:9;Q_!7XMW/BJ._M?MGF
MMJG@JU\&S>+=%L2+"<Q:GJVC6>GS@VYAN7^U6_F]/J/QV\!:7\0O"?PQN8?&
M\GBCQKIUGJNB26?PU^(%]X:2SOH;V>W.L^,;/PW-X4\/7'EV%QYUGKNL:?=V
MSF".XACDNK990#V.BO#]&_:&^&VO:G\2M(TX^-FO?A/9:CJ'C 7?PQ^(^G6X
MMM+>ZCNSX<O=0\+6UIXSF#6<Y@MO",^M7%VHB>UBF6> R8DW[5/P@M_AA;_%
M^>X\?1>";GQ"?"\<K?"'XKGQ$NKB*:;;/X+7P8WC&"P*0/MU>;0TTIG,<8O#
M)+&K 'T77\UC:?HWP]_9_P#^"FO[-/[3WP@\??$/]KO]H?XW_M7:]\-4L?A7
MXG\<:Q^T;X4^*>H:LG[(.L_#'XAZ7H>I^'M(TKX9^%7\$>!+2/5O$OAM_@IK
MGPZU?6]2@T"RMK?7M1_>G5?V@?AIHWBCX=^#K^[\5+KGQ3L-+U/P<EO\._B#
M>Z=/::PVVQ;7-:LO#-QHWA.9CQ<6OBJ_T:YLL@WD4 YIVE_M ?##6?&/CWP%
MI^I>(I/$WPST_4-3\7VL_@'Q]9V%I9Z6(S>/I>NWGAJWT+Q+*HEC,-MX;U+5
MKF[R?LL,VU]H!_,Q\3_ 6O>&];_:G\(?'KXP?M,:U\=])_X(8_ CX6?$6\\&
MZ]\<M3\&^.OVGO#OACXSZ7\1/#7ARY\->%KGPOXFOM1UW7?"&O/H6AW=Y-/<
M?$O5-2%GY_B;6%MO2M#^*GQ6\"W'P(\+:)XN^/WQ"_9OU;]D-/#WB+1-8TKX
MNWVOZ3+:?LT_$G4/%&I>-_#/B[X7:EI/Q/\ ASIOCJXL-*U[Q?IGB[P=\</A
MQXJT?P%\.+/P?XR^'^H1VUK^^]K^UA\$;SX97_Q@AUWQ4/ >EZ]%X:O]0F^%
MOQ3@U>#5IX[:6.+_ (1*;P8GBV:T,=W;LVIV^ARZ:F]E>[5HI0FQK/[2?P?T
M"X^&=MJFOZY#+\7[2POO /D^ /B'?1ZI;:F]E'9MJ<MAX5N8O"TCOJ%H)8/%
MCZ)/;>8YNHX1!<&( _FG^!GQI^/_ ,)_@U\,?A/X+^(?[5'BCX;2_L;?\$UO
M&'QWU&/P!X_'COX#>%9/'/C'X>_M=GX'6$/PUTFX\*ZO\./AE:?#6#Q'X)\(
M6FN>./"GAV+4/B#X?T;4/%\=YJ<WN'A+QC^U7XY_:%_9Q^#DO[3_ .UCHWP0
M\6_$3]M>7X4:_:>&I-%\5_%OX+^$M$^%'B[]G/4?BQ\2M:^%>J7^CM=>.8?B
MEX'\+>(O&%_X>U[Q_P##?P\+N_MI]4UQ];U#]^[#X^_"O4OB5XE^$-GK^IR?
M$#PCIUQJNOZ/)X-\;V]E:6%K9V-_-/;^)+CPY%X7U,K:ZE9NL&E:U>W$CR/!
M%$\]O<11<MI7[6/P'UKX>^*_BGIOB[6)_ W@G5;;1?$VK/\ #OXF6MWI^HW?
MV/[/##X?N_!\'B/4XF^WVNZ[TG2+ZSB\QO.N(_)G\L _-[_@E]XY_:R\>?$C
MX@:]\??BQJ.O1:A\.+%?B=\$=8\#?%FPU#X,_M#:9XVU&'7U3Q-\1=(\/>&O
M#VF:OI-YJ'AO2OAY\*;;Q!\/[W3_  -;>.-#UM++5;>[\0_M;7SWKG[5'P*\
M.:)\-/$6L>,KVVT?XO[O^%>W47@GQ_>MKFR:QMV%Q:6'A:ZO?#Y6;4K-"/$E
MOHY!D<_=@N#%TB?'OX4R?%R;X%+XEN?^%I6^FR:Q)X<?PQXNCM_[.BTV'5I+
MB+Q))H*^%)]EA<13-#!KDDX9C;^5]I1X5 /8**^<M%_:T^ 'B'P?\0_'NC^.
M;B[\*?"FXBM?'NIGP9X]MGT*>:5H(U33;OPO!JVKJTJ,AET*QU.)<%G=5^:H
M=>_:\_9X\,^!_ OQ(USX@M8>#/B5=WEAX*UAO"/CJ=M8N["9K>\A?3+7PS/J
M^EM#,K(6UFPT]&()1F7F@#Z3HI 0P##H0".HX(R.#R/QYI: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC+
MPY_RD,^,7_9F7[-G_J[_ -JZOLVOC+PY_P I#/C%_P!F9?LV?^KO_:NH ]0_
M:H^.$W[,W[-WQQ_:(C\%W?Q$M_@=\,?%_P 5M6\%Z=KNF^&]2U[P[X#T:Z\2
M^)K;2]8UB.33(-4A\/:=J=WIEO>B.'4;ZWM]--Q:M>+<1? _Q'_X+$_ ;X3^
M*[;3?'/@OQII?@VW^%'A?QOXF\;0W.C7C>'_ ![XX_9_\<?M.>#OA+'X9CN%
MU36M5UOX2?#CQ5>#Q/I\O]@V?B4:)X=G.[5WOK#]!?VE_@A8_M+_ +/OQD_9
MZU?Q;XA\#:%\;/AUXI^%WB3Q1X3MO#UWXETWPMXVTJX\/^*%T1/%6C>(-"AU
M'4/#]_J6F6]]>Z/?-IKW@U"SC2^M;::/X2UW_@D'^SKXZU+1[SXH^*OB+\0K
M"'X2Z!\./%>AZA)X/T33O'/B;PG\%/&G[.OA3XNZL_AWPIIM]I'CKP_\'/B'
MXN\+V5GX8N]%\'/>7FG>(KCPU+K.C6-R@!Q-C_P6<^#-KXY^"'PZ\;?#3Q=X
M-\2_$3XB_%7X6?%667Q%X7U;P]\"/%?PNUC1= NFUG7;>>VB\;:)JNI>)-#N
MVU3PO;[M"\-WK>(M;M+6UMWA/Z#?LO?M/?#;]K'X:R?$OX::OH][8VGB37/#
M&M:-8^(=)U[6/"NJ:5=>9:Z1XOBTB6:+P_XGN] NM&UZ_P##5Q)+>Z)'K$%A
M>2O=03[? O"?_!-;]G[1/!/A#PMXG@N/B/KN@_&[Q)^T!XD^(OC#PWX G\;>
M-O'WC*XL[GQ?'<W]AX1L[3P=X:\5'1/"NG>)- ^'EGX4MM<\.^%M-\.:F]UI
M-QJEO?\ >?L:?L-_"?\ 8@T3XGZ%\+-8\9:Y;_%'Q^_C?49_&FHZ;?W.BV-G
MI-EH'ACP;HQTK2='A_L#PKHMC'8V%UJ4-_XAU!I9[K6]9U*X:-X@#[.HHHH
M**** "BBB@ HHHH **** "BBB@ HHK\@(OVVOVF_BS\+/VJOVH_V?O#OP8A^
M!_[+/Q$^/?@'2?AI\1M$\:WOQ-_:#;]E;7=;\._&C4].^(.A>,-(\/?!G^V?
M$7A3Q=X8^%]KJ7PZ^*!N[C1].\1^)YM/TW7O[+TH _7^BORQ^&'_  5X_9E^
M*^K>"-+\-^#_ (^Q6OC _LG0WGBW5/A3?Z7X#\(W?[:O@K0O&7P!BUSQ3J>H
MV,.H6WBEO$6E^&I[_P *6OB.UTSQ#.1?/#HT4^L1>:?'C_@IFVI^"_A7X_\
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M?#=Y>Z3J5J=FH^&_$.O^'M4L;BSU+1M9U'3[N"Y?Z%H **** "BBB@ HHHH
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MDR3@'[TT5_/C)KGQ]T3]KSXJ_LX^/?C+\=_!'PX^#/P;T']H[Q]\;M0_;?\
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M3^OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPZA^'UK\(?CW^T?X M/#/Q1\'_$[QK9P?%C7KG3/BEJ^D_$_QS\7_B+?^--
MLSI?A_5-=^/'BSQSJ.F_&"\DTU=)\1>%(]/TJVT.PDT'P_/IWZ%44 %?&?[?
M'_)NB?\ 9P7[&G_K8WP&K[,KXS_;X_Y-T3_LX+]C3_UL;X#4 ?9E%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$?[4B(&8C<VQ$3).U5& /L:B@#X[_X:-^/O_2/[]I+_ ,.;^Q;_ /134?\
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MNELT2NH8$  Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OB']H0$_M<_\$_B 2!XU_:)R0#@9_9Y\6XR
M>@S@XSUP<5]O5_'!_P %B_\ @G3_ ,%#OC#_ ,%@/V'_ !#^S+^T_P#M6^!/
MV</VD=;O+/XG7G@#XP?$W2?#7[,VJ_#GPU&GQ8UOPO!I7B"WTOP"GQ6^#\$E
MGX=BTU-/@UWQO!XAL[E6&HA9P#^Q^BJ&E:=!I&F:;I-M+>36VEV%GIUO-J%[
M=:E?RP65O';12WVHWTL][?WDD<2O<WMY/-=74Q>>XEDED=S?H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O@#]OKP=X6^(B?L?^ O'6@Z=
MXK\%>+?VS/ 6E^*/"NM0_;-"\0Z;'\*/C7J<6GZUISL+;4[&/4M/L-06SO$F
MMC>V-I<-$TEO$5^_Z^)/VR/^1J_8>_[/;\"_^J:^.U %W_AW5^PC_P!&D? /
M_P -MX;_ /D*C_AW5^PC_P!&D? /_P -MX;_ /D*OLZOPL_X*6_MA^(?AW\?
M?@YX(^!GQ]\4:#XE^&6A_M)>+OVD/A#X7U+P?H%O=>$O!O['_P 2OC[\.=7\
M4ZOXV^&?C:XT;1G\1^%/#PE\8>'%O=(L(;R70M?M+FZU".QH _07_AW5^PC_
M -&D? /_ ,-MX;_^0J/^'=7["/\ T:1\ _\ PVWAO_Y"K\9[;_@OYI_@CPSX
MZ\,K\+?#?Q6UOX-_L0_!;]I>+QQJ7[1O@RPN?B-JGB&\_9M\*^,_!WCR;PY\
M,(?#W@;XC0W?[06D^*5AT'3=2T*]L;">:33?"D>K6NFZ7[S\-/\ @LM\2OC5
MXR^ /@WX8_LH^%-17XLW'CS3/&?C35?VB%7P#\.[[X9?%#X\_"[Q_JZ^)-"^
M$VN6U_X2\'ZG\#H[_4[_ ,4#P)K^L6WQ&\*KX-\->)X[#7KFR /T?_X=U?L(
M_P#1I'P#_P##;>&__D*C_AW5^PC_ -&D? /_ ,-MX;_^0J_.']FC_@JUK/[5
M7QX_8A\-W&G>$_AA)\6_'G[;WPS\?_"[X=_'GP;\5%T;Q[^S%X/TU-1T#XDF
M]^$NC:EJ%O=7]RWC+X::A\/?$^BQZQX7U#P]XHU8:MI&LC2;+(^#'[0_Q9A\
M2?M??\)O^TWX_P#$_BG]FW_@H/\ M/V.@_"7Q+XK^%_A":^_9V^$G[+]Y\8/
M GA+Q9#8?"N?Q)8_"[6?$EUITEQ\0&L)-1FTRXTX1^(=05HK2^ /TU_X=U?L
M(_\ 1I'P#_\ #;>&_P#Y"H_X=U?L(_\ 1I'P#_\ #;>&_P#Y"K\5_"/_  7(
M^(/QYLOV?_%OPV^#.D:7X\U+Q+\?X;WX!>'_ -H_P?K>B?%"7P9_P3_T/]K[
MP;X5UGQ0_P #]6\1K<ZMI_C!M&TJ#PK8^'KS3?B/X9T^+5;W7O#5]JFFP?55
MO_P62U+4?%WP'\-Z#^SM8^(='^/7[,6O?M<:%X\MOB_8:'X2T7X/-I^I0>#=
M0OW\7^#_  [K&JZL_BK35L/B+HWAO2M9U/P)X;UC0O$UM9^)?MTFF6X!]_?\
M.ZOV$?\ HTCX!_\ AMO#?_R%1_P[J_81_P"C2/@'_P"&V\-__(5?G"W_  6H
M\3>%O@[\&?CM\5_V7=$\(^"OC)^RUXK_ &J/#NC^$?V@M*^*'CC6/#>E_!S5
M_BYX6\'^'="\.?#NVAF\5^*+#PSXHC5O$EYX8T*WT[0]5FL=8U7Q)I.H>$XD
M_:V_;C^+GC+_ ()N_ S]I_PE=>*_V6OB-X__ &FOV=? EWX.\(?%SX&7NH>)
M?#'C_P"..@_#[Q!X<T'XG>,]%\3?#M;/QKX"UFX\0Z#KFH:=I&I>$YI[+4M>
M@TYM#U.U8 _1_P#X=U?L(_\ 1I'P#_\ #;>&_P#Y"IP_X)V?L)@,H_9)^ @#
M !@/AOX;PP!!&?\ 0N<$ _6OQ/\ A;^WU^V/^Q[^V7\!?V:OVX_B1X1^+FH_
M%#X!_ _1_B'I\7C[X:^'%^%?Q,^)?Q/_ &G4\#>)K/\ L?P!H+?$#Q%=_#SX
M>> /"GQ;U2"X\'>!KGQ!::IXU\'Z9;VU_:Z3J/NGP"_X+>^*OVE?^%,Z)\*/
MV9?A_P"(?'/Q=_:/^-/[/5IH@_:GT*TT)/\ A5?P-\(?M!Z7\1_#GB2X^&"S
M^*?"?BOP'XCND@MQH6D:Q'?1:'<V%IJNG:W/<:0 ?IU_P[J_81_Z-(^ ?_AM
MO#?_ ,A4?\.ZOV$?^C2/@'_X;;PW_P#(5?DU\!_^"_=I\6?C5\,_A/XD_9Y\
M%>$-,^(OQ2L/AQ'XPTC]IKPYXJ.GPZ[\0_VI/A?X>UM?#US\/O#=U<-?>)/V
M7]<U&^TZ>^L1I?ACQ'I^IR7T]U##8:ATOP*_X+JQ?']O .A>$?@3\/K/Q?XW
M_:4\<?!2UO-8_:7T:Q^$]_X2\!?##X=?&"[\6^%_BG/\.([?5_&7B_P-\0O[
M3^&?P]U;P]X=A\<1>%/$=U:^*[*VAC:@#]0/^'=7["/_ $:1\ __  VWAO\
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M'_HTCX!_^&V\-_\ R%1_P[J_81_Z-(^ ?_AMO#?_ ,A5\>?"3]K$>&/V_?\
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M]O=7TFHZ?(T-VUP9CB1W487_  W5^Q%_T>/^RM_XD+\(_P#YKZ/^&ZOV(O\
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M@?\ 0#T?_P %EE_\8H_X1[0/^@'H_P#X+++_ .,5L44 8_\ PCV@?] /1_\
MP667_P 8H_X1[0/^@'H__@LLO_C%;%% &/\ \(]H'_0#T?\ \%EE_P#&*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX?\ #GC;4OASK=[9WWC_ /:9\+VLTNG>-='U30)]/28ZE]IT^[GCM'LX'N0
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MS\+Z?K_P(^,?@7XA>*OAWJPUR[6^L_$VK^#]*-SX?EDM/L%__:,LD,TB:'K
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M_P#$4?C3_P#1FT ?85%?'O\ PBW[?W_1=/V/?_$4?C3_ /1FT?\ "+?M_?\
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M&?\ A&=0\0>"_B5X3^.O@_PM\3X]7O8=2\)W/PTTG4O!UEX@%GH<&E]5H?\
MP5)_;6.A?L3W/B']F[X86^O?M,?&SQU\'?B-9ZO)XV^&VB_#'Q/\"M?B\&_%
MGP1I^L>*M;U,ZYXP^(7B*W\47G[/SK;2-XKTKP=>64/ASQ'J.KVSV%CX>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^*_VY?\ D1/@7_V>I^Q?_P"M&_#ZOM2OD;]M+P7\1O&7PM\%
M3_"WP1<?$CQ3X!_:%_9R^*\G@FQ\0>&?#&IZ_P"'OAE\9?!_C'Q1:Z1K'C'5
M-#\,PZK'H&E7]U8P:OK&FVU[- MF+N*::+(!]<T5\7?\-&?M*_\ 2/GXY_\
MAY/V1?\ Y_M'_#1G[2O_ $CY^.?_ (>3]D7_ .?[0!]HT5\7?\-&?M*_](^?
MCG_X>3]D7_Y_M'_#1G[2O_2/GXY_^'D_9%_^?[0!]HT5\7?\-&?M*_\ 2/GX
MY_\ AY/V1?\ Y_M'_#1G[2O_ $CY^.?_ (>3]D7_ .?[0!]HT5\7?\-&?M*_
M](^?CG_X>3]D7_Y_M'_#1G[2O_2/GXY_^'D_9%_^?[0!]HT5\7?\-&?M*_\
M2/GXY_\ AY/V1?\ Y_M'_#1G[2O_ $CY^.?_ (>3]D7_ .?[0!]HT5\7?\-&
M?M*_](^?CG_X>3]D7_Y_M'_#1G[2O_2/GXY_^'D_9%_^?[0!@?M^?M)?%/\
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MM&BOB[_AHS]I7_I'S\<__#R?LB__ #_:/^&C/VE?^D?/QS_\/)^R+_\ /]H
MJ?L-_P#(O?M+?]GN?M6?^K/U"OMROC[]BSP5\2?"'P^^)NH_%3P+<_#3Q)\2
M?VC?CO\ %BT\$:AXB\+^*=6T+PWX_P#'FH:SX=@UG5_!>JZ[X8DU2?3&AN[J
MVTG6=2@LS.MM)=//'*J_8- !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #: AX# 2(  A$! Q$!_\0
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M-X*\3^ O%RZ<;C=]G&H'PZ-2%C]H*.(/M7E"8HXBW%6QU?\ PN#QY_T'9_\
MP$T?_P"55?RW_#K]C;]I[]FK]G[Q!^V?\*+?X ^&OC-8?L-^#_A_\./AG^R-
M^SWK'@S7M8T[QI>_#GQ+XN^)_P 7-#\0ZGJ<?Q;^.OP]\&6VM:EX9TV'1/(U
M'Q?;W4KVTOF)I=P?%C]I#XP^&/ /Q2NO@9^U#^U)XX_9@LOCA^P3X;\'?M,>
M,/#VH7/QHM_&'Q*\>ZQH_P"TG\,O MWKGPZ\.ZM\0M%L?"D>@ZO>>'IO!NL6
MWA?QA?S^"]+DO8T&EI]1+A:GB*\X99FN'Q-"&(CA)5*M.I>&(4I1K4I3P\8T
M7)/D>&A""GC;8N&';EE^)J3^=CQ'.C1A/,,NK8>M/#O%*$*D%%T&E*E.,:[E
M54;<RQ$I2<,'?#SKI1QE"$?ZD/\ A<'CS_H.S_\ @)H__P JJSY/COXEAU6U
MT&;QI81:]?6-UJECH,MQX9CUR^TNQFAM[[5++1WL5U*[TRQN+FVM[W4+>UDL
M[.XN;>"YGBEGB1_YSO!/[3'Q8\#>.?A-XVU3XR_'OQS^POX8_P""A_CCX>:;
M\<O'_ACQ?K'B/XB_L_:O^SC=7&EV_P 2VTSP)IGBSQEX"\/?M#RW7AOP5XQU
M#PC9RZAJ%K;VCSW M+6OG_P5\;/C1*?AE^TAXXC_ &BO%7COP]^P_P#\%01;
M^(?#WA(2?'#2K"V_;&\-:/\ #^RT.Q\;>&-0TK2M>\.>#8--NM)T_P 2>'=1
M?3?#NAW%\NAZFVFB!YAPCBGSN6+H<G))4I0A.,I8EV5/#5(5JE-T:T.:#Q="
M<U7PW/&G+]Y=NY<389<BCAZW.WSU(N4)*.'C=SKPG2A-5:4[26&K0BZ6(Y93
MBN71?U=S_&CQI;(LEUXE6UC>:"VCDNDT&VCDN;J9+>UM8WGTV-9+FZN)([>U
MMT+37,\B0P1R2.JFEI/Q[\0Z_!=7.@>.--UZVL=2U#1;ZYT.Z\+ZQ;V.M:3.
M;75M%O9].LKF*TUC2;H&UU72[AX[_3;E6M[VW@F!0?R5ZIXV^(?Q8^'J7/Q-
M^-_[17B#X3? 3_@I_P#L9ZWX4^(]OXC^(6LZ_HOP2\?_  ]BU?Q+XZN/'&I_
M!_P/XT\;:!X/\;PWLW@SQS>_#VPL_#.KWVH)I%I<:9<::3[OX=^+WQ0T>32M
M+^+_ ,7_ (\_L\?LLZU^UQ_P4@C\>_&KX*^$+W2_&R^,O"GQ)TB/]GOP+K>N
M^'?AYXFU7P[X.\0:)<^(=:TG5D\.[OB3XCTVQ\.ZOX@N8[AH9]:G"%2G!_[?
M2G6C.<9PAAJ[5H\DXPHTU-XG$XNI1G&4<%3C"NJJE3O4C%S,J?%$)SUP4X47
M"$HSGB**UFI*4ZM1P6'P^&IU8N,L54E.DX.,[0DU _IP_P"%P>//^@[/_P"
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MN6NYK7[%(DSQVT;8NI=1C9-MK;VT>U19(1E"V6;YL8 ^+J^J_@#_ ,>&M_\
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M=5\3A6XXY!XXZ4[^W)-BQ_V/\2O+0*$3_A&K38@1@R!5_P"$HVJ$959< ;6
M(P0*_2_RX_\ GFG_ 'RO^%'EQ_\ /-/^^5_PI679?<O\AW?=_>_\S\T$UR2(
MR-%HWQ*C,I+2E/#-HAE8YRTA7Q0"Y.3DMD\GU-1)JJ1NLD>@?$6.13E73PM9
M(ZGU5E\3!@?<'-?IIY<?_/-/^^5_PH\N/_GFG_?*_P"%%EV7W+_(+ON]/-_Y
MGYGMK3/(97T7XDO*4,9D;PS:-(8V!5HRY\3EBC*2"I.T@D$8-!UIS$(#HOQ)
M, 78(3X9M#$$R#M$9\3[ N0#MQC(!QD"OTP\N/\ YYI_WRO^%'EQ_P#/-/\
MOE?\*++LON7^07?=_>_\S\RSJJE40Z#\12D99HT/A:RVQLQ!9D7_ (2;"EB
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M@^]*NO3H\CII/Q,1Y2IE=?#=JKR%1A3(P\4 N5'"EB<#@<5^EOEQ_P#/-/\
MOE?\*/+C_P">:?\ ?*_X4K+LON7^0[ON_O?IW/S/.M.5E0Z+\22D[%YD/AFT
M*S.<9:5?^$GQ(QP,LX).!D\4\Z].8_).D_$PQ%/+,1\-VICV8V[-A\4;=F.-
MN,8XQBOTM\N/_GFG_?*_X4>7'_SS3_OE?\*++LON7^07?=_>_P#,_,C^T8?^
MA=^(7_A)V'_S34?VC#_T+OQ"_P#"3L/_ )IJ_3?RX_\ GFG_ 'RO^%'EQ_\
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M\96]OX<N=*\=>&?$?C7Q6VI:CJ*ZMI6@^,-&/K%;^=?^"Z/_ ,I#V%+^5_\
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MU?\ Y:?MGX.^*G[//Q$^&>N?&GX?_M?^&/'7P<\,2:K%XE^+/@[XX?#3Q/\
M#/P]+H=M;WFMQ:YX\T22^\+:3)H]I>6EUJJ7^JV[:?;75O/=B&*>)FLZ7\2/
M@+KDOPX@T;]K30]6N/C%;ZM=_".WTWXS_#J]N/BE:Z#YG]NW'PZ@MO,E\;0:
M+Y,PU>7PTFIIIIBE%Z8#&X'YT>"OV0?^"A_A7]E/4O!FF^-?@B?B3HD'Q6BT
MG]G_ .-OBK2/VHO@'\:M?\6V6A-\-/&WQL^,]]^RC\%/B5HD/PI\2)>>(]/\
M"^ /AC#:ZTOACP_I>K^*+M-5N+G1/GCX?_\ !(S]HKPWJWP<UG4;WX8:A?W6
MN? [Q_\ M&>)?%_Q.UOQA\0+_P"+?P/_ &V?BC^VUXY\?^!-3TKX*>#?"TD/
M[6_BSXF7_@GQKX1T_P .?#OP_P#!_P ,P6UOI,'Q)L[9=/E/K%;^=?\ @NC_
M /*0]A2_E?\ X'5_^6G[ :=\<OV7M7L-&U72OVU_ NIZ9XC\<?\ "L?#VHV'
MQ_\ A5>6.N_$CRH9Q\/]&N[>XDM]3\;-!<VTZ>%K*2?7'AN;>5;$QSQ,]GX=
M_&7]FGXO>._$OPN^$W[9W@SXH?$WP7#J5QXQ^'7P[^/7PM\:^._"=OHVJ6^A
MZO/XE\(^&I]3\0:%#I6M7=IH^I2ZII]JECJEU;Z?=-%=S1PM^+5G_P $MOVT
M_&/P?^+.C_$_P+^QQ8?'K]H/X@^#-3\=_$+P?\1/&%I\-?A!X)^%,G@F'X">
M /@+\*=+_9Y\-VA^!'PD\.^!;#PUXX^!WB[4XM5_:&-U)J7C+XL>'[7;HUI]
M.?\ !+?]A#]K/]C3XJ_%3_A<D_@#7OAGXHO/C3JOAS7_  K^T%KWBY(K[X@_
M'35OB?HD.D? K5/V6?AXGP\6YTC7[V+Q)=M^T%\2%BU:Q$5C87=KJ@NM&/K%
M;^=?^"Z/_P I#V%+^5_^!U?_ ):?L&OP_G5E;_A/_B(VU@VUM;TXJV#G##^Q
M>5/0CN,BO0(D\N..,N\AC1$\R4AI)-BA=\C *&=\;G(506)( '%/HJ)U)U+<
M\KVO;W81WW^"$+_._E8J-.$+\JM??WIO;_%.7X6"BBBH+"BBB@ KY\_:!_:?
M^$/[,>F^#M1^*]_XPB;X@>([SPIX0TGP)\,OB1\5_$>MZSIOAO6?%VI10>&O
MAAX5\7:[%9Z=X=\/ZMJ=]J=UI\&FVL5L$FNEFF@CD^@Z_'W_ (*N^,/"/@;7
MOV)?$'CCQ;X6\$:!#\;/BQ:RZ_XR\1Z-X5T.&ZO/V7_C+#9VLNL:_?:?IT=S
M=RD16MN]RLUS*?+@21_EKIP=&&)Q>'P]2;IPK5H4Y37+>$9-IR7.U'2WVFEW
M,,55E0PU>M"*G*E2G4C!\UI.*NHOE3EK_=3?8]N_X>D?LJ_] _\ :>_\0G_;
M _\ G)5]5?!W]H7X3_';X8VOQ@^'WB*\/@2YUWQ;X8EO_&7AOQ-\-M5TSQ%X
M%\6ZQX&\5Z)KOAGXA:1X8\2:#J6C>*M!U729[75]*LY));7SK<36TT$TG\[_
M /PTS^S5_P!')?L]_P#A\?A=_P#-97KWPP^%FL_M0_L!_!_0/A78_#KXDZ-J
MG_!4'X[>+K[5_$_@C2OCS\'E\"Z=^U;^T7<7_BSQ5X+M_%GAG2O'O@RW$UFR
MI9^*[*'[;<Z;J5O=R_9%23V,XRC"Y=1HU*&*E7E4JNG*,G0:C%4W/F_=2D]]
M-5;YGE95FF(Q]6K3K8>-&-.FIQE%5ES-SY;?O8Q6VNFOR/Z)K>YM[RW@N[2>
M&ZM;J&.XMKFWE2>WN()D$D,\$T3-'+#+&RO')&S(Z,&5BI!J:OP4UO\ 9]_:
MM_9<\3^ OA9\$]=^->O:1)J.A^._A,WP(\%^%/ /[+&F?%GXB_M'^*/%/[1O
MA3XS?#R;5?$9^&GP&\,_!G4?"5E\*/"EQX@U'3;"U;XA7?A'5-1^+MSH;#Q?
M]G?XP?MTW7@?X9?&G1!^VI\8/A%JVDZ!?_$6/Q-X?\&Z[XW\5?%'QC\'?VG?
M#MOJOP:T73ET5]4_9_L?%&K?LU:TVIVD\?AW3-9BT_Q.]RLNF?%BZM/GCW#^
ME".6*7?Y4D<GER-%)Y;J^R5/OQOM)VR)D;D;#+GD"F)<6\LDL,<\,DT*QM-$
MDJ/)$LN_RFEC5BT:R^7)Y98 /L?;G:V/Y;_!?AO_ (*:>!KSX5Q:;X5_:5\)
MZG=_%_P-\3_'C:)HL&OZ1\3+[QE\7?A9I_[0TOC^/2M5T;P[X>FTWX66OB;5
M9=3\>W?BFTUU=2N3\'? \/C+0]3U>NM^&/PV_:_^$?PT\+^#6T/]N_1OA3X;
MM=&\*_$&_P#AM%I.N_M,ZCXS\.:=\?H_#2^&?$VOQWFM^*/A2OQ'NO#-S?:G
M'=WNAG2M0^'\U_);_"V_\>9 /Z::89(U=(BZ"217=(RRAW2,H)&1"=S+&9(P
M[ $*70,1N7/XR_LH>'_^"@NF?M"^!O&?[0WB+XO:C8^+=:^*/A'XN>#[RZ\,
M7'P,\+:1H/P"^ .L^#M?\$:-I-A&NE2:I\;4^*MIIWB33]1NO[5-_P"(=%(D
M\.VGAR/3G?M+>$/VQM3_ &T/#?[5/PU^%>C:W\-?V6=>\ _"K0='U'Q#XPMO
MB;X_\ _%&UB7]IW7_ASX#T_19O"'B7PO=P>.OAGJ$FI^(?$>E:W%KW[+NHQ>
M'=-NEOK=M3 /V;IC2QH\<;R(CS%EB1G57E9$,C+&I(+E45G8*"512QP 37\I
M/@WXT_MN?%OPUXDT_P"#GQC_ &F?'FC:2/V7-8_:6UU5T[XD:_H/B_QQ\/OV
MFM3\=WW[,R_ C5=&\3ZA\&/$'Q:TSX17ED/!VMS):^!T\/W6E6$OPKOM?,WV
MM\%O"'[:6N_MG_LR>(?VDK']H3Q)K7@34=9U;7_$,7A_PGX?_9<T?P#J_P"Q
M7'X7LM<;1]"UG7K;0?C=J_QYUCXAZ7XJTG2_$'B&XLCJ<MHU]<>!%^'UU0!^
M[#7]@EV]@U[:+?):?;WLFN85NTL/,:'[:]N7$RVGG*T7VDH(?,5H]^X$"/3=
M6TO6;<WFD:EI^JV@E>$W6FWEO?6XFCQYD1GM9)8A+'N7?'NW+N&X#(K^=?XE
M?LT?M#:C^U'^UMJE_P#"CXB^/-<^*5S^TO;67Q \-_"GX2VM]H?[-/CS]EG_
M (07X=Q_!+]I?Q=K%CK<_P 9].\=V^G^ ='_ &?_ !IJL/PD5+S7O&FN>!=%
MGL=,^*VL>L_"'X#_ +:FF_"#P!X7_9+U>']G;X2>%OVO=%U[0=*^.7[.G@_P
M'\7_ !-\!(/!7A*#Q'K/Q1\"_!GQK^SMX;;3['XC0>.=+M_#.I>$;7QU\1O
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M% !1110!^'E[^V+\=_A5>_M >+]*^+EU^U1\.K.;2_A/X:\5Z?\ !":3X=^
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M>'=)L]1GFUGP,VJ7EK81>)=/,^F3SSQ^1/+&3(/#$_;C_85ET[XLZO!^WO\
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MQ;\/?%G6=4\6:]\9_B-X:\=1:%_8=[^T?X@\427$7BCXQ^$-*TFQ^'5UXO\
M#=RFA>*?!GA'PAJLFE:+KDFLVC_;FQ_[K?\ ?)_PK2-6HXIRLG;5<E+?_P $
MDNE33=DVNCYZG_RTYS_A'Y?^AN^(?_A<Z]_\D4?\(_+_ -#=\0__  N=>_\
MDBNCV/\ W6_[Y/\ A1L?^ZW_ 'R?\*KVD^Z_\ I?_*1>RA_*_P#P.I_\M.<_
MX1^7_H;OB'_X7.O?_)%'_"/R_P#0W?$/_P +G7O_ )(KH]C_ -UO^^3_ (4;
M'_NM_P!\G_"CVD^Z_P# *7_RD/90_E?_ ('4_P#EISG_  C\O_0W?$/_ ,+G
M7O\ Y(K,MX=)O-9U3PY:?$?Q9=>(M#L](U#7/#]M\3-0GUS1-/\ $ OSH%_K
M.DQ7[ZAI5EKJZ7J;:-=7]O;P:HFFW[V,DZV=P8^YC!21'>$RJKJS1MN59%4@
ME&91N 8#:2O(!XP:_-#X(_L8_&7X/_%O]K/QCXO^*?A[]H'P[^U9X6^'_A;Q
M+J.O>%;+X4>/GFMK_P",]KXL\0>+-;\'_P!L2^((_!_@OX@>'O!?@+1M%E\-
MFX\-V,.E:?<^$?\ A$]+N-5F56HFK).][^Y2T[?\NN_X#5*GK=6_[?J?_+3Z
MZT'XG?!CQ59Z+J/A;]I+2O$^G^(_%UW\/_#U_P"'/V@-+URRU[QY8+OO?!.C
M76E^(;J#4_%MHA1[CP[923:M$DUN[V@6YMS+Z!I=G8:W86^JZ+\0/&>L:7=^
M?]DU/2OB-JNHZ==?9KF:RN3:WUG>36MP(+RVN+69H97$=Q!-"Q$D;J/R)^$?
M_!,KXCP_#SQ!'\:/$NCO\4)];^"7A;X>WWA/QFL^D_"WX6_"C1?!_AG4=2M[
MWP3\)_@KIOB_6KNW\(:#XF\)Z!JO@N'5(-<\ _#:7Q=X]U::TUJ*OT4_91^'
M?QG^%OPGM_ WQI\0>&?$.I^'M4BTKP6GA.& :=H?@+2O#/AK1[#2?/M?#_AB
M)X)O$.G^)=<T2PETF74/#OAG6=$\,ZMKOB35-'N]:NU&M5;7-%1T_DI[_P#@
MH'2I]%?7^:I_\M/<?^$?E_Z&[XA_^%SKW_R11_PC\O\ T-WQ#_\ "YU[_P"2
M*Z/8_P#=;_OD_P"%&Q_[K?\ ?)_PJ_:3[K_P"E_\I%[*'\K_ / ZG_RTYS_A
M'Y?^AN^(?_A<Z]_\D4?\(_+_ -#=\0__  N=>_\ DBNCV/\ W6_[Y/\ A1L?
M^ZW_ 'R?\*/:3[K_ , I?_*0]E#^5_\ @=3_ .6G.?\ "/R_]#=\0_\ PN=>
M_P#DBLR^BTG2[W1--U3XC^+-,U+Q-?W.E>&=.U'XF:A8W_B35++3+O6[W3?#
M]E=7\5SK6H66BZ??ZQ>66FQ75S:Z58WFHW$<=G;33)VVQ_[K?]\G_"OS_P#C
M/^R5\7/'?[8W[//[5'AWXQ:5=>'/@IKE]-#\'?%?P^T65/#WAZ^^$/Q2\(>)
M[;X<_$**YFU72-6^+'BKQ9X93QW?W^AW-S::)I6F75C>W5MX,TOPWJRE5J*U
MDGJMH4M%U?\ "0U2I]K:/[53?HOXI];>(-7\'>$FF3Q7\8-7\,26_A[6?%\\
M7B+XNRZ+-#X2\.W&GV?B#Q3)#J6J6TJ>'-#O-6TFRU?7"G]F:=>ZKIMG=W45
MS?VD4U[2'T'Q!O.@?$[Q/KPCT_1M6D.B_%"^U4)I?B.TDO\ P]J3FPU"X"6&
MO6$,M]HMXQ%OJEG&]U8R3P*9*_/[6OV#?'_C_P#:RU?]H;XJ?$^Q\7> O'WP
M9\=^!?$_PN'AO3]*\9_#>6]U_P"!WC?X6?#CX9?&71_L>I7?@3X<_$'X8ZGX
M\LO$5UX:T74KGQBTFLZMHFM#Q?J,>C=]^R-^S/\ '+]G/Q=K&E:MXP\)7GP5
MU;PC;7S>$]):XU#4+/XAR:5X"TS3]-TZ]U/P_:^(&T3X?6.@^+?#6G^(-8\4
M:E'XI\(WW@B"+PKX;U?1-<N]0E5JK:O&ROUA2V[_ ,(;I4_5_P".I_\ +3[<
M_P"$?E_Z&[XA_P#A<Z]_\D4?\(_+_P!#=\0__"YU[_Y(KH]C_P!UO^^3_A1L
M?^ZW_?)_PJ_:3[K_ , I?_*2?90_E?\ X'4_^6G.C09D(<>+?B"2I# -XWUQ
MU)7D!D:<JRY'*L"&&000:^B;5=EM;KO=]L$*[Y7,DCXC4;Y';EW;J[GEF))Y
M->+LCX/RMT/\)]/I7M4'^HA_ZY1_^@+7%C).2IW:T<MHQ71?RPA^-_D=6&C&
M+GRJUTKZR?5_S3E^%B6BBBN$Z@HHHH *QM>M/#UQIT]QXGMM&GTG38YM2N9]
M>AL9=.T^&U@E>XOYY-05K:UCMK;SGFNI&C6&#S6>18]QK9KXE_:<_8 _9_\
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M\6^-O!WB;P9X9U_Q/HOCGPQH^J>#[S2=)OIEUL2V\D*^(_ +_@G9-\,_A_\
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M_P#GV\0_^%QXW_\ FAH_X5#X'_Y]O$/_ (7'C?\ ^:&O3:*KZUB?^?\ 5_\
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M_P T->FT4?6L3_S_ *O_ (&_\@^KT/\ GS3_ / ?_MCS+_A4/@?_ )]O$/\
MX7'C?_YH:/\ A4/@?_GV\0_^%QXW_P#FAKTVBCZUB?\ G_5_\#?^0?5Z'_/F
MG_X#_P#;'F7_  J'P/\ \^WB'_PN/&__ ,T-'_"H? __ #[>(?\ PN/&_P#\
MT->FT4?6L3_S_J_^!O\ R#ZO0_Y\T_\ P'_[8\R_X5#X'_Y]O$/_ (7'C?\
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MWWC;XZ_"K7[;XFZ*W@6_ATC['XGF\+-J_P"R0S@;L;L#=C.,XYQG!QGIGG%
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M3::<^2RY-;WUUTMYG;ZM_P I+OA__P!F,?%__P!7[\#Z^YZ^&-6_Y27?#_\
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MH_V"[TS5[*:SNIP9!'^+N]_[S?\ ?1_QK[6_X)>$G3_VTB223^V#9Y).2?\
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MU]I_^G*9]E4_AU/^O=3_ --S/S<U7_D*:E_U_P!Y_P"E$E4*OZK_ ,A34O\
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MTU)M7T47I)O9Z.ST/RR=.ISS?LYV=644^25FY3J.*6FKDM4NJU5T>M5]@?\
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M0^('[1'Q'\+?!/2?B%8_%'X??LTZC<Z'<:SX:_M3Q]XU\$>(OB%=>*]5T_\
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M-.TEHU9M:II69W93B,QGCZ4,37K5*4HUTXSJ1G!RA3;2?*K735UK;9J]U?\
M>*BBBOAC[ _F*^ 5W=)\'_"2I<W"JNI?$@*JS2*J@?%KQ[@ !@ /8#%>O?;;
MS_G[N?\ O_+_ /%U^:1\=_&'P##\,KKPEXEL;_PK>? 7]O'Q1H?PL@\*17%U
MKGQ+^%OB?5/$?AG7=>UY[RXU/6X(;_4TT[1_"FBV6C6J1W>H2:G<:U=WMA_9
ML7@7XT>(8O@Q^U(_A[]H[2/B;_PB'PK\%>(_A9\;O'OB+PE<66F_$#QQ\!SX
MS\<65WKO@3PTUA=>'_AIKLND>.KG3K+PMKVI?#S0?$/]D:Y;W.FZ7#%%^K87
M%0AA\-3<97CA:5W>"O[/"4:GNIS3:DM$]%%\O/RJ<6_S?$X:<J^(FI1M+$U-
M+3TY\35A[S46DXNS:UYE?DYG&1^F7VV\_P"?NY_[_P O_P 77T+_ ,$\999?
MVM?VJFEDDE8?LW?L? &1V<@?\+0_;5. 6)(&23CIDU^!VC?$_P#:)TOP/;>(
MO"_Q-L?B5!\(OBUJ/PS\2:S%\3+/XH>'/CQXSUA?ACK?A^V\&:_;> M!O?&/
MAQM"USQ)X*U3PII<.EW?P^\;V?B/Q)_;VK:=HB+I_P"N?_!%GXL:;\8OB[^T
MEXCL;O7]1N](_9Q_8Q\-:]J_B-=&^WZ[KD7BK]K'Q)/KJ2>';F[T7[/J^G^)
M]-O3I]E-YOAV\EO/"NI1QZKH5Z#Y/$&*A6RNK!1E"3J8::4N7WDJLD^5Q;3Y
M6FFT[:73E%IOT\DPTJ68PFY1E%4\1!N-[Q;IP:YDTG'F3377WK-)II?T(444
M5^?GVI_,1\$2O_"NK&+<OFS>/OCT88BRB681?M!?% 2F&(GS)5B,T(E:-6$1
MFA$A4RQAO3;6_P!/O[1=0T_4=.U#3G%P5U&PO[.^TYA:/)'=D7]K--:$6DD,
MT=V?.Q:R0S)/Y;12!?S,UOX&^,/%TNO>-?AQINO'Q5XL_9R_X*#?"./Q/)XI
MU.VT?2?$VO?M&32?#_PKI,-WJRZ5X.N?$LEAXEN9-6T6PL&N[V"?4]=U,O9V
M3113?#3Q1J'[/'[6_@SX<?L\^.OA;X?^.%I8P?"OX-2>&?#?@Z[\,V_AOX6?
M#3PC\1]2O/#ND>(U\+>']7\9ZMIVO7G@SPSJ.JV>G?%G5/#4P\03VVE>+;F]
MO/U3"XBI#"X:/L6U'"4W%KG?/R86C*%K4W%<SM&2NVG*/)SVGR_G.)H0EB<1
M+VJ3EBIJ2:@N3GQ%53O>HI/E5Y)V2:C+FY+PYOTTM]4TJ\33Y+/5M*O(]7BE
MGT>2TU.QNH]8@@023SZ.\%Q(FJP01D23S:>;B*%"'E9%(-?4/_!-R2.;]I3]
ML>6&2.:*3X5_L=O%-#(DL4J-=?M,E7CEC9HY$8<JZ,RL.02*_GQT+]E3XAW7
MPT@UWP[H_COPO\0;?XP_%?\ X5Q9:EX5\#?".>W^'_BS7-4\:VOC;Q-X \*S
MWGA_]GZ>XN;GQ+X8T[P1\-Y].LM3-_X(O=<TC29+K5H;;]I?^"+%Y\0+OX@?
MM51?$GP9:> =;TCX8_LB:!I/ANTTD^'Q;^$-%D_:-L?#DD_AYM6UUM"GCACN
M--2Q?5KQ[FRTVSUEGB.J^1%Y'$->I5RMQJ494[UL+-/WI1?O5$XMN$>62W2>
MK3CU;/3R.C"GF"E"K&=J6(@X^ZI+2G9I*3YET;6B:?D?OM1117P1]F?R%?LU
M?&W08O#7PW^#4GACQXNI>&_V<'^+=]XK_P"$6U&3POJ6F:?XMMM%NO#?A 0Q
M2ZQXW\36_P#;UC=W=OX9TV_LK::6'0ENY_$,LNFVOM_PW^.7A+X@?!F/XZ:C
M9:W\-?!L<'CB]UJV^(-O!INO>%M/\ ^*O$?A76I_$FGV$]^MC>_:/#=U=#1X
M9[K4(6N;?2FCDU7=;'S[]FCP+8-X,^ ?Q;^WWPUG2/@#?_#6#20+?^RI=*UO
MX@6'C*?4I7,9O5U*"_\ #=K:0I',MH;2YN6DB:<1.O1C]FOP/?\ PVMO@]XI
MNM7\8?#!?$'BGQ;K'AF]N+O0+O6?$FN?%F7XQ:%JS>*_!M_X>\4:*?!'BFYG
MCT:WT74[.'4819W.L_:;NQA+?K&%^L+#8=IPE'ZM!04N6,=:&$]@Y23<DE^]
M4K)R:LVN9Q2_-,1[!UZZ:E%_6)<S5Y.RK8KVW*FE%M_NW&[23ND[)M^.Z7^W
MK\.KS1/AMXBU7P#\1?"NG_$GPAKOBZWLO$=MI=IXH\/_ -F>(/BAX9TWP_J7
MA6.ZEU*]UW5=7^%.KZ?J5OIS2+X0U7Q'X*T?7#]OU]4MOV-_X)@WQU/XA?M@
M:FT,=L^H:A^S;>R6L5]9:I'9S7/P0T^6>R&I:;+-IVH-8SM)9RWEA-+9SRP2
M26\CQ%37Y5:5^Q]\-=)^"N@? 2/6_&MWX$T36_'^OW$^I:_>:QXIUF]\>7GB
MK5EBN_%&OSZQK-K9^&-?\2VGB/2+.TNTM;[7_"GAO5-9@O;B&^-[^B__  1X
M^%VE?!S7OVQ/ NCZI?:S;6GC'X,:O/J%[::=I8GU#Q)\-)-?U$6&B:/#;Z-X
M?TJ*\U&:+3=$TJ".QL+5(XX][F21_#XB^M++$J_+*+K85MQY4XU+5.:-HKWD
MW=J2LEJK643V<B^KO'MT>9-4<0K2YFI0YH<LKM^ZTK73NWIK>Y^V]-?[C?[K
M?R-.IK?=;_=/MV/K7P9]D?QE_LD77Q2N+KX5>"(_B;&GAK6_^"=_P \5?#WP
MY<>#=/N?#WPY\32W]KX2F\27]HFIV^I>/]8O?)^U7YU+6-%T]M.@T_0[#3["
M.&]O]1K)\4?';?L&^ O$FJ_&2:+XF72Z)=^-_&U]XQ\"_#?XA^*/ VG_ !^?
MP5XYO_#?B/7K>T\%> /$VO: \/AG0/&.JVVC^#?"NMZIIMM/KGAR26QU>S^E
MOV7;[2;']E[]FN>]U#2+&4?L_?"",SWE_I]G*(E\!:"_E&:XFBD$2OF3RB^Q
M9"7VAR34OC[]H[]G3X=:YX?\+>-/'7@VVU'Q7#/IEI!:6]IX@TVVTN[N5M[F
M/Q'>Z3!?Z;H6AWUV=MQ'JTD-G<R1R7-Q T,$EQ'^T95D>;9K&EA\JP.99A7J
M8.I-4<%@\?C*BI1PU#$5:BCAZ-3W</3HU)2DFN6FY1BOAIS_ "3-L^R?*'5Q
M.;9AE>6X>&+I4Y5\?CL!@Z;JSQ%?#TJ;GB:]/WL14K4XQBXOFJ)2DU:52'Y[
M0?&/]I:V^%?A7XTP>/==N/!NJCXR>$_">AW&KZ9XP\;ZQ\/O NM_&L-\3[U=
M%T>'PC\1M>TWX;V7@GQS8?%FTU>UT>XU+P-9V=LFM:=\0WUC5/Z"?^",OC[3
M?B?X:_;&\:Z39:EI]EJ7[2OA/3EMM5U&SUJZ^T^%OV6/V>/"5_<Q^(=-)TSQ
M-87]_H5S?Z7XGTW%AXATVYM-8M4BCO!$GP9?_M,?LU:25COOC=\)(&M86M8X
M8?%FAW9M[<(D+6MO%I\MR([8Q110FW@40M%'%%L,:(H]G_8._P""A'[%?P,N
M_P!K2Y^('QT\+>'-,\:_'7P1K_@==-\/>,=8M-8\-Z-^R[^S_P""+J\TB+PS
MX6U&!+*R\4^%/$7AX6ZK"\-WHMPJP+;-:2S\V;\"\:8O 0C@>%^*\P<JU&3A
M0X<SZL[QA4YJJE_9:4:>J5KJ*O!<][WTR[CS@G!XN53'<5\)Y?&-*M%5*_$N
M048^].%J3_X59<U3W6UO-M3M#33^C"N+^)'_ "3OQ[_V)?BG_P!,=]7YY0_\
M%A/V'M49D\*>+OB9XV8'$?\ PB_P,^+EPL^>GD/J7A'2TD#<!2& 8D $URWC
M[_@J1\-=8\%>+[#PO^S-^W#XN&H>&-?LHK_0_P!FW7O[+A-UI5W"+F\OM0U:
MR-I91!_.N+IX'6"!7D9#MVGYQ>%_B(ES5>#L\PL=^;'T,)EB2[R>:YQE?+;K
MS*-NJT9['_$5?#=RY:7&F0XJ72.7U\9FC=]N593DV:\U^G+*5^CU/PY^&/PO
M^*6A?"OP_P#%3X%:#\))/&_C?]BC]D;PKX2L_&QET;16^)'ABTU'Q!KGCSQD
MVE^&M7.IW>F:#XJTS4?#UW/!?W^K^(M#L]-U273],B2]'77/P*\9ZM\ ])^&
M&N_"#X8^*[VV\<:7\5O&'A[XE?&;Q;XHL?BIX[@^)TGC3Q1?^*/''A;X=>#;
MFW\2>,9IIO&,.O/X0U'P=HNOBS\&W7P]U/PI:P7%OS/P4_:.\::;\%?@QX?T
M']E/]H/Q6N@_!_X7:#%KUKI>@:5X=U\:-X#T#35UK0M0U#42UWH6KBU&H:1?
M/#&;K3KFVN&C0R%%P?'W[3'[8UM\0_ &E^#?V4/$&B^'-9F$5_HGBI8==O\
MQ#+]JV7,<WC#0)QHG@.VM;0QO'<ZHI9)3+>77VBR005^L9=X:<0XZHL--Y+E
M\_J6(K369\6<(X2DHT,,L37BDL^S"HJM147&*=)TVXI59TZ2G-_FF8^)_#>
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MCU"R\.S:7:MJ.KW]I9K=WU[:V%NTPENKJ"!7E7]"?#_[&_[(_A54'AS]E_\
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M&>P/AF\-^(UO+-V]*))ZDGOR2>?6OI7_ ()O_P#)S'[97_9+?V//_2O]IFO
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M,MB_18#@=RBNUIW7=G\9?P*M_P!M6\^#?PR7PCJ?[-V@^$O^$6MQX??7=/\
M'>L^(?[,^VWVQM72TE73?MWF^=O6S9[<H$",3DG.^+'P7_;^\;:MX%OM/^.?
MP]TZ/1=7:XNXO (U_P  V&F%I[:1=7U:RN8KR3QI'#$DL,>E7#/&(U:'[(ZW
MDTR?6O[,W_)N_P &?^Q'M/\ TXZG7N%?KF3\>8W+G@\;@>&^!,/5AA%&,/\
M4_ 5Z:CB,%[":MC<QS&5HTZ\E"]VK).3BY\WYCF_A]@<SI8S 8_B;Q Q-*IB
ME.<WQIF%"JY8;&JO!J6 RW+(J]2A%S2LG=M)24.7Y /P7_:KOW+:I^V5/9*S
M$M'X7^"?@O3QM).1'+>7D\L6,\!5]CT%?27[$'[)'Q7^)'CK]I[2)OVXOVD_
M!]UX:UWX.IKNM?#RX\,^$-2\8OK7PNLM1TZ?4WAL=0M[1_#]D1H=@+*WC\VQ
MMX);MYYPOE=;7UM_P36_Y*O^VG_V,'[//_JF+.OG>(N.^(<+EWM,)_8&#FL1
M0@GAN#>"Z=E)5;V]KPQCFI:*TKN2UM+5W^@R/@#AO%8V5+%OB+&0=&K-K%\;
M<;U>:47!J_L^*<#>.KO!<L'I>+LK=%%_P2XT>]E,_B[]M[_@H9XRD;[T6J?M
M*W5G9.O]QK/2_#%I&4  "_-O _C)))LR_P#!([]D[48G3Q;J7Q]\=[U(E;Q9
M\?OB/<R3 AM_F/IFK:5GS,_/M"@D XZY_3^FO]QO]UOY&OA5XH>(,5:CQ9F>
M#6ONY?3RG*TK](K*^'<N<5_ADK=+'US\*O#J3O7X1RK&/OF-3.,U;\Y?VKQ)
MF:D^_-&5^MS^-#]G+]CS]FOQ5\!?@=XU\2_"S3=>\2^+?A!\-O$_B#4-4UOQ
M1.E]K6N>#]'U/4[E;%=;BL+.*>\N9I([.RMK>SMD816\,<2J@]FU#]B#]E74
M+[0K\?!W0-.;0+K[7!::/=ZOI^FZFWF1RB#Q%8)?O#KMHKQ*1;WNY2C2PNSP
M32Q-V'[*?_)K?[-?_9 O@_\ ^H!H%>]U^GT>..-90H5I<7\42JO#P3F^(,VO
M:KAH4ZBY?KJI^_"I.+?LKI2;BZ<N6<?@*O ? T'6P\.#.%(T5B)2]FN'<H4>
M:CB95*4G_L3FW"=.$E>H[N*4E4BY0GYIIWP6^#>CX_LKX1_#'3]IRIMO 7A9
M&7'3:YTHNH'H& Z>@Q]X_P#!+OPQX937/VVEC\->'81IO[2/P_@T\0:'I4'V
M&"7]C_\ 9FNY+>S,5HAMK=[N:>\-O#LA^UW-U=;/M%U<22?+-?8/_!+W_D._
MMS_]G*_#O_UCC]F*O@^,,QS'$9=&6(S',,0WBZ5WB,PQ]=N\*U[NOCJ][];W
M]#[GA7+,LPV.E'#9;EN&2PU2RPV6Y=ADK3I6LL/E^'M;I:UC]751$4*BJBC@
M*JA5 ]   !^ KCOB.2OP\\>$$@CP9XH((.""-#OB"".00>01TKLZXOXD?\D[
M\>_]B7XI_P#3'?5^8'Z,?S8_LZ?\FZ?L[_\ 9 ?@G^GPP\*XKV,,P! 8@-C<
M 2 V.1D=#@\C/2O'/V=/^3=/V=_^R _!/_U6'A6O8J_9**7L:6B_A4NB_P"?
M5(_*IM^TJ:OXZG5_\_*GF%?8'_!,C_D</VW_ /LMWPD_]93^!U?']?8'_!,C
M_D</VW_^RW?"3_UE/X'5\_Q5_P BR/\ V%T/_2:Q[G#G_(PE_P!@U7_TJD?K
M!7@W[5'_ ";#^T=_V0;XO_\ JO?$5>\UX-^U1_R;#^T=_P!D&^+_ /ZKWQ%7
MYV?<GX5_#[_DG7PW_P"R<?#_ /\ 4/T6NMKDOA]_R3KX;_\ 9./A_P#^H?HM
M=;7[/'X8_P"&/_I$#\HE\4O\4O\ TJ05]K_\$N_^0=^VC_V>#9_^L>?LB5\4
M5]K_ /!+O_D'?MH_]G@V?_K'G[(E?-<5_P#(MI?]AE+_ --5CW^&_P#?ZG_8
M+4_].43]2:^2?V_?^3$?VUO^S2?VC_\ U3GC*OK:ODG]OW_DQ']M;_LTG]H_
M_P!4YXRK\^6Z]5^:/MWL_1_DS\C+'_D'Z;_V#--_](;>K-5K'_D'Z;_V#--_
M](;>K-?LRV7HOR1^4/=^K_-A7W'_ ,$NO^1._:N_[/)\=?\ JG_@97PY7W'_
M ,$NO^1._:N_[/)\=?\ JG_@97S'%G^X8?\ ["X_^F:I]%PU_OM;_L%E_P"G
M:9^GM?$/_!2[_E'C^V]_V:O\=/\ U7/B&OMZOB'_ (*7?\H\?VWO^S5_CI_Z
MKGQ#7P,?BC_BC_Z5$^TE\,O\,O\ TF1^9.H_\?\ >_\ 7U/_ .C6JG5S4?\
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M277/#GBDZ)%J_AS7?#>F^"=)T3X/>'-=T[7=0N=4\/V%O^NU !1110!^>_\
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MA#_R+?C+_LXO]L7_ -;"^/%>HU^O8#_<<'_V"8;_ -,4C\PQO^^8O_L)K_\
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M_P!QO]UOY&OSD^Z/Y9OV4_\ DUO]FO\ [(%\'_\ U - KWNO!/V4_P#DUO\
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M "3KX;_]DX^'_P#ZA^BUUM<E\/O^2=?#?_LG'P__ /4/T6NMK]GC\,?\,?\
MTB!^42^*7^*7_I4@K[7_ ."7?_(._;1_[/!L_P#UCS]D2OBBOM?_ ()=_P#(
M._;1_P"SP;/_ -8\_9$KYKBO_D6TO^PRE_Z:K'O\-_[_ %/^P6I_Z<HGZDU\
MD_M^_P#)B/[:W_9I/[1__JG/&5?6U?)/[?O_ "8C^VM_V:3^T?\ ^J<\95^?
M+=>J_-'V[V?H_P F?D98_P#(/TW_ +!FF_\ I#;U9JM8_P#(/TW_ +!FF_\
MI#;U9K]F6R]%^2/RA[OU?YL*^X_^"77_ ")W[5W_ &>3XZ_]4_\  ROARON/
M_@EU_P B=^U=_P!GD^.O_5/_  ,KYCBS_<,/_P!A<?\ TS5/HN&O]]K?]@LO
M_3M,_3VOB'_@I=_RCQ_;>_[-7^.G_JN?$-?;U?$/_!2[_E'C^V]_V:O\=/\
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MT76-=L[&7Q9>Z+J&IQWNC:=J5A=?B1\#[WXQWEW^Q./'VB?M8^&OCS9_"_\
MX)V:;\!]&\6ZQ\5-?LW\!:5XDU#2?VX=8^,&M>%=1U;X7:MXI\0?#RSU37/B
MC<_&#4)/&(L;[X7-;VNF>+FTNRB /U[_ ."B7_)KNH_]ES_8_P#_ %L#X$U]
MOU^;_P#P4WG^*T?P1\(0^#M,^'EW\.Y_CY^RP/BI?^)]=\2Z=XSTRR3]K;X
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M?[IA?^P;#_\ IBB?EN)_WG$?]A%?_P!/50KZV_X)K?\ )5_VT_\ L8/V>?\
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M]DH_P:7_ %ZI?^FJ9^4U/XE3_KY4_P#3E0*^P/\ @F1_R.'[;_\ V6[X2?\
MK*?P.KX_K[ _X)D?\CA^V_\ ]EN^$G_K*?P.KY_BK_D61_["Z'_I-8]WAS_D
M82_[!JO_ *52/U@KP;]JC_DV']H[_L@WQ?\ _5>^(J]YKP;]JC_DV']H[_L@
MWQ?_ /5>^(J_.S[D_"OX??\ ).OAO_V3CX?_ /J'Z+76UR7P^_Y)U\-_^R<?
M#_\ ]0_1:ZVOV>/PQ_PQ_P#2('Y1+XI?XI?^E2"OM?\ X)=_\@[]M'_L\&S_
M /6//V1*^**^U_\ @EW_ ,@[]M'_ +/!L_\ UCS]D2OFN*_^1;2_[#*7_IJL
M>_PW_O\ 4_[!:G_IRB?J37R3^W[_ ,F(_MK?]FD_M'_^J<\95];5\D_M^_\
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M%W@C]G/Q!XVU_7M.OOBI<_#[QCIFK^ /#VG>%/'?PZ\::/-K5[<16MM7Z_>
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MD?\ "0Z!KF@?VIK&A_VYH^IZ1_;7AZ]_LW7]'_M*RGLO[4T/4?*G_L_6-/\
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..4UJ* "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= B8# 2(  A$! Q$!_\0
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M\._"OPCH_P '+_\ L6+5KC0_"]O\0/B!XD\7^"C9>*?%S:?>7L$<GE'[:?Q
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M>=>W(CD,$$@C?;_+W\/_ /@H'\3-5\"_ 6]F^+7QU\5Z_P"!/^"7W[0_B_\
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M $'KC_P$T;_Y4T?\+?\ 'O\ T'KC_P !-&_^5->8T4 >G?\ "W_'O_0>N/\
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M7ZE_8K/_ )]+;_OQ%_\ $4?8K/\ Y]+;_OQ%_P#$5!9^6G_"9:&.!IWC@ #
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M)Z]>>:/^$ST3.1I_C@'(.1X$U<$$'(((8;2#SD8YK]2_L5G_ ,^EM_WXB_\
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M^6S^-M'D&'LO';#<SX/@?6"-[XWOC=C>^!O?[S8&XG IG_"8Z&?^8=XY]/\
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M !%'V*S_ .?2V_[\1?\ Q% 'Y9_\)CH?_0.\<_\ A#:Q_P#%4?\ "8Z'_P!
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M7?Q+7XE>$]5_9&^#'BGQ.?!/QF_:%^.O@SPO\9(]6NK;Q._Q1U_]HJYU34?
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MXU^'>H> ?%'QA/@/X>^*]#^.#?M6:7\6? .K:_HG@K0_A3)JOA+5/&E]KO\
M0#_P3C^%?C#X*?LD?#OX9^._A%!\$_$WAK4/&:W_ (+@M/V;]/+C5/&&M:U;
MZY/IO[)G@#X7_ BPN-7@U&.9X/!_@C1IG5$N?$!O_$-QJ>HW1[>I_P!._P#P
M30_^4A["G_?_ /!U?_Y<?6^D>'M=T^]CN;[QUX@URW0/NT_4-.\*6]M*6BD1
M2\NE>'M/O!Y;NLRB.Y0&2) ^Z,R1OUU%%9RFYN\K7M;W8P@K>D(P77>U_/8T
MC%05HWM>^LI2?WSE)_*]O(****DH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K\]?V_?C!^T_\*]%^&Q_9L\-7&I6LMQ\0
M_&OQI\4:7X<^''C?Q'X0^%/PY\%W&J7MQX;\$?$?XQ?!G3M>U74?$&J:$J_8
MM=U"X6"RFTH6=K<:W9ZE:_H57A?QQ_9G^ W[2FG^'-,^.?PQ\-_$:T\):E>Z
MGX=&MQWD5SIDFJV+:7KMA'?:9=V%]-H'B;2V.E>+/#%U<S^&_%NEJFG>)-*U
M2RCC@4 ^%/@9^V5\8/BC\=_A[J)U7X=ZM^SI\;OBG\9O@G\//"^G^#]>T?XD
M:%+\'?A9)\2M*^+NO>*K[Q)-:WMI\15T+Q-!>>!)?!6CMX6TW7? #0Z[>:C;
MZ\-6^[/%?[1/PX\#_&#P!\$?%,7CO2/%GQ1F;3_ FN2_#'XA3_#+7O$*Z!XN
M\5?\(?'\6+3PW/\ #FR\9MX:\">*M=3PMJ7B6SUF33M+,R6C&\L$NH_#W[,7
MP!\*?&/7?V@/#GPK\*Z/\8/$FE'1M6\;65K-'>RV<FGZ#I%W):6'V@Z+I6I:
MII'A7POI&M:UI6FV6LZYI'AOP_I>L7]]8:+IMO;>.?M=?\E-_P""??\ V>TG
M_K(O[6U 'VU1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/LL/BU
MY9"OQ)\6Q*'DPB6'@G8B)NR=TGA5B%55+NSMA0&8E5''&VOCO2K[PW/XSL?V
MC["^\&6MW)I]WXSLO$WP?N_"%GJ$-[%ILMA>>*;?2)-!M;Z/4;BWT][.XU".
MY6^N;>S,0N+B&-_)_P!MGX*>-/VD/V2/VD?@'\.O%=EX)\<_%SX5^*O!/ACQ
M'JEQJMGHMOJ6J+&W]E>(+W0@=<L?#7BFU@N/"?B2^T9)-4LM!US4;JRAGN(D
M@D_&/XT_\$X_VE?VF/@1)^SIX,_8F_8$_P""?7PI^*_QYT;XA_M >"/#/C._
M^,'@3QMX/^$GP=D\/?#^V\<>!_@UH/P'M-9UC7?BQ=:!X@\-OX(U/2[K0=)^
M%GAW6_B#=ZCJM\VDW7J3J2BTE2IM<M[^QHN[LMK4>G5/5WTV//5.+5W.HM=O
M;5EW_P"GR7IT1_0+J_B-_#VIZ#HOB'X\3^'M:\57<NG^%=%U_4_A;HFL>*;^
M *9K'PSI6J:#::AX@O8=Z"2UTBWO)T:2-6C#.H.7H_C_ $?Q%XBU;P?X>_:1
MT_Q#XPT 3G7O"&@^)_@]K7BO0A:SK:W9UKPUIFD76MZ3]DNF6UN_[0L;?[+<
ML(+CRY2$K^<?XI?\$X/^"C7Q*LO!_B7QG\+?V._C-^T'XM^$'[(OPOUSXX?'
M'7/!?Q-M_P!FGQ+^RGJ_BS2O&/B+PEX5\??#7Q9=ZUX _:/2X\-_'J\NO@_K
M'@GXL^&OB7+?>%=?DU"PLK#4;7W+]E;_ ()7?&7X"_M]^'OVP_%=KX'\7Z'X
MC_:!_P""A/C;Q'X?TG_A4W@_Q3\(D_:!\;>,-4^$/Q:M/'GA/X>:1\2_C]H/
MC+P!K-YX6\>?!+XK>/M?C^%WBOQ#I'C'P6CQ>&Y-*M956;?\&FES).]&CHFE
MU]COKT5N@_902_B5&[75JU;>[Z>UVLOU/WW\CQ=_T4WQA_X+_ __ ,R='D>+
MO^BF^,/_  7^!_\ YDZUJ*WNOY*?_@FC_P#*3/D7\U3_ ,'5O_EID^1XN_Z*
M;XP_\%_@?_YDZ/(\7?\ 13?&'_@O\#__ #)UK4477\E/_P $T?\ Y2'(OYJG
M_@ZM_P#+3)\CQ=_T4WQA_P""_P #_P#S)T>1XN_Z*;XP_P#!?X'_ /F3K6HH
MNOY*?_@FC_\ *0Y%_-4_\'5O_EIC2+XIA5'G^*?BFW22XM[2)[BU\!0)+=W;
M^5:6D33>%D62[NY1Y=K;(6GN)/W<,;OQ2NGBJ-X(Y?BEXKBEN9FM[6*6T\!Q
MRW5PD3W#V]K$_A59+FX2WCDG>"!9)4@CDF9!&C,/S=_X*;_LZ_%K]H#PA\*X
MO@_X!TKXC^)/#LWQ@\/II7BJP\ >(?"'A#4/B?\ #K_A&?#7Q7N?#?Q!\=_#
MJUL?%GP^U^RM;KPA\4O#6L>)O%_PJ74=>U+1_AKXX&MSVMCQO[3_ .SI\</B
MOXT^%U_IWPFN_B#KGA7X6>!/A%X)^+7B7QCX$TNZ^ OQA\!_&OP#XX\4?M4Z
M='?>*!XDBTKXC^#M"E^PZQX(LKKXKWUWX2MO!'B?PIH^A^,+JZBSE4:;2HP=
MK:^QHV_],_E\RE3C_/46_P#R^K:=O^7W7_AM3]4D_P"$GE&Z+XJ^)Y09I[8&
M&W\ 2@W-L\D=U:@Q^%F!NK5X94NK8?O[9XI%GCC,;@2>1XN_Z*;XP_\ !?X'
M_P#F3K\L? _[+/QV_9X^/VA:Q\#-'A\3_!IOB/=Z/)%\2-4\*7>J:%X4U^V^
M$6F?$'XD10Z7>Z#_ &/J7B?P-H.O^'8/%-EI?B;XG^)/%OP[TW4O&=E);_&?
MQ=J5O^LIQDXSC)QD8..V0"0#CJ,GZU49\RUITUY.C1_6B)P2^U4?_<:M_P#+
MC(\CQ=_T4WQA_P""_P #_P#S)T>1XN_Z*;XP_P#!?X'_ /F3K6HJKK^2G_X)
MH_\ RD7(OYJG_@ZM_P#+3)\CQ=_T4WQA_P""_P #_P#S)T>1XN_Z*;XP_P#!
M?X'_ /F3K6HHNOY*?_@FC_\ *0Y%_-4_\'5O_EIE"W\7L0J_$SQBS,0JJ-.\
M$$EB<  #PGDDD@ #DDX%1PKXIN8_-MOBIXIN8=\\?GVUMX!N(!):.\5W&9X?
M"SQ![26*6*Z0N&MI(I(Y@CQN%R?B'IFN:W\//B%HGA>.PF\3ZWX"\::-X:AU
M35=5T'3)O$6J^&-5T_0HM2UW0F37-#T^75;BT2]UG1735M*MFEO]-=+VW@<?
MC/\  +]D#XY^ ?V'_P!J+]G'4OA3XXT>_P#C'I5F/!-@^M?LZ^%-<36/"'P4
M^&OA[Q#IWBO2/A5XK@^#]IX8^)7C3P7?^'])O=,\OQ+\6]%U3Q#J_P ?-5\,
M:CXG;Q2L2FTTE2IO2]_8T=^W\!HI4XM?'46J_P"7U;[_ .-T/VKC?Q),+5H?
MBQXDF6_@>[L&AA^'\HO[2,0M)=V!C\+L+VTC6XMVDN;7S8(UGA9Y%$L9:58O
M%CJKI\3_ !<Z,H9'2Q\"NCJP!5T=?"A5T8$,K*2K*002"#7X?>'_ -@'X\7/
MPFTGQ4-+L_ /QON_&OQON?"GPU\,-X(^&?PK^$'PA\5:/X\OM"^'UGX=\(^*
M?B$GPXC\:WWB/Q!X9U;P9\*OB=XET&UE^).EZ]XO\2ZQ/\,=.N(?UX^ 3?$[
M_A4?A"+XP>'M#\*>.;.+5M-G\/\ AZTTG3;'3O#.EZYJ6G> X[C1_#^K:]X=
MT+5W\#VWA^36]!\.ZYJ^A:/JC75AIE_-;0*J$9M[TJ<=+ZT:/_RD3II;2J/_
M +C5O_EQZ5Y'B[_HIOC#_P %_@?_ .9.CR/%W_13?&'_ (+_  /_ /,G6M15
MW7\E/_P31_\ E(N1?S5/_!U;_P"6E_PC'XA37;7^T/&WB+6[4I<F2PU&S\+P
MVTI%O*$+OIF@6%V/+=EF7R[E,R1('W1F2-_8:\M\,_\ (:MO^N=S_P"B6KU*
MO/Q7\1:17N+2,8Q6\ND(Q5_.U_,[,.K0:O)^\_BE*3V76<I/Y7MY!1117,;A
M1110 4444 %%%% !1110 4444 %%%% !13&EB62.)I(UEE#F*-G422", R&-
M"0SA RERH.T,"V,BJEIJ>FZA8QZI8:A8WNF2QO-%J-I=P7-C)#&7626.[AD>
MW>.-D</(LA52CAB"IP 7J*K6=Y::A:V]]875M?65W#'<6MY9SQ7-K<P2J'BG
MM[B%GAFAD0AHY(W9'4AE8@YJS0 4444 %%%% !1110 445#<7$%I!-=74\-M
M;6\;S7%Q<2)#!!#&I>26:61ECBCC0%GD=E55!9B ": )J^)?VNO^2F_\$^_^
MSVD_]9%_:VK[)CUC2)M5N="BU33I=;LK.VU&\T>.^MGU6TT^\DFAM+ZYT]93
M=P6=U-;W$5M<RPI#/)!,D3LT3A?C;]KK_DIO_!/O_L]I/_61?VMJ /MJBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \HE^%222/)_P )[X_CWDML
MCO?#80$]=H;PNS<GDY8\D]N*9_PJ9/\ HH'Q"_\  [PS_P#,K7K5%='UK$?\
M_/\ R2C_ /*##ZO0_P"?:_\  JG_ ,M/)?\ A4R?]% ^(7_@=X9_^96C_A4R
M?]% ^(7_ ('>&?\ YE:]:HH^M8C_ )^?^24?_E ?5J'_ #[7_@53_P"6GDO_
M  J9/^B@?$+_ ,#O#/\ \RM'_"ID_P"B@?$+_P #O#/_ ,RM>M44?6L1_P _
M/_)*/_R@/JU#_GVO_ JG_P M/)?^%3)_T4#XA?\ @=X9_P#F5H_X5,G_ $4#
MXA?^!WAG_P"96O6J*/K6(_Y^?^24?_E ?5J'_/M?^!5/_EIY+_PJ9/\ HH'Q
M"_\  [PS_P#,K1_PJ9/^B@?$+_P.\,__ #*UZU11]:Q'_/S_ ,DH_P#R@/JU
M#_GVO_ JG_RT\E_X5,G_ $4#XA?^!WAG_P"96C_A4R?]% ^(7_@=X9_^96O6
MJ*/K6(_Y^?\ DE'_ .4!]6H?\^U_X%4_^6GDO_"ID_Z*!\0O_ [PS_\ ,K1_
MPJ9/^B@?$+_P.\,__,K7K5%'UK$?\_/_ "2C_P#* ^K4/^?:_P# JG_RT\E_
MX5,G_10/B%_X'>&?_F5H_P"%3)_T4#XA?^!WAG_YE:]:HH^M8C_GY_Y)1_\
ME ?5J'_/M?\ @53_ .6GDO\ PJ9/^B@?$+_P.\,__,K1_P *F3_HH'Q"_P#
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%!X!."<#H,9/L,D#)]R!ZD4
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MW\4]6^)OC)OBA/XL&O\ AWQ;;ZHMO/X=MTM+7RN[^Q<Y_P"A1FG_ (;L;_\
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MW3;#6]9TC[']BU/5[.VU.]AGO84G'XLT5^Q_\0[X8_Y\8W_PX5O_ )4?E/\
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M#J*W76/#6BV&G6GC+3M#\5R:SJBZQKO@#Q':7>C:-I]YX8U7Q!)^UUJVE?\
M"X/^"?6B?VGIW]M']L]-0&D?;;;^U#8#]DG]K:(WHT_S?M9M!*#&;D0F$.&4
MOE3@ ^ZJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"5X'!'_)4Y1_U^K_ /J'BSVN,/\ DF\T_P"O5'_U+PI^&]%%%?T<?@A/9?\
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M@\5>.?$&@:3J7BKQUK.DZ3:7_B=Y++C_ -KKX<_#W_AHK_@GS\5?^$#\&?\
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MHT7P/X9U+PS^T_XH;]GB?2_VGOCA\,=<\5?M:_#[PO\ '+4(_A?8?L]CX??
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MDH_:A_Z\?@'_ .J4\,U_<%7\/O\ P5K_ .4E'[4/_7C\ _\ U2GAFO6\//\
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M\=?]FR_LT?\ J6_M(5_:-7\7/_!:W_E)-XZ_[-E_9H_]2W]I"L. /^2IP/\
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M@O0O$>A:SXK\'Z)X@O=>T73[^66[LE?1]?CTGSC]KK_DIO\ P3[_ .SVD_\
M61?VMJ\^\ _L??%3PQ^TU:^.-7\;> +OX#^"OC7\=OVCOA[I>G:5XBB^*]Y\
M1_V@_"&H>%?$GA?QA<W%P?"<?@SPE)XM^(.K:)JFD^?K.N#5_"VF7VFZ,/"U
M]J7B>/\ :Y^&]D/VH?\ @GU\6/\ A+?B/]O'[5 \%_\ "$?\)WK_ /PJEK9_
MV5?VN-0.OR?#?[3_ ,(U)XP5W-O'XH-I_:J6:0VHG\F)4H _07Q)_P B[K__
M &!=5_\ 2&>O\TKX3?\ ))OA5_V3+P!_ZB6D5_I:^)/^1=U__L"ZK_Z0SU_F
ME?";_DDWPJ_[)EX _P#42TBOU3PM_P!\SG_L#P?_ *EU3\U\1_\ =LI_["<7
M_P"H]$[^BBBOV0_*3^AW_@W?_P"1W_;E_P"P)^RC_P"@_M$U_3G7\QG_  ;O
M_P#([_MR_P#8$_91_P#0?VB:_ISK^:>+O^2FSO\ [&%3_P!-X8_H+A?_ ))[
M)_\ L"A_Z<Q 5_FI>%_^1<TG_<U#_P!/&I5_I6U_FI>%_P#D7-)_W-0_]/&I
M5];X7?\ (RS;_L7T/_4X^8\1_P#<,L_[#J__ *AF[1117[2?DA^[W_!O9_R<
MC^V+_P!D%_9D_P#5D?M-5_5E7\IO_!O9_P G(_MB_P#9!?V9/_5D?M-5_5E7
M\W\:?\E1G/\ V$P_]1<&?OO"7_).93_V#S_]2<4%?YR'C;_DI7QJ_P"SB_VG
M/_6B_BG7^C?7^<AXV_Y*5\:O^SB_VG/_ %HOXIU]'X8?\C?,O^Q8O_4VB>#X
MB_\ (KP'_8Q?_J'6.>HHHK]M/R _:;_@@G_R>S\5O^S3[W_U<OA&OZZJ_D5_
MX()_\GL_%;_LT^]_]7+X1K^NJOYSXX_Y*G-O^OF&_P#4+"G[UP=_R3>6?X,1
M_P"IF)"O\\[]H[_DZ3]K_P#[/+_:W_\ 6A/B'7^AC7^>=^T=_P G2?M?_P#9
MY?[6_P#ZT)\0Z]KPR_Y'N,_[%5;_ -2L(>/XB?\ (GPG_8SI?^HN*/(****_
M<C\=/UM_X(9_\I%A_P!F=?M!_P#JXOV3Z_LCK^-S_@AG_P I%A_V9U^T'_ZN
M+]D^O[(Z_G?CW_DJ<Q_P8+_U"HG[KP5_R3>!_P >,_\ 4RJ%?PA?\%+?^4D7
M[<G_ &5OX8_^LE_LW5_=[7\(7_!2W_E)%^W)_P!E;^&/_K)?[-U=OAQ_R4B_
M[%V/_P#2<,<O'W_)/O\ [#\%_P"E8@^+****_>S\4/TQ_P""./\ RDB^"O\
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M[U^R;_R=_P#L;_\ 9VWP _\ 4ZLZ_P!!:O\ /I_9-_Y._P#V-_\ L[;X ?\
MJ=6=?Z"U?A7B7_R/\/\ ]BK#?^G\8?LOA[_R)*__ &,L1_Z8PH5_'Q_P7>_Y
M/\\*?]F=?"O_ -7;^T/7]@]?Q\?\%WO^3_/"G_9G7PK_ /5V_M#UY7 G_)59
M7_W.?^H.)/2XT_Y)O,?^Y3_U-PY^.U%%%?T4?A!Z!\'/^2^_LO?]G@?L<_\
MK4OPAK_10K_.O^#G_)??V7O^SP/V.?\ UJ7X0U_HH5^(>)W_ ".L!_V*X_\
MJ9B#]A\._P#D48W_ +&4_P#U$PP5_)O_ ,%__P#DZ[]G+_LVWXE?^K6\"5_6
M17\F_P#P7_\ ^3KOV<O^S;?B5_ZM;P)7@<$?\E3E'_7ZO_ZAXL]KC#_DF\T_
MZ]4?_4O"GX;T445_1Q^"$]E_R%O"O_90_A3_ .K3\%U_I$U_F[67_(6\*_\
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MB7]KK_DIO_!/O_L]I/\ UD7]K:OMJOB7]KK_ )*;_P $^_\ L]I/_61?VMJ
M/L#Q)_R+NO\ _8%U7_TAGK_-*^$W_))OA5_V3+P!_P"HEI%?Z6OB3_D7=?\
M^P+JO_I#/7^:5\)O^23?"K_LF7@#_P!1+2*_5/"W_?,Y_P"P/!_^I=4_-?$?
M_=LI_P"PG%_^H]$[^BBBOV0_*3^AW_@W?_Y'?]N7_L"?LH_^@_M$U_3G7\QG
M_!N__P CO^W+_P!@3]E'_P!!_:)K^G.OYIXN_P"2FSO_ +&%3_TWAC^@N%_^
M2>R?_L"A_P"G,0%?YJ7A?_D7-)_W-0_]/&I5_I6U_FI>%_\ D7-)_P!S4/\
MT\:E7UOA=_R,LV_[%]#_ -3CYCQ'_P!PRS_L.K_^H9NT445^TGY(?N]_P;V?
M\G(_MB_]D%_9D_\ 5D?M-5_5E7\IO_!O9_R<C^V+_P!D%_9D_P#5D?M-5_5E
M7\W\:?\ )49S_P!A,/\ U%P9^^\)?\DYE/\ V#S_ /4G%!7^<AXV_P"2E?&K
M_LXO]IS_ -:+^*=?Z-]?YR'C;_DI7QJ_[.+_ &G/_6B_BG7T?AA_R-\R_P"Q
M8O\ U-HG@^(O_(KP'_8Q?_J'6.>HHHK]M/R _:;_ (()_P#)[/Q6_P"S3[W_
M -7+X1K^NJOY%?\ @@G_ ,GL_%;_ +-/O?\ U<OA&OZZJ_G/CC_DJ<V_Z^8;
M_P!0L*?O7!W_ "3>6?X,1_ZF8D*_SSOVCO\ DZ3]K_\ [/+_ &M__6A/B'7^
MAC7^>=^T=_R=)^U__P!GE_M;_P#K0GQ#KVO#+_D>XS_L55O_ %*PAX_B)_R)
M\)_V,Z7_ *BXH\@HHHK]R/QT_6W_ ((9_P#*18?]F=?M!_\ JXOV3Z_LCK^-
MS_@AG_RD6'_9G7[0?_JXOV3Z_LCK^=^/?^2IS'_!@O\ U"HG[KP5_P DW@?\
M>,_]3*H5_"%_P4M_Y21?MR?]E;^&/_K)?[-U?W>U_"%_P4M_Y21?MR?]E;^&
M/_K)?[-U=OAQ_P E(O\ L78__P!)PQR\??\ )/O_ +#\%_Z5B#XLHHHK][/Q
M0_3'_@CC_P I(O@K_P!DJ_:*_P#3'X%K^U^OXH/^"./_ "DB^"O_ &2K]HK_
M -,?@6O[7Z_GWQ"_Y*C%_P#8+E__ *BG[CP+_P DYAO^PG'?^I*"OX??^"M?
M_*2C]J'_ *\?@'_ZI3PS7]P5?P^_\%:_^4E'[4/_ %X_ /\ ]4IX9JO#S_DI
M\/\ ]@>8_P#J/3)X[_Y)VO\ ]A> _P#3]0_/&BBBOZ /Q ^\_P#@E?\ \I*_
MV-?^QI^.'_K*WQRK^YVOX8O^"5__ "DK_8U_[&GXX?\ K*WQRK^YVOP'Q%_Y
M*>M_V 9=_P"F:Q^V\!?\D]3_ .P['?\ IRB%?Q<_\%K?^4DWCK_LV7]FC_U+
M?VD*_M&K^+G_ (+6_P#*2;QU_P!FR_LT?^I;^TA6' '_ "5.!_Z\8_\ ]0YF
MW''_ "3F,_Z_X'_U*B?EK1117]"GX8>]?LF_\G?_ +&__9VWP _]3JSK_06K
M_/I_9-_Y._\ V-_^SMO@!_ZG5G7^@M7X5XE_\C_#_P#8JPW_ *?QA^R^'O\
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M.6NDSW<NL7US%%8+/O!KZ;_B)N??] F5?^",5_\ -A\]_P 0\R;_ *"LS_\
M!V&_^93^;7_@CAXC\;_LF^+/VJK_ ..?[,_[:7A&Q^)6D_L^0>#;F']C']IG
M7EU:?P0/C./$\)C\/_#'5)[)M,_X2O0"7U"*UBNQJ %C)<FVO!;_ +5>)/\
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M.+J8BG'#U9UH/#SIPDY3I>R:DZE.JG'EU223OUMH?P:?\,W?M3_]&??MD_\
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M/ XF=:G2G4HU7*A*$:BE1FYQ2<X5(V;;4O=;:V:W/X./^&;OVI_^C/OVR?\
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MX[JX@NKKQO\ VI8W]E/X36W&OVD]A?K=Z?!]BNC%]I_Q$W/O^@3*O_!&*_\
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M0PQ(D<4:+'&JJH L444 %?,7[78^-H^#-_/^SG\*_ _Q8^,MIXC\,3^"]/\
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M*.E:)X9O[O7_ !QXUEM-*AN_#WA[2-=TOQY^E=% 'X>>#/V#OC3XL^"_Q?\
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "1 BD# 2(  A$! Q$!_\0
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M4+>RN;'2K?7;&T;3[F^NTU&SCMK59%N9[B=((H7=D#4_%'PP^(_@O6=:\/\
MB?P+XLTG5O#FH0Z3KEO+H.I3PZ=J=R;46]A-?VEM<:>US<O?6<5JD-U*+J:Z
MMXK8RO/$'N& R&:@X8+)I*K!5*=L)EUYTWR-3BG13<7[2GKRK^)"Z3E%/.6-
MSF#FI8S-(NG-TYWQ&-]R:<TX2?M&E).G/3F^Q+5\K:^C/^&_OVNO^BU>*/\
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MYC:*=L?^ZW_?)_PHV/\ W6_[Y/\ A7JV?9_<_P#(\VZ[K[U_F-HIVQ_[K?\
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MM/\ ]^G_ ,*/L=W_ ,^T_P#WZ?\ PHL^S^Y_Y!==U]Z_S*U%6?L=W_S[3_\
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M']GW_P#SY77_ 'XE_P#B:TL^S^Y_Y&=UW7WK_,IT5<_L^_\ ^?*Z_P"_$O\
M\31_9]__ ,^5U_WXE_\ B:+/L_N?^077=?>O\RHIP0?0@_D:_.JV_8P^*.I^
M(;WP_P"+OC%X)3X#I^U/X[_:PTGP]X*\#>)-+^,$OC3Q/J&NZMX;T+5O'VJ>
M*[OPW8Z/X2UC7!K"WF@>$X-5U"ZTNRMFN8K:6X<_I!_9]_\ \^5U_P!^)?\
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MR].,E1NX**C>K-KW)1E%N#ER.2Y(KF=.[C%1;M=R_*+P3_P3?U;P;XL_9O\
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M=?[+/_1,O"__ (3NA?\ RNK[HHH]M6_Y^U?_  ;5_P#E@>RI?\^J7_@NG_\
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M  94_P#DP]G3_DA_X!#_ .0/C'_A@_\ 9[_Z%&Q_\ K#_P"1:/\ A@_]GO\
MZ%&Q_P# *P_^1:^SJ*/:5/\ GY4_\&5/_DP]G3_DA_X!#_Y ^,?^&#_V>_\
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MX_"4ZM.:M>%2G.M&<)*ZO&44U=76J/V%HK\>O^'^W_!(K_H\GPY_X;#XZ_\
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MZE^P+_T<)I?_ (0WQ2_^8>O2_L'//^A-FO\ X;\9_P#*#S_[:R;_ *&V6_\
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M[ NHQ3M<@6>EW1=HWD ).HZ=?[> N!'Y>,'.[/'RY_PU!\7?^AC/_@H\+_\
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MY0;7LF[-Q:NKZV[ZG8?\-0?%W_H8S_X*/"__ ,SU'_#4'Q=_Z&,_^"CPO_\
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MK<=((1C<1^Z3JT8B8_=_BB C;UC 0_+Q3HH8805ABCB4G)6)%C!. ,D( "<
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MMT19VL-=T/5M&OD>*&:WOM/E4+);/;7$_DQ@A8$-#$00P(,:$$.XD<$$<AG
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M\V%?TO?\'3.E:I>_\%*_#<UGIM_=PC]E_P"%\9EMK2XFC#KXR^*+,F^.-EW
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M7>FZ?HGB[Q-HKZK:W++!K>IV$6FOK\:7ELD,'QK6Q_PCVO\ _0$U;_P77?\
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M[2BX_P!FR5-Q3@U%TU746DZ<=6G-I*+J2C&$:=GP]_P4?\":7XZTK5+OP?\
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MSG\5B6)\*,2_E;R8P3)Y"E;?S"8,O]G4D6^_/D D1;*7_AG;XL_]"S/^;_\
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M?^)$Z9_\[NC_ (;-_;8_Z,,TC_Q(G3/_ )W=']DXG_H(RO\ \/&6_P#R\?\
M:=#_ )\9E_X:L?\ _*3]4:0JK## ,/0@$?D:_*__ (;-_;8_Z,,TC_Q(G3/_
M )W='_#9O[;'_1AFD?\ B1.F?_.[H_LG$_\ 01E?_AXRW_Y>']IT/^?&9?\
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MORR_X;-_;8_Z,,TC_P 2)TS_ .=W1_PV;^VQ_P!&&:1_XD3IG_SNZ/[)Q/\
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M&0^&?_#_ -E_\PM'_#7/[;G_ $9#X9_\/_9?_,+1_9&(_P"@G*?_  \9=_\
M+ _M.C_T#9G_ .&O'?\ R!^H5%?E[_PUS^VY_P!&0^&?_#_V7_S"T?\ #7/[
M;G_1D/AG_P /_9?_ #"T?V1B/^@G*?\ P\9=_P#+ _M.C_T#9G_X:\=_\@?J
M%17Y>_\ #7/[;G_1D/AG_P /_9?_ #"T?\-<_MN?]&0^&?\ P_\ 9?\ S"T?
MV1B/^@G*?_#QEW_RP/[3H_\ 0-F?_AKQW_R!^H5%?E[_ ,-<_MN?]&0^&?\
MP_\ 9?\ S"T?\-<_MN?]&0^&?_#_ -E_\PM']D8C_H)RG_P\9=_\L#^TZ/\
MT#9G_P"&O'?_ "!^H5%?E[_PUS^VY_T9#X9_\/\ V7_S"T?\-<_MN?\ 1D/A
MG_P_]E_\PM']D8C_ *"<I_\ #QEW_P L#^TZ/_0-F?\ X:\=_P#('ZA45^7O
M_#7/[;G_ $9#X9_\/_9?_,+1_P -<_MN?]&0^&?_  _]E_\ ,+1_9&(_Z"<I
M_P##QEW_ ,L#^TZ/_0-F?_AKQW_R!^H5%?E[_P -<_MN?]&0^&?_  _]E_\
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M4 %%%% !1110 A53U4'Z@'^=)L3^ZO\ WR/\*=10 W8G]U?^^1_A1L3^ZO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? BP# 2(  A$! Q$!_\0
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M2++QE\2/ 'A_P/X?U/P?X8O_ -K'7/V6[?X-ZGXX^'7BR;7V.DZI\/?!-O\
M&O2;[P_I&G:[<:E87JM<^)O[:'[9GB'XB_!JV\(?%7_A0-CKW[-?[+WQ&^$-
MA^T;K?A[X-I\</'_ (\U>>W^*T/Q)\":-\"_B/'\5-:DELK?PS>^ / 'B/X6
MCX?VNLZ=XVLP\6I![%QX,Q\W'EQN Y7/&P=27UR$8O!1I2FFI82-64I*LG*%
M*A6>&A3K3Q#C&C)2F7%F#C&3>$QO-&.$DH+ZK*<EBW446G'$RIQ472DHRJ5J
M2Q$I4H4+RJQ:_J'UG]H;5O#<4$_B;X@:!X9@NI'AM)_$NK>#O#T%W-&@DEAM
M)]9MK**YFBC(DDB@>22.,AW55()T;3XW>+]1M+:_T[Q/!J6GWD2W%EJ&FGP]
MJ&GWMNQ(6XL[ZSTZ>TNX&*L%FMYI(F*L Q(./PF_X*K_  TUSXO_ !>_X)L^
M -!^'OP,^(^N:[\<OCQ]F\#?M(Z1XB\1? _49;+X ZAJ=U;^-['PO#+K]S:V
M264USHDED@<Z]::5-<+Y"3 ?(/Q6T;XF_P#!-W]GGP)^S]9_M#>*_A=\1?B!
M<?M?_M&^'HOV?;32O 7[/.@^(H]/TC5_!GP$\$:M\1O ?Q>^(.JV&@ZW-%/X
M)^"GAK1-.U+XC?VCK]QK&M>'].LK:[.&#X=HX[!Y;*CF,(9CF4JTJ>"G1=2,
M</0Q.*P];$7P_-B%"DL/"K*<ER355PI4W*C4F]\5GM3!XG,(U,!.>"R^--5<
M7"K&%ZU;#X>O2HKV[C1<ZCK2IJG&TX^SC.<^6K""_J<_X7-XW$@A_M\^>8S,
M(/(T/SS '$9G\G^R_-\@2$1&;9Y7FD1[]YVT_P#X7%X[_P"@U-_X":-_\J:_
MDK\4_';X[>%OB#\:_P!IGP7\3?&VI?M%?$?_ ()(_LB_%7P'X+\C2K[PCK^K
M:]K$\'QPUWP7X#M_"FI?VKI_P1TFXU_XJVFA:5+J/_",^)=2U74M<L_$.E_8
MM M_7_ OQW_:Q\:Z)^SUX1T[]KZTUSP?\6/^"AGPX^#&D_%KX0?$GPK\</B+
M9?"KQ%\$/''B'XA> O&WQ$U#X!_#3P5K^HVOB?1]/UWP=K%O\.YI_#O]HPZ;
MJES>W/AY()=ZG!^)A3C56/P:II4U5=2GBXRA5^JX[$XF,(PI5?:4Z"P%:%.?
M/2EBG&I[&"E0K4XX0XIP\INE]2Q3F^>5-0GAI*5-XC!X>@Y.=6GR3JO&T9U(
M*-2.&BX>VE:K3J2_IS?XS>-X_+$FOF,RR"&$20Z'&9IF5W6&$/I:F69HXY)!
M%&&D,<<CA=L;D9\WQ\\06VIV>B77C;2K77-2BEGTW0KJ]\*6VN:G! ',\^F:
M-/9QZGJ,$ BE,\UE:SQ0B*4R.OEOM_EUTGQO\0?&?Q2_X)Y>)?CG^T9\6$M/
MA%_P49_;N_9I3XC7NH>&_#P\36'P\T[5])^$DWCZXLO!JZ'>^//B!'/%\+=0
MU)+/3T\4>']0O--TBUT[7+EM9BZK_@J7<ZS\/OV__@?^U#X>T6^U;7?V,/V1
M;O\ :6.E:='*)]7\*^%?VI?"WA7XG>&48*8W.K_#+QIXOMA;SRJH.)CD1L:F
MGPK*6.PV GCX>UQ. S7$PJ4\/45%8G 5H4,-AE4KSIJ4<95Q&!4ZGNSPBQ<5
M4IR<+SJ?$B6$Q&,A@IN%#&Y;AG3E6@ZTJ..I2K5J_LZ49.+PT:.+Y8>]'$_5
MI.G47-:'],-E\>_$.I7.HV6F>-=*U2^T>=;76;'3+WPKJ-]HMVV_9::S9V5G
M/<Z3=OY<FRVU&*VG;RY-L9\M]N@WQD\=*K,VN2(B*S.[6VBJB(H+,[LVE!51
M5!9F8A54%F( )K^+7X3>*/VAOV8],_:\\4>#=1O/!?B_XX_&[_@GYX\_:/\
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MZ:5;R:G<SRP0ZGKDMQ;3[K=3Z]X4\?\ QO\ &7A7X _%WXB_&3QW\0KOQO\
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M_BT58((8(6EYKQ9^T3>^+?V$?'_B>P_;5\?_ +1/QFU+P5^Q[XQ^+WPA\?\
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M=.3_ *0?^%Q>._\ H-3?^ FC?_*FC_A<7CO_ *#4W_@)HW_RIK^5[X=?M_\
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MUTC4O%TOB:[M]$\'16EUJ=_J=AXF'R2I6S3!8#_:YT\=0H8BC5PV$56M*%;
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MW-O.Z03B:]0PSND,FV1E4_Q[?LP1?L[Z.+Z7XE0>/?!5KX4_8>_:^T?_ (+
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MG32L)C0E(S$$*(2BD*2"K>.O#;JBO;^)I%CD$T2R^!O$<JQ3  ":(2::PCF
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M221O&WAAR2]IXDD)1HB9/ GB*0M$QRT+%]-8M"YY>)B8V/+*3S7ZI_V9IO\
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MTBV\37>DM=::&T71[R'0M-6+0[1OL=N878%S(<>HOXV\+R9\RR\129>60[_
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M)XAE)A 4"$E],;, "K^Y/[KY5^3Y1C]4O[,TW_H'6/\ X"6__P ;H_LS3?\
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M>6&TXB,Q+Q$4"F,<(5%?JA_9FF_] ZQ_\!+?_P"-T?V9IO\ T#K'_P !+?\
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MT[7=ONO;\ _K9?Y?UYGY62^-?"UPP>XL?$-RP 56N? .OW#*H  5&FTMRB@
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M%#]H#Q)\'/CE\+_@M\-+$?$'XW:I\:O@/^R[\(M*^)FG^+/BU::/X4\9:O\
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M"2=_=I4H/MO"$6UKLW;K;0N-.,'=.;;5O>J5)K[IRDD_.U_,****S+"BBB@
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M .7/3[P]DO\ G]4Z_P#+ZKVT_P"7G7RT/[#/.^(W_129O_".\.?X4>=\1O\
MHI,W_A'>'/\ "KME()K#3Y1!J5J)-/L'%KK+1R:S:AK.$_9=9DAN+N&76+?_
M %.JRPW=W#+?I<2175S&RS/9K>Z?_+NC_P"$]#_Y41RO^>M_X.J__)F3YWQ&
M_P"BDS?^$=X<_P */.^(W_129O\ PCO#G^%:U%%U_P ^Z/\ X(H?_*@Y7_/6
M_P#!U7_Y,R?.^(W_ $4F;_PCO#G^%'G?$;_HI,W_ (1WAS_"M:BBZ_Y]T?\
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M_?/TU\[XC?\ 129O_".\.?X4>=\1O^BDS?\ A'>'/\*UJ*TNO^?='_P10_\
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M$EX5_P#D.O9:*/KF(_FA_P"":'_RH/JM'M/_ ,'5O_EAXU_PK+Q1_P!%,O\
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M "H/JM'M/_P=6_\ EAXU_P *R\4?]%,O_P#PDO"O_P AT?\ "LO%'_13+_\
M\)+PK_\ (=>RT4?7,1_-#_P30_\ E0?5:/:?_@ZM_P#+#QK_ (5EXH_Z*9?_
M /A)>%?_ )#H_P"%9>*/^BF7_P#X27A7_P"0Z]EHH^N8C^:'_@FA_P#*@^JT
M>T__  =6_P#EAXU_PK+Q1_T4R_\ _"2\*_\ R'1_PK+Q1_T4R_\ _"2\*_\
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MGQ&C^'_PDN_@9X6%O;?&WX(7WB_X\^(/'_[7/Q=_9[\=:OX0TJT_9]5?VV_
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MT7;T+E REU579-PWJCE@C%<Y"L4<*Q&&*, 25.'5^%?A'X5_% _\%.]/\?\
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MX$S_ /Q=<!\-?^29?"__ +)A\./_ %"="KLZ_9H?!#_!#_TB!^4S^.?^.?\
MZ5(N?VCJ'_/]>?\ @3/_ /%U](_\$XYII_VE/VSWFEDF<?#W]D!0\KM(P46G
MQ^(7<Y)P"20,X!)]:^8J^F?^";W_ "<E^V?_ -D^_9!_](_C[7S_ !1_R*G_
M -A.'_.J>UP[_P C)?\ 8/7_ "IG[#T445^<GWA_+M^SC_R0GX9_]@SQ#_ZG
M/BJO::\6_9Q_Y(3\,_\ L&>(?_4Y\55[37[!@_\ =,)_V"X?_P!,43\NQ?\
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MAX<OM(T$>#X=1TCQ0GPLOOL?C#X;?#86&FZCX:\+6FGQ:?9>"?\ "QOVP?\
MH_']H+_PV7[%/_T)]'_"QOVP?^C\?V@O_#9?L4__ $)]>I_JOFO\N&_\*8__
M "H\[_6++>^(_P#!#_\ EA^UO[-WP$\"_LN_ KX7_ #X;6@M/!WPO\*V?AW3
MG,4<$^J7N^;4-?\ $=_%#BWCU7Q3XBO=6\2ZNMLL=K_:FJW?V6&&W\N)/;:_
M&O\ 8K^,O[1.H_M:GX3?$W]H7QS\:O!&M_LV>//B3'8>//!?P,\/W>A^+/"G
MQ4^%_A33KO1]2^$/PE^&%T]K<Z-XPUB'4+'6GUB"6865Q:BSDMY//_92O%Q6
M&JX/$5,-6Y55I.*GR24X^]&,U:22O[LET6MUT/6PV(IXJC#$4N;V=1-QYH\L
MM)2B[QN[:Q?5Z:A7XE?M%?M;:-\==1^*7P9\6_L'^%OC[\,_AA\8O$G@2._^
M(7QF\#^'#?\ C'X=21Z=J/B/1= OO"VK:IX>&[5+[3;'4+?5H=0O]%O-0L[L
M16.J7VGR?MK7\W>G?\E'_:G_ .SQOVA__3_I5>CD> H9AC)T,1[3V<</4JKV
M<^27-&5)+7EEI:;NK:Z:Z'#G&,K8'"QK4.3G=:%-\\>=<LHS;TYHZWBM;]]-
M3Z+?]LWQ3(_A=V_X)W?#O9X*\&Z]\.O"-LO[0?PRCL?#7@'Q1;>'K+Q#X+T7
M3H_ATMAI_A;6++PGX9L[_0K:VCTR>ST+3+5K;R+2*-?//AQ\=M&^$&E6>A_"
M[_@F1\,? .D6.L:[K\&G>%OVB_ 6CVIU?Q)X</@_5[RYCM/ T8O6E\)^7X9M
M8KW[1!I>@6UCI&E165A865O;\W17UO\ JOE?_45_X4?_ '(^9_UBS'_J'_\
M!/\ ]T/LS]G']M[5KSXE? S]FG4OV4K+X)>$/%FD^(?!/PWO/"WQ?\(>-M"\
M+VGPJ^'=WXFL/#K>&='\.:%<:;HD/A?P\VE:5-9RSQVDT5E:M:+;LTT/ZJ5_
M/O\ ![_D]/\ 8H_['#X__P#K.GC:OZ"*^.SG!T<#CZF&H<_LXTZ,E[27/*\X
M.4KRY8Z76BMHNY]5E6*JXS!0KUN3VDJE6+Y(\L;0FHQTO+6V[OJ%?S\?&3_D
M];]M+_L9?V?/_6?O"]?T#U_/Q\9/^3UOVTO^QE_9\_\ 6?O"]=7#/_(VI?\
M7C$_^FXG+Q!_R+*G_7[#_P#IQF-1117Z2?!',:M_R4+]EW_L\?\ 9N_]2^XK
M^D>OYN-6_P"2A?LN_P#9X_[-W_J7W%?TCU^>\5?\C*G_ -@='_TY7/N.&_\
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MVC_^Q3T7_P!3;PQ7WM7P3_P5 _Y,+_:/_P"Q3T7_ -3;PQ7Q=+^+2_Z^T_\
MTY3/K:G\.I_U[J?^FYGYR:K_ ,A34O\ K_O/_2B2J%7]5_Y"FI?]?]Y_Z425
M0K]E>[]7^;/RH*^UO^"67_(M_MB_]GI>)O\ UGC]FVOBFOM;_@EE_P BW^V+
M_P!GI>)O_6>/V;:^6XL_Y%]#_L,C_P"F:Q]%PU_OM;_L%E_Z=IGZE5X9^U!_
MR;3^T/\ ]D,^+7_J ^(*]SKPS]J#_DVG]H?_ +(9\6O_ % ?$%?GY]L?@_\
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M\&_M\_\ (O\ [*W_ &?E^R1_ZLRUK[RKX-_;Y_Y%_P#96_[/R_9(_P#5F6M
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MN_A8'_K[7_\ 3=,^HX8_BXS_ *]4/_3E0^\Z^"?^"H'_ "87^T?_ -BGHO\
MZFWABOO:O@G_ (*@?\F%_M'_ /8IZ+_ZFWABOBZ7\6E_U]I_^G*9];4_AU/^
MO=3_ --S/SDU7_D*:E_U_P!Y_P"E$E4*OZK_ ,A34O\ K_O/_2B2J%?LKW?J
M_P V?E05]K?\$LO^1;_;%_[/2\3?^L\?LVU\4U]K?\$LO^1;_;%_[/2\3?\
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M/^QP^/\ _P"LZ>-J_H(K^??X/?\ )Z?[%'_8X?'_ /\ 6=/&U?T$5^;<2_\
M(VK?]><-_P"FF??</_\ (LI?]?<1_P"G$%?S\?&3_D];]M+_ +&7]GS_ -9^
M\+U_0/7\_'QD_P"3UOVTO^QE_9\_]9^\+T<,_P#(VI?]>,3_ .FXBX@_Y%E3
M_K]A_P#TXS&HHHK])/@CF-6_Y*%^R[_V>/\ LW?^I?<5_2/7\W&K?\E"_9=_
M[/'_ &;O_4ON*_I'K\]XJ_Y&5/\ [ Z/_IRN?<<-_P"X3_[":O\ Z12"OPW_
M &SO^3^-4_[,S^%?_J]OC/7[D5^&_P"V=_R?QJG_ &9G\*__ %>WQGKBX?\
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M?]G>_LS?^K"MJ^8P/^^X/_L*PW_I^D?0XS_=,5_V#8C_ -,U3X&HHHK]>/S
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M5?6<)?[YB_\ L%C_ .I$3YKB;_=<-_V$2_\ 3+/8:***^\/C#U/]C/\ Y/\
MM#_[,P^,7_J]_@-7[FU^&7[&?_)_VA_]F8?&+_U>_P !J_<VOS#B#_D;XS_%
M2_\ 3%(_0\E_Y%>$_P -3_T]5"OYN]._Y*/^U/\ ]GC?M#_^G_2J_I$K^;O3
MO^2C_M3_ /9XW[0__I_TJNWA7_D95/\ L#K?^G*!R<2?[A#_ +":7_I%4Z2B
MBBOT(^'-CX/?\GI_L4?]CA\?_P#UG3QM7]!%?S[_  >_Y/3_ &*/^QP^/_\
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MX%_%7_DDWQ;_ .R3?$__ -0/Q!7[Z?LX?\F\? ;_ +(Q\+O_ %!]"KXCB_\
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M)_X*@?\ )A?[1_\ V*>B_P#J;>&*^+I?Q:7_ %]I_P#IRF?6U/X=3_KW4_\
M3<S\Y-5_Y"FI?]?]Y_Z4250J_JO_ "%-2_Z_[S_THDJA7[*]WZO\V?E05]K?
M\$LO^1;_ &Q?^STO$W_K/'[-M?%-?:W_  2R_P"1;_;%_P"STO$W_K/'[-M?
M+<6?\B^A_P!AD?\ TS6/HN&O]]K?]@LO_3M,_4JO#/VH/^3:?VA_^R&?%K_U
M ?$%>YUX9^U!_P FT_M#_P#9#/BU_P"H#X@K\_/MC\'_ (:_\DR^%_\ V3#X
M<?\ J$Z%79UQGPU_Y)E\+_\ LF'PX_\ 4)T*NSK]FI_PX?X(?^D0/RF?QS_Q
MS_\ 2I!7TS_P3>_Y.2_;/_[)]^R#_P"D?Q]KYFKZ9_X)O?\ )R7[9_\ V3[]
MD'_TC^/M?/\ %'_(J?\ V$X?\ZI[7#O_ ",E_P!@]?\ *F?L/1117YR?>'\N
MW[./_)"?AG_V#/$/_J<^*J]IKQ;]G'_DA/PS_P"P9XA_]3GQ57M-?L&#_P!T
MPG_8+A__ $Q1/R[%_P"]8G_L(K_^GJH5Z[^Q9_R?E#_V9MX]_P#5Z_#6O(J]
M=_8L_P"3\H?^S-O'O_J]?AK7E\1_\BC$_P"/#_\ I^)Z&1?\C3#_ .&O_P"F
M9'[AT445^9GZ"?S::'_R/7[3G_9Y/[3_ /ZL:YKJZY30_P#D>OVG/^SR?VG_
M /U8US75U^LY5_R+<!_V"4/_ $@_,\Q_W_&_]A-;_P!+"M_X*?\ )Z_[&O\
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MFTT/_D>OVG/^SR?VG_\ U8US75URFA_\CU^TY_V>3^T__P"K&N:ZNOUG*O\
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MPX@_Y&^,_P 5+_TQ2/T/)?\ D5X3_#4_]/50K^;O3O\ DH_[4_\ V>-^T/\
M^G_2J_I$K^;O3O\ DH_[4_\ V>-^T/\ ^G_2J[>%?^1E4_[ ZW_IR@<G$G^X
M0_[":7_I%4Z2BBBOT(^'-CX/?\GI_L4?]CA\?_\ UG3QM7]!%?S[_![_ )/3
M_8H_['#X_P#_ *SIXVK^@BOS;B7_ )&U;_KSAO\ TTS[[A__ )%E+_K[B/\
MTX@K^?CXR?\ )ZW[:7_8R_L^?^L_>%Z_H'K^?CXR?\GK?MI?]C+^SY_ZS]X7
MHX9_Y&U+_KQB?_3<1<0?\BRI_P!?L/\ ^G&8U%%%?I)\$<QJW_)0OV7?^SQ_
MV;O_ %+[BOZ1Z_FXU;_DH7[+O_9X_P"S=_ZE]Q7](]?GO%7_ ",J?_8'1_\
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MK\-:\BKUW]BS_D_*'_LS;Q[_ .KU^&M>7Q'_ ,BC$_X\/_Z?B>AD7_(TP_\
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M?L8_]&B_LP_^&#^%/_S)U9'[&/['H  _90_9J    'P*^%P  X  'A;  '
MZ5ZN4YH\KK5JJHJO[6DJ7*ZCI\MJBGS74)WVM:R[WZ'FYGEZS&E2I.JZ/LZC
MJ74%.]X.%K.4;;WO=]K'XI_\)AX+_P"AW\$?^%EX9_\ EK1_PF'@O_H=_!'_
M (67AG_Y:U^UO_#&7['W_1J/[-?_ (8OX7__ #+4?\,9?L??]&H_LU_^&+^%
M_P#\RU>]_K?+_H C_P"%,O\ Y2>-_JO'_H-E_P""(_\ RT_)/]D?XD?#C1?V
M]M NM6^(G@'3[63]C;XPVT=Q=>-?#,4#W!^.GP(E$ E;5!&9C$CR"/=O**S
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M=)$.,.C*ZDJP)]I_X3#P7_T._@C_ ,++PS_\M:_:P?L8_L>@ #]E#]FH
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LM(^,_%\FJ:P=3FNTCE\,_P!D2QSIJ3:U:S--8?9OV4HH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #< B,# 2(  A$! Q$!_\0
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M:WK'[,,^I^()[9(XDMFBAU6]NQ/96C.FG,YL]D.U8A\'?LTV'[)_AWQ?X,\
M?M(_LX_%7XA_\%1U_;=\1^*/$NN^'O _C_3OC'+<W7Q=UG4_!WQIM?CFG]A^
M&3^S/X>^&DFA7-]I$/C6+PS>^'[*YT(^';RXD:.;"/#T55S"E*MB:L\#A<!6
M=/!X?#UJO/C<)7Q%6M5C7Q>%A3R_ U,.Z6(Q*J>U2KX>3A2E/EJ:_P!N.5+!
MU8T:%.&+Q.-HQJ8FM6I4^7"XJE0I4H2I8>O.>.QD*RJT,/R.FW2KQ4JBBG'^
MH:P^.WB;5K>>[TGQI8:O9VMW>V%U>:3<>&=3M+74--E:#4]/NKJQLKB"WO\
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MJ&'K3E"HE6C-0II/G3/ZUO\ A<'CS_H.S_\ @)H__P JJ/\ A<'CS_H.S_\
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MTZUN0) 4.&!%;7_"X/'O_0=G_P# 31__ )55_)/_ ,%(]%^&WAW]L'XU>/\
M_A'-/^(/QEU6S^!P\.?LY?M!_LS_ !/\9:A\<Y/"=CI*>&;O]A+]J'X*7TGB
MWX1W+W(:S\5Z=>7_ (:M=.\<6>H7VM07.F7$@/U)\4OVO/C)X3^*7QO^#FH_
M$/XH>%_BKJ'_  4P_8OM?ACX$.C:W?W>D?LC_$*S^$Z?$/3-.UZR\/7'A_\
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M?ME>!?B/X;CG\,?!OQ%HO@B>+X(:YX/O;3P+X>.E:OXYU">XT*R@MM<\4?\
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M>1K,4^KVEC+/:7<L6GW4T???\$I?C7^U'\8/'&K7/QO^-^D^.K"Z^$.G:O\
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M3\,VFH>$[KQ)IEG=E!:W>I^'[>UDUC3[2Y,D8M[F\LH()S)'Y4C>8F[^<_\
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M56+3XN>.I;JVC?7)RDD\2,/LFCC*LX4C(TK(R">1R.U>45;L/^/ZS_Z^8/\
MT8M?/GMGZ):)>2:CHND:A* );[2["\E P )+FTBG<#  QN<XP /:BJ?A3_D5
MO#7_ & -'_\ 3=;44 ?'_P =M4L].\;7:7=EXEG>X%O/$^D>'Y=4MC"NF:;;
M9:=+J ))Y]O,IC*<*JN&8/A?%?\ A)-)_P"@9XY_\(VX_P#EA7ZBO##(<R11
M.?5XU8_FP)IGV6V_Y]X/^_,?_P 30!^7O_"2:3_T#/'/_A&W'_RPIZ^)],7&
MW3O':[22N/!UR,$C!(_XF'!(X/M7Z?\ V6V_Y]X/^_,?_P 31]EMO^?>#_OS
M'_\ $T ?F$GBK3X\;+'QZF %&WPA=+@*Q90,:B,;6)9?0DD8--/BC36.3IWC
MLDOOR?!UP?G/5O\ D(?>.!D]3WK]/_LMM_S[P?\ ?F/_ .)H^RVW_/O!_P!^
M8_\ XFBR[ ?F$/%6GJ0RV'CU64NRL/!]R"#(,2$$:CD;QP^/O#@Y%!\5V#%B
M;'Q\2RJC$^$+H[D4$*ASJ/*J"0J]%!( %?I[]EMO^?>#_OS'_P#$T?9;;_GW
M@_[\Q_\ Q-%EV7W+_(+ONS\PH_%6GQ B*Q\>Q@L'(3PA=*"Z\*V!J(&Y02 W
M4 D \T@\4Z<#D:?X\!RQS_PA]SG+D%CG^T>K$98]2>M?I]]EMO\ GW@_[\Q_
M_$T?9;;_ )]X/^_,?_Q-%EV7W!<_,-?%EBI++9>/E)VDE?"-TI)0DH21J(Y0
MDE3U7)P1DTQ?%&FHY=-/\>(Y# NO@^Y#$."'!8:B"0X)# G# D'.:_3_ .RV
MW_/O!_WYC_\ B:/LMM_S[P?]^8__ (FBR[+[D%WW?WO_ #/S!;Q3ISEF?3_'
MC,X569O!]RQ94 "J2=1)*J  HZ   # %,'B72U.5TWQT"00<>#K@<$8(_P"0
MAT(X-?J#]EMO^?>#_OS'_P#$T?9;;_GW@_[\Q_\ Q- 'Y@+XHTU"I73_ !XI
M52JE?!]R"JG.5!&H\*<D$=""01BG_P#"66.]I/L7C_S& #2?\(C=[V"G<H9O
M[2W,%;E<DX(!&"!7Z>?9;;_GW@_[\Q__ !-'V6V_Y]X/^_,?_P 319=E]R_R
M"[[L_,$^*=.)W?8/'F[>'W?\(?<[MX& ^?[1SN Z'.12CQ5IX8.+'QZ'4E@X
M\(708%AAB&&HY!(X//(XZ5^GOV6V_P"?>#_OS'_\31]EMO\ GW@_[\Q__$TK
M+LON"Y^8+>*=.<DOI_CQB4$9+>#[DYC7&U.=1^X,#"]!V%.7Q98)G99>/DSC
M.WPA=+G:I09QJ(Z(2H_V25Z$BOT\^RVW_/O!_P!^8_\ XFC[+;?\^\'_ 'YC
M_P#B:++LON"[[O[V?E^?$VED '3?'1 )('_"&W& 6.6Q_P 3#N>3ZFG_ /"5
MV&SROL/C[R]NSR_^$0NMFS.[9M_M'&S=\VW&W=SC/-?I[]EMO^?>#_OS'_\
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M.!R>/>GGQ3IQ78;#QX5&!M_X0^YQ\N"./[1[$#'IBOT^^RVW_/O!_P!^8_\
MXFC[+;?\^\'_ 'YC_P#B: /S#/BRQ9@S67CYF4, S>$+IB YR^"=1)&X\M_>
M/)S0OBRQ5BRV7CY6.W++X0NE)V$E,D:B#E225/52<C%?IY]EMO\ GW@_[\Q_
M_$T?9;;_ )]X/^_,?_Q-*R[+[E_D%WW?WO\ S/S"7Q5IZ#"V'CQ1DG \'W(&
M2<D_\A'J223ZFHO^$DTH]=,\<_\ A&W'_P L*_4+[+;?\^\'_?F/_P")H^RV
MW_/O!_WYC_\ B:8'Y>_\))I/_0,\<_\ A&W'_P L*MV'B32?MUGG3?'"C[5
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M?_,91_PA>M?]%,\=_P#?OP1_\QE=_11]8J_S1_\ !5#_ .4![&GVG_X-K?\
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M%X-\.> OA9?^%]%^%_AS3(_#GBTZSINEV%Q='UBK_-'_ ,%4/_E >QI]I_\
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MS7["&/3(3;WVK0P+<,+N+1-"CU.2-HY=730- 75'O!H>E"S\*_:7_P"3CO\
M@G7_ -G)?%K_ -8F_:EH ^UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,%T?_E)'LX_W_\ P;6_^7&'_9WB'_HHOCS_ ,"_#G_S,4?V=XA_Z*+X\_\
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M_@&&_AAU);_7];UX^9:B.36I=/E>W 6X9A";#3=.4"0LOF>8LA(BCVE,-O\
M0:XGP9_J]1_ZZ6W_ *!+7;5Y>(=ZTWINMDDOA72,8I?)+[]3NHJU.*5]+[MR
M>[ZR<F_FV%%%%8FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\4_M+_\G'?\$Z_^SDOBU_ZQ-^U+7VM7Q3^TO_R<
M=_P3K_[.2^+7_K$W[4M 'VM1110 4444 %%%% !1110 4444 %%%% !1110
M57N[9;RTNK1I9H5NK>:V::VD,-Q$L\;1&6WE )BFC#;XI "4D"M@XQ5BBA.S
M36Z::]4[K\4#UT>ST^_3]3RD_"73B21XO^(2Y).U?%$@49/11]DX Z =A2?\
M*DT[_H</B'_X5,G_ ,B5ZO171];Q/_/V7_@-/_Y28?5J'_/I?^!5/_EIY1_P
MJ33O^AP^(?\ X5,G_P B4?\ "I-._P"AP^(?_A4R?_(E>KT4?6\3_P _9?\
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MJ33O^AP^(?\ X5,G_P B4?\ "I-._P"AP^(?_A4R?_(E>KT4?6\3_P _9?\
M@-/_ .4A]6H?\^E_X%4_^6GE'_"I-._Z'#XA_P#A4R?_ ")1_P *DT[_ *'#
MXA_^%3)_\B5ZO11];Q/_ #]E_P" T_\ Y2'U:A_SZ7_@53_Y:<OX9\*V_A>.
M[CM]6U[51=M"SOKNIMJ3Q&$2@>0S11>4'$N).#O$<738,]1116,YRG)RF^:3
MW;LKV27116R6R7ZFL8QA%1BK16RU=M;]7)[OJV%%%%24%%%% !1110 445\[
M_M'?M&Z#^S=X>\$Z_KG@KXA>-E\<_%+X:_"VTA\">&YM6L_#EQ\2/'7ASP+!
MXM\<:].]IH'A'P=H-[XELKG4M1U?48;S47,6D>'-/UK7+RUTZ0 ^B**^$M=_
M;.\6:#\7O$GPBN?V5_C%-JMYX6^+/B'X'7,>N_"^WNOCA-\%?$'A'PMXS6UT
M:_\ &=G=?#?PU?ZOXXT&[\%^-OB'/H^@>)/#?VO6YY='>?P_IWB#G$_X*,_#
M*+]D)/VLM3\-7.G:?<_$*[^#VE>%CXY^'<N@Z_\ %"W^)MW\(XK;0OC(_B.W
M^%%_\-[CQ997E_\ \+6;Q%;^'+?PE8ZCK-Q FIV,WA^@#]$**\=^ 'Q>MOCS
M\(/!'Q:L]$B\/6WC+3KB]BTRU\8>"/B#IBBTU&]TQKS0_''PYU[Q+X,\5^']
M2>Q;4= US1M6<7^D75G+?V.CZH;W1[#V*@ KXT_;G^)OQL^$'P9TOQY\%=0\
M!Z1<:?\ %?X+Z3X[U+QIIFIZ[>)X!\7?%KP3X,\0:=X-T>SEM-.D\4ZS:^(6
MTRUU;7KX:;X>M[BXUA-+UJ]MK6P?[+K^;K]I3_@MXOASXJ?&KX#7W[#WA;XJ
M^$/A;\7?$?P[GU'QK\?[31(/%&L_"KQ;!]G\0R>#7^ _C2STU+?Q+HUKK6A)
M+KFHW5K-9:?J!>UO8Q%;]N!R['9G6EA\OPM;%UXTY594J*C*:IQE&,IM2J4U
MRJ4XI^]>\EH^G)C,?@\NI*OCL32PM&514HU*SDHNI)2E&"<85'S-0DU[MK1>
MJZ_4G[2_[4?[2?PE^+WQ-T3X<?&#P%XX\/\ Q"^#G[1VG?!E-8L?@EX2^&/P
MR_:0^&=KX0L?!/PNF^(-]\0+_P 0V_C[PXE[XK\:?&*[^.EEH/PTNK8^%O#7
MA+^Q_$;W'AW5?JG]F7XF_'CQY^SY\6=&N-6MM:_:;^$'Q&\=_"77M2^,ESX-
MU+P1%X]T>Q\/^)--N#K/P!\'^ ],\4^";/PQXNT&[*:3X1\)>*AJ::IX.\1I
MHWB#2M1O[?\ !*[_ ."Q/PRO_%OC[Q[?_P#!*3]GR_\ &OQ5\-W7@[XF>*;[
MXW^&[S7?B!X4O[6UL-1\.^,=2N?V49;GQ'HVJ6-AIUCJVG:M)=6NJV6EZ5::
MA'<V^EZ?';;GP_\ ^"V/AKX4:?X?TKX9?\$R_A!X TSPKHFN^'/#FG>#_P!H
MZQ\/66C:)XHUBR\1>)=.L;72_P!EVVAA@\0Z_IMCK>N$)YFJZM;1ZC?O/=[I
MF];_ %1XG_Z$>/\ _!=+_P":CS/]:.'?^AQ@?_!E3_YF/Z.OV//B)XP^+G[*
M/[-_Q1^(6H:?JWCSXA?!+X:>,?&>J:3I<>AZ5J7BCQ#X1TK4]=O],T6*XO$T
MC3[O4[FYGL],6\O/L%M)':F[NC$9Y/H^OP]_X)P_\%4K;]J3XT:9^RI9?LH:
M#^S[H/A[X'>+?'O@ZZ\'_%RS\<^&]-T/X8^)?A=X+'@V#PQ!\)_ANFA6QM_B
M1IL^CS:?->V=O;Z-=63V5N)+:0_N%7BXS!XK 8B>%QM"IAL334'4HU4E."G!
M3@VHSFO>@U)6D]'TV/6PN+PV.H0Q.$K4\1AZCDH5J;;A)PDX3LY1@_=FG%^Z
MM4]]PHHHKF.@**** "BBB@!KND:L[LJ(BL[N[!51%!+,S$@*J@$LQ(  ))Q7
MREXF_;H_9!\'^#_"_P 0-=_:%^&L/@CQKXE\:^%/"_BK3]<&NZ'K&I_#;Q#=
M^%/B->6^H:%%J5O'X8^'WB*QN-*\<^-KAX?!OA&Y$/\ PD&O:='=6LDWU)J&
MGV&K6%[I6J65IJ6F:G:7.GZCIU_;PWEC?V%Y"]M>65[:7"26]U:75O))!<V\
M\;PSPR/%*C(S*?QU^)'[+7[3?ACX(Z5^S[\(OA%\)?$7PQ\;_%K]KN[^,EEX
M=^)VG_![Q38?L\_%SXS^)O'?@OX(_#/5;CX5>*=,\+Z!\1/#>O:;HOQ7FTBR
MTR\\+:)X??0? TG]MZCI'C7PH ?I)X9_:5^ _C+XO^*_@)X6^*/A;6_B]X)T
M]]3\2^![&[EDU*PM;>+19M1$-R8%TO5+O0XO$OAJ3Q)IVDW]]J'AE?$?A\^(
M+73?[;TS[5XU^TO_ ,G'?\$Z_P#LY+XM?^L3?M2UX;\%?V4OC=X2_:,\+:SX
MET;X9^'O@M\(/B3^U+\7_ ?B#PSXJU74O&WC._\ VI[Q-1A^'>M>#9/">EZ7
MX7TKX4G5_$VE7>NQ>*]>C\66^B_#Z\TS2=)8ZU::3V/[1O@"2V_;9_X)_P#Q
M)/C[XE3QZG\:_B;X9'PWG\2VS_"FQ:T_8Q_:DNSXGLO"8TA;N/Q?,!]C;6&U
MMX5L)KRW%@6N!+$ ?HO1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$A
M1EB ,@9) &6(51SW9B% ZDD <F@!:*A2XMY)IK>.>&2XMA$;B!)4::W$REX3
M-$K%XA*JLT7F*OF*I9,@$TLL\$,$MS--%#;0QR337$LB1P10Q*SRRRRNPCCC
MC16:1W8*BJS,0 30!+12 @@$$$$ @@Y!!Y!!'!!'0TM !6=JFL:3H=JE[K6J
M:=H]E+?:9I<=WJE];:?:R:GK>I6NC:-IR7%W+#$]]J^KWUCI6F6BN;B_U*\M
M;&UCENKB&)]&OC7]M/\ 9^A^.WA'X276G^";/QGXW^$W[2?[-OQ2\'O?ZDEG
M'X4M_"'QZ^&NO^//%UC;7^I6.B7&LZ-\.])\3O8SW=O>ZM!!)?6OAM$U7446
M8 ^N$UG2)-7N?#\>JZ;)K]GIMEK-YH:7UJ^KVFD:G=:A9:;JMSIJRF]@TW4+
MW2=5M+*^E@2UN[K3-0MX)9);.Y2/C/$?Q@^$O@[P-'\4/%WQ1^'7A7X:3+8-
M%\0_$?C;PUH?@:5=4N$M-,:/Q;J>IVN@.NHW<D=K8%=0(N[ATAM_,D95/RCI
MW[)?A8_M8_M1^.-0^'5JOPS_ &DOV=?@OX1^(>NIKUY'J'Q!\;^&/'/QW'B3
M1M5GMM;7Q5:V&E>!_%'@ZRLH+=]/\/0Z=J4^FZ,BG^U[<>;_  P^'/QT^#W_
M  3F\)?L\>#/@TUM\;_ G[+;^'O FGR2_#2Z^'_A7XDV,$WASP?X?0W?B)],
MDN?"4UQI_B>WMTTI_"K:)HS6,6M+?-#I[@'Z(>"/'G@?XF>&=.\:_#?QGX4^
M('@W6#>#2/%O@CQ%I'BOPSJAT^^N=+U :=KV@WE_I5\;'4K*\TZ\%M=RFVOK
M2YM)MEQ!+&G5UY=\$_@_X)^ 'PE^'WP8^'6F0Z3X-^'/AC3/#.C01PPQ3W8L
MH1]NUK5'@CC%[KWB'4GO->\1:K*&N]8UW4M1U2]EFO+R>5_4: "OR>_:B_X*
M ?\ !.#Q-;>+_P!GWXF_M:>'/!OB+P-\6/ \OB^TT;1_%.K:CH?C3X$?&'PK
MX]N_"UU=6OA'6-':5/$_@)?#/B.*"::XLDDU*WBEMM1MU>']8:_SV/VD;BXC
M_:G_ &OTCGF11^V/^U?A4E=5&?CWX\)PJL ,DDGCDDFOIN%<@I<19A6P57$U
M,+&E@ZF)52E2IU9-PJT:?(XU)0BDU5;NG=.*5K-GSW$N=U,AP-+&4L/3Q,JF
M*IX=TZE2I2BE.E6J.:E3C*3:=)))JS4F[Z(_>6W_ &K?V&(_BK^T'\49/^"M
M>LQ:I\<XK^UTC5=+^#5OIWQ ^$.D6&L6.L_#;P=X ^(+_#"]NU^'7PXN+.9H
MO 6K:/>Z#XWNM;\3:IX]A\0:MXBU2^GI6_Q^_P""7R_"F?X<77_!1:VGU6X^
M*]M^TBGC6#X/16,VE_M-:)X[\*^.O"'Q/T#P=!\*3X%T;P]X;E\)VF@-\-;?
M0'T37-*O]5U76=0N?&FH77BR7^<;[7=_\_-Q_P!_I/\ XJC[7=_\_-Q_W^D_
M^*K[_P#XA;@_^ASB_P#PCPO_ ,N/B/\ B(^+_P"A3A/_  KQ/_RD_M:_X)]_
MM&_L5>)='N?V>_V<_P!I?3_CQ\1[,_$KXZ>/KJ[TB\\.>)?$VK?$#XF2^*?B
M?X_C\/+X4\)^'-(T*;XB_$F"&'0_"VGQZ9X;MM;T72]DKN+V[_2ZOX\O^"%4
MTLO_  4(UKS99),?L9?&_'F.SXS\<?V5LXW$XSWQ7]AM?FG$.50R3-\5EE.O
M/$0PZH-5JD(4YS]MAZ=9WA"4HKE=1Q5F[I7=F['Z#D69SS?*\-F%2C"A.NZR
M=*$Y5(Q]E7J45:<U&3YE#F=TK-V6BN%?Y\_[5W_)W?[8W_9W'[0O_JP=2K_0
M8K_/G_:N_P"3N_VQO^SN/VA?_5@ZE7U7AG_R/\3_ -BK$_\ J1@SYOQ"_P"1
M)0_[&6'_ /3&*/!Z***_=#\:/UF_X(<?\I&K3_LS_P#:(_\ 5M_LHU_957\:
MO_!#C_E(U:?]F?\ [1'_ *MO]E&O[*J_GCC[_DJ<P_Z]X'_U"HG[KP3_ ,DW
M@/\ KYC?_4RL%%%%?''U84444 %%%% !1110 5\4_M+_ /)QW_!.O_LY+XM?
M^L3?M2U]K5\4_M+_ /)QW_!.O_LY+XM?^L3?M2T ?:U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>:_%WXM>"_@
MAX!U?XC^/;G58= TJ[T#28;3P_H&M>+/$NO^)/%WB'2O"'@WPEX5\+>'+'4M
M>\2>*O%_B[7=$\,>&]#TFQN;W4]:U:RM(D42-(@!Z517QEH?[>W[/'B;5OA_
MHGAR[^)NO:CX\%NM]#HWP4^+.I_\*IN;OQ[XC^%%K8_'8V7@^?\ X4O?R_%+
MP?XO^'SVGQ!&ARVGB'PGXG-\MKI&@:MJEIZ'K_[4OPF\/?&O3/@%-)XXU?QY
M=MX?AUF[\+?#/Q_XL\#^ [_QC!J-SX)TGXD_$'P[X=U'P=X U7QC!I-_/H%E
MXGUC3I98!I\][]A@U_PY)JX!]%4444 %9NLZSH_AW2=3U_Q!JNFZ%H6BV%WJ
MNLZUK-]:Z9I.DZ980/<WVHZGJ5[+!9V%A96T4EQ=WEU-%;V\$;RS2)&C,-*O
MD3]NKX7ZC\7?V9?''A+1_#FO>,-8L]<^&WC?2?"WA_0O!?BZXUW4OAO\3?"'
MCZSL-3\"?$3Q/X)\&?$;PT9O#BS>*/ASK?C'PL/'7A^'4?"^F>(=&UK4]-U&
MW /H*/XG_#26?P1;1?$/P-)<_$VUFOOAO;Q^+= >?X@V5M81ZK<7G@B)=0,G
MBRU@TN:+4IKC05OXHK"6.\=UMW60YFM_&GX.>&O&FF_#?Q'\6?AGH'Q$UEM-
M31_ 6M^._"VE>--6?6;DV>CKIOA:_P!5@UR^;5;P&UTU;6QE-]<@P6HEE^6O
MP>L/V6OVD[;P'\'/#UY^S/?77Q0UG]I:T_: \.?$33O#O[.V@^%_ /@FU_:\
MUGXVVGP%^,^F/XC\0>._@1X%\-^%Y]-^*&FZ;^SA\0?&-]?>,[B_^&^H>(?$
M/V?6(O'_ .FGC7X/K^T!^U'^S9\0_%WP332OAW\'_#7COXORZQXU\->!'\3S
M_'O2M7TKP'\&=)U2:"ZUK7(H?!/A77/BG\0M%CM+V728/$%[X(U\7%MKWA^R
MBMP#[YHHHH *^(_VVO@[J/Q2TW]G77-%L/'>N:Q\+/VMOV9/'4&@^%/$?B'3
M="_LC3_CE\/I?%_BGQIX<T?4;'3?%FE^#O!UMKVK0Q>)8=3TO05:]UVWL?[3
MM+*[M?MROX9?BS_P42_X*"?\+I^/]CI/[9WQ@\,:'X>_:0_:2\&>'/#?A[PM
M^SU'HN@>%? 7QY^(W@CPIHNG?VU\#=;U>2#2_#?A[2K(W.J:OJ6H7<D$EU=W
MDT\TCGV<DR+'9_B:N%P#H*K1H/$3^L571A[-5(4O=DJ=2\N::TY5I=WTL_)S
M?.<'DE"EB<:JSIU:WL(>PI>UESNG*IK'VE.T>6#UN];*VMS]V_@/^SIXHUK]
MI#QMI&O?"OXM?#'7+ZP_;<T;]JSX^Z?;ZS\.'^.VE?%O]H+PIXL_9AC\"_&3
M0=5M-:\<7/ASX5:=?VOAW4?#EY_:7P*\.0ZE\/TN?!5_J\.D7CO%?PH\52?\
M$R/V6?@?KOPQ^)-SXL^#W@+]E3QEXO\ A=JOP4\9_&7P7XALO .L:)I&H_#/
MXO\ @C2-;TK7OB/H%A/9KJWC/P1X>U3Q7X[MXM)TKQ9/X*\<6%G=:'J_\\__
M  \/_P""B7_1]7QY_P#"9_9H_P#H>:/^'A__  42_P"CZOCS_P"$S^S1_P#0
M\U]-_P 0VXC_ )LL_P#"U_\ S*?/?Z_Y!VS#_P (U_\ -)_87_P3\\&_$OP#
M^R)\(O#'Q;TF;PYXTMT\=:H?"MQ9MI<G@WPCXE^)?C+Q+\-_!"Z&_B#Q4_AJ
M'P5\.-7\*>%;;PF_B37'\)V^D1>&WU.[;2S*WV57\SG_  1?_:Z_:M^-_P"U
M%\3_ (=?'3]H7QY\9O"%E^SX_CC2M*\;:'\*K!M&\36?Q*T#P^NH:;>?#WX;
M^!+PK/I.J75M=6NHS:A;.WDS110RQ;G_ *8Z^/S/+L1E..KY?BW2>(PS@JCH
MS]I3O4I4ZL>6?)#F]RI&_NJSNM;7?U678^AFF#HX[#>T]A74W3]K#V=3W*DZ
M4N:'-.WO4Y6]YW5GULBOX)?V@_VDOVGY?VD?VI((?VKOVL-(L-&_:O\ VI/"
M^B:+X8_:;^-WA'PYH7AKPC\?OB)X8\+Z!H7AKPQXWTG0=&TG0O#VDZ9I-A9:
M=IUM$EM9QM())VEED_O:K_/!^/O_ "<K^UK_ -GF?MC?^M-_%2OK_#O!X3&Y
MQBZ6,PN'Q=..6SG&GB:-.O",UBL/%3C&I&45)1;CS)7LVKV;/EN.\5BL)E6%
MJ87$5\-4EF$(2G0JSHSE!X>O)Q<J<HMQ<HI\K=KI.UT6_P#AHO\ :A_Z.]_;
M-_\ $O?VC/\ YY%'_#1?[4/_ $=[^V;_ .)>_M&?_/(KR*BOV3^P,B_Z$V5_
M^$&%_P#E1^4?VWG/_0VS+_PMQ/\ \L/W8_X(@_&WXZ>-?VT?''@OX@?'KX\?
M$_PA-^RWXU\5#PW\6/C/\2/BGI%IXET?XM_!_1]-US3+3Q_XD\0II.I6VEZ_
MK5@;C2_LC7%KJ,T=T)PD!B_JXK^/S_@@]_R?QXS_ .S//B/_ .KM^!%?V!U^
M"\9X>AA>)<RH8:C2P]&#PO)1H4X4J4.;!X>4N6G!1C'FE)R=DKR;;U;/VKA.
MO6Q'#^7UL15J5ZTUB>>K6G*I4ERXO$1CS3FW*5HQ45=NR22T2"O\]+]I3_DZ
MG]L#_L\?]J[_ -7UX\K_ $+:_P ]+]I3_DZG]L#_ +/'_:N_]7UX\KW?#+_D
M?8O_ +%5?_U*P9XWB'_R)<-_V,Z/_J-BSQRBBBOW,_&S]?\ _@A-_P I"-;_
M .S,OC=_ZO']E:O[$:_CN_X(3?\ *0C6_P#LS+XW?^KQ_96K^Q&OYWX\_P"2
MJS+_  X+_P!0<.?NW!7_ "3>7_XL9_ZFUPK_ #Y_VKO^3N_VQO\ L[C]H7_U
M8.I5_H,5_GS_ +5W_)W?[8W_ &=Q^T+_ .K!U*O4\,_^1_B?^Q5B?_4C!GG>
M(7_(DH?]C+#_ /IC%'@]%%%?NA^-'ZS?\$./^4C5I_V9_P#M$?\ JV_V4:_L
MJK^-7_@AQ_RD:M/^S/\ ]HC_ -6W^RC7]E5?SQQ]_P E3F'_ %[P/_J%1/W7
M@G_DF\!_U\QO_J96"BBBOCCZL**** "BBB@ HHK\AO\ @JO^TA\?_@58?#.Q
M_9^\77?AG5Y?A_\ M'?%_P 5II;_  <T^^DT/X(^#_"^HZ9K6MZA\<K.]\.:
MU\-/#_B/Q7IDOQ+^'7P^6Q^.'C71;VU?X>:WH=CH?BF^ !^O-?%/[2__ "<=
M_P $Z_\ LY+XM?\ K$W[4M?*O[/W[4GQ;\??M3>$(-0^,%IXN\'?%WX@_M;>
M KSX!0^%O"&CQ_!GPA^SXWAL_#?XBVKPZ3:?%FQU;QG:7>GZEXS@^(VLZKIM
MR/C%X+M=&T?PNFCZ8-9]I_:-^('VK]MG_@G_ /#7_A!/B5!_9?QK^)OB?_A8
MEQX4\OX4WOVS]C']J6T_X1JR\9?V@?.\7Q9^UOH?]F#-A#=W/VL?9O+D /T7
MHHHH **** "BBB@ HHKF/&?C?P9\./#&K>-OB'XN\,> _!N@01W.N^+?&>OZ
M5X7\,Z+;37$-G#<:MKVMW=CI6G0RW=Q;VL<MY=PI)<SPP(QEE16 .GHKP5OV
MJOV7T\3>#_!3_M'_  %3QC\0[7PW?> /";_%_P"'J^)?'-EXSV#P?=^#]";Q
M"-4\36OBLN@\-W&BVM]%KI=?[+>ZW#/H$OQ1^&<'Q"M?A)/\1? L/Q6OM D\
M5V7PRE\7>'X_B%=^%H9I+:7Q+:^"WU >)+C0(KB&6WDUF+37TY)HI(FN1(C*
M #NJ*** "BBOF7]L7Q2? /[-OQ8^(Q^(OQ%^&*?#KPIJ?CAM=^%2_#Q_'&JR
M^'K6:\L?!NBCXH>!/B/X1%UXTU$6?ANW-YX7N+@W>HVRVEU9RMYM 'TU17XL
M:S\3OVG?@%XA_8X\,?$+]K7_ (6G\0K7Q5^SU\.OVMO!:Z+^SK86.E3?'OQ/
MXFT:#Q-K_A32/#OASXL>*)O&'C+4M#^&OP=U7X06WAC1O"6D_#O7_B!\1=$\
M5Z7#XU:'[2\9?$;XR:/^W%^SYX"MO&/@Y?@#\3/@U\>M9/@[3?#7VCQ?K/C?
MP!<_".XLO$^L>-[S4KB*'0M,L/%U[8Z)X<\-:/8?:YM2O]4\0ZUJ0@T73M/
M/M6BBB@ KRSXT^,/%_P_^&OBCQMX*T?X?ZUJGA;3Y==U"'XH_$+5_A;X(L/#
M6E*U]XFUK6_&NB?#_P")VH:5!HFB07NI@)X0OHK@VWD3W%A$[7<7J1( ))P
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M:5X?7X4_'+PIINAZ%\4;?Q%HUI>-I]SXKBN=-\63W_A*Z\#_ ,@__""> O\
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MJ5JU3#<U2K5FYU)R]MB5S3G*\I.T8J[Z)+H%?YT7Q2_Y+?\ M*_]G;_MA?\
MK4OQ@K_1=K_.B^*7_);_ -I7_L[?]L+_ -:E^,%?4>&/_(YQ_P#V*W_ZF8<^
M<\1/^13@O^QBO_42N<91117[>?CY^T__  03_P"3V/BK_P!FH7W_ *N3P?7]
M=-?R+?\ !!/_ )/8^*O_ &:A??\ JY/!]?UTU_.?'/\ R5.;?X\-_P"H6%/W
MG@W_ ))O+/\ #B?_ %,Q(5_G@_'W_DY7]K7_ +/,_;&_]:;^*E?Z'U?YX/Q]
M_P"3E?VM?^SS/VQO_6F_BI7M^&/_ ".\;_V*ZG_J7ACR/$/_ )$^$_[&5/\
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MEWNFR:#/!/:C3;^WGCN8)8KQ666(?J?7\T__  ;Q_P#'_P#ML_\ 84_9T_\
M44^(E?TL5^)Y_@Z&7YUFF"PL90P^%QE2C1C*<JDHTXQI-*4Y6E)WG+WGJ[KL
M?KN28JMCLHR[&8B495\3A:=6K*,%"+G*55-J$;QBK0CHG9?,CF_U4O\ US?_
M -!-?YG7PM)_X5?\-N3_ ,B#X0[G_H V-?Z8LW^JE_ZYO_Z":_S.?A;_ ,DO
M^&W_ &(/A#_TPV-?>>%O^^YQ_P!@>$_]2ZA\7XD?[GE/_87BO_42!W>3ZG\S
M1D^I_,TE%?LI^3679?<O\C^A_P#X-X"3XS_;DR<_\2C]E3_T5^T'7].-?S'?
M\&[_ /R.?[<G_8(_94_]%?M!U_3C7\T\7?\ )39W_P!C"I_Z;PQ_0?"__)/9
M/_V!0_\ 3F("O\W_ %O_ )&CQ_\ ]E:^-G_JY?'M?Z0%?YO^M_\ (T>/_P#L
MK7QL_P#5R^/:^K\+_P#D:YG_ -BVG_ZG4SYKQ&_Y%N7?]C"I_P"H<S/HHHK]
MK/R(_H1_X-W_ /DI7[<__8D?L?\ _IY_:RK^G^OY@/\ @W?_ .2E?MS_ /8D
M?L?_ /IY_:RK^G^OYKXP_P"2GSO_ +#I?^F<*?T!PK_R3N3_ /8''_T]B@K_
M #DO''_)3?C9_P!G&_M/?^M&_%2O]&VO\Y+QQ_R4WXV?]G&_M/?^M&_%2OI_
M##_D;YE_V+%_ZFT3Y[Q%_P"17@/^QB__ %#K'.4445^VGY ?OM_P;R_\EQ_;
M:_[)#^R1_P"IK^UI7]35?RR_\&\O_)<?VVO^R0_LD?\ J:_M:5_4U7\V\9?\
ME1G7_86O_4;"'[_PG_R3F4?]@G_N?%!7^=%\4O\ DM_[2O\ V=O^V%_ZU+\8
M*_T7:_SHOBE_R6_]I7_L[?\ ;"_]:E^,%?1^&/\ R.<?_P!BM_\ J9ASP/$3
M_D4X+_L8K_U$KG&4445^WGX^?M/_ ,$$_P#D]CXJ_P#9J%]_ZN3P?7]=-?R+
M?\$$_P#D]CXJ_P#9J%]_ZN3P?7]=-?SGQS_R5.;?X\-_ZA84_>>#?^2;RS_#
MB?\ U,Q(5_G@_'W_ ).5_:U_[/,_;&_]:;^*E?Z'U?YX/Q]_Y.5_:U_[/,_;
M&_\ 6F_BI7M^&/\ R.\;_P!BNI_ZEX8\CQ#_ .1/A/\ L94__4;$'EM%%%?N
M)^.G[&_\$'O^3^/&?_9GGQ'_ /5V_ BO[ Z_C\_X(/?\G\>,_P#LSSXC_P#J
M[?@17]@=?SKQU_R56:>N$_\ 4'#'[QP9_P DWEOIBO\ U-Q(5_GI?M*?\G4_
MM@?]GC_M7?\ J^O'E?Z%M?YZ7[2G_)U/[8'_ &>/^U=_ZOKQY7K^&7_(^Q?_
M &*J_P#ZE8,\OQ#_ .1+AO\ L9T?_4;%GCE%%%?N9^-GZ_\ _!";_E(1K?\
MV9E\;O\ U>/[*U?V(U_'=_P0F_Y2$:W_ -F9?&[_ -7C^RM7]B-?SOQY_P E
M5F7^'!?^H.'/W;@K_DF\O_Q8S_U-KA7^?/\ M7?\G=_MC?\ 9W'[0O\ ZL'4
MJ_T&*_SY_P!J[_D[O]L;_L[C]H7_ -6#J5>IX9_\C_$_]BK$_P#J1@SSO$+_
M )$E#_L98?\ ],8H\'HHHK]T/QH_6;_@AQ_RD:M/^S/_ -HC_P!6W^RC7]E5
M?QJ_\$./^4C5I_V9_P#M$?\ JV_V4:_LJK^>./O^2IS#_KW@?_4*B?NO!/\
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MA.&O^2?R?_L7T/\ W*8GB;_D7/$'_8$U7_T@N*_S2OA)_P DE^%'_9,?A_\
M^HEI%?Z6OB;_ )%SQ!_V!-5_](+BO\TKX2?\DE^%'_9,?A__ .HEI%?;>%O^
M]YS_ -@N"_\ 4JL?(^(_^[93_P!A.+_]1Z)Z!1117[&?E)_1Q_P;Q_\ '_\
MML_]A3]G3_U%/B)7]+%?S3_\&\?_ !__ +;/_84_9T_]13XB5_2Q7\T<6?\
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MU+\8*^C\,?\ D<X__L5O_P!3,.>!XB?\BG!?]C%?^HE<XRBBBOV\_'S]I_\
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MOVE/^3J?VP/^SQ_VKO\ U?7CRO7\,O\ D?8O_L55_P#U*P9Y?B'_ ,B7#?\
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M_P"H]$] HHHK]C/RD_HX_P"#>/\ X_\ ]MG_ +"G[.G_ *BGQ$K^EBOYI_\
M@WC_ ./_ /;9_P"PI^SI_P"HI\1*_I8K^:.+/^2ESS_L8UO_ $G#G]!\,_\
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M_P"2?R?_ +%]#_W*8GB;_D7/$'_8$U7_ -(+BO\ -*^$G_))?A1_V3'X?_\
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M"O\ .B^*7_);_P!I7_L[?]L+_P!:E^,%?Z+M?YT7Q2_Y+?\ M*_]G;_MA?\
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M)O\ GY@/_""G_P#+SQ/]0>'OY<?_ .%T_P#Y0?CG_P $K_AQ^V7^P[X:^/\
MHGQ7_8,^/&LW/Q3^)GA7QGX=D\#_ !0_8VUF&VTO1/A?X1\%W<.K-?\ [4.C
M_9;UM5T&\F@BM_M<<EC);RO+%*SPK^D7BW]N;X@^!M;^''AWQ/\ L#?M;Z?J
M_P 6O&EU\/? -M'XG_8SO5UGQ=9^!?&GQ)N-,FGM/VM)H-+C3P9\/?%VJB^U
M)[:R9]+2P68WU[9P3?H14$UK;7#VTL]O!/)9S&YM))HHY'M;AH)K4W%L[JS0
M3&VN;BW,L160P3S1%O+E=6^-QN+K8_%XG&XAP=?%5IUZSA!0@ZE1IRY8)R48
MW2M%-V[GUF$PM+ X7#X.AS*CAJ4*-)3DYSY()J/--J+E+5WDTK]CX2\9?M$?
M'OQ!X0\5:#9?\$]?VK$O-;\-ZYI%H]QXZ_8GBMUN=2TRZLH&GD3]K>5XX5EF
M0RNL4C(@9EC<@*?Y+/!O_!*#_@IKH'@WP=X?OOV+/&CWV@>$?"^A7KVWQN_9
M'>V>\T;0M/TR[>V>3]H:*1[=[BUD:!Y(HG>(HSQQL2@_O'KYJ^/O[6?P;_9K
MN-#M_BA=^,H_[6TC6_%6I7/A#X<^.?'MCX(^'_A>YTNS\5?$WXBW_@_0=9M/
M _P\\,W.MZ3'K7B;Q!-9VMLEW)=1I/9:;K%SI_IY+Q#F602Q,\NE0C+%0I0J
M^WH1KIQHSG.'*I3AROFG*[5[JRTL>=F^18#/(X>&/5=K#2J3I>PKRHN]6,83
MYFH3YE:$;)VL[O6Y_'A_PZV_X*5_]&5>.O\ P]?[(G_T1-'_  ZV_P""E?\
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MUGQ=\0_$-O\ L3^/8[3Q=\6/C'X[TZ*7XU?LBK<0Z1\0?BSXU\=:+!=H?VB
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MAM;2XM?B5X>&E36]U=RW$UOJR7%O:I;V\MW^LOQ(_;K\??"3PL?&GC[]@?\
M:WT;PX/$G@;PD;Z'Q-^QIJDG]O\ Q(\<>'?ASX.LA9Z;^UG<W175/&'BO0=+
MDN1%]GL([QK^^D@LK:XGC^O_ (3?$^R^+OA%/&%AX-^)G@6WDU&]TT:#\6?
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M9INM(\2V-KH'Q2NO^$Q\1^%[N?Q1!Y8MFT6[?5;K0[7Q)X,\8?N510 4444
M%?"_[;OP:_:6^.NB>!_ 7P;USX/P_"B]O->D_:!\"_$W5/B%X:N_BUH'V6PC
M\-?#^+Q;\/K#5-1TGX?ZE=OJLOQ0T6&S@O\ QSHT.G^#WU>Q\,:IXKL-:^Z*
M* /S>^%?[&OQ.\*?M Z5XS\8>-?ASJ/P6^'GCS]H7XN?##PIX=\.Z]:^.'\<
M_M/O]L\;Z#XSU#4+]_#4O@KP'>ZSXYM_!9T?2XM1UW3=>\/1ZS;Z-<>$)I/$
MVY\.?V-_%7A?PG^QCX'\4^,_#7B+PS^S)X\^(7Q.\5Z=%I.HI%XW\::II7Q
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $P F\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHKP;_A/?C3_T0R#_ ,.CX?\ _E31_P )[\:?^B&0?^'1\/\ _P J:/[9PO\
MSZS'_P -6:?_ #*'URC_ "8G_P (\7_\H/>:*\&_X3WXT_\ 1#(/_#H^'_\
MY4T?\)[\:?\ HAD'_AT?#_\ \J:/[9PO_/K,?_#5FG_S*'URC_)B?_"/%_\
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MNVT>A_7_ .(HVCT/Z_\ Q%>$^?\ M)?] OX+?^#WQK_\S]'G_M)?] OX+?\
M@]\:_P#S/T?VDO\ H7YO_P"$$_\ YJ#ZS_U#8W_PG_\ NI[MM'H?U_\ B*-H
M]#^O_P 17A/G_M)?] OX+?\ @]\:_P#S/T>?^TE_T"_@M_X/?&O_ ,S]']I+
M_H7YO_X03_\ FH/K/_4-C?\ PG_^ZGNVT>A_7_XBC:/0_K_\17A/G_M)?] O
MX+?^#WQK_P#,_1Y_[27_ $"_@M_X/?&O_P S]']I+_H7YO\ ^$$__FH/K/\
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MA?F__A!/_P":@^L_]0V-_P#"?_[J>[8/0]A@<-G\]N<<]*>N>_;VQ^7 _'Z
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M_P %$KS]FK]O+]E/]DCXB?!B-?A9^UQ)JOA;P)^T=I_Q#9H/#?Q9M=$UW5]
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M?\(UXS\(>*)(]-L]<\+^)],\6V=A(WZY_P#!)SX7?'3X-_L=^'O '[0/PW\
M?#+QIIWC_P")NKVFD^ ],\2:,^OZ/XL\7ZCXKD\;^.-,\6_$OXQ>(8/B+XP\
M0:UK^L^++K5?B;XOOM7O+E-;O-0BNM1FL;4 _2JBBB@!O\*_\!_F*\)^(W_)
M5?@%_P!C%XZ_]5WKU>[?PK_P'^8KPGXC?\E5^ 7_ &,7CK_U7>O5X^<?[G'_
M +#LJ_\ 5K@#EQ?\&/\ V$8/_P!2Z![Q1117L'4%%%% !1110 4444 %%%%
M!1110 G<?0_S6O#_ -H__DAGQ,_[%BZ_]#MJ]P[CZ'^:UX?^T?\ \D,^)G_8
ML77_ *';5Y&>?\B3-_\ L59E_P"H6*.3'_[CC?\ L#Q7_J/5/<:***]<ZSX2
M_P""BW[:<'["7[.3?%VS\$M\1O'?C#XE_#/X%_"#P/-JAT'1_$/Q<^,GBBU\
M'^![?Q1XB6UOGT#PI9W]U)JOB'4X;*ZNUTVPFM;*$WMU;LO$>)/VJOC;^R#X
M=?QS_P % D^#,'PFEN?A5X.T[XO_ +.?AOXL7D<GQ>^+GC^T\ :%X'UKX6:U
M+XX\1Z!X=MM:U70-/L_B(_BC4=,UR]U^T&HZ1X-> VES]0?M2?LN_!K]L?X*
M^*?@)\=O#MUXA\!>*9='U(/I.KZAX=\3>&O$WAK5;37_  EXT\'>)M(FM]5\
M-^+O">OV%CK6@ZQ8S!H+NU$-U#>:?<7EE<_/'Q$_X)S^ _C1\"/&OP&^./Q[
M_:<^,EAXQUCX4:]!\0?&OC?P):_$#P=JOP1\<Z1\2?AM?>$4\&_##PG\/H+W
M1/&VC6VN7^HZ]X \0:GXI9WT_P 67NN:3#8V%F 5/"W_  5-_9'\:ZY\,?#'
MA?6/B?K'B7XK^-OBIX!\/>'K7X,?$QM:TO7/@K\2K/X1?$JX\6:8WAQ;OPUH
MGAGQ_J%GHU[K>HQ)IZV\W]MF8:##/J<7BW@__@MO^Q=KWPHT_P",OBAOBY\/
M/!VO>/\ XX>%_#O_  D?PC\=W.K7O@+]GG7[#PW\5OCOJFF:/HE_<>&_@MX(
MU35-+L?&'CG5Q!H_A;5;U=&U2Y35+:^MK;H_A_\ \$A/@'\/K?X6V5O\8?VF
MO$^G_"?]HGQ=^U#HUCXL\=^!+Y=8^*OC/XBV?Q5U6_UB^TSX7Z/J]C:?\)G#
MJDQF\'ZEX4U[5/#?BCQ-X#\1Z[K?@+4U\,V_&:W_ ,$/OV1=>\ 6WPTNO&7[
M0%OX6M]=_:0+167C?P;!J%Y\*OVL_%UEXZ^.O[.^H:F_PXEN[[X->+O%.GV^
MJVT-Q(_Q(\/.;F#P_P#$C3+:\NH9@#M_'7_!:']@SX<_$OQU\(_$_C3XFIXW
M^'OBW4_ >LV6D_ KXN:]IVH^,;'X7CXTZ?X>\+:[HWA*^T;Q3J'BKX5;O'7A
M!-#OKV+Q#X?1[VRE95(KTZY_X*F?L0V_C[]G;X9)\8K:[\8_M3> ? WQ)^#N
ME66AZY</K/AGXHV][)\+O[5*V(;P]J_Q&N],U/1_!^AZLEMJ>I:SI]SI\EM;
M2B,R?-WQ#_X(??LT?$#XE^+OBDGQH_:E\#ZWXL^*E_\ %Y=)\#>,OA/8>&_#
M/B:]_9]G_9;CLO#&FZW\%?$$]IH&G_ ^<^#+#3M1OM5F1(XM5N;RYUA3?-ZS
M\)_^"3'[.OP4\;_ _P"(G@'QO\:]/\6_ _X >"/V:K/5KW7OA[J=Q\0?AG\,
M-1U'5/ADGC^:\^&4EPOB3P+=:G/'I7B/P!-X"U#5=/5-'\6MXCTA[FQN #D/
M"G_!;K]@KQUX9\,>+?!VO?'#Q#I'C36[KPWX4-C^S/\ '5;KQ)K^E:MXJT;Q
M)HGAZVN_ ML_B#6/"=]X-UE?$ND:&=1U/38Q92?8YA>P@_KC7Y2Z=_P2"_9[
MTW]D+X=?L1P_%7]HV7X)_#7Q9XQ\7:4MSXS\ R>*M5N_&OQ#N_BG?VNKZROP
MN2T@DT3QKJ.HZOX+\4>'=*\/^/\ P1/?3R>%O&&E7"P3P_JO&BQ1QQ*798T6
M-6D=Y9"$4*"\DC-)(Y RSNS.YRS,6)) 'UX?^T-_R2_4?^QL^&7_ *LKPE7N
M%>'_ +0W_)+]1_[&SX9?^K*\)5Y6=?\ (IS/_L Q?_IIG)CO]RQ?_8-6_P#3
M<CW"BBBO5.L**** "BBB@ JM>6RW=K<VKL52YMYK=F'4+,A1B.F" <CGKZ8J
MSD<^W7_/XTG!X]NGM2:3335TTTUW3337S3:^8FDTT]FFGZ--/\&?,?@[QMJ_
MPL\+Z'\/?%7P\^(-[>>#M+L_#6G:SX.\,7OBO0->T;18%T[1]8MKO2S/-83W
MNG06\E_INI0VUU:7QGC59H!#<2]*?CMIO;X;_&D?3X7>)>O/./L^,_R[5[FV
M,CKR.<,1G&1V;GITSGWY-)CN"V!VRV/QPY(_^M7C4L!C</2IT,/FKA0H4X4J
M,:N7X2O4A1IPC3I1G5=:DZKA3A"G[25.$I*G%S7.Y2ER0P]>G&-.&+:ITXQA
M34\-1J2C""481<W.+FXPC&/,XIM13?O7;\-_X7MIO_1-_C1_X:SQ)_\ (U'_
M  O;3?\ HF_QH_\ #6>)/_D:O<LCU;\W_P#CE&1ZM^;_ /QRK^KYE_T-H_\
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MNZ/^%B_$G_H@7CS_ ,*GX4__ #=U[=M'^0O_ ,31M'^0O_Q-'U#&?]#?&_\
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MM/#?^%[:;_T3?XT?^&L\2?\ R-1_PO;3?^B;_&C_ ,-9XD_^1J]RR/5OS?\
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M ,&0_P#DSJZ*Y3_A-?!O_0V>&O\ P=Z9_P#'J/\ A-?!O_0V>&O_  =Z9_\
M'J/K6&_Z"</_ .#Z/_RX/:TO^?M/_P &0_\ DSJZ*Y3_ (37P;_T-GAK_P '
M>F?_ !ZC_A-?!O\ T-GAK_P=Z9_\>H^M8;_H)P__ (/H_P#RX/:TO^?M/_P9
M#_Y,ZNBN4_X37P;_ -#9X:_\'>F?_'J/^$U\&_\ 0V>&O_!WIG_QZCZUAO\
MH)P__@^C_P#+@]K2_P"?M/\ \&0_^3.KHKE/^$U\&_\ 0V>&O_!WIG_QZC_A
M-?!O_0V>&O\ P=Z9_P#'J/K6&_Z"</\ ^#Z/_P N#VM+_G[3_P#!D/\ Y,ZN
MBN4_X37P;_T-GAK_ ,'>F?\ QZC_ (37P;_T-GAK_P '>F?_ !ZCZUAO^@G#
M_P#@^C_\N#VM+_G[3_\ !D/_ ),ZK/'?\CG\L?TI<Y__ %$?SKD_^$V\&_\
M0U>&_P#P>:7_ /'ZO:?XF\.:I<"TTW7=%O[HH\@M[+4[&ZN"B ;W6*WE=RB
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MF?\ QZC_ (37P;_T-GAK_P '>F?_ !ZCZUAO^@G#_P#@^C_\N#VM+_G[3_\
M!D/_ ),ZNBN4_P"$U\&_]#9X:_\ !WIG_P >H_X37P;_ -#9X:_\'>F?_'J/
MK6&_Z"</_P"#Z/\ \N#VM+_G[3_\&0_^3.KHK)TS7-&U@3?V3JVFZG]GV>?_
M &??6MYY/F;MGF_9I'$>_:VS?@MM;&<&M8D#DUM"<9Q4H2C.+VE"49Q=FT[2
MC*479Z.TG9Z/70M-22<6I)[.+4D_1IM/Y-A1115C"BBB@#YZ\?>&?#?BCXW?
M#&P\3:!HGB&R@^&OQ?NX+37M*L=7M8+I/$7PAB2ZB@OX+B*.=8I)(_-15?RI
M)(R=DC*W:_\ "FOA$/\ FEWP[_'P9X=R 2?G.; <<<+SQZ]3C^(/^2\_#7_L
MEWQB_P#4F^#W7V]?:O8QW^I_F>G<IZC\J\#"X/!U\1FM2OA,)6F\SFG4JX7"
MU9M1P66J*<ZN'J3:BFU%.;44VE96BN&C1HU*F,E4HT:DOK<ES3I4IRLL/A;+
MFG2G*RZ+FLNB1YI_PIGX1?\ 1+_AW_X1?AS_ .0J/^%,_"+_ *)?\.__  B_
M#G_R%7IF??\ 7_[91GW_ %_^V5W?V;EW_0OP'_A%@_\ YC.CZMAO^@;#_P#A
M/0_^5'F?_"F?A%_T2_X=_P#A%^'/_D*C_A3/PB_Z)?\ #O\ \(OPY_\ (5?
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M-N?V9E[_ .8# ?\ A%@__F(/JV'_ .@;#_\ A/1_2A^I^Q/_  IGX1?]$O\
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M^HX!ZK!X1IJZ:H46FNZ?(TUZ,\-_X9O^#G_0H'_PHO%7_P NZ/\ AF_X.?\
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M>X\(_%VU.O>!+31]>\5_"C1M$M-4N3?LTP!]R_"?X]?"+XYS?$2+X2^-M/\
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MC>KJ4]IX6\5?#OX?^.;2*P\,W_C6Z\-V<_A^Y^X_^";G@_\ :4\,:M\2+_\
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MZ;7[-/>(]K%*\ZE!T7_"F-2_Z+7\:_\ P?\ AC_YE*?UO,?^A1+_ ,.F7_\
MRL?ML3_T!/\ \*\/_P#(GNF1[?D/_B*,CV_(?_$5X7_PIC4O^BU_&O\ \'_A
MC_YE*I6OPJ-[/?6ME\>_B]=W.ESI:ZE;VOBGPC//IUS)#'<QVU]#%X7>2TGD
MMY8ITAG6.1H)8Y54HZL3ZWF/_0HE_P"'3+__ )6'M<3_ - 3_P#"O#__ ")]
M Y'M^0_^(HR/;\A_\17A?_"F-2_Z+7\:_P#P?^&/_F4H_P"%,:E_T6OXU_\
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M*>._$UG(UKJ=\MU]C\$^%)]P1O\ A)?$R0W$4E[;E][>'M#CU+7)679<6]A
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MB?$__9&O O\ ZF?Q KW$]_Q_]J5X=I__ "<3XG_[(UX%_P#4S^(%>XGO^/\
M[4KQ\L^''_\ 8VS'_P!.X8Y\/MB/^PS$_G3)****]@Z HHHH \5U_P#Y+O\
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M'G_1O_Q(_P#"B^#7_P \BL^;+/\ H(S[_P "XC_^8B;X;^?,/OS3_P"5$?\
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M>%_$C_DI_P"S_P#]C9XW_P#59^*:]T;J/\_Q+7A?Q(_Y*?\ L_\ _8V>-_\
MU6?BFO-S;_=(_P#8;E?_ *M< <^+_@Q_[",'_P"I= ]VHHHKUSJ"BBB@""6U
MMII+>6:"&62TE:XM9)8TDDMIVAEMFFMW<%H96MYYH&DC*NT,TL1.R1PTV!C&
M![4M%)12;:23=FVDDVTK)MI7;2T5V[+166@K+[]_/U[]M>FAX9IW_)PWBO\
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M._1117N'<?SE_M8^()/ .N_\%./C%X<_;%^/7PX^+O[/GQ'^$&K?LV>"+?\
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M(TP^+^O=_@7\9P>X^Q_#XX(Z\CQ^01GISR.037N?<Y/0KGT/?')Z9R<=O>D
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M_JL_%->1FW^Z1_[#<K_]6N .7%_P8_\ 81@__4N@>[4445ZYU!1110 4444
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M9N3:456A23;45-R:3]LHHHKUCJ/"M/\ ^3B?$_\ V1KP+_ZF?Q KW$]_Q_\
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MX;>&=)5AEK72=)\&ZYI=W<Q X#7?B+4]:OI6!>.6WC<P+2USX8?"KPO9I?\
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M !3_ /#V_&+_ .;FC_A1W@S_ *"_Q3_\/;\8O_FYK^;CPU_P49_;7'P/NO\
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M[=HYZ%NF(G\#_%RU9&TSXSQW,:#YH?$OP^T/4C*!DA6N-%O_  \\98X!<(V
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M^"J]F';\/_:=>,_''_D5?#G_ &5CX)?^K;\%5Y6;?\BW&?\ 7K_W-A3GQ?\
MNU;_  Q_].TCVG.>F.HZ^^/UYXK@?BAXGO?!OP]\9>*-.B$NH:+X?U&^LD*"
M1!>1P8MI)(SQ)%#,RRS(>'B1E) (8=]@>G^1C_ ?E6=JNE6.M:9J&CZG;I=:
M=JEG<Z??6K[MEQ:7D#V]S"Y5@P66)V4E2&4'((;D=F*A6J8;$TZ%3V->IAZ\
M*-5ZJE6G2JPI5-+OW*DH3T3?NW2;5GI5C.=*K&G+DJ2IU(TY_P DY0E&$O\
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M:;2-;2TEU75KBPLK2XOI): /PX\-_P#!0;]I*3QMJ7CGQ5^TQX(\*^ ?B/\
M##X$6^E7&O? U$^'OP3T?Q+\5/C5X'\=?M&P+:_$R]A\=>"M!\2^$/ ?@75_
M$J>)1X&U ?$[PGXP_P"$CT?PM9V0U"X/^"DO[;<O@_XY>,&\4_ ;^T?A7X"_
M9GCN_!L/@74/#]KX;'QV\7^(/!^K?M)>*?&GB+Q?J T3X0Z3X:\,Z)\7-#T?
M4_#3B'2OB.FG^(=;CT/2M(U_4OZ5:* /QA_9"_;@_:!^+'[3WPY^#OQ8\3_
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M4)86NKS4M7O<-?ZUK6IW4^H:SK-^R_N_M6I:E<W%T\28@MUD6VMDCMX8HU[
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M8?\ QRC_ (:(^!G_ $5CP'_X4=A_\<KVGR8O[B?]\1__ !-'DQ?W$_[XC_\
MB:/8YO\ ]!.6_P#A#C?_ )O%RXW_ )_87_PFJ_\ S2>+?\-$? S_ **QX#_\
M*.P_^.4?\-$? S_HK'@/_P *.P_^.5[3Y,7]Q/\ OB/_ .)H\F+^XG_?$?\
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MR?\ 1)/C3_X0R?\ RPH_X7;)_P!$D^-/_A#)_P#+"NC^V,M_Z"'_ .$V._\
MG<:_7,/_ ,_/_*6)_P#F<]SVG_(;_P")HVG_ "&_^)KPS_A=LG_1)/C3_P"$
M,G_RPH_X7;)_T23XT_\ A#)_\L*/[8RW_H(?_A-CO_G<'US#_P#/S_REB?\
MYG/<]I_R&_\ B:-I_P AO_B:\,_X7;)_T23XT_\ A#)_\L*/^%VR?]$D^-/_
M (0R?_+"C^V,M_Z"'_X38[_YW!]<P_\ S\_\I8G_ .9SW/:?\AO_ (FC:?\
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MVUQ<107&HW%O:S7L\%C#+*)+N:&RMKB[FB@21X[6WFN'58HG=;A'?./S'?\
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M>D?$KPYIFH^'/AKXE\0GQ!X;\,V":3XF\=Z3ID/B#2=0_M7Q9H_S5>?LZ_\
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MX> =/\9>&_%?Q!UKXF_"O7)OA_X&CB\)^.=*TV75K/6+;7?AQJNARZ\/</\
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MOP*N-+\+ZM82V?Q'\1^"->U2#3?B%H\^J^(/$YT#2HM*TVY.AZAITOA7P_\
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MFFCWFBO!?^%@?&'_ *(-=?\ AR/!W^-'_"P/C#_T0:Z_\.1X._QKJ_M?"?\
M/O,/_#5F?_S&:_7*7\N)_P#"/%__ "@]ZHKP7_A8'QA_Z(-=?^'(\'?XT?\
M"P/C#_T0:Z_\.1X._P :/[7PG_/O,/\ PU9G_P#,8?7*7\N)_P#"/%__ "@]
MZHKP7_A8'QA_Z(-=?^'(\'?XT?\ "P/C#_T0:Z_\.1X._P :/[7PG_/O,/\
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MK7]-/^%@?&'_ *(-=?\ AR/!W^-'_"P/C#_T0:Z_\.1X._QH_MC"?\^\P_\
M#3F?_P Q!]<I?RXG_P (\7_\H/>0         ,  <  #@ #H*6O!?^%@?&'_
M *(-=?\ AR/!W^-'_"P/C#_T0:Z_\.1X._QH_M?"?\^\P_\ #5F?_P QA]<I
M?RXG_P (\7_\H/>J*\%_X6!\8?\ H@UU_P"'(\'?XT?\+ ^,/_1!KK_PY'@[
M_&C^U\)_S[S#_P -69__ #&'URE_+B?_  CQ?_R@]ZHKP7_A8'QA_P"B#77_
M (<CP=_C1_PL#XP_]$&NO_#D>#O\:/[7PG_/O,/_  U9G_\ ,8?7*7\N)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $8[?A_[3KQGXX_\BKX<_[*Q\$O_5M^"J]F
M';\/_:=>,_''_D5?#G_96/@E_P"K;\%5Y6;?\BW&?]>O_<V%.?%_[M6_PQ_]
M.TCVJBBBO5.@0@$$$ @C!&.".G/X5Y'K?P:\&:A?W&MZ+%J?@7Q'=.9+G7_
M>I2^&KV\F+9>;5+2UW:+K4[@[&N-:TN_F$>8U=4.*]=_G[4PG@\_Q=B21GUY
M&#[=,]JYL3A<-BHQAB:-*LH/FASP3E3E:W/2FN6I1G;13HU:4[:<S6AG4I4J
MR2JTX5%%\T>97<9;<T)*TH2MIS0E&5M+V/%$T+XV>'B#I7C7PKXYM58L;7QG
MH$N@:HT:_<@BU_PQ.;)#@ -<S^&[IV89*=<S#Q_\0M/&->^#'B.0KDS77@WQ
M+X0\2::N/XHAJNJ>%M=G1ARH301-UW1J #7LIX .<\>IY_\ 'OSQGVI-O [Y
MZ]#^N0?R/_U^-9?.GIALPQU%=(5*M/&TUMHEC:56JEY?67^5L?J\H_PL3B*:
MZ1E.->"]%7A.:7E[7[CQ=/CGX8A+)J_ASXE^'W3 ;^UOAMXP6#<0,B.^L=*N
M]/N,9&3!=3 <<_,*;)^T'\)H>;OQ//8X S_:'A[Q-9D>H;[1I"!2,-NR0%VM
MG[K8]G(R?FR/8Y(_)C[=J38#_!D?[O\ ]:I='-5\&886:UUJY;9_/V&.A'[D
MK]D/V>+3TQ-*2_OX6S^?)72^Y(\8C_:$^$$X!M?%Z7N>GV#1O$%Z3UZ?9M*E
M!Z'H>Q]#B5_CKX-=0-,TWQ_KC_PQZ+\-_&]\Q'9BZZ((HT.1^\EDCC 9=S*I
MS7L115/W0 ?8?K@4N-O3'_ 21_Z"0?SH]CFVTL?@X=W3RV3:7DJV/E%?--"Y
M,6]\31C_ (,*W]W/B&OOT/'?^%E>+M14GP_\&?'URK9$=UK]YX/\+6.<<&>.
M^\1S:Y"F2,E-#F91D;"PVF)K3XZ^(05GU3P'\.K25"/+TBTU'Q[KD##(!CU/
M5%\-Z-DC&Y)- NE0CY7<#+^U!01D8^G]#DG'X$'^BC/.01P>N['XDG^GOFJ>
M K5-,1F.-JQ=[PHNA@8/NF\)2]M;R^LQ>_O7LT_J\Y?Q<5B)KK&FZ>'B_P#P
M3#VB7E[5>O4\8MO@GX<OYDOO'VJ:_P#$V]21)TC\9:@)_#T,X )-MX.T];'P
MNL8D_>P+>:9>36S*K0SJP+'V.W@AMH(K>VAAM[>&-(X8($6.&*-%VI'''&%1
M$4 !508 &!QBG@D9!ZCW_P 6_,<>A]*?T!_'IU]>*Z<+@L+A.=X>A3IRJ6]K
M4LYUJKBW9UJ]257$5FKNWM:T^6[48PNT:4J%&C?V5.,'*W-+64YV5DYU)N52
M;71SG*UW:UQ:***[#4\*T_\ Y.)\3_\ 9&O O_J9_$"O<3W_ !_]J5X=I_\
MR<3XG_[(UX%_]3/X@5[B>_X_^U*\?+/AQ_\ V-LQ_P#3N&.?#[8C_L,Q/YTR
M2BBBO8.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_A7O@#_H2O"G_A.:1_\ (M'_  L]\G^[-?\ ,/\ ;_\ J!_\NS-_X6W\*O\
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MMOX5?]%)\!?^%?H7_P ET?\ "V_A5_T4GP%_X5^A?_)=:7_"O? '_0E>%/\
MPG-(_P#D6C_A7O@#_H2O"G_A.:1_\BT?\+/?)_NS7_,/]O\ ^H'_ ,NS-_X6
MW\*O^BD^ O\ PK]"_P#DNC_A;?PJ_P"BD^ O_"OT+_Y+K2_X5[X _P"A*\*?
M^$YI'_R+1_PKWP!_T)7A3_PG-(_^1:/^%GOD_P!V:_YA_M__ % _^79F_P#"
MV_A5_P!%)\!?^%?H7_R71_PMOX5?]%)\!?\ A7Z%_P#)=:7_  KWP!_T)7A3
M_P )S2/_ )%H_P"%>^ /^A*\*?\ A.:1_P#(M'_"SWR?[LU_S#_;_P#J!_\
M+L\F\)^)?#OB?]H/Q==>&]>T;Q!;6WP@\"V]S/HNIV6J06TY\8_$!UAEDLIY
MDB=E.Y%8@NN2 0"1]&$'G YS_5^?ZBLC2/#N@:")_P"P]$TC1_M)3[1_9>FV
M=CYWE[O+\TVD49E\LR/L\PMMW-@#<<[70?S/]?\ /2M\!A:V'I55B)T9U:^+
MQ.*FZ$:D:4?K%2$HP@JTI5&HQIQ3E-IRDVU%121>'ISIQFJDH2G4K5:LO9J2
8@G4<7RQYVYM145J]6V]$K"T445Z!N?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  $ # 2(  A$! Q$!_\0
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M74.F_$%)_#UU=>(-=UV/P[H=GIMEXN'C?3=&L/$_AO494TPVJ6U[&EU^VO\
MP3/^*_[)O[''[+&FV2V/B&Q^*_Q"O_#/C/XK:7X=TG6-3MO&']HKX>\/6'Q4
M^$EIJL>C6]Y^S5HUIXBTNWT/Q1;6]M-I@O)=!\3K+XZ$NF/+I)1T]^3<K6B[
M]+73LU;:ZOK=/79\SYVG9144FKK1[MOY-+5_)+5_T$1MVV9(.=W3//MMR1@\
ML,#G/M94L3\R,21C/3+#(P,8X..?SIB94NF<-&SJVWD$H?F[9Y//3/0' (J4
M<DELCC(QN'KT&.3GG )Y(/?C )JZNDFM-=;_ .74BE<1QM*Y6-(PTCNS!$A
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8%0".#R<' (SR>]<I4V[=//IVV7]61__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] #X# 2(  A$! Q$!_\0
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MEA8Z8LSJ9ETVRM; 2NH*(\HM(H?,=$^16?<0GR@XJX=TC*7=G(R 7.X@,<D
MG)QDDD9Y//6M98F35H1]FM+6;=K-/31+IU3MYW)5&*:;<FM=&[IM]=;_ )WZ
MZ;'^:C^TC_P3>_:O_9>\>>(/"?B#X/\ Q0\2^&M"\7S7ND_%;PIX4N_$'@?Q
M?X3TG6WDT/Q"-8\*P7>E:?JC:9<Z5<ZGIVLVMG<Z#XBO;_3[>WED@GU&']G_
M /@FQ^T]_P %0_&W[2?PETA_&'QT^+'PU\0>*]/TGXD:/\5_#%U/X#TSPCI,
M$5O\0-8C\?MX;TO3-#U#P_ITGGZ#IJZN^HW7B"VM-/73K_[;<RQ_V&)B-"J
M(LAPZH-JOYA+-O485PQSN# [LDGGFIXA\OE@[8R0WEH B;ANRVQ1MW''+8W'
MN2>:F5=SBTX0O:2NKZ.22;2=]=$]]T-4TFK-I;M7=V[;WOY=4_E=EE"!DC!4
M9(W8W=1@D#D''7';(]"905R26)S@CH1@#']W )X/'X\BHD4;=W<_>)P=VT@#
F((QT//'/XU(%!&.X9LL."=I '3![],FL F]4K^=K>JO_ , __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !& #T# 2(  A$! Q$!_\0
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M?7?J-!9C=XU>TC7=J:4I1K5HPE'V5H.$J2I.$N6$IQ:E4ITZCJ4X/?;@-R
M#P >!C(YX[\=:K-AA(,8))YQ]3R"3UVX(Z$<>X**X#O*N 7!;D9P!@' #'U[
M9SP, #U- 0'@GC// _A[#MCD=AD#GI110%_T_#8GP N3S\F[&!@ @ #H,XJ0
M ?<YX&3SGG&.IZ]<]!R,T44 /2,#J>05*]3SC//(.!SQSVJQ$X*YY&23@8/?
*&23R2<444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>fimg_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fimg_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  H 0(# 2(  A$! Q$!_\0
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MIWB33O$U[%X=N=0T"&]TS6=!FU'3[NXFMHVLOZ-_V_?^3'OVN/\ LW7XO?\
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M^O<3>[&,=.(LP@O=C&.D*<HTX+W=(4XQA!6A",81A&/R7^RE^Q;\%OV-=/\
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M]H'P'%^T7X:UC]H"_P#"-_;77[0=K+%'^UC\*_A'<^&?B3\1%T[X6^&Y=:\
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5^7RZ_P!-E%%%(U"BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex10-7_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-7_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !& #T# 2(  A$! Q$!_\0
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MSQ9X#TSQ!-&OP]T*[?6=2L4<F75+I JV]NPQA80&E+G.3E5 &2P\5_X*8_!
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ML)[GH/P+^ ,_PEU[6M4O?B'XP\<7%]$MI''XBU)YH;:,'?\ *F<%R3RYYQP
...<^U*W'/-%%)E+8__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
